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ABSTRACT 
 
During ovulation, the oocyte and associated cumulus cells are expelled from the ovary and 
travel to the ampulla of the oviduct where fertilization occurs. Concurrently, granulosa and theca 
cells of an ovulating follicle luteinize and form lutein cells of the highly vascular corpus luteum, 
which secrete progesterone for pregnancy maintenance. Just prior to ovulation, the gene 
endothelin-2 (Edn2) is highly yet transiently expressed for a two-hour window. Mature endothelin-
2 protein (EDN2) is a 21 amino acid peptide that is classically described as a potent 
vasoconstrictor. EDN2 is produced exclusively by the granulosa cells of mature follicles, and is 
an important factor in ovulation; mice that are pharmacologically treated to block action of the two 
endothelin receptors ovulate fewer oocytes and form fewer corpora lutea. Similar effects are seen 
in mice that globally lack Edn2, though they also expire at a young age. While it is clear that EDN2 
plays a vital role in ovulation, the exact role for EDN2 has yet to be elucidated. Previous work 
suggests that EDN2 may cause contraction of mature follicles during rupture, but may also be 
involved in the critical processes of angiogenesis and leukocyte migration. To understand the 
pattern of expression, an Edn2-iCre mouse was generated and Edn2 expression was characterized 
throughout the body; Edn2 has widespread expression, particularly throughout the skin and ovary, 
with additional punctate expression in the GI tract, uterus, brain, kidney, and pituitary. This mouse 
model will be a useful tool for examining EDN2 signaling targets. Next, to address the role of 
EDN2 in ovarian contraction, the effect of EDN2 on ovaries from cats, dogs, and chickens was 
compared; all species’ ovaries exhibit a strong and sustained contraction relative to the amount of 
smooth muscle present in the ovary. Thus EDN2 has an evolutionarily conserved contractile 
response. To further characterize EDN2 action in the ovary, Edn2 was removed from either the 
whole ovary, or only the granulosa cells using a novel Esr2-iCre model. In each model, loss of 
EDN2 prevents follicle rupture but not folliculogenesis or corpus luteum formation. RT-PCR 
revealed that expression of genes critical in angiogenesis and leukocyte action are not modified by 
Edn2-ablation, implying no significant involvement of EDN2 in these ovulatory biological 
processes. To determine whether endothelin receptor A (Ednra, EDNRA, ETA) mediates EDN2 
contractile action during ovulation, a conditional gene knockout approach was employed to 
selectively ablate Ednra in smooth muscle cells through a tamoxifen-inducible Cre recombinase 
system. However, all mice including wild type controls treated with tamoxifen had severely 
iii 
impaired ovulation; while ovulation occurred, the role of EDNRA cannot yet be determined. 
Alternatively, available data indicate that granulosa cell-specific loss of Ednra causes subfertility, 
indicating that EDN2 likely exerts an effect through EDNRA receptors on granulosa cells. Lastly, 
temporal regulation of Edn2 expression by progesterone receptor (PGR) was confirmed using 
PGR-knockout mice. Overall, it is proposed based on results herein that EDN2 targets EDNRA to 
induce periovulatory contraction as a conserved mechanism leading to follicle rupture and 
subsequent corpus luteum formation, and that this action is under regulation by PGR. Therefore, 
EDN2 is critical for normal ovulation and fecundity. 
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CHAPTER 1: OVERVIEW 
  
2 
Ovulation is the fundamental biological process in vertebrates during which the unfertilized 
oocyte and associated cells of the cumulus oocyte complex are expelled from the ovary in order to 
enter the oviduct for fertilization by the sperm and eventual transport to the uterus (or shell gland). 
In humans, it is both a necessary step in the establishment of pregnancy and also allows for corpora 
lutea (CL) formation, which is critical for pregnancy maintenance. Though the global population 
continues to rise alarmingly fast, there is now an increasing rate of infertility in the developed 
world that lacks a singular causal explanation. Infertility is now the single most common reason 
to see a doctor in multiple countries, and there is a growing number of infertility clinics 
worldwide2. Additionally, 1-3% of couples experience recurrent miscarriage with three or more 
consecutive pregnancy losses, and the majority of these cases also go undiagnosed3,4. In diagnosed 
infertility cases, ovulatory disorders account for about 30% of female infertility5, and are thus a 
major contributor to millions of cases of infertility each year. Understanding the mechanisms 
central to ovulation will help alleviate growing issues within infertility and improve treatment 
procedures used through assisted reproductive technologies, and may also lead to new safer or 
more economical contraceptive techniques.  
 
This dissertation focuses on the role of the protein endothelin-2 (EDN2) in ovulation. 
EDN2 is a vasoconstrictive agent produced in ovarian granulosa cells of mature follicles just prior 
to ovulation6-8. Elucidating the role of EDN2 will further identify pathways and targets for use in 
treating infertility and improving ovulation rates during assisted reproduction. 
 
This dissertation is divided into a total of nine chapters, with all references listed after the 
final chapter. Figures and tables are located at the end of individual chapters that they are 
referenced in. Chapter 2 provides a brief background on current issues in female reproduction, a 
brief summary of the female reproductive system and species differences associated with it, a 
history of the identification and study of endothelin-2 relative to reproduction, and the specific 
aims and hypotheses of this work. Chapters 3-8 are data chapters that each address a specific aim; 
each is formatted as an individual manuscript, except that figures and tables with associated 
legends are listed at the end of the chapter. Chapter 3, the only chapter published at the time of 
dissertation composition, discusses the generation of an Edn2-iCre mouse model and identification 
of cells and cell lineages of Edn2 expression, and has been published in the journal Genesis in 
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2015 (PMID 25604013). Chapter 4 explores the contractile properties of ovaries in response to 
EDN2 peptide in dogs, cats, and chickens as well as smooth muscle distribution to demonstrate 
that EDN2 presence causes ovarian contraction across vertebrate species. Chapter 5 describes the 
generation of a new Esr2-iCre mouse model that has consistent and robust iCre expression in the 
granulosa cells. Chapter 6 describes the resulting phenotype of ablating Edn2 in the whole ovary 
or in the granulosa cells using the model described in Chapter 5 and explores the intraovarian 
mechanism by which EDN2 modulates ovulation. Chapter 7 describes the use of a mouse model 
where endothelin receptor A is lost in smooth muscle cells in an inducible manner and the effect 
this has upon ovulation. Chapter 8 briefly explores the regulation of Edn2 expression by 
progesterone receptor and hypoxia, and generates a hypothesis for future study of potential Edn2 
regulation by RUNX1. Lastly, Chapter 9 provides a brief summary of data presented in this work, 
conclusions that can be drawn those data, and future directions for study of EDN2. 
 
 It must be noted that this dissertation deals exclusively with animal models, and nearly 
exclusively with mouse models, for practical considerations to investigate the fundamentals of 
human ovulation. The findings herein are believed to be salient with human physiology and 
genetics given that humans and mice share a common ancestor only 80 million years ago9, while 
both ovulation and the endothelin system are far older. Indeed, humans and mice share 
approximately 75% percent of their genome10, with even greater homology among the protein 
coding regions of approximately 85%, and about 99% of mouse genes have homologues or 
analogues in humans11. As a cautionary point, it has been demonstrated that despite genetic 
similarity, physiological responses between humans and mice may differ greatly in the specific 
genes activated10. However, the final active form of endothelin-2 differs by a single amino acid 
between species and each isoform shows the same activity across species12,13. Given such high 
conservation across evolutionary time and retained responses in tissues, the following information 
is presented under the operating notion that EDN2 acts homologously between humans and mice14, 
that the mechanisms of ovulation are also highly conserved, and that it may be logically upheld 
(pending further contradictory evidence) that findings in one species directly translate to the other 
for direct application in assisted reproductive technologies and infertility treatment. Greater 
elaboration on the evolution of the endothelin system and its conserved role in mammals leading 
to this governing postulate is located in the following chapter.  
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CHAPTER 2: INTRODUCTION AND REVIEW OF RELEVANT 
LITERATURE 
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Contemporary concerns in reproduction: population growth, contraceptives, and infertility 
Current issues within reproductive study are centered about two opposite yet related issues: 
methods to decrease rates of pregnancy achievement in the face of the rapidly rising world 
population, and treatments for couples that have been unsuccessful in achieving or maintaining 
pregnancy by natural means. Currently, the world population is at about 7.3 billion people, an 
increase in global population by 300 million (the approximate size of the US population) since 
October, 201115. It has been estimated that the carrying capacity of the world, the maximum human 
population that can be maintained by current food production efficiency and distribution, is about 
9 billion people, though estimates range from 5 billion to 15 billion15-21. The population is expected 
to reach this level by 2050; increases in the human population beyond this point are predicted to 
result in increased starvation and mortality, and, as a succinct understatement, a decrease in the 
average quality of life22,23. Indeed, human population-driven changes are becoming readily 
apparent in the climate itself23-27 as well as the total amount of animals28 and species29 present. 
Reduction in the number of human births per year is a necessity, and can only be achieved through 
proper contraceptive education and use throughout. Development of new contraceptive techniques 
that are cheaper and safer or have fewer side effects than conventional estrogen and progesterone 
birth control pills, and are more culturally acceptable than condoms would greatly aid in the 
struggle against the increasing world population. Thus new contraceptive targets must be 
designated through scientific investigation of the human reproductive process, and subsequently 
developed and tested.  
On the other end of the spectrum, for largely inexplicable reasons, the developed world is 
facing an increasing rate of widespread infertility. This developing-world trend toward low fertility 
in each gender may be partially attributed to the socioeconomic status, career demands in women, 
and/or improvements in contraception30. Though it does little to offset global population growth, 
infertility is now the single most common reason to see an OB/GYN specialist in several countries, 
and there is a trend towards a worldwide increase in infertility clinics2,31. Consequently, the use of 
assisted reproductive technologies (ART)30,32-34 has increased as well. It has been estimated that 
15-20% of all clinical pregnancies in the US end in miscarriage4, and this percentage is expected 
to increase. Most instances of infertility are idiopathic and undiagnosed. A recent register linkage 
study demonstrates that the age of a mother at conception is a major risk factor for miscarriage35, 
and risk of fetal loss increases after 35 years of age35-37. Though increasing age during childbirth 
6 
is one possible contribution to infertility epidemic, age itself is not a direct causative agent. Within 
infertility, 1-3% of couples experience recurrent miscarriage (RM), with three or more consecutive 
pregnancy losses; the majority of cases of RM are also undiagnosed3,4.  
In diagnosed cases, ovulatory disorders account for about 30% of female infertility5. 
Ovulation is the event in which a mature oocyte, the female germ cell, is released from its follicle 
in the ovary and enters the ampulla of the oviduct where fertilization may then occur. Disorders 
may be caused by failure of follicles to be maintained, to grow and develop in response to 
gonadotropic signals, to produce or respond to normal ovarian hormones, to undergo cumulus 
oocyte complex expansion, to undergo luteinization and produce progesterone, or to rupture from 
the ovary and allow the oocyte entrance to the oviduct. Changes to these functions may be caused 
by cancer38-40, infection, or cysts41 within the ovary itself, by hormonal imbalances of ovary-
derived hormones caused by either primary or secondary endocrine signaling disorders42-44 such 
as polycystic ovarian syndrome (PCOS)45-48, by autoimmune diseases that target the ovary49-51, or 
by exposure to endocrine disrupting chemicals (EDCs) that modify hormonal or genetic signals52-
56 within the reproductive signaling axis, to name a select few causes. Thus the ovary is one 
particular area that may be studied to understand the genetic and molecular basis leading to a large 
percentage of infertility cases. An increased knowledge of the basic mechanisms of ovulation may 
also lead to creation of improved female contraceptives and provide greater hope for slowing and 
eventually halting global population growth.  
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The female reproductive system: an essential overview of ovulation 
 Understanding ovulatory function and disorders arising from malfunction requires a grasp 
of the female reproductive system as a whole, as multiple organs work in a synchronized temporal 
manner to stimulate ovulation and allow for fertilization and pregnancy. Though it is not possible 
to provide an in-depth review of multiple systems, a brief overview is possible with a particular 
focus on ovulation itself.  
 The female reproductive system directly involves the ovaries, oviducts, uterus, cervix, 
vagina, external genitalia57, and also requires signaling and cellular interplay with the brain, 
pituitary gland, and spleen58. Of these, the brain, pituitary, and ovary are the primary components 
in reproduction leading to ovulation and fertilization, with more recent evidence also including the 
spleen58 (Figure 2.1A). The ovary undergoes predictable and repeated changes as women or female 
animals go through their respective reproductive cycles. The primary function of the ovary is to 
maintain the germ cells (oocytes, egg cells), to prepare them for fertilization, and to generate 
hormones necessary for germ cell growth and also for pregnancy maintenance (in most species). 
Germ cells in the ovary are organized into follicles, which grow and develop prior to ovulation. 
Follicles within a healthy and mature ovary may be morphologically and functionally classified as 
primordial, primary, secondary, antral, or Graafian (periovulatory)59; follicles sequentially develop 
in this order leading up to ovulation. Graafian follicles are the largest and most mature follicles, 
and contain an oocyte surrounded by a zona pellucida and a layer of cumulus granulosa cells60-62 
(Figure 2.1B). Together, these make up the cumulus oocyte complex (COC), which is released 
during follicle rupture into oviduct where fertilization occurs. The COC is surrounded by antral 
fluid and is contained within the wall of the follicle, which consists of the inner mural granulosa 
cell layer and outer theca cell layers. The theca cells may be further divided into the theca interna 
and the theca externa cells; prior to ovulation, vasculature is present in the theca cell layer but does 
not pass the basement membrane between the theca and granulosa cell layers until follicles are 
mature and near ovulation63. Both the granulosa cells and the theca interna cells are 
steroidogenic64,65, and produce estrogen and testosterone, respectively; however, the theca externa 
cells are contractile, possess smooth muscle actin, and retain a shape similar to that of a 
fibrocyte/fibroblast66. 
Many events leading to ovulation and follicle rupture are controlled by two hormones, 
follicles stimulating hormone (FSH) and luteinizing hormone (LH), which are secreted from the 
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anterior pituitary under the influence of gonadotropin releasing hormone (GnRH) from the 
hypothalamus of the brain via the hypophyseal portal blood system59. GnRH is in turn regulated 
by neuronal stimuli such as kisspeptin and is released in a pulsatile fashion, where low frequency 
pulses stimulate a slight increase in FSH to enhance follicle growth, and high frequency pulses 
lead to a sharp rise in LH (the LH surge)67. The LH surge is necessary for ovulation and formation 
of the corpus luteum (plural corpora lutea, CL), which develops in place of the Graafian follicle 
after ovulation occurs and secretes progesterone to maintain pregnancy68. The ovary has a 
concurrent necessary role in signaling feedback during these processes by producing molecules 
such as activins, inhibins, androgens, and estrogens69,70. In particular, estrogen is produced by the 
granulosa cells of developing follicles starting during the secondary follicle stage as aromatase 
expression becomes active, which converts testosterone from the theca interna cells into estrogen71-
73. Estrogen diffuses from the granulosa cells into the bloodstream and travels to the brain, where 
it exerts negative feedback upon GnRH production until a critical threshold is reached, after which 
it instead exerts positive feedback to increase the frequency of GnRH pulses and cause the LH 
surge, leading to ovulation74,75.  
The CL develops from the cells of a follicle following the release of an oocyte during 
ovulation76,77; theca and granulosa cells luteinize into the small and large luteal cells, respectively, 
and endothelial cells (ECs) migrate into the developing CL to form new vessels via angiogenesis78-
82. The CL is an organ of prolific angiogenesis on a dynamic timescale, as vessels invade to deliver 
progesterone (P4) precursors and carry P4 out to the body83,84. This angiogenesis requires local 
production of vascular endothelial growth factor (VEGF). Luteinizing granulosa cells secrete 
VEGF, activating two VEGF receptors (VEGFR-1 and -2) that are localized to luteal ECs and 
steroidogenic cells85-87. VEGF receptor activates endothelial cells lining vessels and causes 
proliferation88,89. Other factors, such as hypoxia, have been identified as playing a role in inducing 
VEGF in luteinizing granulosa cells90. Angiogenesis in CL formation proceeds after VEGF 
induction with matrix metalloproteinase (MMP)-mediated dissolution of the follicular basement 
membrane, sprouting of new vessels with proliferating ECs, and eventual vessel anastomosis that 
is mediated by macrophages through the surface proteins TIE2 and NRP191. Tissue inhibitors of 
metalloproteinases (TIMPs) are highly expressed in the ovary just after the LH surge92-96. TIMPs 
are released in large quantities during ovulation from the granulosa cells and subsequent lutein 
cells 97-99, and are also produced in the growing CL97.   
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Until the mid-1960s, it was thought that an increase in intrafollicular pressure was the 
driving force for follicle rupture100. However, artificially increasing pressure by saline injection is 
insufficient to induce follicle rupture101,102 and more accurate measurements of follicle pressure 
report that there is not much change during ovulation100. It is now known that a decrease in follicle 
wall strength is necessary during ovulation103-105; this change in tension is caused by proteolytic 
enzymes such as matrix metalloproteinases (MMPs) and the plasminogen system106. Both ovarian 
cells and leukocytes, which enter through circulation, secrete proteases into the ovary. MMP-2 and 
MMP-9 have been previously implicated in degradation of the follicle wall during ovulation107,108. 
Additionally, a decrease in activity of TIMPs has also been correlated to ovulation, specifically of 
TIMP-1109,110. Ovarian modulation of TIMPs and MMPs may occur through leukocytes, which 
double in the ovary prior to ovulation in the rodent while decreasing by a similar amount in the 
spleen58. Macrophages, dendritic cells, and lymphocytes are all localized to the Graafian follicle 
during ovulation, and dendritic cells in particular have been reported as necessary for normal 
ovulation103,111. Additionally, other recent physiological studies have implicated contraction of the 
follicle wall, specifically of the theca externa layer, as a contributing final factor in follicle 
rupture6,66. It is this contribution to rupture by ovarian contraction upon which this dissertation is 
focused. A summary of the molecular pathways leading to and required for ovulation has been 
recently generated by Dr. J.S. Richards (2010)67,112. These pathways include interactions between 
key reproductive hormones and their receptors as well as multiple downstream genes and 
transcription factors (Figure 2.2). Thus ovulation is a multi-faceted process with many genetic 
interactions contributing to several key physiological processes including leukocyte invasion and 
weakening of the follicle wall, and potentially an increase in ovarian tension as well.  
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Specifics of mouse reproduction  
Unlike humans, rodents do not go through a menstrual cycle and do not repeatedly shed 
uterine lining in preparation for implantation. Instead, mice go through an estrous cycle. After 
reaching puberty at approximately 35 days of age, though this varies highly by strain used, the 
vaginal tract opens (vaginal introitus) in response to elevated estrogen levels113. Mice then go 
through a 4-5 day long, light and nutrient-dependent cycle that may be divided into four distinct 
phases: diestrus, estrus, metestrus, and proestrus114. These may again be subdivided into as many 
as 13 different cycle periods, although this extensive subdivison is not routinely considered. The 
stage of the estrous cycle can be established by performing vaginal cytology115; the cells lining the 
vagina vary in appearance under different hormonal conditions: rounded and nucleate during 
proestrus, cornified and anucleate during estrus, cornified and anucleate with some leukocytes 
during metestrus, and predominantly leukocytes during diestrus116. Changes in estrogen 
concentration correspond to cyclic changes in the estrous cycle. Estrogen is highest in proestrus 
(10.5pg/mL), and decreases through estrus (8.5pg/mL) to a low of about 7.0pg/mL during 
metestrus, before rising slightly again during diestrus (8.0pg/mL) as follicles mature116. Mice of 
normal reproductive age show relatively high variability in estrous cycle length compared to other 
model species117, such as rats118. Proestrus marks the period of follicle growth in mice, whereas 
estrus begins with the ovulation of fully mature oocytes. Metestrus marks the end of receptivity, 
the closure of vagina, and movement of the egg through the oviduct. After metestrus, mice that are 
not pregnant enter diestrus where unfertilized eggs are eliminated and new follicles begin to be 
selected for potential growth to ovulation. Mice may also enter a pseudopregnancy period after 
metestrus that may last for 1-2 weeks after sterile copulation owing to prolactin signaling119.  
Mice are spontaneous ovulators, with ovulation occurring during estrus between 12 and 14 
hours after the LH surge6. Ovulation in the mouse may not occur every estrous cycle, particularly 
in young virgin females after vaginal introitus. The gonadotropins LH and FSH may be mimicked 
by administration of equine chorionic gonadotropin (eCG), which is also known as pregnant mare 
serum gonadotropin (PMSG), as an FSH analogue and human chorionic gonadotrope (hCG) as an 
LH analogue in mice to control timing of ovulation6. Injections of PMSG followed by hCG are 
normally done at 48 hour intervals with 5 international units of each (5 I.U.), with ovulation 
occurring 12-14 hours following hCG injection (Figure 2.3A). Multiple corpora lutea form in the 
mouse ovary after ovulation, and persist for 2-4 estrous cycles (up to three weeks). Though an 
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average of 8 follicles mature to the antral/Graafian stage per mouse ovary (Figure 2.3B), only 
about half of these are ovulated, with the rest undergoing atresia of the oocyte119. Ovulated oocytes 
travel through the oviduct to the ampulla where fertilization occurs (Figure 2.3C); this passage 
takes 2-3 days, with uterine implantation occurring on day 4120. In the ovary, the lifespan of the 
corpora lutea modify the level of progesterone in the mouse ovary relative to humans: murine 
progesterone is lowest during diestrus, is approximately four times this during metestrus, is 7.5 
times higher at proestrus than diestrus, and is eight times higher during estrus than diestrus121,122. 
Thus progesterone rises prior to ovulation in the mouse estrous cycle unlike in menstrual species. 
Also, interestingly, the lifespan of the corpora lutea is under regulation by prolactin in mice, as 
opposed by prostaglandins in humans123. Prolactin secretion is sensitive to prostaglandins and LH, 
and will increase after copulation. Prolactin is necessary for angiogenesis to occur during 
functional CL formation124. After successful mating, pregnancy lasts between 19 and 23 days, 
though it is best approximated by 21 days in C57B/6 mice. Mice may become pregnant while 
nursing one litter and may give birth one gestation period after parturition. 
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Species differences during ovulation: domestic cats, dogs, and chickens 
 Though rodents are important tools for understanding key processes that cannot be directly 
manipulated in humans and human tissues, it is important to validate findings across multiple 
species when possible. Though not all processes are directly conserved across evolution, retention 
of signaling pathways in highly divergent species lends great evidence for similar mechanistic 
retention in humans as well. Three readily available species for reproductive study include the 
domestic cat, the domestic dog, and the domestic chicken.  
Cats normally have an abundance of different follicle populations, cycle repeatedly through 
the majority of the year, provide a readily available tissue pool from local routine veterinary spays 
(ovariohysterectomy)125, and are important to study reproductively given the over-population 
issues that currently plague veterinary medicine126. Additionally, cats have been previously studied 
in response to superovulation protocol and CL formation, and new knowledge of the factors 
necessary for ovulation and luteal maintenance may importantly impact the currently low success 
rate for IVF among the 36 (of 37)125 endangered felid species. Cats enter puberty between 6 and 9 
months depending on breed, light cycle, and nutrition, but there are reports that pregnancies can 
begin as early as 4 or 5 months. Cats are induced ovulators, and if not bred they will cycle in heat 
every 2-3 weeks, with estrus lasting an average of 6 days127-131. Coital stimulation during mating 
triggers hypothalamic GnRH release, causing the LH surge within approximately 20 minutes of 
mating132,133. Ovulation is reported to occur 24-56 hours after mating, though few studies have 
looked specifically at the time of follicle rupture. Results vary from a range of 24-36 hours to 22-
56 hours and few studies used precise measures to determine ovulation timing134,135. As in other 
mammals, CL formation begins at the time of ovulation, but luteal cells do not reach their 
maximum size in the cat until 12-16 days later. Progesterone (P4) rises above a basal level 
(<1ng/mL) in 2-4 days after mating136-138, and peaks 21 days after mating in both pregnant and 
pseudopregnant cats129,137. CL become histologically visible 2-3 days after ovulation129. Multiple 
studies have reported good efficacy in superovulating cats. In a study by Chatdarong et al. (2007), 
treatment with 100IU human chorionic gonadotropin (hCG) after estrus induced ovulation in 95% 
of cats139. An equal dose of pregnant mare serum gonadotropin (PMSG) has been used to bring 
95% of cats in estrus when given 3 days earlier140. On average, 3-4 oocytes are ovulated per 
stimulated cat141. Similar results are obtained (3.4 oocytes/cat) even when exogenous 
gonadotropins are given during mid-gestation127.  
13 
Similar to cats, tissue from intact canine females (bitches) is readily available from local 
pets that routinely undergo veterinary ovariectomy and ovariohysterectomy to prevent undesired 
pregnancies. Dogs are generally considered monoestral polyovulatory nonseasonal spontaneously 
ovulating species142. Like cats and mice, dogs go through an estrous cycle, though there is a long 
period of anestrus between follicular phases. Generally, dogs go through a 2-3 week long ‘heat’ 
cycle, consisting of proestrus and a 5 day estrous period with ovulation occurring on day 1 of 
estrus. Dogs then go through a mandatory luteal phase of approximately 64 days if pregnancy does 
not occur, whereas pregnancy is 65 days on average143. Following the luteal phase or pregnancy, 
bitches enter a highly variable anestrous cycle that ranges from 5-12 months in length. The end of 
anestrus in the dog is not yet well understood, and may depend on interplay between photocycle, 
pheromones, and an endogenous circannual cycle in the brain143. Interestingly in bitches, blood 
progesterone concentrations increase prior to ovulation and the LH surge. Serum progesterone is 
approximately 2ng/mL at the time of ovulation; this is caused by the occurrence of preovulatory 
luteinization144. Also, oocytes are ovulated in the immature diploid stage and complete maturation 
in the oviduct prior to fertilization142,145. Ovulated oocytes are 5-7mm in diameter. Implantation 
occurs after 2.5-3.0 weeks after ovulation146. Beyond the early increase in progesterone, which 
may be used as a clinical marker to determine timing of breeding, ovulation is similar to other 
mammalian species and is dependent upon FSH, LH, estrogen, and progesterone signaling147,148. 
Both dogs and cats have a similar follicular structure to mice and humans149. 
Laying hens have a relative unique ovulatory system compared to mammals. In hens, only 
the left ovary is present, and ovulation occurs daily at approximately 24 hour intervals. Hens are 
light sensitive, and eggs are laid 9-10 hours after the onset of darkness; the time of lay from 
darkness onset increases until the lay is ~20 hours after darkness onset and at this point the hen 
may miss a day of ovulation to ‘reset’150. The ovary physically resembles a ‘bunch of a grapes’ 
where preovulatory follicles are arranged in a hierarchy, with size being indicative of the next 
follicle to ovulate151. The leading, or F1 follicle, consists of an oocyte, granulosa cell layer, theca 
cell layer, and blood vessels152,153. However, the granulosa cells of mature follicles are a single 
avascular cell layer, and the theca cell layer has high contractile potential. Ovulation occurs at a 
break in the follicle called the stigma that can be recognized by the lack of vessels more than 48 
hours prior to ovulation154. Unlike mammals, progesterone is the principal steroidogenic endpoint 
of the growing follicle and is produced by the granulosa cell layers, particularly of the F1 and F2 
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follicles. Alternatively, estradiol is secreted by the theca layer of the smaller follicles and estradiol 
production decreases over 10-fold in the 5 days leading up to ovulation in the follicle155. Thus 
aromatase is active in the theca layer, not the granulosa layer as in mammals. Further, it is 
progesterone produced by the granulosa cells that induces the LH surge to cause ovulation; LH 
peaks 3-6 hours prior to ovulation150 and progesterone peaks at 8 hours prior to ovulation156,157. 
Estradiol does not stimulate LH release in the laying hen150, though it does stimulate progesterone 
receptor upregulation in the hypothalamus and pituitary. Treatment of hens prior to ovulation with 
tamoxifen, a dual estrogen receptor antagonist, does not prevent ovulation, though long term 
treatment does as estradiol is necessary for basal LH secretion. The chicken is an important 
ovulatory model owing to the large follicle size, which easily allows examination of cells of 
ovulatory follicles compared to non-ovulatory F2 follicles within the same animals. Chickens are 
also easy to time ovulation in and do not require exogenous gonadotropins to induce ovulation. 
Their quick time to maturity, daily ovulation schedule, and potential use as a comparable non-
mammalian out-group to other species make them an excellent, and often under-utilized, model 
reproductive species. 
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Previous investigations into the role of ovarian contraction during ovulation 
 Within the ovary, there is a network of smooth muscle cells that is conserved across 
species. This network is composed of both the cells surrounding the arteries and arterioles of the 
ovary that control vascular tension, and also the theca externa of mature follicles (Figure 2.3D,E). 
Consequently, the topic of contraction as a mediator of ovulation has long been debated and was 
a particularly active area of research in the 1970s and early 1980s158-165. This is discussed in further 
detail in Chapters 4 and 7. It is well established that ovaries have high contractile potential and 
even respond outside the body to exogenous agents66. Despite the presence of autonomic nerves 
in the ovary and the production of contractile agents such as prostaglandins, no definitive ligand 
or neurologic signal has been identified as a physiological trigger for ovarian contraction. This, in 
addition to inconsistent reports on changes in follicular pressure and seminal work showing that 
increasing intrafollicular pressure does not cause ovulation101,166-168, resulted in a shift away from 
the focus on contraction for many years. It is now well known that collagenase and proteinase 
activity are required for ovulation, and it is widely believed that weakening of the follicular wall 
is one of the most critical ovulatory events70,112.  
Recently, a return to the idea of ovarian contraction has been suggested by Matousek et al. 
(2001)100, who demonstrated that there are mild and short-term increases in follicular pressure in 
the rat ovary just prior to ovulation. Related to this, a unique continuous imaging method by Dahm-
Kahler et al. (2006) of in vivo rabbit ovulation showed that blood flow ceases in the apex of an 
ovulating follicle three minutes before ovulation and the follicle protrudes from the ovarian 
surface. This is rapidly followed by rupture: fluid first leaks from the apex, followed within 10 
seconds by granulosa cell extrusion. Though rupture occurs rapidly and the entire follicle is 
removed from contact with the stroma, follicles remain attached to the surface of the ovary for 
over an hour and a half169, which may imply that there is an initial ‘pushing’ force from within the 
ovary prior to sufficient dissolution of the extracellular matrix to fully free the follicle from the 
ovary. The cessation of blood flow in the follicle apex is also of interest, as this would require a 
highly local vasoconstrictor or clotting agent to be very rapidly produced, or previously produced 
and sequestered from the blood supply, until just prior to ovulation lest the follicle and oocyte 
become oxygen and nutrient starved. More recent work6,170,171 suggests that contraction plays an 
important role in the ability for a follicle to rupture from the surface of the ovary. However, 
definitive proof for a ligand or signal for ovarian contraction induction in vivo remains elusive.  
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New tools for genetic investigation in ovulation: the Cre/LoxP system 
The Cre-LoxP recombination system has been widely used in bacterial and whole animal 
studies to mediate tissue specific gene ablation. The removal or modification of individual genes 
or portions thereof has been a powerful tool in molecular biology, and allows in vivo examination 
of the roles of various ligands, receptors, enzymes, cell types, etc. that could not have been 
individually characterized previously. It is common to explore the role of a particular target by 
removing it from a cell or animal and then observing the resulting phenotypes. The next stage in 
such exploration, after validation of target loss, is to the phenotypes that are likely influenced by 
removal of the original target.  
The enzyme Cre recombinase, originally isolated from the P1 bacteriophage, belongs to 
the integrase family of site-specific recombinases172. It is a 38kD protein that catalyzes 
recombination of DNA sequences between specific sites (LoxP sites) within a DNA molecule173. 
A LoxP site is a 34 basepair stretch of DNA consisting of a core spacer sequence of 8 basepairs 
with two 13 basepair palindromic flanking sequences. A LoxP sequence is recognized by its unique 
sequence: ATAACTTCGTATAGCATACATTATACGAAGTTAT (spacer sequence is 
underlined). When a portion of DNA within a cell has a LoxP sequence on each side of it, it is 
flanked on each side by LoxP, and hence is “floxed.” Thus DNA with a floxed gene has two LoxP 
sequences within a portion of a specific gene. Two LoxP sequences in one DNA stretch, when 
oriented in the opposite direction, mediate inversion of that DNA sequence. When LoxP sequences 
have the same directionality, the DNA between them will be excised instead of inverted, leaving 
only a single LoxP behind the now-joined regions of DNA. Also, if LoxP sites are found on two 
different chromosomes, Cre recombinase may mediate chromosomal translocations174. LoxP sites 
can be introduced into genomic loci of interest by homologous recombination coupled with 
chemically or electrically-induced transfection. Most commonly, LoxP sites are inserted into the 
genome in the same directional orientation. In mammals, this is most commonly done in C57BL/6 
mice, though it has also been done in other inbred mouse strains such as 129. It is also a common 
practice in some immortalized laboratory-specific cell lines. Thus activity by Cre recombinase will 
generally recognize those two LoxP sites and will excise the DNA stretch between them in 
conventional transgenic mouse biology. 
Coupled with the ability to remove a floxed sequence of DNA, Cre recombinase may be 
expressed throughout all of the cells of a mouse or only in specific cells. Generally, the DNA 
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coding for Cre protein is placed after the promoter for a specific gene that is active in only one or 
a few cell or tissue types, or after a promoter that is only active at a particular stage of development, 
or both. For targeting specific cells, this requires prior knowledge of the promoter being used. 
However, it is conversely possible to place Cre recombinase after the promoter of a gene of interest 
and to then use Cre activity to characterize cells and times when that promoter, and hence the 
original gene, becomes active174. The Cre/LoxP system has been utilized to ‘turn on’ genes for 
characterization purposes, usually by interposing a floxed polyadenylation (polyA) sequence 
(which will cause transcriptional arrest) within a gene of interest. Cre activity removes the 
polyadenylation sequence, allowing that gene to then become active. Two common reporter lines 
utilize this conditional on-switch technology coupled with expression of genes not normally 
present in the mouse genome that can be easily detected or visualized. ROSA26 mice175 express 
beta galactosidase in cells that are positive for Cre expression; beta galactosidase can be detected 
by x-gal staining, wherein cells that produce beta galactosidase will induce a blue color change in 
an x-gal substrate of galactose linked to indole176. One potential issue with this system is the action 
of endogenous beta galactosidase or similar enzymatic activity in WT mice, such as in the gut or 
kidney cortex, which may confound the blue signal. A second approach uses mice where a 
jellyfish-derived fluorescent protein is preceded by a floxed transcription arrest sequence; these 
mice demonstrate fluorescence of a particular wavelength only in cells where Cre recombinase is 
active177, which has been characterized as a more accurate method for Cre activity observation. 
Several other recent Cre/LoxP approaches have utilized synthetic genes with floxed transcriptional 
arrest sites to add voltage or calcium-dependent channels linked to fluorescent reporters for real-
time imaging of cell signaling178-180, to add specific toxin receptors to only membranes of desired 
cells prior to toxin exposure allowing for cell- and time-specific in vivo cell death181,182, or to color-
code numerous identical cells within a particular tissue (usually brains) to trace their unique sites 
of interaction183-185. 
The ability of Cre recombinase to remove a target floxed DNA sequence is limited by the 
distance between the two recombination sites186, by genomic position and local interaction with 
other DNA sequences or protein molecules, by what cell type Cre recombinase is expressed in, 
and by the level of Cre recombinase expression in the target cell population172,187. This may mean 
that not all floxed DNA sites are successfully removed in a tissue in vivo, and thus not all Cre 
systems demonstrate 100% successful recombination188. To enhance the level of Cre 
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recombination in mammalian systems, because Cre is originally derived from a prokaryotic source 
and its codon usage is not optimal for eukaryotes and it has an excessive amount of CpG 
dinucleotides which may induce genetic silencing, a codon-improved version of Cre recombinase 
(iCre) that is optimized for mammals was generated in 2001172. The newer transgenic mice that 
utilize iCre have a generally higher success rate in gene ablation than traditional Cre mice. 
 Another limitation of Cre (or iCre) recombinase is that it is active in a cell whenever its 
added promoter is active, and promoter activity may be very different in developing animals (mice) 
from adults. Many attempts to remove floxed genes to study their function in adult mice have 
resulted in embryonic death from unperceived early or additional gene functions189,190. To 
overcome this hurdle, mice that have inducible Cre recombinase have been generated. In these 
animals, Cre is only transcribed when a particular cofactor is present that is not normally produced 
in the transgenic mice. Cre activity may occur globally when that particular factor is present, or it 
may be limited by activity of a specific promoter to a particular cell type. Examples include 
doxycycline-dependent global Cre recombinase expression191, RU486-induced Cre expression in 
the salivary glands192, and smooth-muscle cell specific Cre expression in the presence of 
tamoxifen193. Many transgenic mouse lines are now available for commercial purchase from 
Jackson Laboratory (Bar Harbor, Maine). 
In addition to Cre recombinase, other recombinase systems have also been identified, and 
may be utilized for similar purposes. Flippase (FLP) recombinase and flippase recognition target 
(FRT) sites were originally identified in yeast and, after modification for successful activity at 
mammalian body temperatures, are also commonly utilized194. Most importantly, FLP 
recombinase may be coupled with Cre recombinase systems to allow modification of a gene, in 
vivo or in vitro, when a LoxP site is also present and modification of the floxed DNA is undesirable. 
FLP technology is now normally used for insertion of Cre recombinase and LoxP sites into 
genomic constructs with drug-dependent targeting vectors. Drug-resistance sequences can then be 
later removed without modifying the desired Cre or LoxP insertions174.  
A new and growing-in-popularity transgenic technology, the CRISPR-Cas9 system 
(clustered regularly interspersed short palindromic repeat-Cas9 system), can also be used to 
generate and modify gene presence or function in vitro or in vivo195. The CRISPR system utilizes 
microbial nucleases to modify genomic DNA. The Cas9 protein can be targeted to specific DNA 
sites using a custom RNA guide196. One key advantage of CRISPR is that multiple RNA sequences 
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can be used at the same time, allowing for multiple modifications within the same cell. However, 
Cas9 may itself also be modified by fusion to modular functional effector domains, essentially 
allowing for any known enzymatic modification to be targeted to a specific DNA site(s) 
concurrently196. This process can be further controlled with genome and epi-genome modifying 
elements under inducible control systems197. It is likely that future transgenic mouse studies will 
utilize CRISPR systems for Cre or FLP recombinase insertion, for direct stem cell modifications, 
or for in vivo modification in place of the Cre/LoxP system. 
The evolution of new tools, such as the Cre/LoxP system and CRISPR-Cas9 system, fueled 
an increased interest in the genetic and molecular mechanisms governing female reproduction, and 
ovulation in particular, over the past decade. The application of emerging tools allowed scientists 
to search for new molecules beyond classic hormones and cell signaling mediators with the hope 
of improving both contraceptive methods and infertility treatments. 
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The search for the genetic mechanisms of ovulation: identification of endothelin-2 
To identify new molecular mediators of ovulation and CL formation, microarrays were 
previously generated examining gene expression at different time points throughout the ovary in 
rat and mouse models by multiple labs in the mid-2000s6,7,198. Ovaries were collected from 
gonadotropin-stimulated rodents and collected at various time points before and after ovulation; 
these data were also used to create ovarian gene data bases, rOGED and mOGED199 and the 
Ovarian Kaleidoscope Database. The rOGED database is publicly accessable, as is the Ovarian 
Kaleidoscope Database. Two separate labs, the Ko Lab and the Bagchi Lab, independently 
published on increased expression of the endothelin-2 (Edn2) gene in 2006. The Ko Lab identified 
Edn2 through the rOGED, while the Bagchi Lab identified Edn2 after microarray in progesterone 
receptor knockout (PRKO, PgrKO) mice. EDN2, the final protein product of the Edn2 gene, is a 
21-amino acid peptide with two internal sulfide bonds. Interestingly, expression of the Edn2 gene 
increases several thousand fold in approximately a two hour window, hCG11-12 hours, that occurs 
after the LH surge (hCG0) and just before the average time of rodent ovulation (hCG12-14)6,7,14,200. 
This has been previously indepenently confirmed by multiple groups.  
In the rat, Edn2 mRNA is increased specifically in the granulosa cells (Figure 2.4A). The 
Ovarian Kaleidoscope Database from Stanford University confirms this level of increased 
expression in the ovary as a whole (Figure 2.4B)198, as do data from the rOGED (Figure 2.4C)199 
and the mOGED (Figure 2.4D) databases. When Graafian (periovulatory) follicles were collected 
and fixed from rats, in situ hybridization confirmed Edn2 transcription occurs in the granulosa 
cells of mature follicles6,7 (Figure 2.4E), but not in other local immature follicles or corpora lutea. 
This induction was absent in mice lacking the progesterone receptor gene7. Mice that lack the 
progesterone gene fail to ovulate7,201. Similarly, in rats and mice that are treated with an antagonist 
for the receptors of EDN2 during ovulation, the number of oocytes released from the ovary are 
significantly reduced6. In 2006, EDN2 was best known as a potent vasoconstrictor202,203. This 
raised significant questions about the mechanism of its action within the ovary, and also helped 
expand the field of endothelin study into its present day form204. 
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Overview of the endothelin system 
EDN2 has two similar isoforms, coded by separate genes: edn1 and edn3. EDN1 is the 
most commonly studied endothelin. Endothelins were originally discovered in 1988; EDN1 was 
isolated from porcine aortic endothelial cells, hence their name12. EDN1 and EDN2 differ by only 
two amino acids in their final form, while EDN1 and EDN3 differ by 6 amino acids, as do EDN2 
and EDN3 (Figure 2.5A). Current antibodies commercially available (583151, Cayman Chemical 
Company, and ab2793, Abcam) have 100% affinity for all three active endothelins, as well as their 
big form and their prepro forms205-207 owing to the high similarity between peptide forms. Other 
available antibodies have no data listed on specificity (ab117757 Abcam, sc-21625, Santa Cruz). 
This is an important consideration in clinical vascular pathologies, where endothelin measurement 
is done by ELISA in hypertensive cases, though this is usually only interpreted as an increase in 
EDN1 presence14.  
Endothelins are first synthesized as inactive 212 amino acid-long precursors in the 
cytoplasm known as prepro-endothlins; they are then cleaved by peptidases such as furin-like 
endopeptidase or chymotrypsin into a 39 amino acid form known as big endothelins; lastly, they 
are converted to their 21 amino acid active form by one of two endothelin converting enzymes 
(ECE-1 and ECE-2, encoded by the ece-1 and ece-2 genes)208 (Figure 2.5B). ECE-1 is a zinc-
dependent type II membrane protein with an active domain in the ectodomain209; ECE-2 is a 
membrane-bound protein with similar metalloproteinase-like activity but is localized to an 
intracellular compartment210 and functions optimally at lower pH211. 
All endothelins exert their actions through two G-protein coupled receptors (GPCRs), 
EDNRA and EDNRB, which are produced by the Ednra and Ednrb genes, respectively212-214. 
EDN3 has different receptor affinites from EDN1 and EDN2 and has a higher affinity for EDNRB. 
EDN1 and EDN2 have equal receptor affinities to each other214-216, yet are produced in a very 
different manner. EDN1 is constitutively expressed in low amounts in the endothelial cells of the 
vasculature and is necessary for maintaining cardiovascular tonicity, while EDN2 appears to be 
produced in higher amounts but is temporally and transcriptionally limited208,217. Endothelin 
receptors are found in a wide range of cells throughout the body, but are classically best 
characterized as present on smooth muscle cells about the vasculature to receive signaling from 
endothelial cells via EDN1 to cause arteriolar contraction.  
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 The genes encoding endothelins are specific to vertebrates218, although ciliates and 
cnidarians have demonstrated chemotactic behavior219 and muscle contractions220, respectively, in 
response to EDN1. Endothelin ligands have gone through two or three rounds of genomic 
duplication and subsequent evolution to arrive in their present distribution. Vertebrate ancestors 
possessed only a single endothelin gene (edn1) that underwent two rounds of duplication prior to 
the common teleost fish ancestor; therefore, at one point in evolutionary history, four endothelins 
were present, EDN1, EDN2, EDN3, and EDN4. This is true today in cartilaginous fishes, the 
spotted gar, and the coelacanth218. An additional duplication of Edn2 and Edn3 has also occurred 
in some fish, such as the zebrafish (Danio rerio), so that these animals actually have six endothelin 
ligands. In tetrapods, in addition to not having this final duplication, the Edn4 gene was lost. Thus, 
to the best of present knowledge, all mammals, birds, amphibians, and reptiles possess Edn1, Edn2, 
and Edn3, but not Edn4 or any duplications of any other endothelin ligand gene218,221. However, 
these genes are individually very important, as a rodent model of global Edn1 loss is embryonically 
lethal222, Edn2 loss is lethal after birth and prior to reproductive age owing to starvation223, and 
Edn3 loss results in postnatal lethal aganglionic megacolon with white spotting as a result of 
abnormal neural crest cell migration224,225. A homologous phenotype is also seen in lethal white 
foal syndrome. 
Endothelin receptors are similarly found in all chordates218. By examining approximately 
30 different species’ genomes, Braasch et al. (2014)221 showed that early jawless vertebrates 
possessed only one endothelin receptor gene similar to Ednra. However, early bony vertebrates 
such as sharks possess three different endothelin receptor genes, which correlate to two early 
genomic duplication events218. Thus Ednrb arose from a duplication of Ednra, and Ednrb2 (which 
is not present in mammals) also arose from a similar duplication. Within telost fish, additional 
genomic duplications have occurred and many fish such as the Japanese and European eels, which 
were both recently genomically sequenced, possess six different endothelin receptor genes226. 
More commonly known species, such as zebra fish, had ancestors that lost both copies of the 
Ednrb2 gene prior to a duplication event, and now possess four endothelin receptor genes, Ednra, 
Ednrb, and their duplicates, but not Ednrb2221. During the evolution from fish to land dwelling 
animals, no duplications or gene loss events occurred, such that amphibians, sauropsidans (turtles, 
lizards, snakes, dinosaurs / birds), and monotremes (playtpi) each have an Ednra, an Ednrb, and 
an Ednrb2 gene221. However, therian mammals (placentals and marsupials) lost the Ednrb2 gene, 
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and at present the receptors EDNRA and EDNRB are only commonly considered in contemporary 
biomedical research221. The function of the additional ligands and receptors in other vertebrate 
species remains largely unexplored, excepting the defined role of EDN1 as a potent vasoconstrictor 
produced by the endothelial cells in many species. Global loss of Ednra is lethal owing to cardiac 
and cranial malformations227, while global loss of Ednrb is similar to global loss of Edn3 resulting 
in postnatal lethality by colonic aganglionosis with white spotting224. Overall, in understanding the 
roles for endothelin expression, knowledge of endothelin evolution may be a useful framework for 
evaluating highly conserved roles. 
In mammals, demonstrated largely via rodent studies, endothelin receptor A (EDNRA, also 
ETA, ETa) is highly expressed in vascular smooth muscle cells. There it exerts its effects through 
coupling to Gq/11 proteins and G12/13 proteins (Figure 2.6A). The Gq/11 pathway, which stimulates 
phospholipase C-beta to induce inositol (PI3) production resulting in opening of store-operated 
calcium channels and receptor-operated calcium channels (SOCCs and ROCCs), as well as the 
G12/13 pathway, which induces the Rho-kinase (ROCK) pathway and phosphorylation of myosin 
phosphatase, each result in vasoconstriction through phosphorylation of calcium-dependent 
myosin light chain kinase and phosphorylation of myosin phosphatase. Summarily, EDNRA 
induces an increase in intracellular calcium concentration that induces vasoconstriction and cell 
proliferation through store-operated and receptor operated calcium channels208. 
Endothelin receptor B (EDNRB, ETB, ETb) generally has the opposite actions of EDNRA 
and is believed to act as a mediator for endothelin ligand clearance and EDNRA attenuation by 
release of vasoconstrictors. Release of the G-protein heterotrimer by ligand binding to EDNRB 
similarly results in an increase in intracellular calcium via phospholipase C-beta (Figure 2.6B), but 
this instead activates calcium-dependent nitric oxide (NO) synthase (eNOS) and calcium-
dependent prostaglandin endoperoxide synthase (Ptgs2, also Cox-2) expression in the vasculature. 
NO acts directly as a vasodilator and PTGS2 synthesizes prostaglandins that then act as 
vasodilators. EDNRB binding and heterotrimer release further stimulate NO production via Akt (a 
serine/threonine kinase) signaling. Also, after ligand binding, EDNRB is trafficked via endocytosis 
to the endosome for degradation, thus clearing endothelin ligands from circulation208. Thus 
EDNRB acts in an opposite manner from EDNRA to cause calcium-dependent vasodilation and 
increased NO and prostaglandin synthesis. 
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Calcium-dependent signaling is important for nearly every cell and triggers a variety of 
intracellular processes depending on the tissue type. SOCC and ROCC activation in smooth 
muscle cells are each triggered by phospholipase C-beta activation via EDNRA and EDNRB to 
cause secondary inositol (IP3) signaling. IP3-mediated calcium release, either by SOCC or ROCC 
activation, occurs through specific transient receptor potential-canonical (TRPC) channels (Figure 
2.6C). In cells receiving endothelin signaling, it is known that TRPC1, TRPC3, TRPC6, and 
TRPC7 are active to induce calcium-mediated signaling; all of these studies were performed on 
smooth muscle cells or cardiomyocytes. Interestingly, TRPC1, TRPC3, and TRP6 are also 
activated by alpha-adrenergic receptors, angiotensin receptors, and purinergic receptors208. 
Together, these data imply that endothelin receptor signaling is similar to multiple other forms of 
membrane receptor signaling, and instead it is the cell type that dictates the action of endothelin 
ligand binding. This is classically seen where EDNRB clears endothelin ligand from circulation in 
endothelial cells, while EDNRA induces contraction through a similar signaling pathway. 
Therefore, to understand the role of endothelins in the ovary, and EDN2 in particular, it is 
necessary to understand the location of each receptor type. This is complicated by the lack of 
available antibodies to localize receptors in mouse models. However, immunohistochemistry using 
anti-human endothelin receptor antibodies has successfully demonstrated where in the ovary 
EDNRA and EDNRB are located14, which has also been confirmed by northern blotting and in 
situ hybridization in the rat228,229. In the human ovary, in women undergoing gonadotropin 
stimulation for IVF owing to male factors or oviduct complications, EDRNA is localized to the 
smooth muscle cells of the theca externa, the theca interna, and the granulosa cells, while EDNRB 
is confined to the theca interna14. The localization of ovarian receptor expression, and a basic 
background of the endothelin system, are useful for interpreting the results of previous 
investigations into the role of EDN2 in the ovary. 
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Previous study of endothelin-2 in ovulation 
Findings from past investigations clearly indicate that EDN2 plays a role in oocyte release, 
and may act as a direct trigger in follicle rupture6 by causing contraction of the myoid cells of the 
theca externa. This has been studied in both rodents and humans14. It is well agreed that EDN2 is 
produced by granulosa cells during ovulation, specifically from hCG11 – hCG12 hours7. EDN2 
accumulates in follicular fluid230-232 where it is in direct contact with granulosa cells, though it is 
debated if EDN2 may influence other target cells such as the theca interna, theca externa, or 
vascular tissues. The mechanism of EDN2 to enhance follicular rupture during ovulation has not 
yet been determined. Pharmacological treatment with an endothelin dual-receptor antagonist drug 
also results in fewer oocytes released when injection occurs just prior ovulation in rodent models6. 
Work by Ko et al. (2006) shows that EDN2 induces contraction in strips of ovarian tissue ex vivo. 
This phenomenon also occurs when ovarian tissues are treated ex vivo with other vasoconstrictive 
agents such as norepinephrine66, or even with depolarizing agents such as potassium chloride. 
Using drugs that are more or less specific for antagonization of one endothelin receptor, several 
studies have suggested that EDNRA is responsible for ovarian contraction. However, 
pharmacology studies are imperfect in that nearly all ‘specific’ drugs have some binding affinity 
for related receptors and can activate or block both at high concentrations. The original data by 
Palanisamy et al. (2006) oppositely suggest that EDN2 acts through EDNRB7, based on 
immunohistochemical localization of EDNRB coupled with receptor-specific antagonization 
thereof. This study by Palanisamy et al. utilized JKC-301 (10mg/kg) to inhibit EDNRA and 
BQ788 (10mg/kg) to inhibit EDNRB (n=4), and, though the study concluded that BQ788 inhibited 
ovulation, the data reveal a decrease in ovulation from either treatment when drugs were given at 
hCG6 hours.  
To determine which endothelin receptor is involved in endothelin signaling during 
ovulation, recent work by Bridges et al. (2010) examined the effect of EDNRA antagonization by 
BQ123 (10mg/kg) versus EDNRB antagonization by BQ788 (10mg/kg) in the rat ovary (n=5-7) 
and the mouse ovary (n=4-5), and instead found that neither antagonist at these concentrations, the 
same used by Palanisamy et al., or when directly injected into the ovary, had any effect on the 
number of oocytes ovulated170. However, BQ123 did significantly decrease ovarian contraction ex 
vivo. These data suggest that contraction at least occurs through EDNRA, but effect on follicle 
rupture remains inconclusive. 
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In contrast to pharmacological agent injection, a proposed ‘cleaner’ approach to studying 
ligand-receptor interaction utilizes transgenic mice which may lose a specific receptor throughout 
the whole body or in a particular tissue via the Cre/LoxP system. To overcome issues using global 
endothelin receptor knockout mice, which have lethal mutations, an EDNRB-rescued mouse line 
was created where EDNRB is only present in adrenergic cells (ovarian loss confirmed by RT-
PCR)233. These mice were reported to give birth to larger litters than normal, although the average 
litter size of 7-8 pups in the EDNRB-rescued mice is not different from the reported litter size in 
C57BL/6 mice on which they were generated. The control group in that specific 2012 study, 
surprisingly, gave birth to only an average of 5-6 pups. A low but consistent number of pups born 
to controls may indicate a confounding issue in the study, such as animal husbandry, mouse 
obesity, or poor neonatal nursing, or loss of EDNRB may indeed cause hyperfecundity. This work 
by Cho et al. (2012) did not examine the number of oocytes ovulated, but instead used the number 
and size of corpora lutea as a proxy for ovulations that had occurred. The number of corpora lutea 
(CL) were greater in rescued mice; however, ovaries were collected at 10-11 weeks of age233, and 
as CL persist for multiple rounds of ovulation, this number may instead be indicative of earlier 
onset of puberty or longer CL lifespan. The former may be particularly likely if the ‘treatment’ 
group of mice were from a different litter than controls. Data from the same author in a poster 
presentation the previous year indicate that dual endothelin receptor antagonism does prolong CL 
lifespan, though these data were never published in a peer-reviewed journal. Thus, counting CL 
may be taken as a proxy for the ability ovulate, but it should be done with caution and consideration 
to the respect of the animals’ age in the study. Overall, these data suggest that EDNRA, and not 
EDNRB (as knockout animals are normally or hyper-fertile), has a direct influence on ovulation, 
and particularly on ovarian contraction. This matches well with literature from other tissues, which 
suggest EDNRA is the primary mediator of endothelin ligand effects, while EDNRB acts to clear 
endothelins over time and has directly opposing effects to EDNRA, at least in the vasculature200,233. 
Further, this study suggests that EDN2, or its receptors, may influence the number of CL or their 
lifespan. The particular cell types involved in ovarian-EDN2 interaction remain unknown, as 
EDNRA is present in the theca cells, the granulosa cells, and the vascular smooth muscle cells14.  
The physiological actions of EDN2 in the ovary remain up for debate. Although studies 
performed ex vivo suggest EDNRA mediates contraction to cause rupture, further confirmation of 
this hypothesis is yet needed. In the hope of examining the role EDN2 on a whole-body level, a 
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global Edn2 knockout mouse (Edn2KO) was created and extensively characterized by Chang et 
al. (2013)223. This mouse was generated by inserting a neomycin cassette into exon 2 (Figure 
2.7A), the exon containing the active EDN2 protein sequence. Their work concluded that EDN2 
is necessary for thermoregulation, to prevent emphysema, and to prevent starvation; mice with the 
neomycin cassette insertion expired at 24 days of age on average223. These mice were smaller with 
smaller reproductive tracts and ovaries (Figure 2.7B,C). As normal mice respond to gonadotropins 
by 22 days of age, the effect of global EDN2 ablation on ovulation was examined using these mice 
as a loss of function model171. 
In a study by Cacioppo et al. (2014), ovaries collected from five to seven week old Edn2KO 
mice and Edn2+/- littermates (n=5) were serially sectioned and stained. All ovaries contained 
follicles of various stages, but no CL were seen in the Edn2KO ovaries171 (Figure 2.7D). Some 
Edn2KO ovaries had prominent congested blood vessels. Importantly, when Edn2KO mice were 
superovulated and oocytes were collected at hCG16 or hCG24 hours, Edn2KO mice did not 
ovulate more than one oocyte in three of four superovulation trials. This supports previous findings 
that EDN2 is necessary for oocyte release. Two Edn2KO mice did ovulate in this study, but no 
structurally identifiable CL were found in the ovaries. Instead, ovaries contained multiple large 
follicles. Some of these did not contain oocytes, and all failed to stain for P450scc, αSMA, or 
CD31171, and lacked consistent signs of angiogenesis and luteinization234-237. Lack of functional 
CL formation was further confirmed by significantly lower circulating progesterone levels in 
Edn2KO mice (5.1 ng/ml in WT vs 1.2 ng/ml). Replacement of EDN2 peptide into periovulatory 
Edn2KO ovaries was tested by giving a single injection of 20pmols of EDN2 peptide in 4uL PBS 
into one ovary of WT and Edn2KO mice at hCG11 hours. Mice were sacrificed at hCG16 hours 
(Figure 2.7E). Although no significant differences were observed, all Edn2KO ovaries (n=3) that 
received EDN2 supplementation ovulated whereas only one vehicle injected ovary did (avg 8.3 vs 
2.0, p=0.127)171. Use of injection technique was also demonstrated to decrease the number of 
oocytes ovulated in WT mice, additionally suggesting that this trend could represent restoration of 
ovulation by in vivo EDN2 injection. Overall, this study demonstrated that Edn2KO mice have 
major ovulatory defects in regard to oocyte release and CL formation.  
If findings in Edn2KO mice result from ovarian genetic defects alone and not the overall 
unhealthiness of the model, then pharmacological endothelin receptor antagonism should cause 
similar defects in CL formation in WT mice, if antagonization occurs after ovulation and before 
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CL formation is complete6. In unpublished data by Cho et al. (2012), the antagonist drug 
tezosentan was injected into 24 day old mice every two hours from hCG12 to hCG22 hours (5 
mg/kg body weight). Injections were given at 2 hour intervals to maintain the antagonism 
throughout the early phase of CL formation, as the half-life of tezosentan is about 2 hours in vivo238-
240. Mice lacking oocytes in their oviducts were determined to have not ovulated and their ovarian 
tissue was not considered in subsequent analyses. In mice that ovulated, 5/5 failed to form CL and 
instead had large follicles present. Therefore, these initial data suggest that EDN2 may play a role 
in CL formation as well as follicle rupture, though global receptor effects must be considered. 
The time of Edn2 expression coincides with both ovulation of mature follicles and the 
initial transformation process to form CL241,242. CL formation and ovulation are intimately coupled 
events, and it is rare that one occurs without the other, though this does happen in global 
progesterone receptor knockout mice after gonadotropin stimulation7,243,244. In the newly forming 
CL, an extensive capillary network serves as a supply route for oxygen and steroid hormones 
precursors, as well as a route for secreting progesterone in preparation for potential implantation 
and pregnancy maintenance83,84. Vascular endothelial growth factor (VEGF) plays a central role 
in CL angiogenesis by activating endothelial cells and causing proliferation88,8985,86. It is also well 
established that hypoxia plays a critical role in inducing VEGF in luteinizing granulosa cells90, and 
therefore in angiogenesis245. Klipper et al. (2010) recently showed that EDN2 also directly induces 
VEGF in granulosa cells of the bovine ovary246. It is noteworthy that a hypoxia inducing factor-1 
(HIF-1) binding sequence in the proximal promoter region of the Edn2 gene is involved in the 
induction of Edn2 expression under hypoxic conditions based on luciferase assay247. It is possible 
that the hypoxic effect on VEGF expression and angiogenesis, and therefore CL formation, is 
achieved by Edn2 induction via HIF-1. Multiple sources indicate HIFs as upregulating Edn2 
expression246,248-253 and being involved in CL formation90,245,246,254.  
Angiogenesis in CL formation continues after VEGF induction with MMP-mediated 
dissolution of the BM, sprouting of new vessels with proliferating endothelial cells, and eventual 
vessel anastomosis that is mediated by macrophages91. MMP-2 and MMP-9 are known to be 
significantly elevated in malignant ovarian tumors255, and at the time of ovulation and luteal 
formation MMP-2 is elevated in the rat256-259, while MMP-9 is elevated during ovulation in the 
mouse97,244. Though both MMP-2 and MMP-9 are known to be important collagenases for 
dissolution of the follicle wall, they are likely involved in CL formation as well. TIMPs are highly 
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expressed in the ovary after the LH surge92-96. In particular, TIMP-1 mRNA is upregulated 10-fold 
after the LH surge260, is released in large quantities during ovulation from the granulosa cells and 
subsequent lutein cells 97-99, and is highly produced in the growing CL97.  EDN2 may furthermore 
antagonize TIMP-1 expression as well, as excessive TIMP-1 is associated with fewer CL, zygotes, 
and follicles261,262. Importantly, Rattner et al. (2013) recently demonstrated that EDN2 in the retina 
activates endothelial cells into tip cells, which are normally present in the growing vascular 
plexus263. EDN2 acts there through EDNRA, and local elimination of EDNRB sensitizes the tissue 
to the effects EDN2. Together, it is possible that EDN2 may influence vascular formation just after 
ovulation in the CL, which has been otherwise untested. However, EDN1 is thought to act as a 
luteolytic, and given their similar receptor affinity, it would be hypothesized that EDN2 would 
have similar action264-266. Thus the potential influence of EDN2 on CL formation and vascularity 
remains an area of speculation and contention200.  
Although Edn2KO mice generated by Chang et al. have been used to analyze the role of 
EDN2 in ovulation and CL formation, poor systemic health as a confounding factor makes these 
an undesirable model, and this mouse line is no longer available. Nutritional deficiencies can 
compromise all aspects of the reproductive axis, including gonadotropin responsiveness267. Thus, 
use of a global Edn2KO mouse model alone is insufficient to explore the effects EDN2 on 
ovulation, and newer molecular and transgenic tools are required to further investigate EDN2.  
 In summary regarding EDN2 in the ovary, it has been observed and established that Edn2 
is expressed in a two hour window just prior to ovulation in the granulosa cells of Graafian follicles 
of mice and rats, and at a related time in cows and humans. Endothelin receptors, A and B, 
normally mediate EDN2 action; without EDN2, follicle rupture and CL formation are impaired. 
Dual endothelin receptor antagonization with tezosentan results in similar ovulation and CL 
formation deficits. EDNRA or EDNRB-specific antagonization has been a topic of debate, but the 
majority of pharmacological evidence suggest that EDN2 acts via EDNRA to influence ovulation. 
This is supported most strongly by examination of Ednrb-knockout mice, which demonstrate 
normal fertility and possibly increase fertility as well. EDN2 is a potent vasoconstrictive agent and 
induces ovarian contraction when administered ex vivo, though this can be attenuated by 
endothelin receptor blockade. EDN2 is thought to act as a localized inducer of contraction in the 
smooth muscle cells of the ovary to cause follicle rupture after weakening of the follicular wall. 
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Expression of Edn2 is thought to be induced by hypoxia and/or progesterone receptor, though the 
latter is also a topic of debate with a single publication in support and a second against. 
These observations raise several key questions: What is the distribution of endothelin-2 in 
the developing ovary, the mature ovary, the remainder of the reproductive system, and throughout 
the body, and do these latter data increase understanding of endothelin-2 signaling during 
ovulation? What is the specific mechanistic role of EDN2 during ovulation? Is it limited to the 
ovary, to the granulosa cells or the stroma, or does it require signaling in other organs? What is the 
effect of EDN2 loss only in the ovary? How is EDN2 related to corpus luteum formation? Does 
EDN2 have an effect on leukocyte invasion? What receptor(s) does EDN2 act through? Where are 
they located? What signaling cascade is EDN2 downstream of following the LH surge? How is 
Edn2 transcription controlled? Is EDN2 signaling necessary for ovulation in normal ovulation in 
species other than rodents? Though it is not possible to address all portions of these essential 
inquires, this work aims to generate new knowledge through the testing of disprovable hypotheses 
focused on the above questions.  
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The aims of the dissertation 
To advance understanding of the roles and mechanism of EDN2 action during ovulation, during 
corpus luteum formation, and throughout the body in general, as well as to generate novel and 
innovative transgenic mouse tools that may be widely used for the of endothelins, reproductive 
signaling, and beyond, the following aims were created and are achieved through this dissertation: 
 
Aim 1: To generate a transgenic mouse to characterize global Edn2 expression 
1a. Construct a transgenic BAC vector and screen Edn2-iCre founder mice for gene transfer 
1b. Demonstrate that Cre recombinase mimics Edn2 expression in vivo in gonadotropin-
stimulated mice 
1c. Characterize Edn2 expression in adult tissues, previously reported and novel 
1d. Characterize Edn2 expression during development in mouse embryos and pups 
 
Aim 2: To analyze conserved ovarian contraction in response to EDN2 in three domestic 
vertebrates: the cat, dog, and chicken 
2a. Determine if smooth muscle arrangement about mature follicles in the ovary is conserved 
across species 
2b. Investigate the expression patterns of all genes of the endothelin system in the ovary 
2c. Quantify and compare ovarian contraction ex vivo in response to EDN2 treatment 
2d. Determine if ovarian Edn2 expression occurs naturally during ovulation in the hen 
 
Aim 3: To determine the significance of ovarian Edn2 expression in ovulation 
3a. Generate and characterize a novel estrogen receptor beta (Esr2)-iCre knock-in mouse line 
for the successful ablation of mRNA expression within ovarian granulosa cells 
3b. Generate novel whole-ovary and granulosa cell-specific Edn2-knockout mice 
3c. Characterize ovulatory ability, CL function, and fertility relative to Edn2 expression 
3d. Quantify potential EDN2 downstream transcriptional changes during ovulation 
3e. Determine if global adrenergic activation during ovulation can restore normal oocyte 
release to an EDN2 deficient ovary  
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Aim 4: To analyze the role of EDNRA in ovarian contractile cells in ovulation 
4a. Characterize the effect of myoid cell-specific EDNRA loss on ovulation, corpus luteum 
formation, and progesterone synthesis  
4b. Determine the effect of loss of function of EDNRA on total ovarian contractility in 
response to EDN2 and an EDNRA antagonist  
4c. Quantify ovulatory capacity, corpus luteum formation, and progesterone synthesis in an 
ovary-specific deletion of Ednra from contractile cells 
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Figure 2.1. The female reproductive axis and the Graafian follicle in ovulation. A. Following follicle growth to the antral stage and the generation 
of estrogen by granulosa cells, the preovulatory rise of E2 (estradiol) of a critical threshold stimulates release of LH into the bloodstream from the 
pituitary via increased pulsatile GnRH release from the hypothalamus. Then LH triggers leukocyte release from the spleen into the bloodstream and 
subsequently into the ovary in response to cytokines and chemokines that act as leukocyte attractants. MMPs and other proteinases weaken the 
follicular wall making rupture possible; smooth muscle contraction by the ovary may also allow for follicle rupture. Following ovulation, a corpus 
luteum is formed from luteinized cells and secretes progesterone to maintain pregnancy. CL angiogenesis is dependent upon prolactin, VEGF, 
MMPs, and leukocytes. B. The Graafian follicle just prior to ovulation is composed of A) an outside theca externa layer of contractile cells, B) a 
layer of theca interna cells producing testosterone, C) a layer of avascular granulosa cells that produce estrogen and respond to progesterone receptor, 
D) antral fluid, and E) the oocyte itself surrounded by the zona pellucida. This is a cat Graafian follicle with hematoxylin and eosin staining. Image 
1A is modified with permission from Oakley et al. 201158.  
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Figure 2.2. Molecular pathways to ovulation, luteinization, and CL formation. LH induces ovulation, 
COC expansion, oocyte maturation, and luteinization in Graafian follicles. These events are mediated by 
LH activation of the PKA pathway, which induces the expression of multiple mediators such as EGF-like 
factors. These mediators in turn activate signaling cascades and specific transcription factors to affect 
ovulation and luteinization. The specific functions of multiple known mediators in ovulation and 
luteinization remain to be defined. Additionally, oocyte-derived factors affect cumulus cell and granulosa 
cell functions in a gradient-dependent manner. PGR is involved downstream of LH-R in follicle rupture. 
Other events involved in ovulation and selected associated genes are listed. This image is adapted with 
permission from a review by Dr. JoAnne S. Richards, 201067. 
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Figure 2.3. Induced mouse ovulation and smooth muscle about Graafian follicles. A. Timeline for 
gonadotropin injection to induce ovulation at 12-14 hours after hCG injection in 25 day old immature mice. 
B. A murine antral follicle prior to ovulation. C. Expansion of the ampulla after ovulation (hCG24 hours); 
oocytes are indicated by the arrow. D,E. Immunohistochemical staining for smooth muscle actin in the rat 
ovary at low and high magnification. White arrows indicate structures: SMC: Smooth muscle, BV: blood 
vessel: TCl: theca cell layer; GC: granulosa cells. Figures D and E adapted with permission from Ko et al. 
20066.  
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Figure 2.4. Edn2 mRNA expression in the rat and mouse ovary treated for superovulation. A. Edn2 mRNA expression in the rat ovary, 
granulosa cells, and residual tissues after superovulation. This graph was generated by rOGED199. The residual ovarian tissues represent mostly 
theca-interstitial cells. Error bars are difference of two independent experiments. At bottom, an RT-PCR analysis of Edn2 mRNA expression during 
the periovulatory period where Edn2 expression was evident only at hCG 12 hours and Rpl19 was used as an internal control. B. Confirmation of 
Edn2 expression in the rat ovary by the Ovarian Kaleidoscope Project198,268. C,D. Comparison of Edn2 expression to Edn1 expression in the rat and 
mouse (respectively) during and after ovulation. E. External view of rat periovulatory follicles at hCG 12 hours, in situ hybridization localization of 
Edn2 mRNA in the granulosa cells of Graafian follicles, and confirmatory Edn2 mRNA localization (blue) by brightfield microscopy. No Edn2 
mRNA expression was detected at non-periovulatory stages of follicular development7. GC, Granulosa cell layer; TIC, theca-interstitial cells; PoF, 
periovulatory follicle; SaF, small antral follicle. These data adapted and modified with permission from Ko et al. 20066.   
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Figure 2.5. Endothelins and their synthesis. A. Amino acid sequences of the three endothelin isoforms where EDN2 and EDN3 differ by 2 and 6 
amino acids, respectively, from EDN1, which are indicated by closed circles. B. Synthesis and basic regulation of endothelin-1 as a model for 
endothelins, which are produced first as a prepro form, cleaved to a pro form, then a big form, and final to a 21 amino acid active form by an 
endothelin converting enzyme (ECE). This figure is adapted and modified with permission from Horinouchi et al. 2013208.   
EDN1, ET-1 
EDN2, ET-2 
EDN3, ET-3 
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Figure 2.6. Endothelin receptor pathways, signaling mechanism, and localization. A. Stimulation of EDNRA (ETA) can increase vascular 
smooth muscle tone via a Gq/G11 protein–mediated, Ca2+- dependent activation of MLCK and via G12/13 protein–mediated, Ca2+-independent 
inhibition of myosin phosphatase (MLCP) through the Rho kinase pathway. B. EDNRB (ETB) can regulate tone by release of vasodilators, NO and 
PGI2, and via clearance of EDN2 to prevent EDN2 from excessively stimulating EDNRA expressed in vascular smooth muscle cells. C. Molecular 
mechanisms underlying G protein–coupled receptor-mediated Ca2+ mobilization. D. Localization of αSMA, EDNRA, and EDNRB protein in large 
antral follicle. Note that Ednrb expression is specific to theca interna, whereas Ednra expression is seen in the GC, theca interna and theca externa 
where αSMA staining is most intense. PLC-b, phospholipase C-b; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; PKC, protein kinase C; 
CaM, calmodulin; MLCK, myosin light chain kinase; MLC, myosin light chain; MLC-P, phosphorylated MLC; CPI-17, PKC-potentiated inhibitor 
protein of 17 kDa; CPI-17-P, phosphorylated CPI-17; MP, myosin phosphatase; MP-P, phosphorylated MP; Rho-GEF, Rho-guanine nucleotide 
exchange factor; Rho-GTP, GTPbound Rho, COX-2, cyclooxygenase-2; PGI2, prostaglandin I2 (prostacyclin); CaM, calmodulin; PI3K, 
phosphoinositide 3-kinase; eNOS, endothelial nitric oxide synthase; NO, nitric oxide, inTH, theca interna; exTH, theca externa; BL, blood vessel; 
AT, antrum. These images are reproduced with permission from Choi et al. 2011 (A,B,C) and Horinouchi et al. 2013 (D).    
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Figure 2.7. Global Edn2KO mice fail to ovulate or form corpora lutea. A. Confirmation of Edn2KO mouse genotype. B,C. Edn2KO mice are 
smaller with smaller reproductive tracts when collected after superovulation treatment. Low n-values result from the majority of mice expiring prior 
to weaning. D. Edn2KO mice fail to form corpora lutea compared to age-matched siblings, but instead have multiple antral/Graafian follicles present. 
Follicles lack P450scc and SMA staining. E. Replacement with EDN2 allows some Edn2KO mice to ovulate more oocytes and form CL that stain 
positively for P450scc. These data are reproduced with permission from Cacioppo et al. 2014171.  
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ABSTRACT 
A novel transgenic mouse line that expresses codon-improved Cre recombinase (iCre) 
under regulation of the endothelin-2 gene (Edn2) promoter was developed for the conditional 
deletion of genes in endothelin-2 lineage cells and for the spatial and temporal localization of 
endothelin-2 expression. Endothelin-2 (EDN2, ET-2, previously VIC) is a transcriptionally 
regulated 21 amino acid peptide implicated in vascular homeostasis, and more recently in female 
reproduction, gastrointestinal function, immunology, and cancer pathogenesis that acts through 
membrane receptors and G-protein signaling. A cassette (Edn2-iCre) was constructed that 
contained iCre, a polyadenylation sequence, and a neomycin selection marker in front of the 
endogenous start codon of the Edn2 gene in a mouse genome BAC clone. The cassette was 
introduced into the C57BL/6 genome by pronuclear injection, and two lines of Edn2-iCre positive 
mice were produced. The Edn2-iCre mice were bred with ROSA26-lacZ and Ai9 reporter mice to 
visualize areas of functional iCre expression. Strong expression was seen in the periovulatory 
ovary, stomach and small intestine, and colon. Uniquely, punctate expression in the corneal 
epithelium, the liver, the lung, the pituitary, the uterus, and the heart is reported. In the embryo, 
expression is localized in developing hair follicles and the dermis. Therefore, Edn2-iCre mice will 
serve as a novel line for conditional gene deletion in these tissues. 
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INTRODUCTION 
The endothelin system is made of three 21 amino acid peptides (EDN1, EDN2, EDN3), 
two receptors (EDNRA and EDNRB), and several activating peptidases including ECE-1 and 
ECE-2. The system is highly conserved throughout mammals, and within vertebrates as a whole221. 
Though EDN2 (also seen as ET-2, previously vasoactive intestinal contractor VIC) differs from 
EDN1 by two amino acids and has the same receptor affinities, and differs from EDN3 by six 
amino acids and has the same affinity to EDNRB, there now exists a substantial body of evidence 
suggesting that EDN2 acts through unique regulation and synthesis from its familial isoforms217. 
Previously, approaches using Cre/LoxP-mediated recombination have demonstrated the 
importance of EDN1, EDN3, ENDRA, and EDNRB in mice, though with phenotypes unique from 
newly generated EDN2 deficient mice. It is now apparent that EDN2 has a unique role within the 
endothelin system in female reproduction200, and there is also strong evidence that it is involved 
in gastrointestinal function223,269, immune cell function270, heart failure271, and various cancers217. 
It has been previously demonstrated that Edn2 is expressed at low levels in the cerebellum, 
cerebrum, and lung; that it is more highly expressed in the testes and stomach, and it is particularly 
highly expressed in the intestines, ovary, and uterus272,273. Embryonic expression begins by 
embryonic day 15 (e15) and persists until at least e17223,273. Global loss of Edn2 is lethal, wherein 
mice expire around three weeks of age from internal starvation, hypothermia, and emphysema223 
and also exhibit ovulatory defects171, thus demonstrating a critical functional role in the brain, 
lungs, GI tract, and ovary. Although a floxed Edn2 mouse became recently available to selectively 
ablate Edn2263, no tool has yet been available to remove genes in those cells with Edn2 expression. 
Thus the aim of this project was to generate a novel mouse model that expresses codon-improved 
Cre recombinase (iCre) driven by the natural promoter for the Edn2 gene. Two lines of Edn2-iCre 
mice were produced and the sites of functional iCre expression and, presumably, localization of 
endogenous Edn2 expression was determined using two lines of reporter mice: ROSA26-lacZ175 
and Ai9177. 
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METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Illinois Animal Care and Use Committee (Protocol: 11184), and all 
efforts were made to minimize animal suffering. Animal models generated in this study will be 
made readily available to the research community. 
 
Construction of the iCre-polyA-FRT-neo-FRT cassette  
E. coli SW105, pL253, pL451, and pICGN21 were obtained from Frederick National 
Laboratory for Cancer Research (Frederick, MD). An iCre-polyA-FRT-neo-FRT cassette was 
constructed by cloning the following DNA fragments between HindIII restriction site and AatII 
restriction site of pGEM7Zf(+) (Promega, Madison, WI): HindIII-EcoR1 fragment (1100 bp) 
containing the coding region of the codon-improved Cre recombinase (iCre) from pBluescript 
KS(+)-iCre, EcoRI-KnpI fragment (283 bp) containing SV40 late polyadenylation signal sequence 
from pCS2+MT, KpnI-SfiI fragment(1500 bp) containing FRT-neo-FRT from pICGN21 and 
Sfi1/AatII adaptor sequence (5'-CGGCCCTGATCAGTGCTAGCGACGT-3' annealed with 5'-
CGCTAGCACTGATCAGGGCCGCCT-3'). 
 
Insertion of iCre-polyA-FRT-neo-FRT cassette into the Edn2 BAC clone 
The iCre-pA-FRT-neo-FRT cassette was inserted into exon 1 of the Edn2 gene of the BAC 
clone (ID RP23-98J9) that was purchased from Invitrogen (Carlsbad, CA). Recombineering was 
performed according to protocols provided by Frederick National Laboratory for Cancer 
Research274-276. Briefly, the iCre-polyA-FRT-neo-FRT cassette was inserted in front of the ATG 
initiation codon in the BAC plasmid277. A homology arm (upstream from ATG) was amplified 
using primer pairs (5’-ACGCGTTCCTGAAGGTGTTGCAGAGAA-3’, 5’-
AAGCTTAGCAGCAGCGGCAGAGTG-3’) and cloned between the Mlu1 site and the HindIII 
site upstream of iCre-polyA-FRT-neo-FRT cassette. Another homology arm downstream from 
ATG was amplified using primer pairs (5’-GGCCGAGGCGGCCATGGTCTCCGCCTGGTGTT-
3’, 5’-GACGTCCCTTGGTGTTCAGGAACCAC-3’) and cloned the between SfiI site and the 
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AatII site after the cassette. The cassette with the two homologies was cut with MluI and AatII and 
gel purified. Approximately 15ng of the gel-purified cassette was electroporated into red-induced 
E.coli SW105 carrying the BAC clone. The recombinants were selected on LB agar plates 
supplemented with kanamycin (25 mg/ml). The selected bacterial cells were then treated with 
arabinose (0.1%) for one hour to delete FRT-neo-FRT from the BAC. The recombinant BAC 
plasmid purification, plasmid integrity test, and pronuclear microinjection were performed at the 
Transgenic Animal Model Core of University of Michigan. Fertilized eggs from C57BL/6 mice 
were microinjected with the BAC plasmid and implanted into pseudopregnant foster mothers 
(C57BL/6). Genomic DNA was extracted from the tails of 69 offspring from the pseudopregnant 
mothers. The presence of iCre was determined by PCR using the following primer pairs: Cre-F 
(5′-TCTGATGAAGTCAGGAAGAACC-3′) and Cre-R (5′-GAGATGTCCTTCACTCTGAATC-
3′)278. 
 
RT-PCR 
Of those offspring that had correct construct insertions, founder lines #9 and #12 were used 
for further evaluation for ovarian Edn2 expression. It is known Edn2 is induced during ovulation; 
thus female 28-day old pre-pubertal Edn2-iCre mice of these lines and control WT mice were 
injected in the intra-peritoneal cavity with 5 IU of pregnant mare serum gonadotropin (PMSG) at 
25 days old to induce follicle development, and then 48 h later with 5 IU of human chorionic 
gonadotropin (hCG) to induce ovulation. Mice ovulate 12-14 hours after hCG injection, and 
ovaries were collected at 0, 6, 12, 16, and 24 hours after hCG injection (n=5). Animals were 
euthanized by CO2 asphyxiation and cervical luxation, ovaries were removed, and homogenized 
in Trizol solution (Life Technologies, Grand Island, NY) for RNA extraction. RNA was purified 
with an RNeasy kit (Qiagen, Germantown, MD), and cDNA was generated using a reverse 
transcription superscript VILO synthesis kit (Invitrogen). For RT-PCR, iCre was amplified using 
the above primer set; Edn2 was amplified with (5'-CTCCTGGCTTGACAAGGAATG-3') and (5'-
GCTGTCTGTCCCGCAGTGTT-3'), and Rpl19 was amplified as a control housekeeping gene 
with (5'-CCTGAAGGTCAAAGGGAATGTG-3') and (5'-GTCTGCCTTCAGCTTGTGGAT-3'). 
PCR products were visualized on an agarose gel; band intensity was analyzed using ImageJ 
software (NIH, Bethesda, MD) for relative intensity. 
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Visualization of Transgene Expression  
Animals were bred with B6;129S4-Gt27926Sortm1Sor/J (ROSA26-lacZ) reporter mice to 
visualize Edn2-expressing tissues by X-gal staining175. Mice were euthanized by CO2 
asphyxiation; perfused intracardially with cold PBS solution and then a 4% paraformaldehyde 
(PFA) solution to assist in fixation. Tissues were then collected and washed 2 times with cold PBS; 
large and lipid-dense tissues (brain, liver, lungs, heart, stomach, kidney, tubular organs) were cut 
into sections with a scalpel to allow better fixative penetration. Tissues were placed in 4% PFA on 
ice for 1 hour. They were then washed twice with PBS and placed into individual vials with X-gal 
stain solution (Millipore, Billerica, MA), diluted 1:40 according to the manufacturer’s instructions. 
Tissues were incubated in the dark in at 4oC on a shaker for 24-48 hours, washed 3 times with 
PBS, incubated in the dark at room temperature for 1 hour with X-gal holding solution, and then 
fixed overnight in 4% PFA at 4C. Embryos were similarly fixed and stained. Gross images of 
tissues were taken of tissues following this final fixation. Tissues were then dehydrated, embedded 
in paraffin blocks, and sectioned by microtome at 5um thickness. Background staining was 
performed with nuclear fast red (Fisher Scientific, Pittsburg, PA) and images were taken with an 
Olympus BX51 microscope. The Edn2-iCre animals were also bred with B6;129S6-
Gt27926Sortm9(CAG-tdTomato)Hze/J (Ai9) reporter mice177. Gross images were taken immediately after 
euthanasia under a Zeiss SV11 fluorescent microscope. Tissues were fixed overnight, embedded, 
and serially sectioned at 5uM; one section was used for fluorescence visualization and an adjacent 
slide was stained with hematoxylin and eosin (Thermo Scientific, Kalamazoo, MI). 
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RESULTS AND DISCUSSION 
Little is known of the regulation of Edn2, both from the transcriptional and peptide 
conversion perspectives. Although Edn1 has been shown to be largely transcriptionally regulated 
through cis-acting promoter elements, and Edn2 was thought to have similar regulation, it has been 
shown previously to be regulated by transcription factors such as epidermal growth factor, TNF-
α, forskolin, HIF1-α, and pituitary gonadotropins within the reproductive system7,200. Hence a 
strategy that encompassed all potentially involved regulatory DNA regions was mandated to 
ensure correct mimicry of Edn2 expression by Cre recombinase. 
To this end, a bacterial artificial chromosome (BAC) clone that contained the entire Edn2 
gene and neighboring sequences as the vector for iCre insertion was used (Figure 3.1). A cassette 
containing iCre, a polyadenylation sequence, and a neomycin selection marker was inserted in 
front of the ATG start codon of the Edn2 gene (Figure 3.1). Following removal of the neomycin 
selection marker by FLP-mediated recombination, the entire 200Kbp vector was inserted into the 
C57BL/6 genome by pronuclear injection. Sixty-nine pups were produced, of which 12 contained 
the Edn2-iCre vector in their genome (Figure 3.1). Two of these 12 Edn2-iCre positive mice, Edn2-
iCre#9 and Edn2-iCre#12, showed no health issues or major fertility defects and were chosen for 
follow-up characterization of iCre expression. To validate that iCre expression mimics Edn2 
expression in Edn2-iCre mice, the ovaries were examined from 28 day old mice following 
gonadotropin stimulation to induce ovulation. Expression of Edn2 specifically occurs between 11 
and 12 hours after hCG injection6,7, and it was expected iCre expression would be limited to this 
time frame. Ovaries were examined at 0, 6, 12, 16, and 24 hours after hCG injection for iCre RNA 
in wild type (WT) mice and the two founder lines of transgenic mice. As expected, both founder 
lines demonstrated iCre expression only 12 hours after hCG injection concurrent with their own 
and WT Edn2 expression (Figure 3.2). The gene Rpl19, encoding murine ribosomal 60S protein 
L19, as chosen as an internal control based on previous publications280,281. From these data, it may 
be concluded that iCre expression mimics Edn2 temporally in the ovary, and that in addition to 
removing floxed genes at the times and locations of Edn2 expression, Edn2-iCre tissues can also 
be used to localize Edn2 expression sites. 
To typify expression, transgenic mice were crossed with ROSA26-lacZ reporter mice, 
which express -galactosidase under a universal promoter with a floxed stop codon175. Both 
founder lines demonstrated similar staining patterns with X-gal. Of these, Edn2-iCre#9 was further 
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characterized for localization of Edn2 expression. This line was chosen because it provided an 
average number of healthy pups per litter for C57BL/6 mice, approximately eight, while line Edn2-
iCre#12 averaged only four pups per litter. All results described below, using either reporter 
mouse, are from this single founder line; other lines were euthanized and frozen sperm was stored 
for potential restoration of the line if necessary. Of note, positive staining marks cells that are 
expressing or have expressed Edn2, or are descended from cells that have expressed Edn2. No 
phenotypes are associated with homozygosity for the transgene insertion in these animals. 
Pregnant mice were sacrificed and embryos of varying days of development were analyzed 
by X-gal staining. Positive staining was not present prior to day e12.5 (Figure 3.3), though 
placental tissue stained positively past day e8.5 including the umbilicus (data not shown). By day 
e13.5, faint positive staining was visible in the skin of the embryos; staining was present in a 
punctate pattern throughout the skin by day e15.5, and was readily apparent in the sinusoid hair 
follicles of the rostrum (whiskers). This skin staining consistently was present in the outer layer of 
cells of the developing dermis. Staining was also present on the surface of the digits of fore and 
hind limbs, the dorsum, and the tail. By day e17.5 near parturition, staining had expanded 
throughout the skin of the ventrum and was consistently present in the skin surrounding areas of 
the eye, mouth, and ear openings, and between digits (Figure 3.3). Staining eventually expands 
throughout the entirety of the skin by puberty. It is interesting to note early staining presence in 
those areas that must undergo early keratinization for function in neonates282, though these areas 
coincide with those of hair follicle development. This timing of expression is consistent with 
earlier findings that concluded EDN2 is important for normal embryonic development283,284. 
Twenty-eight day old healthy mice were sacrificed and individual organs previously 
implicated to be involved in EDN2 signaling were stained with X-gal to localize Edn2 expression. 
In the majority of the organs examined, staining revealed a punctate pattern (Figure 3.4). Brains 
demonstrated intense staining around the olfactory bulb, although individual neurons stained 
positively throughout the cerebrum and cerebellum (cerebellum histology pictured). Heart staining 
revealed that the majority of the epicardium expressed Edn2, though only a few scattered 
cardiomyocytes and endothelial cells stained positively in a seemingly random arrangement, 
complimenting previous findings285,286. A similar stippled pattern was visualized in the lung 
throughout the pneumocytes of the parenchyma and the respiratory epithelium. In the kidney, 
staining was present in only some renal corpuscles and tubules, although staining was limited to 
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the cortex and not present in the medulla. However, cells expressing iCre in the kidney may 
become more prevalent during renal stress or disease287,288. Interestingly, the entirety of the 
epidermis stained positively, as well as the cells surrounding the hair follicles and the inner root 
sheath of the follicles themselves. Beyond hair follicles289, this is a novel area of EDN2 expression, 
and presents a potential unique application for future gene removal. In the gastrointestinal tract, 
cross-sectional staining was limited to individual villi or to individual tubular glands, and was also 
present in patches on the exterior surface, which may be a reflection of the enteric nervous system 
as endothelins are known to be involved in neural crest cell migration290. Ovarian staining was 
highly prevalent, present throughout the organ stroma, capsule, and small follicles, in addition to 
large follicles and corpora lutea as previously reported6,7. Punctate staining was present in the 
epithelium of the oviduct, while individual myofibers of uterine myometrium stained to create a 
stippled appearance. 
X-gal staining may occur as a false positive in adult tissues through endogenous beta-
galactosidase activity176,291, and may additionally create ‘edge-effect’ artifact staining on any 
tissue. Although the majority of tissues of interest showed little or no negative staining in mice 
lacking the Edn2-iCre mutation, false positive staining was present in the gross view of the kidney, 
GI tract, portions of the uterus, and exterior of the skin (Figure 3.5) though little staining was 
present histologically. Additional false positive staining was present in the bone, adrenal, tarsal 
gland, and liver tissue (not pictured), though decreasing incubation temperature significantly 
reduced gross background x-gal staining. Similarly, control embryos showed no x-gal staining at 
any age except for slight edge-effect staining of the skin which does also not appear histologically 
(Figure 3.5). 
To verify the sites observed as positive for X-gal staining and to identify other novel sites 
of Edn2 expression, Edn2-iCre mice were crossed with Ai9 reporter mice that produce red 
fluorescent protein in cells with functional iCre expression. Tissues from 28 day old males and 
females were visualized grossly under fluorescent light during dissection, and histological images 
were compared with H&E staining (Figure 3.6). Of interest, fluorescence was seen in the anterior 
and intermediate pituitary, the cornea and photocells of the eye, the detrusor muscle of the bladder, 
the male coagulation gland (anterior prostate), and the interstitium of the testes. The majority of 
expression appears in a punctate manner, excluding the epidermis, ovary, testicular interstitium, 
and coagulation gland. These areas are potential key areas for the utilization of the Edn2-iCre 
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transgenic mouse outside of localization of Edn2 expression and removal of potential downstream 
endothelin target genes. Eye expression is particularly interesting, given recent work by Rattner et 
al. showing that EDN2 can override VEGF signaling to inhibit retinal angiogenesis263. Expression 
of Edn2 may act in the cornea and retina continually to inhibit angiogenesis, whereas loss of Edn2 
could eventually lead to vascularization and visual impairment. A summary of fluorescence 
observed grossly and histologically is listed in Table 3.1. No fluorescence was observed in control 
tissues.  
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TABLES 
Table 3.1. Summary of Edn2-iCre expression in multiple adult organs. Expression 
determined by localization of red fluorescence after crossing with an Ai9 reporter mouse line. 
WT tissues were used as controls (no fluorescence observed). Table continued on multiple pages. 
Tissue 
Relative 
Fluorescence 
Notes 
Relevant 
Previous 
Literature 
Adrenal +++ 
Punctate fluorescence throughout adrenal cortex; 
little to none in medulla 
292 
Aorta + 
Very limited punctate fluorescence in tunica media 
in smooth muscle cells 
12,293-295 
Bladder + 
Punctate fluorescence in smooth muscle cells of 
detrusor muscle, not in epithelium 
- 
Blood (circulating) - 
No fluorescence seen (in all RBC and WBCs 
observed) 
250,270 
Bone (femur) - No fluorescence seen in osteocytes or bone marrow 296 
Brain + 
Mild fluorescence throughout cortex and cerebellum, 
extremely limited, 1-2 / 100 neurons. More intense 
in hypothalamus and optic chiasm. Greatest 
fluorescence in olfactory bulb. 
297,298 
Coagulation gland 
(anterior prostate) 
+++ Fluorescence seen in all secretory cells 
- 
Colon +++ 
Punctate fluorescence throughout mucosa; cells of 
mucosa will either all fluoresce or not within one 
tubular gland (all or none expression by gland); not 
present in submucosa or muscularis; punctate pattern 
seen in mesothelial cells of serosa. 
223,299,300 
Duodenum +++ 
Fluorescence in groups of epithelial cells of 
individual villi with punctate expression of some 
submucosal glands; punctate serosal fluorescence 
present. 
223,269,301 
Epididymis ± 
0-1 cells/100 of epithelial cells in lumen of 
epididymis 
- 
Esophagus - No fluorescence visualized - 
Eye + 
Punctate / striped fluorescence in most outer cellular 
layer of corneal epithelium; fluorescence in 
photocell layer with fluorescence extending through 
all retinal layers in striped pattern in limited areas of 
retina approx. 0-1 per section, fluorescence in tarsal 
gland, no fluorescence in lens or iris 
263,302,303 
Heart + 
Punctate fluorescence in cardiomyocytes (2-5/100) 
and the majority of epicardial cells 
284-286,304,305 
Ileum +++ 
Fluorescence seen in villi similar to duodenum - 
punctate in groups of cells and often near crypts, 
fluorescence in individual cells within peyer's 
patches (1-2/100), fluorescence in serosa cell layer in 
patches 
223,306,307 
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Table 3.1. Continued from previous page. 
Jejunum +++ 
Punctate fluorescence seen in villi and serosa similar 
to duodenum, ileum; may not extend entire villi if 
fluorescence seen in crypt 
223 
Kidney + 
Limited punctate fluorescence in a few individual 
cells of corpuscle or proximal tubules, entirely 
limited to cortex 
308-310 
Liver + 
Punctate fluorescence seen in parenchyma, limited to 
cells appearing stellate 
311 
Lung + 
Moderate punctate fluorescence in respiratory 
epithelium; limited in alveoli/pneumocytes (0-1/100) 
223,284,312 
Mouth /  
oral cavity 
+ 
No fluorescence in teeth, present on entirety of 
gingival surface 
- 
Nerve  
(thoracic vagus) 
- No fluorescence visualized 
313 
Ovary +++ 
Fluorescence seen encompassing all of ovarian 
capsule, majority of cells of stroma, corpora lutea, 
and granulosa cells; not seen in oocytes 
6,7,171,246,284 
Oviduct +++ 
Punctate fluorescence pattern in epithelium; more 
prevalent fluorescence in epithelium of isthmus 
314,315 
Pancreas + 
Seemingly random punctate fluorescence throughout 
parenchyma, 2-5 cells/100 
- 
Penis + 
Seen in all cells of transitional epithelium of urethra 
and in the skin surrounding the prepuce 
- 
Pituitary + 
Punctate pattern throughout anterior and 
intermediate pituitary; not present in posterior 
pituitary 
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Preputial gland +++ 
Fluorescence seen in the majority of acini in both 
basal and secretory cells 
- 
Rostrum + 
Visible in epidermis, in inner  layer of dermal root 
sheath of large sinusoid hair follicles 
- 
Salivary gland + 
Punctate pattern present through some cells of acini; 
more prevalent in mucous than serous glands 
316,317 
Seminal vesicle - No fluorescence visualized - 
Skeletal muscle - No fluorescence visualized - 
Skin +++ 
Visible throughout epidermis, extending into hair 
follicles 
289,318 
Testes + 
Interstitial cells, potentially including Leydig cells; 
not seen within seminiferous tubules 
319 
Uterus + 
Seen in some smooth muscle cells of the 
myometrium throughout the uterus in a banded 
pattern (Figure 3.4) 
320,321 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Transgenic vector construct and screening of Edn2-iCre transgenic mouse. A. Schematic diagram of a part of chromosome 4 and 
the Edn2-iCre BAC transgenic vector. Edn2 and its neighboring genes are shown. Exons are shown in blue boxes. Positions of PCR primers for 
screening transgenic mice are indicated by horizontal black arrows.  The cassette containing the coding region of iCre, SV40 late polyadenylation 
signal, and frt-neo-frt cassette was inserted in front of ATG of Edn2 by homologous recombination. The frt-neo-frt cassette was then deleted by Flp 
recombinase. B. Screening of transgenic mice carrying the transgene iCre (a representative gel image). The transgene was inserted into the mouse 
genome by pronuclear injection to C57B/6 blastocysts. Lanes 1-8: founder mouse template genomic DNA (gDNA) from one litter; Lane 9: iCre 
sequence positive control; Lane 10: WT gDNA negative control; Lane 11: No template DNA negative control; Lane 12: 100bp ladder (Invitrogen).
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Figure 3.2. Temporal mRNA expression of Edn2 and iCre in the Edn2-iCre mouse ovary. Twenty-five day old Edn2-iCre9 and Edn2-iCre12 
mice were injected with PMSG/hCG for superovulation induction. Ovaries were collected at the indicated hours (h) after hCG injection, and mRNA 
expression levels were measured by semi-quantitative RT-PCR. Shown is a representative image of n=5 mice of each genotype.  Note the temporal 
expression pattern of Edn2 and iCre mRNA. Rpl19 was used as internal control. Bar graph indicates quantification at 12 hours after hCG 
administration and was normalized to Rpl19. No significant differences were present between groups for Edn2 expression.
Edn2 
Edn2/Rpl19 
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Figure 3.3. X-Gal characterization of Edn2-iCre embryos. A. X-Gal staining detects iCre expression 
and successful recombination in whole mount embryos of Edn2-iCre mice crossed with ROSA26-lacZ 
reporter mice. Faint positive staining is consistently observed as early as e12.5 in the skin of the ventrum. 
It becomes noticeable throughout much of skin in a fragmented pattern by day e15.5. B. Higher 
magnification of dissecting scope images of Edn2-iCre fetuses at approximately embryonic day e15.5 after 
X-Gal staining. Images show a) rostrum, b) dorsal skin and tail, c) whole-mount histological staining 1.25x, 
and d) magnified histological staining of skin of embryo 40x. Staining of sinus follicles of rostrum is visible 
by day e15.5, while wide-spread staining of ventrum begins one to two days later. By day 17.5, staining is 
also visible at opening of mouth, eyes, and ears, and between digits. Closed arrowheads: sinus hair follicles; 
open arrows: staining in developing dermis/epidermis. 
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Figure 3.4. Localization of functional iCre expression in adult Edn2-iCre mouse organs. X-Gal staining detects iCre expression and successful 
recombination in whole organs of Edn2-iCre mice crossed with ROSA26-lacZ reporter mice that have previously been shown to produce EDN2 
peptide. Gross images are shown at left and histology images with nuclear fast red background staining are at right. Kidney tissue was bisected, 
ovary was punctured, and heart and colon were flushed prior to staining. The oviduct is visible in the bottom portion of the gross ovarian image. 
Symbol labeling is as follows: Brain: open arrowhead: olfactory bulb; open arrow: molecular layer; closed arrow: granule cell layer; solid arrowhead: 
purkinje cell layer. Heart: open arrowhead: epicardium; closed arrowhead: cardiomyocyte. Lung: solid arrow: pneumocytes of alveoli; open arrow: 
respiratory epithelium of bronchiole. Kidney: open chevron: cortex; closed chevron: medulla; closed arrowhead: renal corpuscle; open arrowhead: 
tubules of cortex. Skin: solid arrow: epidermis; open arrow: bulge stem cells; closed chevron: dermis. Colon: open arrowhead: muscularis interna; 
closed arrowhead: goblet cells of longitudinal mucosal fold. Ovary: closed arrowhead: oviduct; open arrowhead: oocyte of secondary follicle; open 
arrow: secondary follicle granulosa cells; closed arrow: theca cell layer and stromal cells. Uterus: solid arrowhead: endometrium; open arrowhead: 
uterine glands; open arrow: smooth muscle cells of myometrium. 
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Figure 3.5. Visualization of false positive x-gal staining in embryos and adult tissues. X-Gal staining detects false-positive beta-galactosidase 
activity or edge-effect staining in A,B. whole embryos or C. whole organs of control mice crossed with ROSA26-lacZ reporter mice. For embryos 
in A., higher magnification of dissecting scope images of Edn2-iCre fetuses at approximately embryonic day 15.5 are shown in B. Images show a) 
rostrum, b) dorsal skin, c) whole-mount histological staining 1.25x, and d) magnified histological staining of skin of embryo 40x. For adult tissues 
C., gross images are shown at left and histology images with nuclear fast red background staining are at right. Brain, heart, and kidney tissue were 
bisected, ovary was punctured, and colon was flushed prior to staining. The oviduct and uterus are visible in the gross ovarian image. Note the light 
staining on the edges of the embryos, the brain, lung, and uterus. Additionally, there is staining throughout the cortex of the kidney and visible 
histological staining on the hair from the skin section and in the lumen of the colon. 
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Figure 3.6. Localization of iCre expression by red fluorescence in adult Edn2-iCre mouse organs. Edn2-iCre mice were crossed with Ai9 
reporter mice for rapid visualization. Fluorescence intensity at low magnification (row 2) correlates with the number of Edn2-iCre-expressing cells. 
Red fluorescence indicates areas of cell lineage expression of iCre (row 4). Top rows: gross images and fluorescence comparison. Bottom rows: 
histological images and fluorescence comparison. A-D: pituitary (female, PND28); E-F: Eye; G-H: Cornea of eye; I-L: Bladder (detrusor muscle); 
M-N: Gastrointestinal tract; O-P: Jejunum; Q-R: Male reproductive organs; S-T: Seminiferous tubules; U-V: Female reproductive organs; W-X: 
Ovary. Symbols are used to mark specific organs or cell types. Image A, B, C, D: solid arrow: anterior pituitary (adenohypophesis); open arrow: 
posterior pituitary (neurohypophysis). Image G, H: Solid arrowhead: corneal epithelium (anterior epithelium, outside of eye). Image K,L: solid 
arrow: smooth muscle cells of detrusor muscle (3 layers); open arrow: transitional epithelium of bladder facing lumen. Image M,N: Solid arrow: 
small intestines; open arrow: liver; solid arrowhead: large intestines. Image O,P: Solid arrow head: luminal epithelium of jejunum. Image Q, R: solid 
arrow: seminal vesicle; open arrow: ductus (vas) deferens; solid arrowhead: coagulation gland (anterior prostate); open arrowhead: testis; solid 
chevron: epididymis; open chevron: bladder. Image S, T: solid arrow: interstitial cells of testes. Image U, V: Solid arrowhead: ovary; open arrowhead: 
oviduct; open chevron: uterus. Image W, X: Solid arrowhead: secondary follicle; solid arrow: antral follicle.
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ABSTRACT 
The peptide endothelin-2 (EDN2) is transiently produced in the granulosa cells of rodent 
and human periovulatory ovaries immediately prior to ovulation. Ex vivo experiments showed that, 
upon treatment of EDN2, the rodent ovary rapidly contracts, while when the endothelin receptor 
pathway is antagonized in vivo, ovulation is inhibited. Human and rodent ovaries possess a layer 
of contractile smooth muscle-like cells in the theca externa of developing follicles. In addition, 
ovaries have been documented to spontaneously contract ex vivo.  However, the significance of 
this contraction and its relevance to the role of EDN2 in regulation of ovulation remain to be 
determined. Here the effect of EDN2 on the characteristics of contraction in feline, canine, and 
chicken ovaries was investigated. Immunohistochemical staining for smooth muscle actin was 
present in the theca layer of feline and chicken follicles as well as the vessels, but only in the 
arteries and arterioles of canine ovaries. RT-PCR showed that both mammalian ovaries express 
mRNA for Edn1, Edn2, Edn3, both isotypes of endothelin receptors (Ednra and Ednrb), and 
endothelin converting enzymes 1 and 2 (Ece-1 and Ece-2), though chickens only express Ednrb in 
F1 and F2 follicles. Feline ovaries exhibited a period of strong and sustained contraction when 
treated with 50 nM EDN2. When treated with the dual endothelin receptor antagonist tezosentan, 
contraction was reduced in a dose-dependent manner. A similar contractile in response to EDN2 
was observed in the theca layer of chicken periovulatory follicles. However, canine ovaries 
demonstrated a significantly lower contractile response to EDN2 (0.11±0.07mN) than feline 
ovaries (2.48±0.40mN) or the chicken theca layer (2.04±0.85mN, p=0.038). Taken together, this 
study demonstrates that EDN2 produces a strong contraction in the ovaries of two novel species 
and that this contraction can be localized to the theca layer of the chicken follicle. 
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INTRODUCTION 
The protein endothelin-2 (EDN2, product of the gene Edn2) is expressed in the mouse, rat, 
bovine, and human ovaries near or at the time of ovulation following stimulation with injectable 
gonadotropins6,7,12,217,246. Expression is limited to granulosa cells in rodent and bovine ovaries. 
EDN2 is part of the endothelin system, which in therian mammals consists of three ligands, 
endothelin-1, -2, and -3 (Edn1, Edn2, Edn3); two receptors, endothelin receptor A (Ednra) and 
endothelin receptor B (Ednrb), and two enzymes, endothelin converting enzyme-1 and -2 (Ece-1, 
Ece-2)218,221. Endothelins are produced in a prepro-form, are cleaved by converting enzymes upon 
exiting the secreting cell, and bind to their membrane-bound GPCRs. In birds, reptiles, 
amphibians, and other descendants of lobefinned fish, the endothelin receptor B2 (Ednrb2) is also 
present221. In all vertebrates, the endothelin system is highly conserved, though there are some 
differences in ligand and receptor number221,322.  
Pharmacological inhibition of endothelin receptors during ovulation has been shown to 
decrease ovulatory capacity6,170,171,314; this is believed to occur through inhibition of a contractile 
mechanism through EDNRA, as endothelins are well characterized to induce smooth muscle 
contraction. Exposure to EDN2 induces contraction in rodent ovaries ex vivo, while exposure to a 
dual-receptor antagonist drug decreases the contractile response, as measured on a custom analog 
myograph system6. It has been previously proposed that EDN2 induces contraction of the smooth 
muscle of the theca externa layer323, which surrounds mature follicles, at the time of ovulation as 
a final trigger for follicular expulsion6. As fertility drops sharply when endothelin signaling is 
blocked, study of the endothelin system may generate useful targets to improve assisted 
reproductive technologies or to act as novel nonhormonal contraceptives324,325.  
Considering the highly conserved sequence of EDN2 (Figure 4.1) and previous 
observations of periovulatory expression in humans and several model species, it is hypothesized 
that EDN2, or antagonists of its receptors, causes a similar contractile response in multiple 
vertebrate species’ ovaries. The aims of this study were to 1) use a myograph system as a novel, 
commercially available digital tool for the study of ovarian contraction, frequency, and amplitude, 
and 2) to demonstrate that the ovaries of multiple new species express components of the 
endothelin system and respond in a similar manner to exposure to EDN2 peptide ex vivo. A DMT 
myograph system (DMT-USA, Ann Arbor, MI) was chosen as a commercially available digital 
machine that was highly sensitive (mN range) and took frequent readings at least 10x/ second, 
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could be modified to either pin or tie tissue to the arm of the transducer, and allowed for 
temperature, oxygen, and pH maintenance to keep tissues alive for multiple hours326-329. To 
accomplish our second aim, domestic cat ovaries which were readily available from local 
ovariohysterectomy procedures were first examined. Reproductive tissues from domestic dogs and 
chickens that were similarly available were then used for comparison. 
 Ovulatory regulation and timing varies by considerable degrees between these three 
species. Each experiences the growth of an oocyte and its surrounding cells into a large follicle 
prior to ovulation through pituitary gonadotropin stimulation330. However the timing of this event 
varies by the animal’s lifestyle and survival strategy. Cats are seasonal polyestrous breeders, while 
dogs are generally considered to be seasonal monoestrous breeders. Though each species is 
dependent upon photostimulation for estrous cyclicity, nonferal individuals with access to indoor 
lighting generally cycle year-round74. The average queen cycle transverses a 2 day proestrus, a 
highly variable 6 day estrus, a return to proestrus if no mating occurs or a potential 2-3 week inter-
estrus period, a 7 week pseudopregnancy if nonfertile ovulation occurs, and a possible 2-3 month 
anestrus period134. The average dog cycle moves between a 9 day proestrus, a 9 day estrus, a 2 
month diestrus with a pseudopregnancy, and a 5 month anestrus, though there is considerable breed 
and individual variation, as well as other environmental factors such as nutrition and male 
presence331. Both queens and bitches can ovulate multiple mature follicles in one cycle.  
Alternatively, the laying hen (as opposed to broiler strains) ovideposits a single egg nearly 
each day at a 24 hour interval. Unlike cats and dogs, the hen ovary contains a hierarchy of growing 
follicles that gradually progress towards maturity, with less atresia occurring151. The hen also 
possesses only a functional left ovary upon reaching maturity. The mature follicles of all three 
species, though quite variable in size, each possess common granulosa and theca steroidogenic 
layers. The contractile potential of the cat ovary and chicken follicle have been previously 
characterized, and each is known to possess smooth muscle in the theca externa 
layer144,154,161,332,333. Dogs, like cats and hens, are known to possess cholinergic nerves in the ovary, 
but no data presently exists on smooth muscle presence or contractility. The theca layers of all 
three species also contain small arterioles that are encircled by smooth muscle, which invade the 
granulosa cells during ovulation and luteinization. Though female tract contractions are known to 
be important for fertility, the majority of previous studies have focused on the uterus and sperm 
transport. Here it was hypothesized that EDN2 causes significant ovarian or follicular contractions 
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in multiple species, and that these tissues express some or all of the components of the Endothelin 
system. This was tested by localizing the smooth muscle within each tissue, by performing RT-
PCR for endothelin genes, and by treating feline ovaries, canine ovaries, and chicken theca cells 
with EDN2 and endothelin receptor antagonists and quantifying their tensile response.  
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MATERIALS AND METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Illinois Animal Care and Use Committee (Protocols: 12164 and 
14205), and all efforts were made to minimize animal suffering. 
 
Animals 
Feline reproductive tissues were collected following routine spay procedures from October 
2012 to May 2013 at the University of Illinois at Urbana-Champaign College of Veterinary 
Medicine through the junior surgery program for student training. Cats ranged in age from 8 
months to 3 years old and in weight from 2.1 – 3.1 kg; ages were estimated by dental health when 
no date of birth was available. Following a physical exam, healthy cats were pre-medicated with 
dexmedetomidine 0.008mg/kg, ketamine 5mg/kg, and morphine 0.1mg/kg by IV injection about 
30 minutes prior to spay surgery. At the start of surgery, anesthetic induction was performed by 
IV propofol 4mg/kg and maintained by inhaled isoflurane 1% for the duration of surgery. After 
the abdominal cavity was opened and reproductive tract exteriorized, both ovarian arteries anterior 
to the ovaries and the uterine body posterior to its bifurcation were ligated, cut by scalpel, and the 
entire tract was removed from the body and transported out of the surgical suite. Canine tissues 
were collected in the same manner as feline tissues from the junior surgery program, though dogs 
received atropine (0.04mg/kg) instead of ketamine. Dog weights ranged from 5.8-19.7kg, and age 
estimates ranged from 12 weeks to 2 years. Chicken ovaries were collected immediately following 
humane euthanasia from the Animal Sciences Department at the University of Illinois at Urbana-
Champaign. All chickens were layers of 10-14 months of age and average weight of 1.50kg, and 
had a history of laying eggs reliably for at least three days. Chickens were sacrificed one hour 
before the estimated time of ovulation as observed the previous day, which was based on time of 
oviposition. Theca and granulosa cell layers were isolated as previously described by Gilbert et al. 
1977334. 
 
 
67 
Histology and Immunohistochemistry 
Feline, canine, and chicken ovaries were fixed for 48 hours in a 4% paraformaldehyde 
solution following removal. Tissues were then embedded in paraffin and sectioned at 7 μm, 
mounted on charged glass slides, deparaffinized, and rehydrated. Tissues were then either stained 
with hematoxylin (Harris) and eosin (Surgipath) for cellular visualization, or were processed for 
immunohistochemistry to localize contractile cells. Antigen retrieval was done with X1 Citrate 
Buffer pH 6.0 for 60 minutes in a vegetable steamer, rinsed under deionized water for 5 minutes, 
loaded onto a Shandon-Sequenza system (Thermo Scientific, Kalamazoo, MI), and washed with 
PBS to remove bubbles. Tissues were then blocked with 5% rabbit serum for 30 minutes, treated 
with the primary polyclonal antibody rabbit anti-mouse smooth muscle actin (SMA), Abcam 
ab5694, or Dako (Carpintera, CA) negative control rabbit immunoglobulin fraction (15g/L 
normalized in PBST to the SMA concentrate), washed twice with PBST, treated with fresh Avidin 
Biotin complex solution for 20 minutes at room temperature, washed twice with PBS, and 
incubated with Nova Red for 2 min at room temperature, prior to hematoxylin counterstaining. 
Murine ovaries, bladder, and uteri were concurrently stained as positive controls (data not shown). 
 
Gene Expression 
To assessment whether or not the genes in the endothelin system of the cat were being 
transcribed within the ovary, five ovaries (estrous stage unknown) from five cats ranging in age 
from 8 months to three years were analyzed by semi-quantitative PCR. Whole ovaries were 
removed at the time of spay and frozen immediately in liquid nitrogen. They were stored in a -80 
freezer until analysis. Whole ovaries were ground by mortar and pestle; RNA was extracted by 
Trizol® solution (Ambion, Carlsbad, CA), washed twice with ethanol, and then purified with a 
Qiagen RNA-Easy Kit (Valencia, CA). RNA was analyzed by a Nanodrop machine (Thermo 
Scientific) for quantity and quality. Complementary DNA was then generated by M-MLV Reverse 
Transcriptase using random primers. Template RNA quantities were normalized to 1.0μg/μL prior 
to reverse transcription. 1.0μL of resulting cDNA from each ovary was used as template with 15μL 
Taq Platinum (Invitrogen) and 0.3μL of each primer per PCR reaction for a total reaction volume 
of 16.6μL; reactions were cycled 30x for 94C for 1:00 min, 59C for 1:00, and 72C for 1:30. 
Amplified DNA (3.0 μL) was visualized on a 2.0% agarose gel and was quantified using ImageJ 
freeware (NIH, Bethesda, MD) to measure peak pixel grayscale levels within the defined areas of 
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the bands. Preliminary PCR reactions were used to optimize the cycle number; Rpl19 (L19), which 
encodes a portion of the cytoplasmic ribosomal protein 60S subunit, was used an internal control 
housekeeping gene. This was repeated for canine ovarian samples from five dogs age estimated 
16 weeks to 2 years, unstaged. For chickens, RT-PCR was performed on F1 follicles one hour 
prior to the time of ovulation as above and compared to RNA extraction from F2 follicles from 6 
birds. F1 follicles were collected at one hour prior to the time of ovulation, which was estimated 
through repeated observations of oviposition for four consecutive days. Primer sequences are listed 
in Table 4.1.  
 
Ovary Mounting 
Ovaries used for tension analysis were placed into a 4°C physiological saline solution 
(PSS) in the surgical suite and transported to the laboratory, where a wire myograph system (Tissue 
Bath System 620M, Danish Myo Technology, DMT-USA Inc., Ann Arbor, MI) was located. Half-
ovaries were used for removal of large ovarian vessels, and pin mounting was chosen to minimize 
tissue damage and increase mounting speed. Sectioning was done with a scalpel on the axis 
perpendicular to the hilus, on the axis that runs the length of the kidney-bean shape of the ovary 
(Figure 4.2). The half ovary that did not contain the hilus region was then placed into fresh 6mL 
of 4C PSS in the test chamber of the myograph and was punctured on each end by one of the 4mm 
mounting pins on each arm of the myograph. The myograph was then turned on, to gradually heat 
the PSS to 38.5°C while also slowly bubbling a mixture of 50% oxygen, 45% nitrogen, and 5% 
carbon dioxide through the chamber. Meanwhile, fresh PSS and a 60mM K+ in PSS (K+PSS) were 
placed into a water bath to also reach a physiological temperature. Two ovaries were processed at 
the same time for each set of experiments. Ovarian tensile measurements were recorded via 
LabChart software (ADInstruments, Colorado Springs, CO). After about 20 minutes when the test 
chamber containing the ovary had reached the appropriate temperature, the PSS solution was 
removed and fresh, warm PSS buffer was added. The system was then zeroed.  
Tension was next applied to the half ovary over the following 20 minutes to a tension of 
3mN. The knob controlling pin width was lightly turned at approximately one minute intervals to 
maintain 3mN of tension as the tissue was stretched. Optimal tension-contraction response in feline 
ovaries occurred with ~3mN of passive tension applied per half ovary. Lastly, a ‘wake-up’ protocol 
was used to finish the equilibration: K+PSS was applied to the stretched ovary, and was removed 
69 
3 minutes later. The ovary was then washed 4 times over 5 minutes with PSS, and allowed to sit 
for 5 more minutes. This procedure was repeated twice. The PSS was then replaced a final time 
and the contractile experiment began. Canine ovaries were mounted similar to feline ovaries with 
bisection to exclude the ovarian pole. Chicken theca layers were also mounted similarly, though a 
passive tension of 1mN was used instead of three; reported contraction values were not modified 
to account for this. Pins were passed through each end of the strip of the theca cells. 
 Pilot studies in mice indicate that ovaries remain alive and responsive in this system for up 
to eight hours; ovaries are largely similar to in vivo ovaries, with similar expression of genes at 
the time of ovulation after gonadotropin stimulation (data not shown). However, follicle rupture 
and ovulation itself is inhibited, likely by lack of blood flow through ovaries. 
 
Ovarian Tensile Analysis 
To determine if feline ovaries contract in response to EDN2 agonization, ovaries were first 
allowed to sit in fresh PSS at a physiological temperature and pH with supplied oxygen and CO2 
for five minutes to generate a baseline tensile measurement, the average tension in mN during this 
treatment. For ovaries that demonstrated cyclical contractions during this period, baseline 
measurements were averages of the trough tension for five troughs between peaks. Next, K+PSS 
solution was applied a 3rd time for a duration of 5 minutes. This served as a reference point for the 
relative contractility of that ovary to account for variation in mounting, ovary size, and ovary 
health. Any ovary that failed to demonstrate contraction in response to K+PSS was discarded. 
K+PSS was then removed with four PSS washes at 1 min intervals, and the ovary was allowed to 
equilibrate for 5 additional minutes.  
Next, recombinant human endothelin-2 purified peptide (American Peptide Co, Sunnyvale, 
CA) was added to the PSS solution of the chamber to generate a 50nM solution. After 20 min, 
without changing the buffer solution or removing the ligand, the dual-endothelin receptor 
antagonist drug tezosentan was added to a concentration of 140nM and left for 20 minutes. These 
concentrations were calculated from preliminary titration experiments. Tensile measurements 
represent the difference from resting measurement (the average of 5 minutes prior to the final 
K+PSS addition) to either average K+ contraction (the average of minutes 2:00-5:00 after the 
K+PSS addition at 0:00) or average EDN2 contraction (the average of the 5 minutes prior to 
tezosentan administration for EDN2-induced contraction). The average of the final 5 minutes of 
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the experiment was subtracted from peak EDN2-induced tension to calculate the change after 
tezosentan addition (recorded as a positive, not a negative, number). All measurements were made 
in mN, and were later converted to arbitrary units (AU) for relative comparison by dividing each 
by the contractile response to K+PSS for that ovary. Titrations of EDN2 or tezosentan to determine 
minimum concentrations for optimum effect were made as above, except varying doses of each 
were added in 20 minute intervals without washing away previous buffer solution to those ovaries. 
Canine and chicken tension analyses were performed similarly. 
 
Statistical Analysis 
 Data analyses were performed using statistical software (SPSS, Inc., released 2009, PASW 
Statistics for Windows, Version 18.0, Chicago, IL). All normally distributed continuous data were 
analyzed with parametric tests (student’s t-test and ANOVA) and a Bonferroni post hoc test for 
variance between groups. All non-normally distributed continuous data, solely the data for 
absolute K+PSS induced tension in mN, were transformed by log function to a normal distribution. 
Ordinal data were analyzed with nonparametric tests (Mann-Whitney and Kruskal Wallis). 
Normally distributed data are presented as mean and standard error of the mean, whereas non-
normally distributed data are presented as median and range. For all analyses the alpha value was 
set to 0.05. 
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RESULTS 
 
Cat and hen ovaries possess smooth muscle encircling mature follicles in the theca externa 
It has been previously documented that the ovaries of cats possess a large amount of smooth 
muscle tissue, which is comparable to that of the human ovary. Using immunohistochemistry to 
localize smooth muscle actin, it was demonstrated and confirmed that the follicles of feline ovary 
possess a layer of smooth muscle around them after reaching the antral stage (Figure 4.3). The 
majority of feline ovaries possess follicles of all stages, including primordial, primary, secondary, 
antral, and Grafiaan. The theca externa layer contains the smooth muscle actin-expressing cells 
and continues around the circumference, approximately 3-5 cells thick, of mature follicles. 
Additional staining is seen in vasculature throughout the ovary. Similar smooth muscle localization 
around peri-ovulatory follicles was likewise observed in the chicken ovary (Figure 4.3). However, 
canine ovaries did not demonstrate positive staining in the theca externa layer, only in the vessels 
of the ovary. This is a unique and surprising finding given the smooth muscle network that is 
present about follicles in mice, rats, humans, cats, and chickens.  
 
Feline, canine, and chicken ovaries express components of the endothelin system 
Total RNA was extracted from the ovaries of cats (n=5), dogs (n=7), and the F1 and F2 
follicles of chickens (n=6); RNA was purified, complimentary DNA was generated using reverse 
transcription, and semi-quantitative PCR was performed to determine if ovaries express the 
components of the endothelin system at various points in the cycle. Canine and feline ovaries 
demonstrated expression for Edn1, Edn2, Ednra, Ednrb, Ece-1, and Ece-2 (Figure 4.4). Only feline 
ovaries, not canine ovaries or chicken follicles, expressed detectable amounts of Edn3. Chicken 
follicles, F1 and F2, expressed only Ednrb. There was no difference in gene expression between 
chicken follicles of different ages. Expression of all three ligands and Ednrb were low in feline 
ovaries, and expression of Edn2 and Ece-2 were low in canine ovaries. It should be noted that 
differences in expression level cannot be compared between genes owing to different primer 
binding affinities and amplicon lengths, nor are these representative of a mature follicle but of an 
average unstaged ovary as a whole, excepting the chicken periovulatory F1 follicle when compared 
to the developing F2 follicle.  
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Ovaries respond strongly to a 50nM EDN2 solution 
A passive tension was applied to each ovary relative to the starting mounting tension. To 
determine what concentration of EDN2 causes ovaries to contract, a set of titration experiments 
was performed in which, following the K+PSS wake-up protocol, increasing doses of EDN2 were 
added in 20 minute intervals to ovaries. An increase in tension in response to EDN2 treatment 
reached a maximum response between the concentrations of 5 and 50 nM EDN2 in the K+PSS 
solution (Figure 4.5). 50nM was chosen as the minimal concentration of EDN2 to induce sustained 
contraction in ovaries in further studies. In a similar manner, after adding 50nM EDN2 to the PSS 
solution, tezosentan was added in a stepwise manner. 14.0-140nM tezosentan was the range of 
minimal concentration that maximally decreased contraction caused by EDN2 ligand (Figure 4.5). 
 
Feline ovaries contract in response to EDN2 
To measure the average contractile response to 50nM of EDN2, feline half-ovaries received 
wake-up protocol, were dosed with K+PSS to provide a comparable baseline tension measurement 
change, and then received 50nM EDN2, followed by 140nM tezosentan to determine if tensile 
change was specifically occurring through endothelin receptors (Figure 4.6). The average absolute 
changes in tension in the feline ovary were as follows: K+PSS: 0.80±0.17mN, EDN2: 
2.48±0.40mN, and tezosentan: -1.68±0.26mN. Relative changes in tension, normalized to K+PSS 
where the change from K+PSS = 1.00, were EDN2: 3.65±0.44AU and tezosentan -2.72±0.50AU 
(Figure 4.7). Spontaneous contraction was observed in 30.7% feline ovaries after mounting and 
passive tension were applied. Relative to the baseline tension of these ovaries, recorded as the 
average trough amplitude between contractions, these ovaries spontaneously contracted with 
amplitude of 4.08 ± 2.45mN, duration of 22.2 ± 6.4sec, and a time of 60.9 ± 20.2sec between 
contractions. These contractions continued after EDN2 treatment, but contraction amplitude was 
reduced (1.25 ± 0.95mN) as was the time between contractions (13.8 ± 6.5sec) for all ovaries. The 
duration between contractions after EDN2 treatment was not significantly different (20.13 ± 
4.66sec, p=0.240).  
 
Canine ovaries and chicken follicular theca layers contract in response to EDN2 
To measure average contractile responses to the same dose of EDN2 peptide, the same 
60mM K+PSS, 50nM EDN2, and 140nM tezosentan application regimen was used on canine half-
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ovaries and the theca layer of F1 chicken follicles (Figure 4.6). In canines, the average absolute 
tensile changes were: K+PSS: 0.26±0.10mN, EDN2: 0.11±0.07mN, and tezosentan -
0.08±0.04mN. Relative changes in tension, normalized K+PSS, were: EDN2: 2.83±1.30AU, 
tezosentan: -0.52±0.44 (Figure 4.7). Chicken theca cells, though comparatively smaller than 
canine or feline ovaries, demonstrated marked tensile response to the tested stimuli. The average 
chicken absolute tensile changes were K+PSS: 0.73±0.42mN, EDN2: 2.04±0.85mN, and 
tezosentan: -0.67±0.10mN. After normalization to K+PSS, the relative contractile response to 
EDN2 was 3.70±1.23AU and to tezosentan was -1.64±0.76AU (Figure 4.7). 
 
Feline ovaries and chicken theca layers respond similarly to EDN2 and tezosentan 
When comparisons were made between the average absolute and relative tensile changes 
between species, several significant differences were noted (Table 4.2). There was a significant 
difference between the absolute response to EDN2 peptide between cats and dogs (p=0.002), but 
not between cats and chickens (p=1.000) or dogs and chickens (p=0.081). This may be accounted 
for by the low number of chickens used. Similarly, there was a significant difference in the absolute 
response to tezosentan between cats and dogs (p<0.001), but not between cats and chickens 
(p=0.127) or dogs and chickens (p=0.743). There was a significant difference in the relative 
response to tezosentan between cats and dogs (p=0.024), but not between cats and chickens 
(p=0.905) or between dogs and chickens (p=0.970). No significant differences were observed in 
the average absolute tensile responses to K+PSS treatment (p=0.067) or the relative response to 
EDN2 peptide (p=0.747). P-values close to 0.05 indicate trends towards significant differences 
that are likely masked by the small sample sizes used here, particularly of the low n-value for 
chicken follicles tested.  
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DISCUSSION 
The data presented here demonstrate the presence of smooth muscle-expressing cells 
around the large and peri-ovulatory follicles of ovaries in the cat and chicken but not the dog, the 
expression and functionality of the components of the endothelin system in those ovaries, and the 
novel use of a DMT myograph system to record and compare contraction between those tissues 
when exposed to the peptide EDN2 were demonstrated. To the best of the authors’ knowledge, 
this is also the first quantitation of contraction in a canine ovary. EDN2 concentrations used here 
are similar to estimations of antral fluid endothelin concentrations based on previous studies in 
rats and humans14,335,336. Though of a lesser degree in the canine ovary, potentially owing to lesser 
smooth muscle content333, contraction was demonstrated in all three species, and specifically in 
the theca layer of chicken follicles. The chicken follicle does not demonstrate a similar rise in Edn2 
expression one hour prior to oviposition as has been previously observed in mouse, rat, and human 
ovaries after gonadotropin stimulation6,7,14. Similar study in cats and dogs remains challenging 
owing to seasonal monoestrus in the canine and highly variable timing in response to 
gonadotropins in each species140,337-342. Previous comparison of the contractile potential in cats at 
different stages of the estrous cycle found little difference161, though spontaneous contractions 
were also observed throughout various points of the cycle343. It is also noted in our data that when 
adding tezosentan after EDN2 ligand treatment, no ovary completely returned to baseline tension 
during the time of the experiment, likely owing to prior ligand binding. When tezosentan was 
added before EDN2 ligands in pilot studies, no contractile response was observed in response to 
EDN2, as is expected when adding a competitive antagonist drug. 
Contraction in the ovary at the time of ovulation remains a controversial issue, and has 
been well discussed in previous review by L.L. Espey (1978)66. Although it has been suggested 
that this is a final trigger for the expulsion of a follicle6 from the organ following collagenase 
digestion of the surface epithelium and basement membrane112,344, specifically by EDN2200, it has 
also been shown that there is not a vast increase in ovarian follicular fluid pressure during 
ovulation100,101,345, though there may be increased ovarian contraction frequency at the time of 
ovulation, as seen previously in rabbits given hCG stimulation167. Contractions of the theca wall 
have also been previously observed in chicken follicles, and hypothesized to promote stigma 
rupture332. Thus it is possible that EDN2 of near-ovulatory and ruptured follicles contributes to 
increased ovarian tone and, by shortening muscle cell length, increases the frequency of ovarian 
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contractions, as was trended towards by the spontaneously contracting cat ovaries when receiving 
EDN2 stimulation. Indeed, contractions of the female reproductive tract have been shown to be 
essential for normal fertility, while secretions from the male reproductive organs can modify and 
generally enhance this motion, though previous studies have largely focused on the uterus and 
sperm transport346-349. 
 The widespread expression of the endothelin system is not surprising, particularly the 
receptors and converting enzymes. Endothelin receptors are known to be expressed in a variety of 
tissues, and immunohistochemistry has previously demonstrated their presence in multiple 
components of the ovary14. Furthermore, the constitutive expression of Edn1, which consequently 
mandates the expression of each converting enzyme, has been well defined within endothelial cells 
as well as leukocytes, myofibroblasts, and neuronal stromal cells, which are abundant in the 
ovary350. Endothelin-3 has also been demonstrated to have constitutive expression in the brain, GI 
and reproductive tracts, lung, spleen, and kidney. Similarly, Uchide et al.273,284 have previously 
demonstrated that all three ligand isoforms and each mammalian receptor are expressed in similar 
levels in the murine ovary, though Edn1 and Edn3 possess a broader distribution while Edn2 is 
more limited. The presence of an amplification product and the variability of its individual 
intensity are of interest within our study. Particularly, Edn2 appears to be consistently expressed 
in these naturally cycling cat and dog ovaries, unlike previous observations in rodents and humans. 
It is unlikely that, if Edn2 has only a 2 hour window of expression as in the mouse ovulation model, 
significant expression would be seen in all ovaries collected, as was observed. The gene Edn1, 
which is believed to constitutively expressed at low levels across mammals, has very little variation 
between feline ovaries. Thus expression of endothelin components in the ovaries of these species 
substantiates that receptor expression is conserved among mammals, at least at a low level, though 
not in birds. Potential inductive factors beyond hypoxia6 remain a topic of future exploration.  
The observed differences between species are likely due to the poor response of canine 
ovaries to any K+PSS or EDN2 treatment. Lack of significant difference between absolute K+PSS 
response by ANOVA may be attributed to type II error from the low n-values. Indeed, the average 
dog ovary exhibited little response to EDN2 peptide and had little response to tezosentan 
consequently, despite being larger than feline ovaries and much more massive than the theca layer 
of chicken follicles. Oppositely, the chicken ovary appeared to have a similar contraction in 
response to EDN2 as feline ovaries, though relatively much smaller in mass. This may suggest that 
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EDN2 acts to cause contraction in only ovaries that may be preparing or prepared to ovulate, or 
that endothelin receptors require estrogenic priming prior to contractile signaling. However, as 
relatively few canine ovaries and chicken follicles were examined, differences not observed may 
be due to a type II error, and it is instead possible that chicken, canine, and feline ovaries all 
respond uniquely to EDN2, as the relatively constitutive expression of EDN2 in feline ovaries 
would suggest. It must also be noted that contractile differences between cats, dogs, and chickens 
are also dependent upon the amount of blood vessels present, which have been shown to 
consistently contract in response to EDN2. Though a chicken theca layer possesses some blood 
vessels154,351, these are unlikely to be capable of the magnitude of contractile response possible by 
branches of the ovarian artery in large canine and feline ovaries. It is most parsimonious to state 
that feline ovaries and chicken theca layers contract in an apparently similar manner in response 
to EDN2 peptide, whereas canine ovaries demonstrate little absolute response to EDN2, and the 
cause of these differences is likely attributed to a lack of SMA about the mature canine follicles, 
as well as fewer follicles. This may also relate to the relative long anestrus in the reproductive 
cycle of the bitch and infrequent, singular ovulations. 
In conclusion, endothelin-2 may play a critical role for successful reproduction across a 
variety of mammalian species in addition to humans and rodents. EDN2 may function as a final 
trigger for follicular rupture in ovulation, and/or may act to increase ovarian tone and increase the 
frequency of ovarian contractions during ovulation. Future work with the endothelin system in 
feline and canine tissues is merited both as models for human reproduction and in respect to 
individual animal groups, given the need for feral animal population control352, the need to 
improve breeding in endangered species353, and the need for improved sterilization techniques for 
household pets354. Studies may focus on these species as models of ovulation given the readily 
available tissues and ease of physiological measurements in contrasts to mouse ovaries, the effects 
of novel oral endothelin antagonists such as macitentan324 on ovulation in both species, and further 
work on the genetics of ovulation in the chicken model given the ease of tissue layer separation, 
relative RNA availability, and recent advances in transgenic avian production355.  
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TABLES 
 
Table 4.1. Primers used for RT-PCR. Continued on multiple pages. 
Species Gene Primer Name Sequence 5'-3' 
Amplicon size 
(base pairs) 
Feline Edn1 
FelisET1_F TCT TGG GCG CAG AGC TCA GCA C 
162 
FelisET1_R GGA GTG TTG ACC CAG ATG ATG TCC A 
Feline Edn2 
FelisET2_F CAA GGG CCA GGT GGC TGC TG 
155 
FelisET2_R CGG GAG TGT TCA CCC AGA TGA TGT C 
Feline Edn3 
FelisET3_F GGG GAA ATT TAA GGT GGT GAA 
112 
FelisET3_R TCC GGG TGA TAG GTA CTC CTT 
Feline Ednra 
FelisETA_F TAC CAA GAT GTG AAA GAC TGG TGG CTC 
148 
FelisETA_R GTT TAA GGT GTT CAC TGA GGG CAA TTC 
Feline Ednrb 
FelisETB_F CTT GCC GAG GAC TGG CCC TTT G 
101 
FelisETB_R CTT AGA GCA CAT AGA CTC AAC ACA G 
Feline Ece-1 
FelisECE1_F CGC CCC CAG TGT GCC TAA GTG A  
205 
FelisECE1_R AGG TGC TTG ATG ATG GCT TGG TTG TG 
Feline Ece-2 
FelisECE2_F TGT GGG AAC AGT GCC CTG AGC T 
279 
FelisECE2_R ACT CAG CAC CTG GTC CAC AGT G 
Feline Rpl19 
FelisL19_F GCT CAG GCT TCA GAA GAG GCT TGC 
100 
FelisL19R GTT GGC ATT GGC GAT TTC ATT TGT CTC 
Canine Edn1 
K9_ET1_F GGT CCT GGG TGC GGA GCT CA 
167 
K9_ET1_R CAG GAG TGT TGA CCC AGA TGA TGT C 
Canine Edn2 
K9_ET2_F AAG GGC CAG GTG GCC GCT G 
154 
K9_ET2_R CGG GAG TGT TCA CCC AGA TGA TG 
Canine Edn3 
K9_ET3_F ATT GGT ACC TTG CCC CCA GCC T 
284 
K9_ET3_R GAG TGT TGA TCC AGA TGA TGT CCA 
Canine Ednra 
K9_ETA_F CAG AGC AGT TGC CTC CTG GAG T 
194 
K9_ETA_R CAT GAA TTT TGA TGT GGC ATT GAG CAT 
Canine Ednrb 
K9_ETB_F ATC GAG CCG TTG CCT CTT GGA GT 
201 
K9_ETB_R GCA TGA AGG CTG TTT TCT GGG TAG GA 
Canine Ece-1 
K9_ECE1_F ACC CCC CCA GTG TGC CTA AGT G 
209 
K9_ECE1_R AGG AGG TGC TTG ATG ATG GCC TG 
Canine Ece-2 
K9_ECE2_F CAT CCC ACA ACA CCT GCC TCA CA 
211 
K9_ECE2_R AGC AGG TGC TTC AGT ATG GCC TG 
Canine Rpl19 
K9_L19_F GCA GAT ACG AAA ACT GAT CAA AGA TGG 
112 
K9_L19_R CAT ATG CCT GCC CTT CCG GCG 
Chicken Edn1 
Gallus_ET1_F CTC CTG TTC GTC GCT GCT GGA C 
162 
Gallus_ET1_R CTG GCT CCA GCA AGC ATC TCT G 
Chicken Edn2 
Gallus_ET2_F GAC CAA GCG GTG CTC CTG CAA C 
140 
Gallus_ET2_R GCG ATC TCT TGC GCC GTC GT 
Chicken Edn3 
Gallus_ET3_F CTT CCC AGC CTT CAT TTC GGT GC 
243 
Gallus_ET3_R GTT CAC GTG CCC TCA GAA TGG C 
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Table 4.1. Continued from previous page: 
Chicken Ednra 
Gallus_ETA_F GAA TGG CCC GAA TGC ACT GAT AGC 
184 
Gallus_ETA_R GAC TGT GAT TCC CAC TGA TGC CTT C 
Chicken Ednrb 
Gallus_ETB_F ACA GGG TAC CGA GCA GTT GCT TCT 
110 
Gallus_ETB_R CTT CAG GAA CAG CCA ATA CCA CCG 
Chicken Ednrb2 
Gallus_ETB2_F CTG GGA CCA AGA CCT GTG GGT G 
89 
Gallus_ETB2_R GCC ACC AGT CCT TCA CAT CAC GAT A 
Chicken Ece-1 
Gallus_ECE1_F TGC TGG GGC TCG TCC TGC AGT A 
141 
Gallus_ECE1_R CGC AGG CAT AGC TGA AGA AGT CC TC 
Chicken Ece-2 
Gallus_ECE2_F CTG ACT ACA AGC ATG CCA CAC TGC A 
251 
Gallus_ECE2_R ACC CCA GCA TGG CGG TCT CCT A 
Chicken Rpl19 
Gallus_L19_F TCG GGC ACG ATG CAG GAA GAA CA 
142 
Gallus_L19_R CTG AGA ATC CGC ATC CTC CTC ATC 
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Table 4.2. Relative differences in ovarian contraction between species. 
 n-value Abs K+PSS Abs EDN2 Abs tezo Rel K+PSS Rel EDN2 Rel tezo 
  (mN) (mN) (mN) (AU) (AU) (AU) 
Feline 13 0.80±0.17 2.48±0.40 -1.68±0.26 1.00 3.65±0.44 -2.72±0.50 
Canine 7 0.26±0.10 0.11±0.07 -0.08±0.04 1.00 2.83±1.30 -0.52±0.44 
Chicken 3 0.73±0.42 2.04±0.85 -0.67±0.10 1.00 3.70±1.23 -1.64±0.76 
ANOVA p= 0.067 0.002* <0.001*  0.747 0.027* 
 
Abbreviations used: Abs = Absolute, Rel = Relative, tezo = tezosentan, mN=milliNewtons, 
AU=Arbitrary Units  
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EDN2 Peptide Sequence Comparison: 
Human (Homo sapiens):  CSCSSWLDKECVYFCHLDIIW 
Cat (Felis catus):  CSCSSWLDKECVYFCHLDIIW 
Dog (Canis lupus familiaris): CSCSSWLDKECVYFCHLDIIW 
Chicken (Gallus gallus): CSC SWLDKEC YFCHLDIIW 
Mouse (Mus musculus): CSC SWLDKECVYFCHLDIIW  
Zebrafish (Danio rerio): CSCSSWLD EC YFCHLDIIW 
 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Comparison of the biologically active portion of the EDN2 peptide sequence among 
vertebrates. Differences from the human sequence are highlighted in red. Data were obtained from the 
National Center for Biotechnology Information, US National Library of Medicine.  
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Figure 4.2. Measurement of ovarian contraction. A. Diagrammatic sectioning of a cat ovary for placement onto two 4mm pins of the DMT 
myograph system, which is composed of two chambers with a force transducer to sense tissue tension, a heated base to optimize tissue temperature, 
and gas and vacuum lines to supply tissues with oxygen and remove solutions. Electrical signals are sent to an amplifier and then to the LabChart™ 
software on a connected computer. B. Image of a bisected feline ovary after mounting. C. The DMT myograph system and adjoining LabChart™ 
Software output with timer. 
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Figure 4.3. Alpha-smooth muscle actin is present around the feline and chicken follicle. Images are shown at 4X (left) and 20X magnification 
(right). A-D feline tissue; E-H canine tissue; I-L chicken tissue. There is staining of myoid cells of the theca externa layer around large follicles in 
the feline and chicken ovary, and consistent intense staining of the large vessels throughout all ovaries. Contractile theca externa cells are not present 
around immature follicles. The theca externa is approximately 3-5 cells thick in mature follicles in all three species. No anti-SMA staining is seen 
in the granulosa cells of follicles. Positive staining is also seen in the vessels within corpora lutea in felines and canines (not pictured). Tissues are 
sectioned at 5uM. 
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Figure 4.4. Ovaries express ligands, receptors, and enzymes of the endothelin system. A,B. Semiquantitative PCR of cDNA generated from 
RNA extracted from whole feline ovaries (grayscale units, n=5). PCR gel images were analyzed by ImageJ software for relative intensity; all 
amplicons for a single gene were run and imaged at the same time to reduce variation. C,D. Semiquantitative PCR using RNA from whole canine 
ovaries (n=7). E,F. Semiquantitative PCR comparing RNA from chicken F1 and F2 follicular cells (n=6). Expression of Edn2 is absent in both F1 
and F2 follicles.
Edn1    Edn2     Edn3   Ednra   Ednrb  Ece-1   Ece-2   Rpl19 
Edn1    Edn2     Edn3   Ednra   Ednrb  Ece-1   Ece-2   Rpl19 
Edn1    Edn2     Edn3     Ednra   Ednrb   Ednrb2   Ece-1   Ece-2    Rpl19 
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Figure 4.5. Ovaries respond to various doses of EDN2 and endothelin antagonists. A. A representative feline ovary demonstrates continuous 
peaks for rhythmic spontaneous contraction as increasing doses of EDN2 peptide are applied at 20 minute intervals. Contraction frequency decreases 
after reaching a solution concentration of 5.00 nM EDN2. A sustained contraction is present after achieving 50nM EDN2. A 5-10 minute time lapse 
occurs between dosing with 50nM EDN2 and ovarian contraction in response. B. A representative feline ovary, after stimulation with 50nM EDN2, 
decreases in contractile tension in response to increasing doses of an endothelin receptor antagonist drug, tezosentan. After reaching 1.40nM 
tezosentan, spontaneous contractions of low amplitude and high frequency return to the ovary, and increase in amplitude as the dose of the 
competitive antagonist drug increase. Following washing away of all ligand and antagonist (4 washes), spontaneous contractions return to normal 
frequency. Vertical axis: tension in millinewtons where 9.81mN = 1.00gram-force. Horizontal axis: Time (Hours:Minutes:Seconds). 
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Figure 4.6. Ovaries contract in response to EDN2 peptide and relax during receptor antagonization. 
A. a representative feline ovary response to a 60mM K+PSS solution (for normalization), a 50nM EDN2 
solution, and a 140nM tezosentan solution. This ovary demonstrates spontaneous contractions, which are 
not present during K+PSS exposure. This treatment schema was similarly used to measure responses in B. 
canine and C. chicken ovaries. Vertical axis: tension in millinewtons where 9.81mN = 1.00gram-force. 
Horizontal axis: Time (Hours:Minutes:Seconds). 
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Figure 4.7. Feline, canine, and chicken ovaries respond similarly to EDN2 and tezosentan. Comparison between species of absolute (left) and 
relative (right) responses to endothelin receptor agonization and subsequent antagonization. Ovarian contraction was normalized to the response to 
K+PSS to compare relative contractile responses. Significant differences (p<0.05) are noted. 
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CHAPTER 5: GENERATION OF AN ESTROGEN RECEPTOR 
BETA-ICRE KNOCK-IN MOUSE 
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ABSTRACT 
A novel knock-in mouse that expresses codon-improved Cre recombinase (iCre) under 
regulation of the estrogen receptor beta (Esr2) promoter was developed for conditional deletion of 
genes in estrogen receptor beta (ESR2, also ER[b], ERbeta, Estrb, ERβ, NR3A2) expressing cells 
and for the spatial and/or temporal localization of Esr2 expression. ESR2 is one of two main 
estrogen nuclear receptors that alters a wide variety of gene signaling pathways, and is important 
for maintaining normal fertility in females. It is also implicated in a variety pathologies affecting 
ranging from immunologic function to memory to cardiovascular health. A cassette was 
constructed that contained iCre, a polyadenylation sequence, and a neomycin selection marker. It 
was inserted in front of the endogenous start codon of the Esr2 gene in a mouse genome BAC 
clone and then transferred by homologous recombination to a C57BL/6J embryonic stem (ES) cell 
line. ES cells were verified and then used to generate females by blastocyst injection. Resulting 
Esr2-iCre mice were bred with ROSA26-lacZ and Ai9 reporter mice to visualize areas of 
functional iCre expression. Strong expression, observed as color/fluorescence after reporter 
crossing, was seen throughout the ovary, the posterior pituitary, the interstitium of the testes, the 
head and tail but not body of the epididymis, skeletal muscle, the coagulation gland (anterior 
prostate), acini of the salivary gland, acini of the pancreas, the lung, and the prepucial gland. 
Additional diffuse or patchy expression was observed in the cerebrum, the hypothalamus, the 
heart, the adrenal gland, the colon, the bladder, and the pads of the paws. To confirm effect of 
ovarian gene ablation, Esr2-iCre mice were crossed with progesterone receptor floxed (Pgr-flox) 
mice. These mice demonstrated significant loss of Pgr expression in the ovary, loss of PGR protein 
staining in the granulosa cells, anovulation, complete loss of fertility, and continued normal estrous 
cycling. Therefore, Esr2-iCre mice will serve as a novel line for conditional gene deletion in Esr2-
expressing tissues, for generating homozygous Esr2-knock out mice, and for differentiating the 
downstream functions of ESR2 and ESR1.  Specifically, Esr2-iCre mice may be used to remove 
Edn2 in ovary and determine the effect on ovulation in a more efficient manner than other available 
granulosa cell-specific Cre mouse lines, as is further discussed in Chapter 6. 
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INTRODUCTION 
 Estrogens, and estradiol (E2) in particular, are a group of one of the most important steroid 
hormones in the human body with a plethora of actions and functions in nearly all organs. 
Estrogens act primarily through their two cognate receptors, estrogen receptors alpha and beta. 
Estrogen receptor beta (ESR2, also ER[b], ERbeta, Estrb, ERβ) is a classic nuclear receptor356 with 
widespread expression throughout the body. It has also been demonstrated and confirmed that 
ESR2 can act as a membrane receptor as well357,358. The mRNA for Esr2 has been found at high 
levels in the ovary, prostate, and hypothalamus with expression also seen in the testis, uterus, 
bladder, and lung359-361. ESR2 also plays a prominent role in many cancer sites, including the 
breast, bladder, and ovary362,363. Additionally, ESR2 has been found to play a critical role 
specifically within the granulosa cells of the ovary for successful ovulation364. Mice that lack ESR2 
give birth to fewer and smaller litters365 that are the result of aberrant expression of over 300 genes 
in the granulosa cells366. These mice also develop bladder and prostate hyperplasia in old age, 
though future work on the exact pathways underlying ESR2 signaling remains. Current available 
mouse models include one commercially available (Jackson Laboratories, Bar Harbor, ME) global 
Esr2 knockout (KO) that was generated by neomycin cassette insertion365 and one mouse line with 
a floxed 3rd exon of Esr2366. However, no models exist for conditional deletion of genes either 
downstream of ESR2 or localized to Esr2-expressing cells. Therefore, this study aimed to create a 
novel knock-in mouse that expresses codon-improved Cre recombinase (iCre) under the Esr2 
promotor for conditional gene deletion and localization of global Esr2 expression. It was 
hypothesized that this mouse would serve as an excellent model for gene ablation specifically 
within the granulosa cells of the ovary, and that it would have increased effect relative to previous 
granulosa cell-specific Cre lines 188,367. In order to visualize localization of Esr2 expression, Esr2-
iCre mice were crossed with two lines of reporter mice: ROSA26-lacZ175 and Ai9 mice177. 
Additionally, the Esr2-iCre mice were used to generate homozygous ESR2 knockout mice. Due to 
the function of ESR2 within the granulosa cells of the ovary, this knock-in model can be utilized 
for removing genes specifically in granulosa cells and for marking sites of Esr2 expression. It is 
an important and useful new tool within the field of reproductive biology.  
 The choice to develop this model was made following other attempts to remove Edn2 in 
the granulosa cells of the ovary using Edn2-Floxed mice (described in the following the chapter). 
Results with Cyp19-iCre and Pgr-Cre mice did not display total loss of Edn2 mRNA by RT-PCR. 
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Thus it was postulated that Esr2-iCre mice could instead be used for ablation of Edn2 expression, 
which would in turn cause an impaired reproductive phenotype. The details and outcome of this 
specific hypothesis is discussed later, and the current chapter will instead first characterize Esr2-
iCre mice and their potential ability to remove genes within the ovarian granulosa cells. An 
understanding of locality of Esr2-iCre recombinase activity is critical for data presented in the 
following chapter, particularly in comparison to Edn2 localization as described in Chapter 3.   
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METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Illinois Animal Care and Use Committee (Protocols: 11205 and 
14222), and all efforts were made to minimize animal suffering. Animal models generated in this 
study will be made readily available to the research community. 
 
Targeting Vector Construction 
 An iCre-polyA-FRT-neo-FRT cassette (3266 bp) was generated similar to previous 
transgenic study from a pBluescript KS(+)-iCre plasmid368 and was modified for insertion into the 
mouse Esr2 gene. The cassette was inserted before the translational initiation codon of the Esr2 
gene of a BAC clone (ID RP23-342B14) that was purchased from Invitrogen (Carlsbad, CA) by 
recombineering according to protocols provided by Frederick National Laboratory for Cancer 
Research274-276. Briefly, a homology arm (upstream from ATG at exon 2) was amplified using 
primer pairs (5’-CGTCGACAAGGCCTCTCGAGCCTC-3’, 5’-
CGAATTCGAATTAAAAAACCTCCCACACCTC-3’) and cloned between the EcoR1 site and 
the Sal1 site upstream of the cassette. Another homology arm downstream from ATG was 
amplified using primer pairs (5’-AGGATCCGGAATAGTAACTTCTCCATGGTAG-3’, 5’-
CGCGGCCGCGATGTGCTGCAAGGCGATTAAG-3’) and cloned the between BamH1 site and 
the Not1 site after the cassette. The cassette with the two homologies was cut with EcoR1 and 
Not1, gel purified, introduced into E. coli SW106 (heat-induced) carrying the BAC for insertion. 
Engineered BAC clones were selected on LB plate supplemented with kanamycin (25 mg/liter). 
The engineered Esr2 gene was retrieved in a pL253 targeting vector. Briefly, an upstream 
homology arm (Not1/HindIII fragment) which was amplified with primer pairs (5’-
GACGCGTAGACTGCATCTCTGTAGTCCAA-3’ and 5’-
GAAGCTTGATGCTCTCAGAGACTCACG-3’) and a downstream homology arm 
(HindIII/Spe1 fragment) which was amplified with the primer pairs (5’-
AGGCCGAGGCGGCCATGTCCATCTGTGCCTCCTCT-3’ and 5’-
AGACGTCAACACTGTAGTTCATCACAGCAG-3’) were cloned between Not1 site and Spe1 
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site of pL253.  The resulting plasmid was linearized by HindIII digestion and introduced into E. 
coli SW106 (heat-induced) carrying the engineered BAC. Retrieved clones were selected on LB 
medium supplemented with ampicillin (50 mg/liter). The targeting vector was linearized by Cla1 
digestion and used for ES cell targeting. 
 
Gene Targeting 
The cassette was then inserted into the genome of embryonic stem cells (ES cells) at the 
University of Illinois at Urbana-Champaign Biotechnology Center. C57BL/6N-PRX-B6N #1 
mouse black ES cells were purchased from Jackson Laboratory (Bar Harbor, Maine) and 
maintained in media according to the suppliers instructions. ES cells received cassette DNA 
through electroporation and homologous recombination at 75% confluence, and were then grown 
in selection media with G418 (200ug/ml). ES cell DNA was extracted and sent to the Murine 
Genetic Analysis Laboratory at the University of California Davis. Quantitative PCR, long range 
PCR, karyotyping, and viral screening were performed on 96 cell lines to ensure insertion of a 
single copy in the correct orientation without defect. Long range PCR was performed on the 5’ 
end with primers (5’-TGAGATCTAGGTTCAGAAGGAGAAGG-3’ and 5’-
GGTGCACAGTCAGCAGGTTGGAG-3’) to produce a 3352bp band, and on the 3’ end with 
primers (5’-CTGTCCTTGATCCCTTCTCTGTGC-3’ and 5’-
CGCATCGCCTTCTATCGCCTTC-3’) to produce a 3506 bp band. Six ES cell clones were 
identified as successful for insertion. Cells of one of these lines (#030) were expanded and used 
for blastocyst injection at the University of Illinois to generate black and white chimeric mice. 
 
Animals Used 
Eight chimeric mice containing the Esr2-iCre construct that were at least 50% black in 
color were produced from surrogate mothers. Five female chimeras were bred with albino WT 
C57B/6J male mice. The genotype of their offspring was determined by PCR of ear tissue using 
primers iCre-F (5′-TCTGATGAAGTCAGGAAGAACC-3′) and iCre-R (5′-
GAGATGTCCTTCACTCTGAATC-3′)278 to detect iCre presence. The three-primer set 5’-
CAGGTGCTGTTGGATGGTCTTC-3’, 5’-CTTAGTTACTCCGGCAGCTTGAAC-3’, and 
5’AGGGGAAGTAAGGCTTGATGGTGA-3’ was later used to determine if mice were hetero- or 
homozygous for Esr2-iCre. The 3rd female chimera gave birth to a litter of normal size with eight 
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pups, of which four pups were black in color and all four were positive for the iCre gene. Given 
its normal fecundity and successful gene transmission, this mouse line was chosen for removal of 
the neomycin targeting cassette and subsequent breeding with reporter lines. These mice were first 
bred with B6N.Cg-Tg(ACTFLPe)9205Dym/CjDswJ (FLP) mice (Jackson Laboratory) to remove 
neomycin, and then backcrossed with WT mice to remove the FLP gene369. FLP presence was 
determined with the primers 5’-AACGGAACAGCAATCAAGAGAGCC-3’ and 5’-
TGCTTCTTCCGATGATTCGAACTG-3’. For characterization of expression, Esr2-iCre mice 
were bred with two homozygous reporter lines: B6;129S4-Gt26Sortm1Sor/J (ROSA26) reporter 
mice were used to visualize expression by X-gal staining175, and B6;129S6-Gt26Sortm9(CAG-
tdTomato)Hze/J (Ai9) reporter mice177 were used to visualize expression by presence of red fluorescent 
protein (RFP). Of note, cells that are positive by x-gal staining or RFP presence may be either cells 
that positively express iCre or cells that are progeny of those that have previously expressed iCre. 
Lastly, Estrogen receptor beta knockout mice (Esr2KO) were used for phenotypic comparison to 
homozygous Esr2-iCre mice. Esr2KO mice were generated by crossing Esr2-Floxed mice370,371 
with Zp3Cre mice173 to globally remove exon 3 of Esr2. Esr2KO mouse genotypes were confirmed 
with primers 5’-CTTCTTAGAGGTACGGATCCCAGCCCA-3’, 5’-
AATCTCTTTGCCTTCCAGAGCTA-3’, and 5’-GCATAGCGCAGTTGGTAGAG-3’.   
 
Characterizing Esr2-iCre Expression 
Tissues were collected from sacrificed mice and washed two times in cold phosphate 
buffered saline (PBS). For x-gal staining, tissues were incubated in 4% paraformaldehyde (PFA) 
on ice for one hour. After again washing twice with PBS, the tissues were placed in individual 
vials of X-gal staining solution. Tissues were then placed on a shaker to be incubated for 24-48 
hours in the dark at 4ºC. Following incubation, tissues were washed three times with PBS, and 
then incubated in the dark for one hour at room temperature in X-gal holding solution before being 
re-fixed overnight in 4% PFA at 4ºC. After fixation, gross images were taken of the tissues before 
tissues were dehydrated and embedded in paraffin blocks. Blocks were sectioned at 5um thickness 
using the microtome. Slides were then stained with nuclear fast red (Fisher Scientific, Pittsburg, 
PA) and imaged with an Olympus BX51 microscope. For RFP signal visualization, gross images 
were taken using a Zeiss SV11 fluorescent microscope immediately after sacrifice. Tissues were 
then fixed overnight in 4% PFA, embedded in paraffin, and serially sectioned at 5um. Using an 
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Olympus BX51 microscope, raw sections were used for fluorescence visualization; adjacent slides 
were stained with hematoxylin and eosin (Thermo Scientific, Kalamazoo, MI) to histologically 
confirm structures. Embryos were collected from pregnant females and fixed similar to whole 
organs prior to x-gal staining. Estrus cyclicity was determined by vaginal smears according to 
published guidelines for mice 116. Vaginas were flushed with PBS and cell size, morphology, and 
nucleus presence were determined by bright-field microscopy.  
 
Quantifying Esr2-iCre gene ablation: progesterone receptor 
To quantify efficiency of Esr2-iCre gene ablation within the female reproductive tract and 
phenotypically demonstrate proof of concept, Esr2-iCre mice were crossed with progesterone 
receptor-floxed (Pgr-Flox, PgrF/F) mice243. These mice have a floxed second exon. After breeding, 
mice were superovulated as above and ovary, oviduct, and uterine tissues were collected 6 hours 
after hCG was administered. Semi-quantitative RT-PCR was performed to quantify Pgr expression 
in the reproductive tissues using the primers Pgr_RT_F 5’-GTGCTTACCTGTGGGAGCTGC-3’ 
and Pgr_RT_R 5’-TCCGGAAACCTGGCAGAGAT-3’ at 28 cycles with an annealing 
temperature of 58°C to produce a 481 basepair band, where the forward primer binds in the second 
exon and the reverse primer binds to exons four and five. RNA was extracted using Trizol® 
solution (Ambion, Carlsbad, CA), and then purified with a Qiagen RNEasy Kit (Valencia, CA). 
RNA was analyzed by a Nanodrop machine for quantity and quality. Complementary DNA was 
then generated by M-MLV Reverse Transcriptase using random primers. Template RNA 
quantities were normalized prior to reverse transcription. Amplified DNA (4.0 μL) was visualized 
on a 2.0% agarose gel and was quantified using ImageJ freeware (NIH, Bethesda, MD) to measure 
peak pixel grayscale levels within the defined areas of the bands. The ribosomal 60S subunit L19 
(Rpl19 gene; L19) was used as an internal control with (5'-CCTGAAGGTCAAAGGGAATGTG-
3' and 5'-GTCTGCCTTCAGCTTGTGGAT-3') to produce a 79 basepair band. 
 
Immunohistochemistry 
To compare with other granulosa-cell specific knockout animals, Pgr-Flox mice were bred 
with both Esr2-iCre mice and Cyp19-iCre mice, the latter of which express Cre under the 
aromatase promoter which is expressed in granulosa cells during the secondary follicle stage372. 
Mice of each genotype as well as controls were superovulated and tissues collected from hCG6 
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hours were fixed in 4% PFA, dehydrated, embedded in paraffin wax, sectioned at 5um, and used 
for immunohistochemical (IHC). IHC was performed by P.L and A.G. Slide deparaffinization was 
achieved by drying the slides in an oven at 60˚C for 20 min followed by incubation for 5 min 3 
times in xylene, and for 2 min twice in 100% alcohol, once each in 90% and 70% alcohol, and 
once in running tap water. Heat-induced antigen retrieval was achieved by incubating the slides 
for 1 hour in 10 mM sodium citrate buffer pH 6.0, 0.05% Tween-20 solution in a vegetable 
steamer. Slides were then cooled to room temperature, rinsed under tap water, and incubated for 
20 min in 3% H2O2 diluted in water. Following termination of quenching of endogenous peroxides, 
slides were briefly rinsed under tap water and incubated twice for 5 min in Tris-buffered saline 
pH-7.6 with 0.1% Tween-20  (TBST; 20 mM Tris, 150 mM NaCl) and blocked for 20 min at room 
temperature in 5% goat serum (S-1000, vector labs, Burlingame, CA, USA) in Tris-buffered saline 
pH-7.6 (TBS; 20 mM Tris, 150 mM NaCl) with 1% serum bovine albumin (BSA) and avidin (SP-
2001, vector labs, Burlingame, CA, USA) (200 µl/1ml). Following the serum block, a rabbit anti-
mouse PGR antibody (A0098, Dako, Carpinteria, CA, USA) in 5% goat serum, TBS (pH 7.6), 1% 
BSA, and biotin (SP-2001, vector labs, Burlingame, CA, USA)(200 µl/1 ml) solution was applied 
for 60 min at room temperature in a 1:200 dilution. Slides were then incubated twice for 3 min in 
TBST, and a secondary biotinylated goat anti-rabbit antibody (Vectastain ABC kit, Vector labs, 
Burlingame, CA, USA) in 1% BSA was applied for 20 min at room temperature. Slides were then 
incubated twice for 3 min in TBST and incubated with avidin biotin complex solution (Vectastain 
Elite ABC kit, Vector labs, Burlingame, CA, USA) for 20 min at room temperature. For 
chromogen development, 3,3’-diaminobenzidine Nickel (DABN; SK-4100, Vector labs, 
Burlingame, CA, USA) was applied until color optimally developed.  
 
Fertility Assay 
For the fertility assay, control (Pgr-Flox/Flox), Esr2-iCre Pgr-Floxed, and Cyp19-iCre Pgr-
Floxed mice were bred for a period of 10 days with proven male breeders. Mice were then 
separated from males and allowed to give birth. The percentage of females that gave birth from 
each treatment group, the average number of pups per litter, and the gender distribution of the pups 
was recorded. Litter sizes describe the number of pups present at birth. Females repeated the 
breeding assay two to three times. Average age describes the age at the start of mating period. 
Vaginal cytology was also performed in immature mice (35-60 days of age) prior to fertility assay. 
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Vaginal smears were assessed according to established methods116. A repeated 4-5 day estrous 
cycle was considered normal; estrous cycles were considered abnormal if estrus was not achieved 
or if diestrus lasted longer than three days. Additionally, some mice were euthanized at hCG20 
hours and reproductive tissues were removed. Oocytes were counted after ampullary dissection of 
the oviduct and quantified to determine ovulatory ability prior to fertilization and implantation. 
 
Statistical Analysis 
 Data analyses were performed using statistical software (SPSS, Inc., released 2013, PASW 
Statistics for Windows, Version 22.0, Chicago, IL). Continuous data were tested for normal 
distribution by a Shapiro-Wilk test. All normally distributed continuous data were analyzed with 
parametric tests (student’s t-test, ANOVA) and a Bonferroni post hoc test. All non-normally 
distributed continuous data were analyzed by non-parametric tests (Mann Whitney U, Kruskal 
Wallis ANOVA). Ordinal data were similarly analyzed. Data are graphically presented as the mean 
and standard error of the mean unless otherwise indicated. For all analyses the alpha value was set 
to 0.05. 
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RESULTS AND DISCUSSION 
 The goal of this work was to generate a novel mouse line that faithfully expresses codon-
improved Cre recombinase in place of endogenous estrogen receptor beta (Esr2) expression for 
future use in removing genes within the granulosa cells of the ovary. Generation of a knock-in 
mouse was chosen ensure that there was as little disruption of the normal Esr2 promoter as 
possible, which may DNA sequences upstream, downstream, or within the Esr2 gene itself. 
Additionally, though heterozygous mice have a normal phenotype, homozygous knock-in mice 
may be used as global knockout for the modified Esr2 gene while retaining the ability to remove 
Floxed genes through Cre activity in cells that would normally express Esr2. Expression of Cre in 
place of Esr2 is useful for both removing genes in Esr2-expressing cells as well as visually 
characterizing novel areas of Esr2 expression.  
To generate this model, a bacterial artificial chromosome containing a portion of the Esr2 
gene sequence was purchased as a vector for modification. A cassette containing iCre, a 
polyadenylation sequence, and an FRT-neomycin-FRT selection marker was inserted into exon 2 
of the Esr2 gene (Figure 5.1A). The second exon contains the functional region of the ESR2 
protein. Homologous recombination was used to insert the iCre cassette into exon 2 of the Esr2 
gene within the BAC clone. Two homology arms were amplified from the endogenous Esr2 gene 
by PCR and inserted on either side of the cassette, resulting in a total cassette length of 16193 base 
pairs (Figure 5.1B). The cassette was linearized by Cla1 digestion, inserted into C57BL/6J black 
embryonic stem (ES) cells at the University of Illinois, and selected for with neomycin. To confirm 
single copy number, correct direction, and completeness, ES cell DNA was sent to the Murine 
Genetic Analysis Laboratory at the University of California Davis (Figure 5.1C). One ES cell 
colony (#30) was selected for blastocyst injection and chimera generation. One chimera gave birth 
to a normal number of black pups that were positive for the iCre gene. These offspring were then 
bred with an FLP mouse to remove the neomycin targeting vector; their pups were crossed to 
generate a final knock-in Esr2-iCre mouse line that expressed neither FLP nor had the neomycin 
portion of the cassette (Figure 5.1A). 
 All following mouse breeding was performed using mice heterozygous for Esr2-iCre to 
avoid homozygote, and Esr2-knockout mouse, generation. Mice that are heterozygous for Esr2-
iCre have lost one functional Esr2 allele, however this is expected to have little or no impact on 
reproductive parameters as global Esr2-KO mice are fertile373. Loss of both alleles results in fewer 
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litters and fewer pups per litter, with fewer antral follicles and fewer corpora lutea in the ovaries373, 
but possessing a single functional allele is expected to be sufficient to restore function. 
The Esr2-iCre mice were crossed with homozygous ROSA26 and Ai9 reporter mice, which 
produce beta-galactosidase and red fluorescent protein (RFP), respectively, in cells or cell lineages 
of Cre expression. Esr2-iCre ROSA26 mice and Esr2-iCre Ai9 showed identical reporter 
expression in tissues examined and otherwise maintained normal phenotypes and fertility; 
ROSA26 staining data are omitted here as ROSA26 reporter lines have increased background in 
control tissues relative to Ai9 reporter mice176,291.  
 To characterize expression, adult Esr2-iCre Ai9 mice were collected at 2-4 months of age 
and examined for RFP. Mice were first examined as a whole during dissection, then on the 
individual organ level, and lastly histologically. Wild-type (WT) mice were sacrificed and imaged 
as negative controls: no fluorescence was observed grossly in WT mice and little background was 
observed histologically in unstained sections. However, it was observed that WT tissues that were 
fixed for more than 24 hours in PFA were subject to increased auto-fluorescence grossly and 
histologically. Similar increased auto-fluorescence was observed in tissues that were in 70% 
ethanol for extended periods of time (>2 months). Histological auto-fluorescence could be 
quenched by quickly staining with Sudan Black B solution (CAS 4197-25-5, Santa Cruz; data not 
shown), though this also diminishes any normal RFP signal. 
 The primary interest in generating Esr2-iCre mice was as a tool for the removal of ovarian 
genes, specifically within the granulosa cells. Expression of Esr2 has been well characterized in 
granulosa cells of growing follicles beginning in the primary follicle stage374-377. Expression of 
Esr2 has been controversial in the oviduct, with rodent and sheep models reporting little to no 
expression in the adult female reproductive tract outside of the oviduct377,378, while hormone-
dependent expression has been reported in the bovine oviduct379. In the immature uterus, 
expression of Esr2 has been reported in both the epithelium and the stroma of the mouse380, while 
in adults expression is localized in the glandular epithelial cells381 where it is believed to play a 
role in modulation of ESR1 activity380 and also likely to the stroma during days 7-15 of 
pregnancy382. In Esr2-iCre Ai9 mice, RFP was noted grossly in the ovary, oviduct, and uterus 
(Figure 5.2). Fluorescence was most notable from the ovary, where it was present throughout the 
granulosa cells as described, as well as the theca cells and stroma cells. This suggests that ovarian 
Esr2 expression may be active during development in ovarian precursor cells, or during low levels 
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in the adult ovary. It must be noted that Ai9 reporter mice will express RFP in any cell that is or 
has previously expressed, or is descended from a cell that previous expressed, Cre recombinase. 
The oviduct demonstrated punctate expression in some of the epithelial cells, particularly 
concentrated towards the ampulla and away from the isthmus. Spotted expression was also 
observed in a few cells of the muscularis layer about the oviduct. In the uterus, few cells 
demonstrated RFP expression. These cells were present throughout the epithelium and stroma of 
the endometrium, and also present in a few myofibrils of the myometrium (Figure 5.2). These data 
are consistent with previous findings, and indicate that estrogen receptor beta likely does not play 
a major role in the oviduct or uterus.  
 In the male reproductive tract, multiple tissues demonstrated red fluorescence, including 
the testes, epididymis, ductus deferens, coagulation gland (anterior prostate), and prepucial glands 
(Figure 5.3). In the testes, RFP was present in the interstitium between the seminiferous tubules. 
This pattern has been previously reported383, though expression has also been reported in the sertoli 
cells and germ cells. However, sertoli expression was not observed. Further, germ cell expression 
was not observed, either in the spermatogonia or spermatids of the testes, or in the sperm 
themselves visible throughout the epididymis; no pups were born with global RFP expression. 
This is similar to more recent reports of human Esr2 expression384. Punctate staining was present 
throughout the epithelium of the rete testes, the head of the epididymis, and the tail of the 
epididymis, but not the body of the epididymis (Figure 5.3). Similarly, expression was seen in the 
epithelium of the vas deferens as well. These data are similar to previous reports using 
immunohistochemical localization384-386. 
 In addition to a plethora of other functions, the pituitary and brain (specifically the 
hypothalamus) are important in reproductive regulation and hormonal feedback loops in both 
genders. Not surprisingly, both organs had presence of red fluorescence in each gender (Figure 
5.4). Expression in the brain and pituitary was similar between genders in adult mice. In the brain, 
diffuse fluorescence was grossly present throughout the cerebrum, though it was absent in the 
hindbrain, the cerebellum, and the optical tracts. More marked fluorescence was grossly visible in 
the hypothalamus, through histologically expression was not observed in the arcuate nucleus. 
Points of increased fluorescence were also present on the ventral cerebrum, which may represent 
the Islands of Calleja, a portion of the limbic system387, though this requires future analyses to 
confirm. Previous reports on Esr2 expression in the brain have demonstrated expression in the 
102 
olfactory bulb, the amygdaloid nucleus, the medial geniculate nucleus, the posterior hypothalamic 
nucleus, and the suprachiasmatic nucleus, which are estrogen-dependent388. The data presented 
confirm previous findings, and also implicate additional Esr2 expression throughout neurons of 
the cerebrum. Previous studies have also reported pituitary expression of Esr2: in fetal rats, ESR2 
is present within the developing pituitary from post-natal day 12 (PND12) onward, though 
expression decreases in the adult and is then limited to the periphery and area adjacent to the 
intermediary lobe, with no differences between genders389. The data confirm previous findings 
regarding limited expression in the anterior pituitary near the intermediary lobe (Figure 5.4). 
However, strong fluorescence within the posterior pituitary was also observed in contrast to 
previous IHC data389. This may be reflective developmental expression in the posterior pituitary, 
especially as these cells are descended from the developing hypothalamus where Esr2 expression 
has been previously observed. 
 Beyond the reproductive organs, Esr2 has a widespread distribution throughout the body 
and has also been implicated in multiple types of cancer as well390-397. Global survey of Esr2-iCre 
mice identified RFP in multiple organs (Figure 5.5). In particular, RFP was present in a wavy or 
patch pattern throughout parts of the adrenal cortex, diffusely present in the detrusor muscle of the 
bladder, in several cells in a spotted pattern in the mucosa of the colon (but very limited in the gut-
associated lymphatic tissues therein), in the most interior layer of the cornea of the eye, in the 
epicardium and atrial myocardium, throughout the entirety of the lung, in some acini of the 
pancreas, in the some serous cells of the acini of the salivary glands, and throughout the skeletal 
muscle fibers (Figure 5.5). A detailed list of all organs examined, as well as previous related 
literature, are presented in Table 5.1. Future work may specifically identify the cell types or timing 
of expression within these non-reproductive tissues. The expression of Esr2-iCre within the 
pancreatic islets is particularly interesting. 
 Lastly, as proof of concept and to quantify Esr2-iCre gene ablation within the ovary, Esr2-
iCre mice were bred with progesterone receptor-floxed mice (Pgr-flox/flox, Pgr-F/F)243. It has 
previously been demonstrated that mice globally lacking progesterone receptor fail to ovulate 
owing to a lack of follicle rupture70,201,244. It was hypothesized that mice that were lacking Pgr 
expression in the ovary as a result of Esr2-iCre action would fail to ovulate similar to global 
progesterone receptor knockout (Pgr-KO) mice after stimulation with exogenous gonadotropins 
by superovulation. Loss of Pgr was tested in the female reproductive tract by RT-PCR. Results 
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demonstrated that Pgr expression, which peaks at hCG6 hours after gonadotropin injection in the 
ovaries but remains relatively constant in the oviduct and uterus throughout ovulation, was sharply 
reduced in Esr2-iCre PgrF/F ovaries as expected when examined at hCG6 hours (Figure 5.6A). 
However, there was no difference in Pgr expression in the oviducts or uteri of Esr2-iCre PgrF/F 
mice at hCG6 hours. These data indicate that Esr2-iCre is capable of gene ablation in the ovary, 
specifically in the granulosa cells, but not within the oviductal or uterine epithelium or stroma.  
In addition to control mice and Esr2-iCre Pgr-Flox/Flox mice, a third genotype of mice 
were generated by crossing Pgr-Flox mice with Cyp19-iCre mice. Cyp19-iCre mice are established 
as having granulosa-cell specific expression of Cre recombinase372, as Cre activity is under the 
aromatase enzyme promoter which becomes active in granulosa cells during estrogen production 
in the secondary follicular stage. However, there are also reports that Cyp19-iCre does not 
completely ablate gene expression within granulosa cells188. Immunohistochemistry for PGR in 
ovaries collected at hCG6 hours from control mice (Figure 5.6B) indicates that PGR is present 
throughout the granulosa cells of mature / antral follicles. In Cyp19-iCre Pgr-F/F mice, there is 
decreased staining within granulosa cells of antral follicles of the ovary at this time point, however 
there are some mural and cumulus granulosa cells that still stain positively (Figure 5.6B). By 
comparison, Esr2-iCre Pgr-F/F demonstrate no positive staining for PGR within the ovary at hCG6 
hours. These data indicate that at the protein level, Esr2-iCre Pgr-F/F mice lack PGR. To test the 
functional significance of this, a fertility assay was performed with mice of either Cyp19-iCre or 
Esr2-iCre Pgr-F/F vs control animals (Figure 5.6C). Though there was no difference in fertility or 
fecundity between control and Cyp19-iCre Pgr-F/F mice, Esr2-iCre Pgr-F/F mice instead gave 
birth to 0 litters after breeding with 9 different mice (p<0.001 relative to control and Cyp19-iCre 
mice). However, vaginal cytology in all three genotypes of mice indicated normal estrous cycles 
(data not shown), indicating that Esr2-iCre Pgr-F/F maintain normal hormonal signaling and 
hypothalamic/pituitary feedback to influence vaginal keratinization. As a final test, to bypass 
hypothalamic pituitary feedback necessary for the luteinizing hormone surge, immature mice of 
all three genotypes received superovulation stimulation. Oocytes were collected from the ampulla 
of the oviduct at hCG20 hours and counted. Control mice ovulated an average of 24.8 
oocytes/ovary, while Cyp19-iCre Pgr-F/F mice ovulated only 13.6 oocytes/ovary (p=0.005). 
However, Esr2-iCre Pgr-F/F mice did not ovulate any oocytes from any ovary (n=10, p<0.001, 
Figure 5.6D), a phenotype that matches global PR-KO mice. 
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Overall, these data demonstrate that ovarian PGR activity is likely critical for follicle 
rupture to proceed during ovulation; future studies may focus on differences in Pgr expression and 
protein in the brain and pituitary as well between Esr2-iCre Pgr-F/F and control mice during 
ovulation to confirm there were no major differences in PGR action outside of the ovary in this 
model. In conclusion, novel knock-in Esr2-iCre mice express Cre recombinase in cells and cell 
lineages that mimic endogenous Esr2 expression. Cre activity, examined by RFP through Ai9 
reporter mice, is present throughout the ovary and functionally ablates gene expression there in a 
manner superior to Cyp19-iCre mice. Additional high activity is observed throughout the testicular 
interstitium, the head and tail of the epididymis, in the hypothalamus and generally throughout the 
cerebrum, in the posterior pituitary, in the lungs, and in the coagulation gland. Homozygous Esr2-
iCre mice are also useful as global Esr2 knockout models. This new animal model will be useful 
across multiple fields for better understanding the tissue locations and the specific pathways 
utilized by estrogen receptor beta signaling or by other genes within Esr2-expressing cells. 
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TABLES 
Table 5.1. Summary of Esr2-iCre expression. Expression was visualized in multiple tissues in adult intact mice (60+ days of age) 
through RFP signal after crossing with an Ai9 reporter line. Fluorescence marks cells that may be expressing Cre recombinase or cells 
that previously have, or have emerged from a cell lineage with a progenitor cell that had, expressed Cre. Continued on multiple pages. 
Tissue 
Relative 
Fluorescence 
Notes 
Select Relevant  
Literature 
Adipose Tissue - No fluorescence visualized. 398-400 
Adrenal ++ 
Punctate or streaked fluorescence throughout the three layers of the 
adrenal cortex; little to none in medulla. 
401,402 
Aorta - Limited fluorescence to skeletal muscle near aorta. 403,404 
Bladder + Diffuse, weak fluorescence throughout the detrusor muscle. 359,365,393,405 
Blood (circulating) - No fluorescence seen (in all RBC and WBCs observed). 391,406 
Bone (femur) - No fluorescence seen in osteocytes, bone marrow. 407,408 
Brain + 
Diffuse fluorescence throughout cerebrum and hypothalamus; none in 
optic chiasm, cerebellum, or hind brain. Marked increased fluorescence 
at several small points on the ventral surface. 
409-413 
Coagulation gland 
(anterior prostate) 
+++ Strong fluorescence seen in secretory cells. 
407 
Colon ++ 
Diffuse to patchy fluorescence throughout mucosa, stronger and more 
widespread than in proximal GI tract.  
357,414 
Ductus (vas) deferens + 
Limited, punctate fluorescence in some luminal epithelial cells; weaker 
than head and tail of epididymis. 
415 
Duodenum + 
Limited punctate fluorescence in mucosa and stroma of the submucosa. 
More points of expression are visible at the more distal portion. 
416 
Epididymis ++ 
Strong fluorescence seen in the epithelium of the tubules connecting to 
the rete and in the head of the epididymis. No fluorescence in the body of 
the epididymis. Fluorescence again present in the epithelium of the tail of 
the epididymis. 
384,385,417 
Esophagus - No fluorescence visualized. 418 
Eye + 
Fluorescence visible in the most interior cellular layer of the cornea, not 
present in the lens or retina. 
419,420 
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Table 5.1. Continued from previous page. 
Heart ++ 
Patchy fluorescence in some of the epicardial cells, particularly those near 
the coronary arteries or surface adipose deposits. Fluorescence also 
present throughout majority of the myocardial cells of each atrium. 
394,421,422 
Ileum + 
Limited punctate fluorescence in mucosa and submucosa similar to the 
duodenum, stronger distally. 
416 
Jejunum + 
Limited punctate fluorescence in mucosa and submucosa similar to 
duodenum and ileum. 
416 
Kidney + 
Little fluorescence visualized, limited to cortex and particularly in some 
glomeruli when present. 
423,424 
Liver - No fluorescence visualized. 425-427 
Lung +++ 
Strong fluorescence throughout entirety of lungs and respiratory 
epithelium. 
428-430 
Nerve 
(thoracic vagus) 
- No fluorescence visualized. 
396 
Ovary +++ 
Fluorescence seen throughout ovary, including granulosa cells, theca 
cells, stromal cells, and epithelial cells. Not seen in oocytes. 
362,365,386,431,432 
Oviduct + 
Punctate fluorescence in epithelial folds of the proximal oviduct 
(ampulla). Fluorescence diminished or not present in distal oviduct 
(isthmus). 
379 
Pancreas ++ 
Fluorescence present in endocrine pancreas only within some of the 
pancreatic acini, approximately 5%. 
433 
Penis - No fluorescence visualized externally. 434 
Peyers Patch (Gut-
associated lymphatic 
tissue) 
+ 
Very limited punctate expression visualized within follicles, 0-2 
cells/100. 
 
Pituitary ++ 
Fluorescence visible throughout cells of the posterior pituitary, none 
visible in intermediary pituitary, punctate or diffuse expression in medial 
anterior pituitary with decreased prevalence near lateral edges. 
375,435,436 
Preputial gland +++ 
Fluorescence seen in the majority of acini in both basal and secretory 
cells. 
 
Salivary gland ++ 
Fluorescence present throughout the serous cells of acini, overall spotted 
pattern histologically. 
397,437 
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Seminal vesicle - No fluorescence visualized  
Skeletal muscle +++ 
Obvious, strong fluorescence throughout skeletal muscle throughout the 
body. 
438-440 
Skin ± 
Fluorescence limited to 1-2 cells/hair follicle, otherwise not seen 
histologically in skin; fluorescence also present on pads of feet.  
441-443 
Spleen - No fluorescence visualized. 444 
Stomach - No fluorescence visualized. 445,446 
Testes +++ 
Strong fluorescence in interstitial cells, potentially including Leydig 
cells; not present in sertoli cells of seminiferous tubules; punctate 
expression in epithelium lining the rete. 
383,385,386,447 
Uterus + 
Seen in some smooth muscle cells of the myometrium and some epithelial 
and stromal cells of the endometrium throughout the uterus. 
364,382,448,449 
Vagina + Expression seen in the stratified mucosa of vagina in cycling adult mice. 449 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Generation of Esr2-iCre mice. To generate mice that faithfully express codon-improved Cre recombinase under regulation of estrogen 
receptor beta, A. an iCre-polyA-FRT-PGK-neomycin-FRT cassette was inserted into exon 2 of the Esr2 gene in a BAC clone. The targeting vector 
B. was inserted into the genome of C57BL/6J embryonic stem cells using homologous recombination, thus creating a knock-in mouse line. Stem 
cells were screened for C. single copy insertion in the correct orientation using long range PCR. One chimeric mouse that gave birth to multiple 
black offspring was chosen as a founder and was crossed with FLP recombinase-expressing mice to remove the FRT-PGK-neo-FRT targeting vector.   
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Figure 5.2. Functional expression of Esr2-iCre in the ovary, oviduct, and uterus. Female reproductive organs from post-natal day 120 females 
were collected; mice were unstimulated and had previously been pregnant. Top: Strong fluorescence was seen throughout the ovary, in the granulosa 
cells as well as the lutein cells of the corpora lutea and the stroma. Middle: Punctate fluorescence was seen in the oviduct, particularly in the proximal 
oviduct (ampulla). Fluorescence was limited to few individual epithelial cells. Bottom: In the uterus, diffuse fluorescence was observed throughout. 
Punctate expression was observed in few cells of both the endometrium (epithelial cells) and myometrium (smooth muscle cells).   
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Figure 5.3. Functional expression of Esr2-iCre in the male gonad and accessory organs. Mature post-natal day 60 male mice were sacrificed 
and organs were fixed for histology. Grossly, fluorescence was observed in the testes, epididymis, vas (ductus deferens), the prepucial glands, and 
strongly in the coagulation glands (anterior prostate, top left corner). Histological analyses revealed expression in the interstitium of the testes (top 
right), punctate expression throughout the epithelium of the rete testis, head of the epididymis, and tail of the epididymis (mid-right), and the mucosa 
of the ductus deferens (bottom right).   
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Functional expression of Esr2-iCre in the brain and pituitary. Esr2-iCre mice were crossed with Ai9 reporter mice. Adult mice were 
sacrificed at 2-4 months of age. Expression was similar in both the brain and pituitary of adult mice of each gender. Diffuse expression was observed 
throughout neurons of the cerebrum, though this was sharply limited to the forebrain. Few neurons in the cerebrum demonstrated RFP. Ventrally, 
expression was present throughout the hypothalamus and the ventral portion of the cerebrum; expression was absent from the optic nerve chiasm 
and from the arcuate nucleus (histology images at right, low power above and high power below). Uniquely, expression was observed in bilaterally 
symmetrical ventral point structures about the olfactory tubercle, which may represent the Islands of Calleja of the limbic system (arrows, ventral 
brain view). In the pituitary of each gender, expression was prominent throughout the posterior pituitary lobe. Expression was punctate throughout 
the medial anterior pituitary (arrow), with limited lateral expression. No expression was observed in the intermediary pituitary (histology at right).   
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Figure 5.5. Expression of Esr2-iCre throughout the body. Esr2-iCre mice were crossed with Ai9 reporter mice and adult mice were sacrificed at 
2-4 months of age. Outside the reproductive organs, multiple other areas of expression were grossly visible. Expression was observed in a wavy and 
fragmented pattern throughout the adrenal gland which does not correspond to underlying cell layers, consistently throughout the detrusor muscle 
of the bladder, the mucosa of the distal GI tract (colon, cecum), the interior cornea of the eyes, the epicardium surrounding the coronary arteries, the 
entirety of the lungs, select acini of the pancreas, the serous-associated acini of the salivary glands, and throughout the skeletal muscle of the body.  
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Esr2-iCre conditional Pgr-knockout mice are infertile. Esr2-iCre mice were crossed with progesterone receptor floxed (Pgr-floxed) 
mice. A. Semi-quantitative RT-PCR revealed a marked decrease in expression in the ovary, but not in the ovary or uterus. Lanes 1,3,5 are control 
cDNA and lanes 2,4,6 are Esr2-iCre Pgr-Floxed cDNA; lane 7 is a positive control of cDNA from a WT hCG6 hour ovary and lane 8 is a negative 
control from PCR mastermix without template. B. When checked by IHC for PGR, no positive staining was observed in Esr2-iCre Pgr-Floxed mice, 
though staining was still present in some granulosa cells of Cyp19-iCre Pgr-Floxed mice. Unlike both control and Cyp19-iCre Pgr-Floxed mice, 
Esr2-iCre Pgr-Floxed mice, C., were completely infertile and did not give birth to any litters. However, cyclicity by vaginal smear was normal in all 
mice with 4-5 day estrus cycles. D. Lastly, Esr2-iCre mice did not ovulate when stimulated by exogenous gonadotropins to bypass pituitary signaling, 
confirming that there is efficient ablation of Pgr within the ovary, that this ablation is superior to that of Cyp19-iCre mice, and also that ovarian Pgr 
is necessary for ovulation. 
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ABSTRACT 
Successful ovulation is inherently dependent upon a myriad of intrinsic ovarian and 
extrinsic factors that signal for follicular growth, vascularization, leukocyte invasion, and 
ultimately oocyte release prior to fertilization. Prior to ovulation, granulosa cells of periovulatory 
follicles transiently produce the potent vasoconstrictor EDN2, a gene product of endothelin-2 
(Edn2). It was previously shown that antagonization of the endothelin receptor pathway 
significantly reduces ovulation, indicating a potential role of contraction in ovulation. To 
determine the significance of EDN2 production in the granulosa cells, the Edn2 gene was 
selectively ablated by crossbreeding a floxed Edn2 (Edn2Flox) mouse with an Esr2-iCre mouse 
that express codon improved Cre recombinase under the promoter of estrogen receptor beta (Esr2). 
In the ovary, Esr2 expression begins during follicular recruitment in the primary follicle stage and 
is spatially limited to the granulosa cells. It was hypothesized that the loss of Edn2 in granulosa 
cell results in reduced ovulation and therefore smaller litter size. The ablation of Edn2 by Esr2-
iCre significantly reduced the numbers of ovulated oocytes compared to wild type littermates when 
treated with gonadotropins for ovulation induction (3.75±0.88 vs 16.36±1.85 oocytes/ovary, 
p=0.001, respectively). Furthermore, Edn2 ablation resulted in smaller litters than controls 
(4.29±1.02 vs 8.50±0.60, p=0.008, respectively). Though fecundity was decreased, the number of 
pregnancies to term per pairing was not different between groups (p=1.000), implying that some 
follicles ovulated successfully in the absence of Edn2 expression. Histological examination 
showed that the ovaries of the conditional Edn2 knockout mice had a significantly higher 
percentage of antral follicles and fewer corpora lutea than controls (p=0.019 and p=0.013, 
respectively), suggesting that follicles progress to the antral stage but some are unable to rupture 
at the time of ovulation. RT-PCR profiler array data suggest that EDN2 does not cause 
transcriptional modification to induce oocyte rupture, but instead acts through its cognate receptors 
to induce follicular contraction and oocyte expulsion. These data strengthen the hypothesis that 
the local EDN2 signaling cascade is a key player in driving smooth muscle contraction during 
ovulation. 
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INTRODUCTION 
Endothelin-2 (Edn2) encodes the peptide EDN2 that is expressed in the ovary during 
ovulation and early luteinization / corpus luteum (CL) formation. Edn2 mRNA is expressed only 
in the granulosa cells of mature follicles immediately prior to ovulation, and the entire duration of 
Edn2 mRNA expression is about 2 hours6,7,14,200. One of three similar endothelin isoforms, EDN2 
alone is known to be transiently expressed in the stimulated rodent and human ovary. It has been 
shown to be necessary for both ovulation and CL formation through pharmacological and knockout 
mouse approaches6,7,171. Recent evidence shows that mice expire from starvation, hypothermia, 
and/or emphysema when EDN2 is lost globally223, and that these mice have impaired ovulatory 
abilities171. Thus, EDN2 is an important molecule to study for a variety of roles within human 
health, and reproduction in particular.  
EDN2 has similar receptor affinity to EDN1, and has nearly the same biochemical 
structure. Each is a 21-residue peptide mediates its action by binding to one of two receptors, 
EDNRA or EDNRB208. However, the physiological and molecular triggers for induction of Edn2 
remain to be further elucidated; to date only hypoxia has been demonstrated to have a significant 
effect on Edn2 expression in culture246,250,252,450, while the effect of progesterone receptor (PGR) 
on Edn2 expression has been controversial7,247. Regardless of the cause of induction, it is agreed 
that EDN2 has a profound effect on ovulation by influencing follicle rupture. However, the 
mechanisms underlying EDN2-modulated follicle rupture have not been directly proven. EDN2 is 
thought to act through EDNRA170 receptors on the smooth muscle about the follicle in the theca 
externa layer and in the associated blood vessels. The gene Ednra is highly expressed in vascular 
smooth muscle cells but is not believed to be expressed in endothelial cells themselves451. It also 
known to be expressed in the theca externa layer around human follicles14. Alternatively, EDNRB 
is expressed largely in endothelial cells452 where it acts to clear endothelins from circulation453-456 
and induce vasodilator production457. EDNRB may be expressed in smooth muscle cells too458.  
The time of Edn2 expression coincides with ovulation of mature follicles and the initial 
transformation process to form CL, which are necessary for pregnancy maintenance and 
progesterone synthesis241,242. Given its timing of expression, EDN2 may influence contraction as 
well as angiogenesis, especially as global EDN2-knockout mice fail to form CL171. VEGF plays a 
central role in ovarian angiogenesis by activating endothelial cells and inducing hypertrophy88,89. 
Luteinizing granulosa cells secrete VEGF, activating VEGF receptors (VEGFR-1 and -2) that are 
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localized to both endothelial cells and steroidogenic cells85,86. Klipper et al. (2010) showed that 
EDN2 directly induces VEGF expression in granulosa cells of the bovine ovary246. Angiogenesis 
continues after VEGF induction with MMP-mediated dissolution of the basement membrane, 
sprouting of new vessels with proliferating endothelial cells, and eventual vessel anastomosis that 
is mediated by macrophages91. MMP-2 and MMP-9 are known to be significantly elevated in 
ovarian tumors255, and at the time of ovulation and luteal formation MMP-2 is elevated in the rat256-
259, while MMP-9 is elevated during ovulation in the mouse97,244. MMP activity is critical to allow 
follicle rupture by weakening the ovarian walls as well as angiogenesis. Tissue inhibitors of 
metalloproteinases (TIMPs) are highly expressed in the ovary after the LH surge92-96. In particular, 
TIMP-1 mRNA is upregulated 10-fold after the LH surge260, is released in large quantities during 
ovulation from the granulosa cells and subsequent lutein cells 97-99, and is highly produced in 
forming CL97. EDN2 may antagonize TIMP-1 action as well, as excessive TIMP-1 is associated 
with fewer CL, zygotes, and follicles261,262. EDN2 has been shown to activate macrophages270, 
which secrete and mediate MMP activity; macrophages are trafficked to the ovary during 
ovulation, are required for ovulation459-461, and may be critically influenced by EDN2. Together, 
these data suggest a role for EDN2 in regulating angiogenic, collagenase and proteinase, 
leukocytic, or proliferative/apoptotic pathways during ovulation and CL formation that should be 
explored in an in vivo functional setting given the involvement of multiple organ systems. 
The Cre/LoxP system has been widely used to remove tissue-specific genetic expression 
and to evaluate resulting physiological changes462. To remove Edn2 specifically in the granulosa 
cells of the ovary, Cre recombinase expression driven by promoters for the progesterone receptor 
(Pgr, PR-Cre)463, cytochrome P450 family 19 A1 (aromatase, Cyp19; Cyp19-iCre)367, and estrogen 
receptor beta (Esr2, Esr2-iCre) may be utilized376,386,464,465. Previous studies have also used Cre 
driven by anti-Mullerian hormone type 2 receptor (Amhr2-Cre)466. Though all are active within 
the granulosa cell, each Cre line is first expressed at a different time point in folliculogenesis, 
ranging from the primary follicle stage (Esr2-iCre)376,432,435,467 to the secondary follicle stage 
(Cyp19-iCre)468-470 to just 6 hours before ovulation (PR-Cre)199,244. This allows for removal of 
Edn2 at different points during follicular development and targeting at what time point EDN2 
translation is ablated, determining if EDN2 is developmentally important in the ovary and allowing 
for a gradient in phenotypic severity of ovulatory defects. Additionally, a mouse with Cre driven 
by the zona pellucida protein 3 (Zp3Cre) promoter, which is useful for removing genes only in 
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oocytes, was used to globally remove Edn2 to examine its effect on ovarian development and early 
follicular growth173. 
The aims of this study were to generate and reproductively characterize novel mouse 
models where Edn2 was lost throughout the ovary or specifically in the granulosa cells, to 
specifically determine the effect of Edn2 loss on the number of oocytes ovulated and overall 
fertility/fecundity, and to determine if Edn2 loss causes aberrant ovarian development, 
folliculogenesis, or CL formation. It was hypothesized that mice lacking Edn2 in all or part of the 
ovary will have decreased oocytes ovulated and consequently smaller litter sizes and will form 
fewer or no corpora lutea, but will maintain normal ovarian development and folliculogenesis to 
the time of ovulation.  
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METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Illinois Animal Care and Use Committee (Protocols: 13032, 14222, 
and 14247), and all efforts were made to minimize animal suffering. 
 
Animals Used 
Mice were generated by crossing Edn2flox/flox mice purchased from Jackson 
Laboratory263 with PR-Cre mice463, Cyp19-iCre mice367, and novel knock-in Esr2-iCre mice 
(Cacioppo et al., unpublished, previous chapter) to remove Edn2 specifically in the granulosa cells 
at various time points during folliculogenesis, or with Zp3Cre mice173 to generate global Edn2 
knockout mice (Edn2KO). Genotyping was performed on ear biopsies using the HotShot 
method471. The following five primer sets were used for genotyping: 
Edn2Flox_F CAT AGA GCG GTG AGG CCA CAG Flox: 170bp 
Edn2Flox_R AAG TTG GCA CCC TTG GTG TTC WT: 130bp 
Edn2KO_R CTG TTC AGC TGG CAG AGT GAA GC KO: 400bp 
   
PR-Cre_F1 ATG TTT AGC TGG CCC AAA TG PR-Cre: 594bp 
PR-Cre_F2 CCC AAA GAG ACA CCA GGA AG WT: 283bp 
PR-Cre_R TAT ACC GAT CTC CCT GGA CG  
   
iCre_F TCT GAT GAA GTC AGG AAG AAC C iCre: 500bp 
iCre_R GAG ATG TCC TTC ACT CTG ATT C WT: no band 
   
Esr2-iCre_F CAG GTG CTG TTG GAT GGT CTT C Esr2-iCre: 401bp 
Esr2-iCre_R1 CTT AGT TAC TCC GGC AGC TTG AAC WT: 181bp 
Esr2-iCre_R2 AGG GGA AGT AAG GCT TGA TGG TGA  
   
Zp3Cre_F GGA CAT GTT CAG GGA TCG CCA GGC G Zp3Cre: 250bp 
Zp3Cre_R GTG AAA CAG CAT TGC TGT CAC TT WT: no band 
 
Fertility Assay 
This assay was conducted to determine if mice were capable of giving birth to a normal 
number of litters with a normal number of pups and gender distribution. Adult female mice, aged 
two months to seven months, were randomly allocated into groups of two or three females of each 
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treatment. Each set of females was paired for 10 days with a proven WT male breeder, aged 3 
months – 7 months. Females were then removed from the male and separated into individual cages 
for 21 days and monitored daily. The percentage of females that gave birth from each treatment 
group, the average number of pups per litter, and the gender distribution of the pups was recorded. 
Litter sizes describe the number of pups present at birth. Females repeated the breeding assay two 
to four times. Average age describes the age at the start of mating period. 
 
Superovulation, RT-PCR, and Histology 
Superovulation was performed by single intraperitoneal (i.p.) injection of gonadotropins 
(5IU pregnant mare serum gonadotropin, PMSG, and 5IU human chorionic gonadotropin, hCG) 
at 48 hour intervals to 25 day old mice. Mice were sacrificed 12 or 24 hours after hCG injection. 
At 12 hours after, ovaries were frozen, RNA was extracted using Trizol® solution (Ambion, 
Carlsbad, CA), and then purified with a Qiagen RNEasy Kit (Valencia, CA). RNA was analyzed 
by a Nanodrop machine for quantity and quality. Complementary DNA was then generated by M-
MLV Reverse Transcriptase using random primers. Template RNA quantities were normalized to 
1.0μg/μL prior to reverse transcription. 1.0μL of resulting cDNA from each ovary was used as 
template for semi-quantitative RT-PCR with 15μL Taq Platinum (Invitrogen) and 0.3μL of each 
primer per PCR reaction; reactions were cycled 30x for 94°C for 1:00 min, 53°C for 1:00, and 
72°C for 1:30. Amplified DNA (3.0 μL) was visualized on a 2.0% agarose gel and was quantified 
using ImageJ freeware (NIH, Bethesda, MD) to measure peak pixel grayscale levels within the 
defined areas of the bands. The ribosomal 60S subunit L19 (Rpl19 gene; L19) was used as an 
internal control with (5'-CCTGAAGGTCAAAGGGAATGTG-3' and 5'-
GTCTGCCTTCAGCTTGTGGAT-3'). Expression of Edn2 was analyzed with primers (5’-
CTCCTGGCTTGACAAGGAATG-3’ and 5'-GCTGTCTGTCCCGCAGTGTT-3'). Expression of 
Edn1 was analyzed with primers (5'-AGCCGAACTCAGCACCGGAGCT-3' and 5'-
ATGATGTCCAGGTGGCAGAAGTAGAC-3'). For quantitative RT-PCR using the Taqman 
system (Life Technologies), primers Mm0432983_m1 were purchased for Edn2, primers 
Mm02601633_g1 for Rpl19, and primers Mm00435628_m1 for Pgr (Life Technologies). Taqman 
reactions were run on an ABI 7500 machine and data were analyzed using the delta delta Ct472 
method. After fixation in the 4% PFA, ovaries from hCG24 hours were embedded in paraffin and 
sectioned at 5 μm, mounted on charged glass slides, deparaffinized, and rehydrated. Tissues were 
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then stained with hematoxylin (Harris) and eosin (Surgipath) for cellular visualization for use in 
follicle counting. 
 
Endothelin Protein Quantification 
Soluble endothelins were extracted following protocol of Chakravarthy et al. (1994)473 and 
measured following protocol by Choi et al. (2011)14. Briefly, individual whole ovaries from 
hCG12 hours were placed in individual 1.5mL tubes with 500uL 1M HCl in 100% ethanol, 
homogenized with a mortar and pestle, and incubated at 4°C for 48 hours on an orbital shaker. 
Tubes were centrifuged at 2000xg for 30 minutes liquid was transferred to a clean tube. Ethanol 
was then removed by 1 hour incubation in an unheated vacuum centrifuge to dry protein. To 
measure endothelin quantity, a commercial ELISA kit (583151) was purchased from Cayman 
Chemical Company (Ann Arbor, Michigan). Individual ovarian endothelins were constituted with 
500uL of EIA buffer and loaded onto the plate, and plates were run according to the manufacturer’s 
instructions. Plates were read at 405nm and analyzed with a quadratic standard curve.  
 
Kidney-Ovarian Transplantation (KOT) 
Ovaries from post-natal day six (PND6) mice were removed following CO2 euthanasia. 
The PND30-32 recipient female mice were anesthetized by continuous nasal inhalation of 
isoflurane (2-2.5%) with 1 liter per minute (LPM) of oxygen flow. After appropriate depth of 
anesthesia is reached, fur was removed from an area centered over the proposed incision sites, 15 
mm wide by 30 mm long. The size of the area clipped was proportional to the size of the mouse. 
Skin was disinfected with surgical iodine and 70% ethanol using sterile applicators. Eye 
gel/ointment was applied to both eyes to prevent dehydration. The mouse was placed on a heat pad 
(37°C) to prevent hypothermia during surgery. The donor mouse was placed in ventral-lateral 
recumbency. A 4-7mm skin incision was made parallel and ventral to the spine midway between 
the last rib and the iliac crest. An incision was made in the underlying abdominal wall. Forceps 
were used to spread open the incision to look inside the abdominal cavity and locate the ovary. 
Forceps were used to grasp and exteriorize the ovarian fat pad. The fat pad was positioned on a 
2x2 Versalon sterile sponge so that the ovary was facing the surgeon and the oviduct was ventral. 
A Moria forceps was placed under the ovary (medial aspect) to clamp the ovarian blood vessels. 
A second pair of Moria forceps was placed immediately proximal to the first pair and used to shear 
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the ovary off of the ovarian blood vessels. Before releasing the first forceps, one drop of 
epinephrine was added to the vascular stump for one minute. The collected ovary was discarded 
and the fat pad was returned to the body. Next the kidney was exposed through the same incision 
site and a 2mm incision was made through the kidney capsule on one pole of the kidney. The donor 
ovary was pushed through the incision and pushed to the opposite pole of the kidney. The kidney 
was returned to the abdominal cavity. The incision in the abdominal wall was closed with 5-0 or 
6-0 absorbable suture with a swaged on needle. The skin incision was closed with the same suture 
in a simple interrupted pattern or with wound clips. The same procedure was repeated on the 
opposite side of the mouse to produce a WT ovariectomized mouse (OVX) with one Edn2KO 
ovary under each kidney capsule. Control mice were also produced with WT ovaries inserted under 
the kidney capsule. Mice were allowed to recover and skin suture or wound clips were removed 7 
days later. Post-surgical mice were transferred to a clean, warm cage. Mice were placed on a paper 
towel in ventral or lateral recumbency with head slightly extended. A paper towel was placed under 
the rodent to minimize bedding adhering to the incision site. Each mouse was given a subcutaneous 
injection of warm sterile saline (1-2 cc/25g body weight) to avoid dehydration. For pain control, 
carprofen 5mg/kg was be injected subcutaneously. Temperature in the recovery area was 
controlled to prevent hypothermia during recovery. Supplemental heat was provided by placing 
the recovery cage on a slide warmer. The cage was warmed to 80-86°F (26.7-30°C) and the animal 
was provided a means to move away from the heat source once awake. The anesthetized mouse 
should was observed at least every 10 minutes until it was able to move about the cage on its own 
to ensure that it did not crawl into a corner and obstruct its nose. Frequent stimulation such as 
touching and moving the mouse was performed. The followings were interpreted as signs of pain 
or distress: constant facial expression of discomfort (orbital tightening, nose bulge, cheek bulge, 
and "pulled back" ear position), facial wiping with the forelimb, licking, biting, and scratching the 
surgical wound, and additional carprofen was administered every 12 hours. 
 
Serum Steroid Measurement 
Progesterone was considered the principle hormone measured and all others were 
secondary. Samples were prepared by spinning down whole blood after clotting and removing the 
serum supernatant. 10 μL of mouse serum was mixed with 50 μL methanol and 1 μL of 2 μg/mL 
D9-progesterone, followed by the rigorous centrifugation. The supernatant was subjected to 
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LC/MS/MS injection at the Metabolomics Center at the University of Illinois at Urbana-
Champaign by Dr. Lucas Li. The standard solutions for the calibration curve used double charcoal-
stripped steroid free mouse serum provided by Dr. Kee Jun Kim and followed the same extraction 
protocol as the serum samples. For detection, samples were analyzed with the 5500 QTRAP 
LC/MS/MS system (AB Sciex, Foster City, CA) in Metabolomics Lab of Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana-Champaign.  The 1200 series HPLC system 
(Agilent Technologies, Santa Clara, CA) includes a degasser, an autosampler, and a binary pump. 
The LC separation was performed on an Agilent Zorbax SB-Aq column (4.6 x 50mm, 3.5μm.) 
with mobile phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in 
acetonitrile). The flow rate was 0.3 mL/min. The linear gradient was: 0-2 min, 60%A; 6-12 min, 
0%A; 12.5-17 min, 60%A. The autosampler was set at 5°C. The injection volume was 5 μL. Mass 
spectra were acquired under positive electrospray ionization (ESI) with the ion spray voltage of 
5500 V. The source temperature was 550°C. The curtain gas, ion source gas 1, and ion source gas 
2 were 38, 50, and 65, respectively. Multiple reaction monitoring (MRM) was used 
to measure progesterone (m/z 315.1-->m/z 97.1) with D9-progesterone used as internal standard 
(m/z 324.1 --> m/z 100.1). 
For additional steroid profiling, samples were prepared by using 20 μL mouse serum 
sample mixed with 40 μL methanol and 1 μL 2 μg/mL D9-progesterone, followed by the rigorous 
centrifugation. The supernatant was subject to LC/MS/MS injection. The standards solutions for 
the calibration curve again used double charcoal-stripped steroid free mouse serum, and followed 
the same extraction protocol as the serum samples. Samples were again analyzed with the 5500 
QTRAP LC/MS/MS system (AB Sciex, Foster City, CA) in Metabolomics Lab of Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana-Champaign.  The LC separation was 
performed on a Phenomenex C6 Phenyl column (2.0 x 100mm, 3μm.) with mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). The flow rate was 
0.25 mL/min. The linear gradient was as follows: 0-1 min, 80%A; 10 min, 65%A; 15 min, 50%A; 
20 min, 40%A; 25 min, 30%A; 30 min, 20%A; 30.5-38 min, 80%A. The autosampler was set at 
5°C. The injection volume was 5 μL. Mass spectra were acquired under positive electrospray 
ionization (ESI) with the ion spray voltage of 5500 V. The source temperature was 500 °C. The 
curtain gas, ion source gas 1, and ion source gas 2 were 36 psi, 50 psi, and 65 psi, respectively. 
Multiple reaction monitoring (MRM) was used to measure steroids with the following transitions 
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(Q1-->Q3) with D9-progesterone as internal standard (m/z 324.1 --> m/z 100.1). Progesterone Q1 
(m/z): 315.1, Q3 (m/z): 97.0; 5β-corticosterone Q1 (m/z): 349.2, Q3 (m/z): 313.2; 
deoxycorticosterone/11β-hydroxyprogesterone Q1 (m/z): 331.2, Q3 (m/z): 97.1; pregnenolone Q1 
(m/z): 317.1, Q3 (m/z): 299.0.  
 
RT2 Profiler PCR Array 
To conduct a rapid and pathway-focused expression analysis of multiple genes, the female 
infertility RT2 Profiler PCR Array (PAMM-164Z, Qiagen) was purchased. Whole ovarian RNA 
from hCG12 hours was compared between control mice and Edn2Flox/Flox Esr2-iCre mice. Total 
RNA from ovaries from five to eight mice was pooled for analysis. Six genes were used for 
normalization. Genes examined and their associated pathways are listed in Tables 6.1 and 6.2. 
Pathway analysis was conducted by averaging the fold change expression from each gene within 
a pathway; pathways were grouped by the manufacturing company and were not modified in name 
or group; data analyses were conducted according to the manufacturer’s instructions. 
 
Phenylephrine Treatment 
Mice, either WT or Edn2Flox/Flox Esr2-iCre, at 25 days of age underwent superovulation 
treatment with PMSG and hCG as above. At 11 hours after hCG injection, the treatment group of 
mice also received injection with 1.0ug phenylephrine HCl dissolved in 100uL of sterile saline. 
Phenylephrine is a specific alpha-1 adrenergic receptor agonist; binding induces GPCR-mediated 
vasoconstriction. Oocytes were collected at hCG24 hours from oviducts of treated mice and 
quantified. As Edn2Flox/Flox Esr2-iCre mice  
 
Statistical Analysis 
 Data analyses were performed using statistical software (SPSS, Inc., released 2013, PASW 
Statistics for Windows, Version 22.0, Chicago, IL). Continuous data were tested for normal 
distribution by a Shapiro-Wilk test. All normally distributed continuous data were analyzed with 
parametric tests (student’s t-test, ANOVA, or paired student’s t-test) and a Bonferroni post hoc 
test. All non-normally distributed continuous data were transformed by log function to a normal 
distribution if possible or analyzed by non-parametric tests (Mann Whitney U, Kruskal Wallis 
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ANOVA). Ordinal data were similarly analyzed. Data are graphically presented as the mean and 
standard error of the mean unless otherwise indicated. For all analyses the alpha value was 0.05.  
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RESULTS AND DISCUSSION 
 
The aim of this study was discover the physiological role of EDN2 during ovulation in the 
mouse as a translational model for human ovulation. Four new mouse models were generated in 
which Edn2 was lost within the granulosa cells of the ovary during the primary follicle, secondary 
follicle, or preovulatory stage, or throughout the entire ovary following surgical transplantation. 
The data demonstrated that loss of Edn2 caused a decrease in litter size because fewer oocytes 
were ovulated, although mice retained the ability to give birth to healthy pups and to form 
morphologically and functionally normal corpora lutea. 
 
Generation of Edn2KO mice by Edn2 exon2 ablation 
 First, global Edn2 knockout mice (Edn2KO) were generated by breeding Edn2Flox mice 
with Zp3Cre mice, and then crossing heterozygotes as breeders. The Edn2KO mice generated were 
comparable to previous reports on global Edn2 loss by Chang et al. (2013)223, though Edn2KO 
mice used in this study were generated by ablating the second exon which contains the biologically 
active peptide sequence as opposed to previous work where a neomycin cassette was inserted into 
the gene. Edn2KO mice here were unhealthy and generally expired by 8-10 days of age (range 0-
18 days), despite supplemental heat and nutrition with Peptamen (Nestle). This is earlier than 
reported by Chang et al., who observed expiration at 3-4 weeks474. Edn2KO mice in each study 
were noticeably smaller by post-natal day 6 (PND6) despite heat supplementation, which suggests 
that observed growth retardation was due to starvation (Figure 6.1). Though not quantified, milk 
was present in the stomachs and intestines of sacrificed Edn2KO pups similar to control siblings, 
confirming findings from Chang et al. that internal starvation is not due to failure to nurse. 
Starvation has a powerful impact on reproductive ability; two days of starvation is sufficient to 
prevent subsequent ovulation in hamsters475, and gonadotropin stimulation is insufficient to induce 
follicle development or ovulation after eight days of starvation475,476. This suggests that previous 
observations by Cacioppo et al. (2014)171 in which gonadotropin-stimulated Edn2KO mice failed 
to ovulate and form corpora lutea (CL) may be, at least partially, due to nutritional deficiencies. 
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Edn2KO mice have normal follicular development to PND6  
 Although Edn2KO mice are nearly half the size of their siblings by mass at PND6 (Figure 
6.1C), ovarian / follicular development is largely unaffected. Ovaries examined at PND6 appear 
histologically normal (Figure 6.1B), and demonstrate follicles of all levels of maturity, excluding 
the antral (tertiary) and preovulatory (Graafian) stages. When these young ovaries were serially 
sectioned and the numbers of follicles were counted (n=10), there was no difference between 
Edn2KO and WT in the absolute numbers of germ cells (1032±152 vs 1496±314, p=0.068), 
primordial (3870±569 vs 3497±385, p=0.520), primary (1482±150 vs 1169±127, p=0.078), or 
preantral follicles (112±102 vs 41±34, p=0.376) per ovary (Figure 6.2). There was also no 
difference in the percentage of these follicles relative to total follicle+germ cell number (Figure 
6.2), excepting germ cells (16.3±0.9% vs 22.6±2.4%, p=0.007) which were slightly but 
significantly elevated in Edn2KO PND6 ovaries. These data, in addition to a trend towards a lower 
percentage of primordial follicles (59.0±1.5% vs 56.9±0.7%, p=0.057) in Edn2KO ovaries (Figure 
6.2), indicate that germ cell nest breakdown and/or germ cell maturation into primordial follicles 
may be slighted retarded. Differences between genotypes may become statistically significant if 
n-values were greatly increased. However, these data indicate that follicle development and 
maturation is largely capable of occurring in a time span comparable to control mice, and the total 
number of germ cells remains intact within the ovary.  
 
Edn2KO KOT ovaries have mature follicles and form CL 
To remove confounding systemic effects and focus specifically on the ovary, Edn2KO 
ovaries and controls were removed at PND6 and grafted under the kidney capsule of OVX WT 
mice (Figure 6.3A) to generate Edn2KO KOT ovaries and WT KOT ovaries, respectively. Ovaries 
were allowed to mature to 24 days of age, when response to gonadotropin stimulation is observed 
in WT intact mice. At grafted ovarian age 24 days (PND50 for the recipient mouse), superovulation 
as performed and ovaries and sera were collected at hCG12 and hCG24 hours. When histologically 
examined at hCG24 hours, corpora lutea and antral follicles were present in Edn2KO KOT ovaries 
similar to WT KOT ovaries and WT intact age-matched mice (Figure 6.3A). Ovaries were 
misshapen owing to space restriction under the kidney capsule, but were capable of successful 
follicle maturation and CL formation. Quantitative RT-PCR was performed at hCG12 hours to test 
that Edn2 expression remained lost in Edn2KO KOT ovaries, and ovarian cells had not been 
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replaced by the surgical process. Additionally, Edn1 expression was examined as EDN1 acts 
through the same receptors with the same affinity as EDN2295. Expression of Edn2 was effectively 
0 in in Edn2KO KOT ovaries, indicating that ovarian EDN2 production did not occur after surgical 
graft and superovulation (Figure 6.3B). Surprisingly, expression of Edn1 was also decreased 
(p=0.006), indicating that compensatory expression did not occur. Additionally, there was a trend 
for decreased Edn2 expression in WT KOT ovaries at hCG12 hours (p=0.086, n=5-7), indicating 
that the ovarian graft process itself likely impedes the ovarian ability to produce EDN2.  
 
Edn2KO KOT ovaries have oocytes trapped within CL and more AF 
No ovulated oocytes were observed under the kidney capsule in either KOT group at 
hCG24 hours, likely because the collagenous kidney capsule prevented extrusion of antral fluid 
and the cumulus oocyte complex (COC) from the ovary. As oocytes were not present in the 
majority of CL from WT KOT ovaries (<20%), oocytes were likely expelled from the follicle and 
then failed to thrive in the environment under the kidney capsule about the ovary. The number of 
CL may be considered a marker for potential ovulation, though it must be noted that the recipient 
mice were old enough to enter a natural estrus and present CL may be resultant from ovarian 
cycling prior to superovulation. Mouse CL persist for multiple estrous cycles71. To quantitatively 
explore folliculogenesis in Edn2KO KOT mice, ovaries from hCG24 hours were serially 
sectioned. By absolute count per ovary, there were significantly more antral follicles (AF) and 
significantly fewer CL in Edn2KO KOT ovaries than in WT intact ovaries, though there was no 
significant difference with WT KOT ovaries (Figure 6.4). Similarly, there was no significant 
difference in the percentage of AF or CL in Edn2KO KOT ovaries compared to WT KOT (Figure 
6.4, Figure 6.5). However, Edn2KO KOT ovaries had a significantly increased percentage of 
oocytes trapped within CL compared to both WT intact and WT KOT ovaries (82.6±7.2% vs 
11.9±7.0% and 16.8±8.4%, p=0.004, 0.004, respectively). These data strongly suggest that oocyte 
release from the follicle is impaired, but not completely prevented, in Edn2KO-deficient ovaries. 
Additionally, as there was a greater percentage of AF (64.3±5.2% WT KOT vs 44.8±4.3% intact, 
p=0.036) and decreased percentage of CL in WT KOT ovaries (35.7±5.3%) compared to WT intact 
(55.2±4.4%, p=0.036), the kidney graft itself may partially inhibit corpora lutea formation. No 
differences in amounts of hemorrhagic follicles were observed (Figure 6.4). No differences in 
serum hormone concentrations of progesterone, 5β-corticosterone, or deoxycorticosterone (Figure 
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6.6) were observed at hCG12 or hCG24 hours, though there may be a trend towards decreased 
progesterone concentrations in Edn2KO KOT ovaries at hCG24 hours (p=0.168). This may be 
reflective of fewer CL were present, though there is a large degree of variability in serum hormone 
concentration in all groups. Taken together, these data demonstrate that ovaries may form large 
antral follicles and functional CL though lacking ovarian EDN2 production, though the ovulatory 
ability of the ovaries cannot be determined. 
 
Generation of granulosa cell-specific Edn2KO mice 
To overcome limitations of surgical tissue transplantation, conditional Edn2 knockout mice 
were generated. The genes progesterone receptor (Pgr), aromatase (Cyp19), and estrogen receptor 
beta (Esr2) are all expressed within the mouse ovary within the granulosa cells. Expression of Pgr 
occurs in preovulatory follicles only six hours before ovulation in the mouse199,477; Cyp19 
expression begins in the secondary follicles to allow estrogen production from theca cell-provided 
testosterone69,478; and Esr2 expression occurs within the granulosa cells of primary follicles 
following recruitment432,479. Thus each of these genes may be used to target granulosa cells with 
the Cre/LoxP system. Mice expressing Cre recombinase (or codon-improved Cre172, iCre) under 
the promoters of each of these genes were crossed with Edn2Flox mice. Mice were superovulated 
at 25 days of age and tissues were collected at hCG12 and hCG24 hours (Figure 6.7A, top), or 
mice underwent a fertility assay with proven male breeders in sets of 10 day pairings (Figure 6.7A, 
bottom). When ovaries were collected at hCG24 hours and histologically sectioned, ovaries from 
each genotype appeared healthy with immature and antral follicles and corpora lutea present 
(Figure 6.7B). Many antral follicles were present in Edn2Flox/Flox Cyp19-iCre and Esr2-iCre 
mice.  
 
Edn2Flox/Flox Esr2-iCre mice gave birth to smaller litters and ovulate fewer oocytes 
Fertility assay revealed no significant difference in the percentage of litters born per pairing 
in any genotype (Figure 6.8A). Occurrence of mating behavior and presence of a vaginal plug were 
not different between groups. However, the average number of pups per litter was significantly 
reduced in Edn2Flox/Flox Cyp19-iCre and Esr2-iCre mice compared to WT mice (4.67±0.71 and 
4.29±1.02 vs. 8.50±0.60, p=0.022 and 0.008, respectively). Semi-quantitative RT-PCR for Edn2 
revealed a graded decrease in expression relative to the time of Cre expression. Compared to WT 
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mice (100±10.7%), Cyp19-iCre (17.8±3.2%, p=0.011) and Esr2-iCre (2.4±0.6%, p<0.001) mice 
had significantly reduced Edn2 expression at hCG12 hours (Figure 6.8B). No increase in Edn1 
was observed in Edn2Flox/Flox PR-Cre (70.4±9.2%, p=0.214) or Cyp19-iCre mice (67.7±11.3%, 
p=0.800) when compared to control mice (100%±13.1%), though Edn1 expression was slightly 
yet significantly elevated in Edn2Flox/Flox Esr2-iCre mice (148.6±11.4%, p=0.047). 
Edn2Flox/Flox Esr2-iCre mice demonstrated the greatest reduction in Esr2-iCre expression. To 
confirm this, quantitative RT-PCR was performed with a Taqman system. Expression of Edn2 was 
reduced by 97.6% percent in Esr2-iCre conditional knockout mice (Figure 6.8C). Additionally, 
endothelin protein expression was significantly reduced in whole ovaries at hCG12 hours as well 
(Figure 6.8D). Total proteins were measured as antibodies are unable to discriminate between 
EDN1, EDN2, EDN3, and their prepro-forms. As Edn1 and Edn3 expression do not change in WT 
ovaries during ovulation199, the increase in endothelin protein from hCG0 to hCG12 is caused by 
an increase in Edn2 transcription. Lack of Edn2 upregulation thus accounts for the difference in 
endothelin protein content between WT and Edn2Flox/Flox Esr2-iCre mice at hCG12 hours.  
To confirm that differences in fertility were due to an ovulatory defect caused by Edn2 
ablation, mice were superovulated and oocytes were collected and counted from the oviduct at 
hCG24 hours. This bypasses pituitary signaling and accounts for possible delayed ovulation by 
about 12 hours. Edn2Flox/Flox Esr2-iCre mice had significantly decreased oocytes ovulated 
(3.75±0.88 vs 16.36±1.85 oocytes per ovary, p<0.001), further suggesting a defect in oocyte 
expulsion. Follicle counting was performed on Edn2Flox/Flox Esr2-iCre ovaries after serial 
sectioning, revealing that they had significantly more AF (43.3±4.1 vs 31.3±2.7, p=0.045), a 
significantly greater percentage of AF (90.5±2.7% vs 77.2±3.9%, p=0.019), and a significantly 
lower percentage of CL (9.5±2.7% vs 22.8±3.9%, p=0.013) (Figure 6.9). There was no difference 
in the number of hemorrhagic follicles, and no or few oocytes trapped within CL were observed 
in any ovary. These data additionally indicate a partial defect in follicle rupture which prevents 
CL formation after loss of Edn2. However, mice may become pregnant to parturition with a normal 
(21 day) pregnancy period despite giving birth to smaller litters. Additionally, there was no 
significant difference in serum progesterone concentration at hCG24 hours (Figure 6.10). The 
ovulation of only four oocytes on average after excessive gonadotropin stimulation and the 
successful birth of four pups/litter on average indicates that defects are likely exclusively in the 
ovary though Esr2 and Edn2 are both expressed in the uterus368,382,449. Overall, the Edn2Flox/Flox 
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Esr2-iCre mouse demonstrates stark loss of Edn2 expression, and consequently endothelin 
proteins, and has obvious defects in follicle rupture from the ovary, and is thus an ideal tool for 
further investigation of the mechanisms underlying EDN2 function during ovulation. 
 
RT2 Profiler PCR Array reveals no major changes in Edn2Flox/Flox Esr2-iCre ovaries 
Next, to determine what genetic pathways may be modified during ovulation as a 
consequence of EDN2 loss, an RT2 PCR Profiler Array (Qiagen) was run to specifically examine 
genes known to be involved in female infertility. RNA from ovaries at hCG12 hours in 
Edn2Flox/Flox Esr2-iCre or WT mice was pooled, reverse transcribed to cDNA, and run on the 
RT2 plate. The array examines differences in expressions in 84 genes, and normalizes expression 
to six housekeeping genes. The genes tested and their alternative names are listed in Table 6.1. 
Complete results from the array are listed in Table 6.2. It was not possible to determine p-values 
for individual gene expression changes as each gene was only examined once per mouse genotype, 
but differences in fold expression were calculated and comparisons were made relative to WT 
ovary expression levels. Of the 84 genes examined, only 10.7% showed greater than a two-fold 
change in genetic expression (fold regulation) (Figure 6.11A); genes with less than a two-fold 
change in fold regulation were considered to not demonstrate noteworthy differences. 5.9% of 
genes were upregulated and 4.7% were downregulated. Progesterone receptor (Pgr) had the 
greatest change in regulation and was upregulated 13.17 fold (Figure 6.11A). Secreted 
phosphoprotein 1 (Spp1) had the greatest downregulation of any gene (-5.28 fold). Other genes 
modified include Areg, Pgf, Cfd, Il6, F3, Hoxa10, and Wnt2. The majority of genes were not much 
changed as observed by RT2 array (Figure 6.12). 
 
Gene expression changes reflect lack of ovulation, not direct EDN2 signaling 
Of those genes with differing expression, each has been implicated in the ovary or 
ovulation to some degree. PGR is required for ovulation and knockout mice are completely 
infertile, and it has highest production at hCG6 hours. It is interesting that EDN2 may 
downregulate the gene governing its own expression, potentially in a negative feedback loop; 
alternatively, Pgr expression may rise in response to delayed follicle rupture. Interestingly, when 
compared to unpublished microarray data using global Edn2KO (neomycin insertion) ovaries171, 
there was no difference in Pgr expression. Amphiregulin is known to be downstream of the Pgr 
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gene, and its upregulation at hCG12 may directly reflect Pgr upregulation480-482. Amphiregulin 
may also be a stimulator of RUNX1, and may be upregulated in response to lack of Edn2 
expression483. As Pgr is upregulated and Pgr-KO mice are infertile, the differences in fertility are 
likely not modified by Pgr. The decrease in Spp1 expression (also known as osteopontin, Opn) 
may be reflective of the lack of epidermal growth factors that are highly expressed during CL 
formation; Spp1 peaks in cultured granulosa cells at hCG16 hours (post-ovulation) and enhances 
progesterone synthesis in the early luteal phase484. Placental growth factor (Pgf) is an angiogenic 
factor similar to VEGF485 which is slightly upregulated in Edn2Flox/Flox Esr2-iCre ovaries, 
though there has been little exploration to its role during ovulation. Expression of Pgf is directly 
related to oxygen tension486. Hypoxia and hypoxic factors normally increase during ovulation, but 
as ovulation does not occur in the knockout ovaries, hypoxia may persist and Pgf may be slightly 
upregulated. However, the RT2 profiler array did not examine expression of hypoxia-inducible 
factor genes. Previous data from the global Edn2KO ovary microarray indicates that HIF factors 
are slightly upregulated (1.4-1.7 fold increase), which may cause this mild change in Pgf.   
Compliment factor D (adipsin, Cfd) is a serine protease that is regulated by C3bB487, which 
has been implicated in trout ovulation in one study488 as a potential contractile agent, though 
expression is highest 12 hours after ovulation in the trout and it is thus likely not involved directly 
in ovulation. Downregulation of Cfd in the Edn2Flox/Flox Esr2-iCre ovaries may result from 
changes protease activity that are normally necessary for tissue organization after ovulation. 
Interleukin 6 (Il6) is a cytokine and potent mediator of immune responses. It is a known regulator 
of the COC expansion process489, and is necessary for LH receptor upregulation during granulosa 
cell differentiation490. As knockout ovaries fail to form as many CL and thus fewer granulosa cells 
differentiate, it is logical that Il6 might be consequently downregulated. The observed upregulation 
of coagulation factor 3 (thromboplastin, tissue factor, F3) is surprising, given that there is no 
difference in observed hemorrhage and that less follicular rupture occurs which would necessitate 
less coagulation. Coagulation factor 3 is known to be upregulated in women with polycystic ovary 
syndrome (PCOS), and may be reflective of the retained antral follicles of the Edn2-ablated group. 
HoxA10 is a homeobox gene necessary for embryonic development of the body axis, but HoxA10 
knockout mice survive to adulthood and ovulate normally491; females only show modified 
implantation, while males retain testes. The ninth gene upregulated more than two-fold, Wnt2, is 
a secreted glycoprotein that is expressed in the granulosa cells and works to counteract activing-
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stimulated signaling492. It has been previously demonstrated that Wnt2 overexpression has no 
resultant transcriptional activity, and though Wnt2 may be modified in response to changed 
activing levels, it is also unlikely to be directly modified by loss of EDN2. 
 
Genes postulated to be involved in EDN2-mediated changes are not differentially regulated 
It has been conjectured that EDN2 modulates ovulation via alteration of angiogenic growth 
factors, collagenase and proteinase activity, or apoptosis. Relevant genes analyzed in the RT2 
Array are listed in Figure 6.11B, and include Casp3, Esr1, Esr2, Mmp2, Mmp7, Mmp9, Ptgs1, 
Pgts2, Timp1, Vegfa, and Trp53. None of these genes had over a two-fold difference in expression 
either up or down. Additionally, the pathways involved did not show a common directional change 
in expression, with the exception of estrogen receptors which were both decreased. For instance, 
Mmp2 and Mmp7 showed decreased expression, while Mmp9 and Timp1 were upregulated. Such 
inconsistencies and low changes in expression suggest that the genes, their effect, and their 
encompassing pathways are largely unchanged by absence of EDN2. To confirm this, the 
expression changes of all genes within a functional pathway were averaged; pathways were pre-
defined by the manufacturer (Table 6.2). No pathway showed an average fold change greater than 
1.50 or less than 1.50, showing that in general there was no specific pathway that was modified in 
response to EDN2 loss. Surprisingly, the pathway that demonstrated the greatest average fold 
change were the control genes (Figure 6.11); as these controlled for contamination in the sample 
and the majority were read at above 35 cycles, these data can be ignored. The next two pathways 
with the greatest change were those described as “General Infertility” and “Receptive / Oocyte 
Support.” As the names suggest, neither pathway has a directed influence on ovulation, but are 
more closely related to the uterine tissue for which this array was originally designed. The high 
standard deviation of each suggests that the differences observed are caused by one or two genes 
per group, such as Pgr, that modify the overall average expression change. The only pathway that 
demonstrated a consistent shift with little variation was upregulation of genes involved in the Cell 
Cycle (+1.17, Stdev=0.09). This may indicate that a greater percentage of actively growing cells 
were present in the Edn2Flox/Flox Esr2-iCre ovaries. As fewer cumulus oocyte complexes rupture 
from these ovaries compared to WTs during ovulation, and the cells of the these complexes are 
highly active, the overall slight increase in the Cell Cycle pathway may represent an increased 
amount of cumulus granulosa cells and oocytes per ovary. 
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The majority of genes were not much changed as observed by RT2 array (Figure 6.12), 
which suggests that EDN2 mediates a direct physiological effect through its receptors rather than 
a transcriptional cascade. EDN2 functions through its receptors to elicit smooth muscle 
contraction. Muscle cell depolarization is caused by Ca2+ influx. Endothelin receptor A stimulates 
this via a Gq/11-driven phospholibase C-β pathway and a G12/13-Rho kinase pathway208. Lack of 
stimulation of this receptor pathway would fail to cause smooth muscle contraction, which may 
normally mediate an increase of follicular pressure to cause rupture of the follicular wall. This 
contraction may also promote local vasoconstriction, which would in turn increase local blood 
pressure, which could then prompt vessel rupture, bleeding into the periovulatory follicle, an 
increase in volume and consequential follicle rupture345,493, and early formation of the corpus 
hemorrhagicum494.  
 
Pgr expression is not significantly modified in Edn2Flox/Flox Esr2-iCre mice 
 To confirm RT2 Profiler Array findings regarding an elevation in Pgr expression, RT-PCR 
was performed at hCG6 and 12 hours in ovaries from Edn2Flox/Flox Esr2-iCre and control mice 
using Taqman probes. Results of RT-PCR analysis revealed no significant difference in Pgr 
expression at either time point (Figure 6.13). The same ovaries used in the profiler array were 
combined with three additional ovaries of each genotype to confirm results. There was a significant 
difference in Pgr expression between ovaries collected at each sampling day. This is attributed to 
slightly different collection times in individual ovaries and individual variation, where those first 
ovaries used for the RT2 Profiler had already likely achieved ovulation and begun forming corpora 
lutea. As Pgr expression rises in CL to allow a feedback loop, the increase in Pgr, and thus 
amphiregulin, is likely caused by differences in timing of collection relative to ovulation and does 
not reflect differences in gene expression dependent upon EDN2 signaling. 
 
Phenylephrine decreases ovulatory ability and does not restore ovulation to conditional knockout 
mice 
 To attempt to restore ovulatory ability to Edn2Flox/Flox Esr2-iCre mice and to test the 
hypothesis that EDN2 ligand operates through calcium channel-induced contraction, mice were 
treated with phenylephrine (1.0ug/100mL i.p.) at hCG11 hours. Phenylephrine is an alpha 
adrenergic agonist, and activates the same three voltage and ligand operated calcium channels as 
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are triggered by endothelin receptor A signaling208. It also has a similar half-life to endothelins. 
However, addition of phenylephrine did not restore ovulatory ability to Edn2Flox/Flox Esr2-iCre 
mice (Figure 6.14). In WT mice, phenylephrine treatment significantly reduced ovulatory ability. 
This is in contrast to previous reports by Branstrom et al. (2001)493. Phenylephrine acts as a 
systemic vasoconstrictor, increasing overall blood pressure. The dose used was chosen as it is 1% 
of the LD50 dose, and is potent without causing vascular changes that could fatally induce 
hypertension. However, increases in blood pressure are inversely related to changes in follicular 
pressure493. It is most likely here that phenylephrine modifies ovulatory ability in control mice by 
systemic changes in blood pressure, which similarly fails to restore ovulatory ability in 
Edn2Flox/Flox Esr2-iCre mice. Differences between these results and previous studies in 
ovulation may be due to differences in dose administered or strain of mice used. Future work may 
focus instead on methods to specifically induce calcium channel-dependent contraction within the 
ovary without modifying global vascular tension as a method to demonstrate ovulatory 
dependency upon EDN2-induced ovarian contractions. 
 
Conclusions and future directions 
In summary, systemic loss of Edn2 causes early juvenile death, likely through starvation, 
though ovarian development is little affected by PND6. Whole-ovarian loss of Edn2 does not 
prevent CL formation in healthy adult mice, though follicle rupture remains impaired. Granulosa 
cell-specific loss of Edn2 at various times during folliculogenesis causes smaller litter size and 
fewer oocytes ovulated (subfertility), although all mice retain the ability to give birth to healthy 
pups and to form morphologically normal corpora lutea. The range of severity varies with timing 
of Cre expression, which is likely because of the time required for Cre recombinase to remove 
Edn2. A novel Esr2-iCre mouse successfully ablates the majority of ovarian Edn2 expression and 
protein production during ovulation. These mice have few changes in gene expression at hCG12 
hours, though protein is sharply reduced. Interestingly, Pgr is upregulated, which may otherwise 
be normally suppressed by EDN2. As few genes are changed, the cause of subfertility likely occurs 
through the normal contractile and vasoconstrictive properties of EDN2. These data support that 
EDN2 acts as a final trigger for ovulation. Speculatively, it may also have an effect on tension in 
the oviduct or uterus to increase the frequency or intensity of their continual contractions for fluid 
or germ cell transport. Future studies may focus on the physiological role of EDN2 through 
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supplementation of endothelins to conditional knockout mice during ovulation compared to other 
contractile agents that act through unchanged receptor pathways. Successful ovulation in 
Edn2Flox/Flox Esr2-iCre would be indicative for an EDN2-driven follicular contractile force 
during ovulation to drive oocyte expulsion and subsequent CL formation. 
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TABLES 
 
Table 6.1. Genes examined in RT2 Female Infertility Profiler Array. Symbol correlates with NCBI gene database. Housekeeping 
genes used for normalization are listed last. Continued on multiple pages. 
Symbol Description Alt. Gene Names 
Akt1 Thymoma viral proto-oncogene 1 Akt/ PKB/ PKB/ Akt/ PKBalpha/ Rac 
Anxa2 Annexin A2 AW215814/ Cal1h 
Apod Apolipoprotein D - 
Ar Androgen receptor AW320017/ Tfm 
Areg Amphiregulin AR/ Sdgf 
Bax Bcl2-associated X protein - 
Bcl2 B-cell leukemia/lymphoma 2 AW986256/ Bcl-2/ C430015F12Rik/ D630044D05Rik/ 
D830018M01Rik 
C2 Complement component 2 (within H-2S) - 
C3 Complement component 3 AI255234/ ASP/ HSE-MSF/ Plp 
Calca Calcitonin/calcitonin-related polypeptide, alpha CA/ CGRP-1/ CGRP1/ Calc/ Calc1/ Cgrp/ Ct/ Ctn/ 
calcitonin 
Casp3 Caspase 3 A830040C14Rik/ AC-3/ Apopain/ CASP-3/ CC3/ CPP-
32/ CPP32/ Caspase-3/ Lice/ SCA-1/ Yama/ mldy 
Ccl5 Chemokine (C-C motif) ligand 5 MuRantes/ RANTES/ SISd/ Scya5/ TCP228 
Ccnb1 Cyclin B1 Ccnb1-rs1/ Ccnb1-rs13/ CycB1/ Cycb-4/ Cycb-5/ Cycb1-
rs1 
Cd55 CD55 antigen Daf/ Daf-GPI/ Daf1/ GPI-DAF 
Cdh1 Cadherin 1 AA960649/ E-cad/ Ecad/ L-CAM/ UVO/ Um 
Cfd Complement factor D (adipsin) Adn/ DF 
Cldn4 Claudin 4 Cep-r/ Cpetr/ Cpetr1 
Comp Cartilage oligomeric matrix protein TSP5 
Crabp2 Cellular retinoic acid binding protein II AI893628/ Crabp-2/ CrabpII 
Csf1 Colony stimulating factor 1 (macrophage) C87615/ Csfm/ MCSF/ op 
Ctnnb1 Catenin (cadherin associated protein), beta 1 Bfc/ Catnb/ Mesc 
Cxcl12 Chemokine (C-X-C motif) ligand 12 Pbsf/ Scyb12/ Sdf1/ Tlsf/ Tpar1 
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Table 6.1. Continued from previous page. 
Dkk1 Dickkopf homolog 1 (Xenopus laevis) mdkk-1 
Egf Epidermal growth factor AI790464 
Egfr Epidermal growth factor receptor 9030024J15Rik/ AI552599/ Erbb/ Errb1/ Errp/ Wa5/ wa-
2/ wa2 
Esr1 Estrogen receptor 1 (alpha) AA420328/ AU041214/ ER-alpha/ ER[a]/ ERa/ ERalpha/ 
ESR/ Estr/ Estra/ Nr3a1 
Esr2 Estrogen receptor 2 (beta) ER[b]/ ERbeta/ Estrb 
F3 Coagulation factor III AA409063/ CD142/ Cf-3/ Cf3/ TF 
Fbn1 Fibrillin 1 AI536462/ B430209H23/ Fib-1/ Tsk 
Fn1 Fibronectin 1 E330027I09/ Fn/ Fn-1 
Gadd45a Growth arrest and DNA-damage-inducible 45 alpha AA545191/ Ddit1/ GADD45 
Gast Gastrin GAS 
Gdf15 Growth differentiation factor 15 MIC-1/ NAG-1/ SBF 
Gpx3 Glutathione peroxidase 3 AA960521/ EGPx/ GPx/ GSHPx-3/ GSHPx-P 
Hbegf Heparin-binding EGF-like growth factor AW047313/ Dtr/ Dts/ Hegfl 
Hoxa10 Homeobox A10 Hox-1.8/ Hoxa-10 
Hoxa11 Homeobox A11 Hox-1.9/ Hoxa-11 
Icam1 Intercellular adhesion molecule 1 CD54/ Icam-1/ Ly-47/ MALA-2 
Igf1 Insulin-like growth factor 1 C730016P09Rik/ Igf-1/ Igf-I 
Igfbp1 Insulin-like growth factor binding protein 1 - 
Il11 Interleukin 11 IL-11 
Il15 Interleukin 15 AI503618/ IL-15 
Il1a Interleukin 1 alpha Il-1a 
Il1b Interleukin 1 beta IL-1beta/ Il-1b 
Il1r1 Interleukin 1 receptor, type I CD121a/ CD121b/ IL-iR/ Il1r-1 
Il6 Interleukin 6 Il-6 
Itga4 Integrin alpha 4 CD49D/ Itga4B 
Itgav Integrin alpha V 1110004F14Rik/ 2610028E01Rik/ CD51/ 
D430040G12Rik 
Itgb3 Integrin beta 3 CD61/ GP3A/ INGRB3 
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Kdr Kinase insert domain protein receptor 6130401C07/ Flk-1/ Flk1/ Krd-1/ Ly73/ VEGFR-2/ 
VEGFR2/ sVEGFR-2 
Lama1 Laminin, alpha 1 AA408497/ Lama 
Lamc2 Laminin, gamma 2 AA589349 
Lep Leptin ob/ obese 
Lif Leukemia inhibitory factor - 
Lifr Leukemia inhibitory factor receptor A230075M04Rik/ AW061234/ LIF 
Maoa Monoamine oxidase A 1110061B18Rik/ AA407771 
Mid1 Midline 1 61B3-R/ DXHXS1141/ Fxy/ Trim18 
Mki67 Antigen identified by monoclonal antibody Ki 67 D630048A14Rik/ Ki-67/ Ki67 
Mmp2 Matrix metallopeptidase 2 Clg4a/ GelA/ MMP-2 
Mmp7 Matrix metallopeptidase 7 MAT 
Mmp9 Matrix metallopeptidase 9 AW743869/ B/ MMP9/ Clg4b/ MMP-9/ pro-MMP-9 
Msx1 Homeobox, msh-like 1 AA675338/ AI324650/ Hox-7/ Hox7/ Hox7.1/ msh 
Muc1 Mucin 1, transmembrane CD227/ EMA/ Muc-1 
Olfm1 Olfactomedin 1 AMY/ AW742568/ Noe1/ OlfA/ Pancortin/ Pancortin3 
Pcna Proliferating cell nuclear antigen - 
Pgf Placental growth factor AI854365/ PIGF/ Plgf 
Pgr Progesterone receptor 9930019P03Rik/ BB114106/ ENSMUSG00000074510/ 
NR3C3/ PR/ PR-A/ PR-B 
Prl Prolactin AV290867/ Prl1a1 
Ptgs1 Prostaglandin-endoperoxide synthase 1 COX1/ Cox-1/ Cox-3/ PGHS-1/ PHS 1/ Pghs1 
Ptgs2 Prostaglandin-endoperoxide synthase 2 COX2/ Cox-2/ PGHS-2/ PHS-2/ Pghs2/ TIS10 
Sell Selectin, lymphocyte AI528707/ CD62L/ L-selectin/ LECAM-1/ Lnhr/ Ly-22/ 
Ly-m22/ Lyam-1/ Lyam1 
Sfrp4 Secreted frizzled-related protein 4 - 
Sod1 Superoxide dismutase 1, soluble B430204E11Rik/ Cu/ Zn-SOD/ CuZnSOD/ Ipo-1/ Ipo1/ 
SODC/ Sod-1 
Spp1 Secreted phosphoprotein 1 2AR/ Apl-1/ BNSP/ BSPI/ Bsp/ ETA-1/ Eta/ OP/ Opn/ 
Opnl/ Ric/ Spp-1 
Stat3 Signal transducer and activator of transcription 3 1110034C02Rik/ AW109958/ Aprf 
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Stmn1 Stathmin 1 19k/ Lag/ Lap18/ Op18/ P18/ P19/ Pig/ Pp17/ Pp18/ 
Pp19/ Pr22/ Smn 
Tgfb1 Transforming growth factor, beta 1 TGF-beta1/ TGFbeta1/ Tgfb/ Tgfb-1 
Timp1 Tissue inhibitor of metalloproteinase 1 Clgi/ TIMP-1/ Timp 
Tnf Tumor necrosis factor DIF/ TNF-a/ TNF-alpha/ TNFSF2/ TNFalpha/ Tnfa/ 
Tnfsf1a 
Tnfrsf10b Tumor necrosis factor receptor superfamily, member 10b DR5/ KILLER/ Ly98/ MK/ TRAILR2/ TRICK2A/ 
TRICK2B/ TRICKB 
Trp53 Transformation related protein 53 Tp53/ bbl/ bfy/ bhy/ p44/ p53 
Vcam1 Vascular cell adhesion molecule 1 CD106/ Vcam-1 
Vegfa Vascular endothelial growth factor A Vegf/ Vpf 
Wnt2 Wingless-related MMTV integration site 2 2610510E18Rik/ Int1l1/ Irp/ Mirp/ Wnt-2/ Wnt2a 
Actb Actin, beta Actx/ E430023M04Rik/ beta-actin 
B2m Beta-2 microglobulin Ly-m11/ beta2-m/ beta2m 
Gapdh Glyceraldehyde-3-phosphate dehydrogenase Gapd 
Gusb Glucuronidase, beta AI747421/ Gur/ Gus/ Gus-r/ Gus-s/ Gus-t/ Gus-u/ Gut/ 
asd/ g 
Hsp90ab1 Heat shock protein 90 alpha (cytosolic), class B member 1 90kDa/ AL022974/ C81438/ Hsp84/ Hsp84-1/ Hsp90/ 
Hspcb 
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Table 6.2. Results from RT2 Female Infertility Profiler Array. Symbol correlates with NCBI gene database. Housekeeping genes 
used for normalization are listed last. Comparison is of Edn2Flox/Flox Esr2-iCre whole ovaries relative to age-matched WT ovaries. 
Pathways are supplied by the RT2 Profiler and were not modified to focus specifically on the ovary. Comments were automatically 
generated by the Profiler software and have not been modified. Fold change is resultant from one run using cDNA combined from 5 or 
8 ovaries from 5 or 8 mice (n=1), and p-values may not be generated. The Ct threshold was set to 35 (default) and values greater than 
35 are recorded as 35. “Comments: A: This gene’s average threshold cycle is relatively high (> 30) in either the control or the test 
sample, and is reasonably low in the other sample (< 30). These data mean that the gene’s expression is relatively low in one sample 
and reasonably detected in the other sample suggesting that the actual fold-change value is at least as large as the calculated and reported 
fold-change result. This fold-change result may also have greater variations if p value > 0.05; therefore, it is important to have a sufficient 
number of biological replicates to validate the result for this gene. B: This gene’s average threshold cycle is relatively high (> 30), 
meaning that its relative expression level is low, in both control and test samples, and the p-value for the fold-change is either unavailable 
or relatively high (p > 0.05). This fold-change result may also have greater variations; therefore, it is important to have a sufficient 
number of biological replicates to validate the result for this gene. C: This gene’s average threshold cycle is either not determined or 
greater than the defined cut-off value (default 35), in both samples meaning that its expression was undetected, making this fold-change 
result erroneous and un-interpretable. Fold-Change (2^(- Delta Delta Ct)) is the normalized gene expression (2^(- Delta Ct)) in the Test 
Sample divided the normalized gene expression (2^(- Delta Ct)) in the Control Sample. Fold-Regulation represents fold-change results 
in a biologically meaningful way. Fold-change values greater than one indicate a positive- or an up-regulation, and the fold-regulation 
is equal to the fold-change. Fold-change values less than one indicate a negative or down-regulation, and the fold-regulation is the 
negative inverse of the fold-change.” Continued on multiple pages. 
  
145 
Table 6.2. Continued from previous page. 
Position Symbol Control Ct 
Edn2Flox/Flox 
Esr2-iCre Ct 
Fold Regulation Comment Pathway 
A01 Akt1 22.71 23.28 -1.19 C 3 Signal Transduction 
A02 Anxa2 21.28 22.07 -1.38  9 Other 
A03 Apod 29.80 30.54 -1.34 A 9 Other 
A04 Ar 23.99 24.58 -1.21  9 Other 
A05 Areg 27.51 25.25 5.97  2 Receptive / Oocyte Support 
A06 Bax 24.64 25.03 -1.04  7 Apoptosis 
A07 Bcl2 26.49 26.96 -1.11  7 Apoptosis 
A08 C2 26.26 26.22 1.29  6 Coagulation 
A09 C3 22.07 22.75 -1.28  6 Coagulation 
A10 Calca 29.44 29.56 1.15  4 Leukocyte Migration 
A11 Casp3 26.22 26.76 -1.17  7 Apoptosis 
A12 Ccl5 30.38 30.91 -1.16 B 4 Leukocyte Migration 
B01 Ccnb1 24.29 24.45 1.12  5 Cell Cycle 
B02 Cd55 24.01 24.35 -1.01  6 Coagulation 
B03 Cdh1 25.19 25.59 -1.05  3 Signal Transduction 
B04 Cfd 25.21 26.91 -2.60  1 General Infertility 
B05 Cldn4 29.38 30.23 -1.44 A 1 General Infertility 
B06 Comp 28.34 29.04 -1.30  1 General Infertility 
B07 Crabp2 25.05 25.31 1.05  1 General Infertility 
B08 Csf1 27.20 27.39 1.10  8 Cytokines 
B09 Ctnnb1 21.84 22.17 -1.00  3 Signal Transduction 
B10 Cxcl12 24.14 24.76 -1.23  4 Leukocyte Migration 
B11 Dkk1 32.84 33.24 -1.06 B 3 Signal Transduction 
B12 Egf 30.92 31.17 1.05 B 3 Signal Transduction 
C01 Egfr 24.75 25.28 -1.15  3 Signal Transduction 
C02 Esr1 24.29 24.81 -1.14  9 Other 
C03 Esr2 24.27 24.88 -1.23  1 General Infertility 
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C04 F3 23.62 22.87 2.10  6 Coagulation 
C05 Fbn1 24.35 24.75 -1.06  4 Leukocyte Migration 
C06 Fn1 23.18 23.94 -1.35  4 Leukocyte Migration 
C07 Gadd45a 24.19 24.66 -1.11  1 General Infertility 
C08 Gast 33.22 33.72 -1.13 B 1 General Infertility 
C09 Gdf15 31.75 31.79 1.21 B 1 General Infertility 
C10 Gpx3 20.35 21.48 -1.75  1 General Infertility 
C11 Hbegf 30.42 30.34 1.31 B 9 Other 
C12 Hoxa10 29.18 30.54 -2.05 A 2 Receptive / Oocyte Support 
D01 Hoxa11 32.38 32.82 -1.08 B 2 Receptive / Oocyte Support 
D02 Icam1 26.74 26.89 1.13  4 Leukocyte Migration 
D03 Igf1 22.55 22.73 1.10  9 Other 
D04 Igfbp1 33.71 33.57 1.38 B 1 General Infertility 
D05 Il11 28.38 28.65 1.04  8 Cytokines 
D06 Il15 29.30 29.86 -1.18  8 Cytokines 
D07 Il1a 31.72 31.75 1.22 B 8 Cytokines 
D08 Il1b 29.96 30.10 1.14 A 8 Cytokines 
D09 Il1r1 23.92 24.23 1.00  8 Cytokines 
D10 Il6 26.75 28.40 -2.50  8 Cytokines 
D11 Itga4 29.23 29.53 1.02  4 Leukocyte Migration 
D12 Itgav 22.67 22.44 1.46  4 Leukocyte Migration 
E01 Itgb3 25.10 25.81 -1.31  4 Leukocyte Migration 
E02 Kdr 25.06 25.27 1.08  9 Other 
E03 Lama1 25.67 25.63 1.28  4 Leukocyte Migration 
E04 Lamc2 26.19 26.68 -1.13  4 Leukocyte Migration 
E05 Lep 31.64 32.12 -1.11 B 2 Receptive / Oocyte Support 
E06 Lif 29.00 30.19 -1.83 A 2 Receptive / Oocyte Support 
E07 Lifr 24.07 24.74 -1.27  2 Receptive / Oocyte Support 
E08 Maoa 27.48 27.83 -1.02  1 General Infertility 
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E09 Mid1 23.61 23.14 1.73  9 Other 
E10 Mki67 23.91 24.00 1.18  5 Cell Cycle 
E11 Mmp2 24.66 25.35 -1.29  4 Leukocyte Migration 
E12 Mmp7 31.07 31.54 -1.11 B 4 Leukocyte Migration 
F01 Mmp9 30.37 30.54 1.11 B 4 Leukocyte Migration 
F02 Msx1 28.70 28.47 1.46  7 Apoptosis 
F03 Muc1 30.16 30.32 1.12 B 2 Receptive / Oocyte Support 
F04 Olfm1 26.11 26.55 -1.08  1 General Infertility 
F05 Pcna 22.13 22.05 1.32  5 Cell Cycle 
F06 Pgf 29.53 28.43 2.67  9 Other 
F07 Pgr 27.48 24.08 13.17  2 Receptive / Oocyte Support 
F08 Prl 32.65 33.26 -1.23 B 9 Other 
F09 Ptgs1 27.03 28.26 -1.87  3 Signal Transduction 
F10 Ptgs2 23.25 22.74 1.78  3 Signal Transduction 
F11 Sell 31.45 31.91 -1.10 B 2 Receptive / Oocyte Support 
F12 Sfrp4 20.93 21.78 -1.44  1 General Infertility 
G01 Sod1 23.58 23.56 1.26  9 Other 
G02 Spp1 24.49 27.21 -5.28  1 General Infertility 
G03 Stat3 24.14 24.59 -1.09  3 Signal Transduction 
G04 Stmn1 23.48 23.70 1.07  5 Cell Cycle 
G05 Tgfb1 24.59 24.72 1.14  5 Cell Cycle 
G06 Timp1 24.70 25.68 -1.58  9 Other 
G07 Tnf 32.30 31.83 1.73 B 7 Apoptosis 
G08 Tnfrsf10b 26.18 26.25 1.19  7 Apoptosis 
G09 Trp53 25.53 25.57 1.22  7 Apoptosis 
G10 Vcam1 28.12 27.78 1.58  4 Leukocyte Migration 
G11 Vegfa 24.41 24.35 1.30  9 Other 
G12 Wnt2 33.31 32.61 2.02 B 3 Signal Transduction 
H01 Actb 18.70 19.19 -1.13  10 House Keeping Gene 
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H02 B2m 20.25 20.56 1.01  10 House Keeping Gene 
H03 Gapdh 20.40 20.67 1.03  10 House Keeping Gene 
H04 Gusb 26.86 27.13 1.03  10 House Keeping Gene 
H05 Hsp90ab1 20.05 20.32 1.04  10 House Keeping Gene 
H06 MGDC 34.66 33.78 2.30 B 11 Controls 
H07 RTC 35.00 35.00 1.25 C 11 Controls 
H08 RTC 35.00 35.00 1.25 C 11 Controls 
H09 RTC 35.00 35.00 1.25 C 11 Controls 
H10 PPC 23.48 23.47 1.25  11 Controls 
H11 PPC 23.52 23.45 1.31  11 Controls 
H12 PPC 24.03 23.41 1.92  11 Controls 
149 
FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Edn2KO PND6 pups are smaller but have normal ovarian development. A. Experimental plan for Edn2KO pups and control litter 
mates. Pups were euthanized at post-natal day 6 (PND6) and ovaries were removed and used for histology or grafted under the kidney capsule of 
28-32 day old control females. Mice were then superovulated and ovaries were collected. B. At PND6, collected ovaries were serially sectioned at 
5uM. Histology images are shown at 10X and 20X. No histological differences are apparent; all ovaries have a mix of germ cells, primordial follicles, 
primary follicles, and a few preantral follicles, despite a C. significant difference in body weight between Edn2KO and control sibling pups. Edn2KO 
pups (2.25±0.10g) are nearly half the mass of control siblings (4.12±0.25g) at PND6 (p<0.001), and the majority expire by PND8.   
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Figure 6.2. PND6 Edn2KO pups have significantly more ovarian germ cells than control mice. Follicle and germ cell counting was performed 
on PND6 Edn2KO and control ovaries (n=10) by PRH. Absolute cell counts are displayed at left and the percentage of total cells per ovary is 
displayed at right. A significant difference was seen between the percentage of germ cells present (p=0.007). No other significant differences were 
noted. Error bars display the S.E.M.  
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Figure 6.3. Edn2KO ovaries grafted under the kidney capsule successfully form corpora. Twenty-one days after transplanting Edn2KO PND6 
ovaries into the kidneys of WT OVX mice, mice were injected with gonadotropins. A. At hCG 24hrs, ovaries were collected and serially sectioned. 
Images are shown grossly before removal from the kidney and at 4X. Grafted ovaries become flattened with a greater diameter and are less deep. 
Antral follicles, corpora lutea, and immature follicles were present in all groups. B. Ovaries were also collected at hCG12 hours; RNA was extracted 
and RT-PCR was performed for Edn1 and Edn2 expression to confirm gene loss. Grafted Edn2KO ovaries had significantly lower Edn1 (p=0.006) 
and Edn2 (p<0.001) expression, confirming CL formation in the absence of EDN2. Additionally, grafted WT ovaries trended towards decreased 
Edn2 expression (p=0.086). KOT=kidney ovarian transplant.  
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Figure 6.4. Follicle counting reveals significantly more oocytes trapped in corpora lutea in grafted Edn2KO ovaries. Twenty-one days after 
transplanting Edn2KO PND6 ovaries into the kidneys of WT OVX mice, ovaries were collected at hCG 24hrs and serially sectioned. The total 
numbers of antral follicles (AF) and corpora lutea (CL) were determined (n=5-7). Absolute counts are displayed at left and percentages are displayed 
at right. When compared to transplanted control ovaries, transplanted Edn2KO ovaries trended towards a higher percentage of antral follicles and 
fewer CL (p=0.088). Grafted Edn2KO ovaries had significantly more oocytes trapped within corpora luteal (p=0.010) and a significantly greater 
percentage of CL with trapped oocytes (p=0.004). Errors bars represent the SEM. KOT=kidney ovarian transplant.  
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Figure 6.5. Follicle counting data for grafted Edn2KO ovaries vs WT intact and WT grafted ovaries at hCG24 hours. Normally distributed 
data were analyzed by an ANOVA and a Bonferroni post hoc test; non-normally distributed data could not be log transformed and were analyzed 
nonparametrically by a Kruskal Wallis ANOVA with follow up Mann Whitney U tests. Both the standard deviation and the standard error of the 
mean are provided. For WT Intact, WT grafted, and Edn2KO grafted, n values are 6,7, and 5, respectively. KOT=kidney ovarian transplant.  
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Figure 6.6. Serum hormones are not different in ovarian graft mice from intact mice. Serum was extracted from mice at hCG12 A. and hCG24 
hours B. Serum hormone concentrations (in ng/mL) were not different between intact WT mice, OVX WT mice with one WT ovary grafted to each 
kidney, or WT mice with one Edn2KO ovary grafted to each kidney. However, a high degree of variability was present between mice within 
treatment groups; future results may reveal a trend towards a lower progesterone concentration at hCG24 hours in mice receiving ovaries grafted to 
kidneys, as a reflection of the trend towards fewer corpora lutea. P-values represent ANOVA score by hormone. Error bars represent the SEM.   
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Figure 6.7. Generation of granulosa cell-specific endothelin-2 conditional knockout mice. To examine the ovarian effects of EDN2 loss without 
surgical transplantation, Edn2Flox mice were crossed with mice from three different Cre recombinase lines: PR-Cre, Cyp19-iCre, and novel Esr2-
iCre mice. A. Experimental plan involving superovulation of immature mice for RNA collection at hCG12 hours, and serum hormone measurement, 
histology, and oocyte counting at hCG24 hours (top line). A breeding study was also performed by placing females with proven male breeders for 
10 days and monitoring daily for the number of pups born (bottom line) from mice ages 2-7 months. B. Representative histological images from 
ovaries of each genotype at hCG24 hours (4X). Ovaries from each genotype appeared healthy and all had corpora lutea, antral follicles, and immature 
follicles with no difference in hemorrhage between groups. Note the multiple antral follicles with trapped oocytes present in Cyp19-iCre and Esr2-
iCre Edn2Flox/Flox mouse lines.   
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Figure 6.8. Loss of EDN2 reduces oocytes ovulated and decreases average litter size. Edn2Flox mice were crossed PR-Cre, Cyp19-iCre, and 
Esr2-iCre mice to remove Edn2 expression in granulosa cells. A. Breeding study and superovulation oocyte collection results. Each pairing lasted 
10 days; litter size represents pups born instead of weaned; oocytes were collected from the ampulla of the oviduct at hCG24 hours. P-values are 
from post hoc test relative to control mice. B. Relative Edn2 mRNA expression in whole ovaries at hCG0 and hCG12 hours determined by semi-
quantitative RT-PCR. Expression of Edn2 is significantly lower in WT mice at hCG0 and in Edn2Flox/Flox Cyp19-iCre and Esr2-iCre mice at 
hCG12 hours. C. Taqman quantitative RT-PCR results comparing WT and Edn2Flox/Flox Esr2-iCre mice at hCG12 hours; 97.6% of Edn2 
expression is lost. D. ELISA quantitation of total endothelin protein per ovary. Endothelin mass is significantly reduced at hCG12 hours in 
Edn2Flox/Flox Esr2-iCre mice from Edn2 loss and is not different from endothelin mass at hCG0 hours in WT mice. All error bars represent the 
SEM. Asterisks denote significant differences from control mice when p-values are not provided.   
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Figure 6.9. Edn2Flox/Flox Esr2-iCre ovaries have more antral follicles and fewer corpora lutea after ovulation. Ovaries were collected at 
hCG24 hours from immature mice, fixed, and serially sectioned. The absolute number of corpora lutea (CL), antral follicles (AF), and follicles with 
hemorrhage present were counted. The each value is also expressed as a percentage of total ovarian structures. A. Graphical presentation of follicle 
counts. Asterisks represent significant differences (p<0.05). Error bars represent the SEM. B. Tabular presentation of data. Standard deviation 
(STDEV) and standard error of the mean (SEM) are provided. P-values of significantly different groups are bolded.   
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Figure 6.10. Serum hormones are not different significantly different after ovulation in Edn2Flox/Flox Esr2i-Cre mice. Serum was extracted 
from mice at hCG24 hours. Serum hormone concentrations (in ng/mL) were not different between intact WT mice, Edn2Flox/Flox Cyp19-iCre or 
Esr2-iCre mice. A high degree of variability was present between mice within treatment groups; future results may reveal a trend towards lower 
progesterone concentration at hCG24 hours in conditional knockout mice. P-values represent ANOVA score by hormone. Error bars represent the 
SEM.  
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Figure 6.11. Differential gene expression between control and Edn2Flox/Flox Esr2-iCre mice. Ovaries from immature mice were collected at 
hCG12 hours and gene expression was compared by an RT 2Prolifer PCR Array kit. A) Genes with greater than two-fold regulation difference 
between ovaries where 1.00 = no change. B) Genes known to be influentially involved in ovulation show no major differences other than progesterone 
receptor, where 1.00 = no change. C) Overall average fold expression change by functional gene group. Functional gene groups were used based on 
grouping from the RT2 kit. Though certain groups have an average that indicates general upregulation or downregulation where no fold change = 
0.00, the high standard deviations and errors of the mean do not allow conclusion that any functional gene group shows significant up or 
downregulation. EDN2 likely plays little role in modifying gene expression. 
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Figure 6.12. RT2 Profiler PCR Array shows few gene expression differences between control and Edn2Flox/Flox Esr2iCre mice. A. Scatter 
plot of normalized gene expression between immature control ovaries (x-axis) and Edn2Flox/Flox Esr2-iCre ovaries (y-axis) at hCG12 hours. Dashed 
lines represent a two-fold increase or decrease from control expression levels. Genes with less than a twofold difference from controls are presented 
as black circles; genes with expression greater than controls are in red and genes with expression less than controls are in green. B. Heat map of 
gene expression between genotypes. Each square represent one gene (and one well on the PCR Array). Square color indicates fold change in 
expression; red cells are upregulated and green cells are downregulated.  
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Figure 6.13. Edn2Flox/Flox Esr2iCre ovaries have no difference in Pgr expression. To confirm RT2 profiler data, whole ovaries were collected 
at hCG6 and 12 hours from immature mice, and cDNA was generated for RT-PCR (n=6). At each time point, there was no significant difference in 
progesterone receptor expression. A. The relative progesterone receptor expression decreases from hCG6 to hCG12 in control and conditional 
knockout animals. B. When normalized to control Pgr expression at each time point (1.00), there is no significant difference when Edn2 expression 
is lost. Large ranges and error bars in conditional knockout mice result from a few ovaries with high Pgr expression, likely from early times of 
ovulation and luteinization. Errors bars represent the standard error of the mean (SEM).   
Relative progesterone receptor (Pgr) expression 
Relative difference in (Pgr) expression 
(control=1.00) 
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Figure 6.14. Phenylephrine treatment reduces the number of oocyte ovulated in WT mice. To determine if activation of calcium channels by 
alpha adrenergic receptors could restore ovulatory ability, twenty-five day old mice received superovulation treatment and also received injection of 
phenylephrine (1.0 μg i.p.) at hCG11 hours. Oocytes were collected from the oviduct at hCG24 hours to quantify ovulatory ability. Phenylephrine 
treatment significantly reduced ovulation in WT mice. In Edn2Flox/Flox Esr2-iCre mice, phenylephrine treatment did not significantly change the 
number of oocytes ovulated. There was no significant difference between Edn2Flox/Flox Esr2iCre mice and WT receiving phenylephrine injection. 
Owing to low n values, Edn2Flox/Flox Esr2-iCre mice from a previous study were used as a historical control in place of vehicle-treated mice. N-
values are displayed at the base of each column and errors bars represent the standard error of the mean (SEM).  
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ABSTRACT  
During ovulation, the precise physiological mechanism governing follicle rupture and 
oocyte expulsion from the ovary remains to be revealed. Ovulation is a multifactorial process and 
it is known that many factors contribute including collagenase digestion of the follicular wall, 
leukocyte invasion of the ovary, cumulus complex expansion, and prostaglandin production. 
However, the exact trigger governing the time of oocyte discharge is unknown. It was previously 
demonstrated that endothelin-2 (EDN2) produced in granulosa cells is important for follicle 
rupture and corpus luteum formation, and that this is mediated by endothelin receptor A (EDNRA) 
through a contractile mechanism in the ovary. To determine if EDNRA on smooth muscle cells in 
the ovary was responsible for contraction and force generation during follicular rupture, mice that 
express Cre recombinase in smooth muscle cells in a tamoxifen-inducible manner were bred with 
EdnraFlox mice to attempt to characterize the effect of Ednra loss on ovulation. However, 
tamoxifen treatment had significant and confounding effects on ovulation. Untreated control mice 
ovulated 34.7±3.5 oocytes/ovary, whereas WT mice ovulated 15.6±4.4 oocytes per ovary after 
tamoxifen treatment and SMACreERT2EdnraFlox mice ovulated 9.2±2.0 oocytes per ovary after 
tamoxifen; p<0.001 before and after tamoxifen treatment within either genotype; p=0.462 between 
genotypes after tamoxifen treatment. In the ovary, Ednra expression is increased 30 days after 
tamoxifen injection, implying gene loss is impermanent as smooth muscle cells are replaced. 
Overall, it was demonstrated that ovulation may occur in tamoxifen-treated 
SMACreERT2EdnraFlox mice, though tamoxifen exposure inhibits the number of oocytes ovulated 
in both control and SMACreERT2EdnraFlox mice. It is possible that Ednra may play a significant 
role in ovulation, either in smooth muscle or other ovarian cells, but SMACreERT2EdnraFlox mice 
do not allow for dissection of this signaling pathway owing to the confounding role of tamoxifen. 
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INTRODUCTION 
The study of ovulation remains an ongoing and relevant issue as new contraceptives and 
molecular targets are discovered to control the rising human population. It has long been debated 
what mechanism within the ovary specifically controls the release of the oocyte from the follicle 
to the oviduct prior to fertilization. The wall of the follicle is composed of the granulosa cells, the 
theca interna cells, and the theca externa cells65. The granulosa cells function for both protein 
synthesis and steroidogenic synthesis during follicular maturation; these cells are responsible for 
estrogen production from a testosterone precursor via the aromatase enzyme495,496. The theca 
interna cells appear fibrotic and steroidogenic, while the theca externa cells are myeloid and 
fibrotic497 and may generate contractile forces. Theca interna cells are responsible for testosterone 
synthesis from cholesterol498. A basement membrane exists between the granulosa and theca cells 
and blood and lymph vessels are confined to the theca layers. Following ovulation, theca and 
granulosa cells luteinize and produce progesterone rather than testosterone or estrogen; these cells 
reside within the corpus luteum, which becomes highly vascular following ovulation499. 
Numerous effects must come together to allow for a follicle to rupture, including growth 
of the follicle and hypertrophy of the granulosa and theca cell layers500, weakening of the basement 
membrane and surrounding collagenous tissue through metalloproteinase action, invasion of 
leukocytes and cytokine release, and expansion of the cumulus cells surrounding the oocyte. It has 
also been debated if there exists a change in pressure or a contractile force that expels the oocyte 
from the ovary at the time of ovulation, though there exists little definite and conclusive evidence 
in this area. It is well agreed that contractile cells containing bundles of thin filaments parallel to 
the long axis of the cytoplasm exist in many mammalian species501-507, thus providing potential for 
a contractile force. Some authors claim that fewer contractile cells are present at the apical region 
of the protruding follicle508,509, while others dispute this510-515. It is likely that species variation 
exists within mammalian ovaries. Other authors have also argued that contractile filaments in cells 
surrounding the follicle function for cellular locomotion rather than a unison contractile effect516, 
especially as fibroblasts are mobile cells517-519 and a large amount of collagen is needed to be 
rapidly deposited within the corpora lutea just after ovulation to maintain internal cellular and 
vascular support66. An excellent review on early literature on ovarian contraction is provided by 
Espey, 197866.  
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Contraction of the ovary as a whole rather than the follicles has been previously well 
documented in the human163,520,521 as well as cats343, rabbits164,165,167, and several other mammalian 
species345,522. Spontaneous ovarian contraction has also been observed, though often ex vivo167; 
however, it has been proposed that such contractions may originate in the vascular hilus of the 
ovary rather than the follicular cortex158-160,162,506,507,523. It has also been debated if there is a 
difference in strength of ovarian contraction during ovulation or not524-526 and particularly if there 
is an increase in intrafollicular pressure just prior to ovulation527,528. This argument has largely 
gone unanswered, and with the advent of new molecular technologies and gene identification, new 
avenues in molecular reproduction have been largely focused on over large-scale contractile 
physiology. However, it has been reported recently that intrafollicular pressure and the follicular 
wall tension index increase in rat ovarian follicles after gonadotropin stimulation100, though the 
necessary role of collagenases during ovulation is noted. Measured changes in individual follicular 
pressure were less than two-fold increases100,493, though a second similar study concluded that NO 
was likely a local mediator of pressure changes as well as systemic blood pressure493. It has also 
been postulated that smooth muscle cells near periovulatory follicles can undergo stress 
relaxation166 to selectively prevent ovulation of certain follicles. Summarily, changes in tension 
occur within the ovary as a whole during ovulation as follicle walls weaken, intrafollicular pressure 
increases during ovulation but not severely, and changes in tension may be mediated by vascular 
tension about the follicles themselves or throughout the body; the necessity of such pressure 
changes in vivo remains debatable. 
Within the last decade, it was reported that the protein endothelin-2 (EDN2, also ET-2) is 
essential for contraction of the follicle and release of the oocyte through the follicular wall6. EDN2 
has been well characterized as a potent vasoconstricting agent212,529. It is a short peptide composed 
of 21 amino acids that acts through binding to one of its two G protein-coupled receptors (GPCRs): 
endothelin receptor A (EDNRA, also ETa, Ednra gene) and endothelin receptor B (EDNRB, also 
ETb, Ednrb gene)217. EDN2 is part of the endothelin system, which is composed of two other 
isomers, EDN1 and EDN3, the two receptors, and at least two endothelin converting enzymes 
(ECEs). EDN1 and EDN2 differ by only two amino acids and have equivalent affinity for each 
receptor213,295,530. Within the ovary, EDN1 is constitutively produced in the endothelial 
cells12,531,532 while EDN2 is produced in the granulosa cells at the time of ovulation6,7. EDN1 is 
involved in follicular development as an inhibitor of premature luteinization of granulosa cells533, 
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an inhibitor of premature luteolysis534-536 and an inhibitor of oocyte meiosis537. The time and 
location specific production of EDN2 at very high concentrations, relative to constitutively low 
EDN1, indicates direct involvement with the ovulatory process. The endothelin-2 gene, Edn2, is 
regulated largely at the transcriptional level287,318,450, and is known to be under regulation by both 
hypoxia inducible factor 1 alpha (HIF1α)245-247,450,538 and progesterone receptor (PGR, PR)7.  
In general, EDNRA is thought to have the opposite effect of EDNRB, which also may act 
to clear the ligand during receptor recycling539. EDNRA acts through the Gs or Gq pathway, 
whereas EDNRB acts through the Gi or Gq pathway218,540. Smooth muscle contraction is initiated 
by an influx of intracellular calcium to cause depolarization. Intracellular calcium is released from 
the endoplasmic reticulum to cause a transient increase in polarity, while the main action of 
endothelin receptors occurs through an influx of extracellular calcium through the opening of 
receptor-operated calcium channels (ROCCs). Additionally, extracellular calcium increases 
through store-operated and voltage-operated calcium channels (SOCCs and VOCCs), though these 
play a minor role relative to ROCCs208,278,541-546. Calcium influx can be modulated by either EDN1 
or EDN26 via EDNRA, though only Edn2 expression increases during ovulation6,170. There is 
evidence that in humans, luteinized granulosa cells have EDNRA, but not EDNRB,547 which may 
act as secondary EDN2 targets. 
Previous work by Bridges et al., (2010)170,200 using specific endothelin receptor antagonists 
suggest that EDNRA is the critical receptor involved in ovulation: EDN2-mediated contraction 
was reduced by a specific EDNRA antagonist but not by a specific EDNRB antagonist. However, 
no effect was observed in vivo on ovulation rate owing to the rapid degradation of these inhibitors 
by proteolytic enzymes. These results are supported by a large body of evidence that EDNRA 
induces prolonged vasoconstriction529,548-550 whereas EDNRB acts in the opposite fashion for NO2-
dependent vasodilation551-553. Additionally, and most convincingly, mice that selectively lack 
EDNRB demonstrate no reproductive deficits; instead, mice with Ednrb ablation throughout the 
ovary give birth to more pups per litter and produce more corpora lutea233.  
The precise physiological responses governed by EDN2 and its receptor-mediated action 
in the ovary remain to be further investigated. Given the limitations in previous studies using 
pharmacological approaches, a transgenic animal model approach was chosen to dissect the 
receptor-mediated action of EDN2 during ovulation. EDN2 is a known potent vasoconstrictor that 
is produced in the granulosa cells specifically during ovulation, Ednra is expressed in the smooth 
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muscle cells that are present around mature follicles and responds to drive cellular contraction in 
response to EDN2, and EDNRA can be pharmaceutically inhibited to prevent ovulation. It was 
postulated that EDNRA, which is expressed by smooth muscle cells, causes contraction of mature 
follicles at the time of ovulation which acts as a final trigger for oocyte release and expulsion from 
the ovary. The LoxP-Cre recombinase system was used to generation a conditional knockout of 
EDNRA specifically in the smooth muscle cells following Cre activation by exogenous tamoxifen 
administration; thus a model that has temporally-controlled removal of Ednra from only smooth 
muscle cells was created. This approach was chosen because global EDNRA knockout is 
embryonically fatal, resulting in facial, cranial, and cardiac defects; additionally, smooth muscle-
specific Ednra knockout mice often fail to survive to reproductive age and exhibit systemic defects 
which may cause developmental abnormalities that may influence reproduction. It was 
hypothesized that, in SMACreERT2EdnraFlox mice, smooth muscle-specific ablation of EDNRA 
within would ovary inhibit ovulation and consequently prevent corpus luteum formation and 
progesterone production.   
  
170 
MATERIALS AND METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Kentucky Animal Care and Use Committee (Protocol 1111M2006) 
and the University of Illinois Animal Care and Use Committee (Protocols: 11184, 12090, 14222), 
and all efforts were made to minimize animal suffering. 
 
Animal models and genotyping 
Animals were maintained under a 12 hour light-dark cycle and given a continuous supply 
of Harlan (Indianapolis, IN) rodent chow and water. A tamoxifen inducible smooth muscle–
specific Cre recombinase transgenic mouse line (SMACreERT2) was provided by Dr. Pierre 
Chambon193,554. To characterize Cre recombinase expression, B6;129S6-Gt27926Sortm9(CAG-
tdTomato)Hze/J reporter mice177 (Ai9 mice) were purchased from Jackson Laboratories (Bar 
Harbor, Maine). These animals have a floxed stop codon in front of a constitutively active red 
fluorescent protein (RFP) gene; thus RFP is produced in cells that have been exposed to active Cre 
recombinase. To generate specific loss of the endothelin receptor A gene (Ednra), a floxed Ednra 
(EdnraFlox) mouse line, which carries two LoxP sites in the introns flanking exon 6, 7, and 8 of 
the Ednra gene (Figure 7.5), was used as a target for Ednra gene excision555. EdnraFlox mice were 
provided by Dr. Masashi Yanagisawa.  
To generate reporter mice for SMACreERT2 expression, heterozygous male SMACreERT2 
mice were crossed with homozygous Ai9 female mice. Offspring were examined for presence of 
the SMACreERT2 gene by PCR using primers TK139 (5’-ATTTGCCTGCATTACCGGTC-3’) and 
TK141 (5’- ATCAACGTT TTGTTTTCGGA-3’)193 with an amplicon size of 349 base pairs. Mice 
lacking the inducible Cre gene were used as controls. To generate smooth muscle-specific loss of 
Ednra, female EdnraFlox/Flox mice were first bred with male SMACreERT2 mice, which resulted 
in the production of F1 heterozygotes, SMACreERT2EdnraFlox/+. Then 
SMACreERT2EdnraFlox/Flox female mice were generated by breeding male F1 
SMACreERT2EdnraFlox mice and female EdnraFlox mice177. To confirm the EdnraFlox gene in 
the pups by PCR genotyping the primers EtaF (5'-CCTCAGGAAGGAAGTAGCAAGATTA-3') 
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and EtaR (5'-ACACAACCATGGTGTCGA-3') were used555 with an amplicon size of 650 
basepairs (floxed) or 610 base pairs (WT allele).   
 
Tamoxifen-induced Cre recombinase activation and superovulation 
To induce Cre recombinase in smooth muscle cells, post-natal day 28 (PND28) mice were 
exposed to tamoxifen (TAM) following Jackson Laboratories protocol by dissolving tamoxifen in 
corn oil at a concentration of 20mg/ml at 37°C in the dark and storing at 4°C and then injecting 
mice with 100uL solution intraperitoneally (i.p.) once every 24 hours for a total of 5 days 
(approximately 75mg TAM / kg body weight)177,556. Mice were monitored for adverse reaction to 
injection and were removed from experiment in that instance.  
To induce ovulation and synchronize follicular development, mice were stimulated with 
gonadotropins following superovulation protocol. Mice were given a single i.p. injection of 5 IU 
pregnant mare serum gonadotropin (PMSG) in 100uL phosphate buffered saline (PBS) followed 
48 hours later by a single i.p. injection of 5 IU human chorionic gonadotropin (hCG) in 100uL 
PBS. PMSG and hCG were purchased from Sigma (St. Louis, MO). Mice normally ovulate 12-14 
hours after hCG injection.  
 
Visualization of Cre recombinase activity  
Twenty-eight day old SMACreERT2 Ai9/+ mice received TAM treatment for 5 days, were 
allowed to recover for two days or 30 days, and were then superovulated (Figure 7.1A). Mice were 
euthanized by CO2 asphyxiation and perfused intracardially with cold PBS solution and then a 4% 
paraformaldehyde (PFA) solution to assist in fixation. Tissues were fixed in 4% PFA overnight, 
then dehydrated in an ethanol series, embedded in paraffin blocks, and sectioned by microtome at 
5um thickness. One section was used for fluorescence visualization and an adjacent slide was 
stained with hematoxylin and eosin staining for cellular visualization (Thermo Scientific, 
Kalamazoo, MI). Images were taken with a Zeiss SV11 fluorescent microscope, or an Olympus 
BX51 microscope for brightfield images and gross tissue images throughout all experiments. 
 
Vaginal Cytology 
Vaginal cytology was performed according to previously established guidelines for rats 
and mice116. Briefly, mice were smeared daily at approximately 1100 hours by application of 
172 
100uL of PBS into the distal aspect of the vagina followed by aspiration of fluids. Samples were 
placed into a clear 96-well plate and read using an inverted microscope (Olympus CKX41, Center 
Valley, PA). Proestrus (P) was characterized by predominantly round to polygonal cells that 
occasionally have a discernable nucleus with several leukocytes; Estrus (E) was characterized by 
many anucleate polygonal cells and a lack of leukocytes; Metestrus (M) was characterized by a 
combination of an equivalent number of leukocytes and anucleate polygonal cells; and Diestrus 
(D) was characterized by a marked dominance of small, round leukocytes. All smears were 
performed by one individual (JC).  
 
Ednra deletion after tamoxifen injection by RT-PCR 
Total RNA was extracted from ovaries 24 hours after TAM treatment and hCG injection 
(hCG 24hrs). Animals were euthanized by CO2 asphyxiation and cervical luxation, ovaries were 
removed, and homogenized. RNA was extracted by Trizol® solution (Ambion, Carlsbad, CA), 
washed twice with ethanol, and then purified with a Qiagen RNEasy Kit (Valencia, CA). RNA 
was analyzed by a Nanodrop machine for quantity and quality. Complementary DNA was then 
generated by M-MLV Reverse Transcriptase using random primers. Template RNA quantities 
were normalized to 1.0μg/μL prior to reverse transcription. 1.0μL of resulting cDNA from each 
ovary was used as template with 15μL Taq Platinum (Invitrogen) and 0.3μL of each primer per 
PCR reaction; reactions were cycled 30x for 94°C for 1:00 min, 59°C for 1:00, and 72°C for 1:30. 
Amplified DNA (3.0 μL) was visualized on a 2.0% agarose gel and was quantified using ImageJ 
freeware (NIH, Bethesda, MD) to measure peak pixel grayscale levels within the defined areas of 
the bands. To confirm the deletion of Ednra in smooth muscle cells, the primer set EDNRAKO_F 
(5’-GAGAACCTACAACTGGGGACACAAACAC-3’) and EDNRAR (5’- 
ACACAACCATGGTGTCGA-3’) was used to produce a 1200bp amplicon (Figure 7.5). PCR 
products were visualized on an agarose gel; band intensity was analyzed using ImageJ software 
(NIH, Bethesda, MD) for relative intensity. The ribosomal 60S subunit L19 (Rpl19 gene; L19) was 
used as an internal control with (5'-CCTGAAGGTCAAAGGGAATGTG-3') and (5'-
GTCTGCCTTCAGCTTGTGGAT-3'). Five animals were used for each treatment and cDNA was 
used from each for each gene.  
 
 
173 
Histology and immunohistochemistry (IHC) 
After fixation in the 4% PFA, tissues were then embedded in paraffin and sectioned at 5 
μm, mounted on charged glass slides, deparaffinized, and rehydrated. Tissues were then either 
stained with hematoxylin (Harris) and eosin (Surgipath) for cellular visualization, or were 
processed for immunohistochemistry to localize contractile cells or those actively involved in 
steroidogenesis. For IHC, smooth muscle actin was chosen as a target to identify smooth muscle 
cells; P450scc, which converts cholesterol to pregnenolone, was chosen as a steroidogenic enzyme 
target. Antigen retrieval was done with Tris EDTA buffer pH 9.2 for 60 minutes in an Oster 5711 
Food Steamer, rinsed under deionized water for 5 minutes, loaded in a humidifying chamber, and 
washed with PBS + 0.2% tween20 to remove bubbles. Tissues were then blocked with 5% rabbit 
serum for 30 minutes, treated with the primary polyclonal antibody rabbit anti-mouse alpha 
Smooth Muscle Actin (αSMA) Abcam ab5694 at a 1:200 dilution, goat anti-mouse Cyp11a1 
(P450scc, also cytochrome P450 XIA) Santa Cruz sc-18043 at a 1:200 dilution, or Dako negative 
control rabbit immunoglobulin fraction (8.7μL in 700 μL of PBST normalized to the SMA 
concentrate), washed twice with PBST, treated with fresh Avidin Biotin complex solution for 20 
minutes at room temperature, washed twice with PBS, and incubated with Nova Red for 2 min at 
room temperature, prior to 10% hematoxylin counterstaining. Molecular reagents were purchased 
from Invitrogen (Invitrogen, Carlsbad, CA). 
 
Ovary mounting and isometric tension measurement 
Ovaries used for tension analysis were placed into a 4°C physiological saline solution 
(PSS) at 37°C, where a wire myograph system (Tissue Bath System 620M, Danish Myo 
Technology, DMT-USA Inc., Ann Arbor, MI) was located. Whole ovaries were used after the 
removal of ovarian vessels, and pin mounting was chosen to minimize tissue damage and increase 
mounting speed. Each ovary was punctured on each end by one of the 4mm mounting pins on each 
arm of the myograph. The myograph was then turned on, to gradually heat the PSS back to 37°C 
(minor cooling during mounting) while also slowly bubbling a mixture of 50% oxygen, 45% 
nitrogen, and 5% carbon dioxide through the chamber. Meanwhile, fresh PSS and a 60mM K+ in 
PSS (K+PSS) were placed into a water bath to also reach a physiological temperature. Two ovaries 
were processed at the same time for each set of experiments. Ovarian tensile measurements were 
recorded via LabChart software (ADInstruments, Colorado Springs, CO). After about 20 min when 
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the test chamber containing the ovary had reached the appropriate temperature, the PSS solution 
was removed and fresh, warm PSS buffer was added. The system was then zeroed. Tension was 
next repeatedly applied to the half ovary over the following 20 min to maintain a constant tension 
of 3mN. Optimal tension-contraction response in ovaries occurred with ~1mN of passive tension 
applied per whole ovary. Lastly, a ‘wake-up’ protocol was used to finish the equilibration: K+PSS 
was applied to the stretched ovary, and was removed 3 min later. The ovary was then washed 4 
times over 5 min with PSS, and allowed to sit for 5 more min. This procedure was repeated twice. 
The PSS was then replaced a final time and the contractile experiment began, time zero.  
To determine strength of ovaries contraction in response to endothelin-2 agonization, 
ovaries were first allowed to sit in fresh PSS at a physiological temperature and pH with supplied 
oxygen and CO2 for five minutes to generate a baseline tensile measurement, the average tension 
in mN during this treatment. For ovaries that demonstrated cyclical contractions during this period, 
baseline measurements were averages of the trough tension for five troughs between peaks. Next, 
K+PSS solution was applied a third time for a duration of 5 minutes. This served as a reference 
point for the relative contractility of that ovary to account for variation in mounting, ovary size, 
and ovary health. Any ovary that failed to demonstrate contraction in response to K+PSS was 
discarded. K+PSS was then removed with four PSS washes at 1 minute intervals, and the ovary 
was allowed to equilibrate for 5 additional minutes. Next, human endothelin-2 purified peptide 
(American Peptide Co, Sunnyvale, CA) was added to the PSS solution of the chamber to generate 
a 50nM solution. After 20 minutes, without changing the buffer solution or removing the ligand, 
the dual-endothelin receptor antagonist drug tezosentan was added to a concentration of 140nM 
and left for 20 minutes. These concentrations were calculated from titration experiments in which 
increasing amounts of EDN2 peptide were added to ovaries and the relative change in tension was 
recorded. 50nM of EDN2 was the lowest dose that consistently produced the strongest contraction 
(Figure 7.8). Tensile measurements represent the difference from resting measurement (the 
average of 5 minutes prior to the final K+PSS addition) to either average K+ contraction (the 
average of minutes 2:00-5:00 after the K+PSS addition at 0:00) or average EDN2 contraction (the 
average of the 5 minutes prior to tezosentan administration for EDN2-induced contraction). The 
average of the final 5 minutes of the experiment was subtracted from peak EDN2-induced tension 
to calculate the change after tezosentan addition. All measurements were made in mN, and were 
later converted to arbitrary units (AU) for relative comparison by dividing each by the contractile 
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response to K+PSS for that ovary. Titrations of EDN2 or tezosentan to determine minimum 
concentrations for optimum effect were made as above, except varying doses of each were added 
in 20 minute intervals without washing away previous buffer solution to those ovaries; aortic and 
uterine tissues were used as smooth muscle controls (data not shown). 
 
Ovarian transplantation 
The mice were anesthetized by continuous nasal inhalation of isoflurane (2-2.5%) with 1 
liter per minute (LPM) of oxygen flow. After appropriate depth of anesthesia was reached, fur was 
removed from an area centered over the proposed incision sites, 15 mm wide by 30 mm long. The 
size of the area clipped was proportional to the size of the mouse. Skin was disinfected with 
surgical iodine and 70% ethanol using sterile applicators. Eye gel/ointment was applied to both 
eyes to prevent dehydration. The mouse was placed on a heat pad (37°C) to prevent hypothermia 
during surgery. The donor mouse was placed in ventral-lateral recumbency. A 4-7mm skin incision 
was made parallel and ventral to the spine midway between the last rib and the iliac crest. An 
incision was made in the underlying abdominal wall. Forceps were used to spread open the incision 
to look inside the abdominal cavity and locate the ovary. Forceps were used to grasp and 
exteriorize the ovarian fat pad. The fat pad was positioned on a 2x2 Versalon sterile sponge so that 
the ovary was facing the surgeon and the oviduct was ventral. A Moria forceps was placed under 
the ovary (medial aspect) to clamp the ovarian blood vessels. A second pair of Moria forceps was 
placed immediately proximal to the first pair and used to shear the ovary off of the ovarian blood 
vessels. Before releasing the first forceps, one drop of epinephrine was added to the vascular stump 
for one minute. The collected ovary and fat pad were placed in a petri dish of sterile PBS. Each 
ovary was dissected free of the ovarian bursa and fat pad using Dumont forceps and fine scissors. 
The donor ovary may also have been bisected at this point.  
The same procedures were performed to the recipient mouse until exteriorization of the 
ovarian fat pad, and the fat pad was positioned the same way as the donor mouse. The ovarian 
bursa was incised cranially at the junction of bursa and fat pad using Vannas micro-scissors. 
Dumont forceps were used to slide the bursa ventrally off the ovary and place it proximal to the 
oviduct. A Dumont forceps was placed under the ovary (medial aspect) to clamp the ovarian blood 
vessels. A second pair of Dumont forceps was placed immediately proximal to the first pair and 
used to shear the ovary off of the ovarian blood vessels. Before releasing the first forceps, 
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epinephrine was again added. The excised recipient ovary was discarded. If bleeding was observed 
from the ovarian vessels, hemorrhage was controlled using direct pressure with a sterile cotton 
tipped applicator. The donor ovary or half ovary was placed on top of the ovarian blood vessels. 
The ovarian bursa located near the oviduct was retracted over the donor ovary and tucked back 
into its original position using one or both pairs of Dumont forceps. The fat pad and ovary were 
returned to the abdominal cavity. The incision in the abdominal wall was closed with 5-0 or 6-0 
absorbable suture with a swaged on needle. The skin incision was closed with the same suture in 
a simple interrupted pattern or with wound clips. Skin suture or wound clips were removed 7 days 
later.  
The post-surgical mice were transferred to a clean, warm cage. Mice were placed on a 
paper towel in ventral or lateral recumbency with head slightly extended. A paper towel was placed 
under the rodent to minimize bedding adhering to the incision site. Each mouse was given a 
subcutaneous injection of warm sterile saline (1-2 cc/25g body weight) and carprofen 5mg/kg was 
injected subcutaneously. Supplemental heat was provided by placing the recovery cage on a slide 
warmer. The cage was warmed to 80-86°F (26.7-30°C) and the animal was provided a means to 
move away from the heat source once awake. The anesthetized mouse was observed every 10 
minutes until it was able to move about the cage on its own to ensure that it did not obstruct its 
nose. Frequent stimulation such as touching and moving the mouse was performed. The following 
were interpreted as signs of pain or distress: constant facial expression of discomfort (orbital 
tightening, nose bulge, cheek bulge, and "pulled back" ear position), facial wiping with the 
forelimb, licking, biting, and scratching the surgical wound, and additional carprofen was 
administered every 12 hours. 
 
Serum Steroid Measurement 
Progesterone was considered the principle hormone measured and all others were 
secondary. Samples were prepared by spinning down whole blood after clotting and removing the 
serum supernatant. 10 μL of mouse serum was mixed with 50 μL methanol and 1 μL of 2 μg/mL 
D9-progesterone, followed by centrifugation. The supernatant was subjected to LC/MS/MS 
injection at the Metabolomics Center at the University of Illinois at Urbana-Champaign by Dr. 
Lucas Li. The standard solutions for the calibration curve used double charcoal-stripped steroid 
free mouse serum provided by Dr. Kee Jun Kim and followed the same extraction protocol as the 
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serum samples. For detection, samples were analyzed with the 5500 QTRAP LC/MS/MS system 
(AB Sciex, Foster City, CA) in Metabolomics Lab of Roy J. Carver Biotechnology Center, 
University of Illinois at Urbana-Champaign.  The 1200 series HPLC system (Agilent 
Technologies, Santa Clara, CA) includes a degasser, an autosampler, and a binary pump. The LC 
separation was performed on an Agilent Zorbax SB-Aq column (4.6 x 50mm, 3.5μm.) with mobile 
phase A (0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). The 
flow rate was 0.3 mL/min. The linear gradient was: 0-2 minutes, 60%A; 6-12 minutes, 0%A; 12.5-
17 minutes, 60%A. The autosampler was set at 5°C. The injection volume was 5 μL. Mass spectra 
were acquired under positive electrospray ionization (ESI) with the ion spray voltage of 5500 V. 
The source temperature was 550°C. The curtain gas, ion source gas 1, and ion source gas 2 were 
38, 50, and 65, respectively. Multiple reaction monitoring (MRM) was used 
to measure progesterone (m/z 315.1-->m/z 97.1) with D9-progesterone used as internal standard 
(m/z 324.1 --> m/z 100.1). 
For additional steroid profiling, samples were prepared by using 20 μL mouse serum 
sample mixed with 40 μL methanol and 1 μL 2 μg/mL D9-progesterone, followed by the rigorous 
centrifugation. The supernatant was subject to LC/MS/MS injection. The standards solutions for 
the calibration curve again used double charcoal-stripped steroid free mouse serum, and followed 
the same extraction protocol as the serum samples. Samples were again analyzed with the 5500 
QTRAP LC/MS/MS system (AB Sciex, Foster City, CA) in Metabolomics Lab of Roy J. Carver 
Biotechnology Center, University of Illinois at Urbana-Champaign.  The LC separation was 
performed on a Phenomenex C6 Phenyl column (2.0 x 100mm, 3μm.) with mobile phase A (0.1% 
formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). The flow rate was 
0.25 mL/min. The linear gradient was as follows: 0-1 minutes, 80%A; 10 minutes, 65%A; 15 
minutes, 50%A; 20 minutes, 40%A; 25 minutes, 30%A; 30 minutes, 20%A; 30.5-38 minutes, 
80%A. The autosampler was set at 5°C. The injection volume was 5 μL. Mass spectra were 
acquired under positive electrospray ionization (ESI) with the ion spray voltage of 5500 V. The 
source temperature was 500 °C. The curtain gas, ion source gas 1, and ion source gas 2 were 36 
psi, 50 psi, and 65 psi, respectively. Multiple reaction monitoring (MRM) was used 
to measure steroids with the following transitions (Q1-->Q3) with D9-progesterone as internal 
standard (m/z 324.1 --> m/z 100.1). Progesterone Q1 (m/z): 315.1, Q3 (m/z): 97.0; 5β-
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corticosterone Q1 (m/z): 349.2, Q3 (m/z): 313.2; deoxycorticosterone/11β-hydroxyprogesterone 
Q1 (m/z): 331.2, Q3 (m/z): 97.1; pregnenolone Q1 (m/z): 317.1, Q3 (m/z): 299.0.  
 
Fertility assay 
This assay was conducted to determine if mice were capable of giving birth to a normal 
number of litters with a normal number of pups (approximately 8/litter) and gender distribution 
(50% male). Adult female mice being tested, age two months to six months, were randomly 
allocated into groups of two or three females of each treatment. Each set of females was paired for 
10 days with a proven WT male breeder, age 3 months – 7 months. Females were then removed 
from the male and separated into individual cages for 21 days and monitored daily. The percentage 
of females that gave birth from each treatment group, the average number of pups per litter, and 
the gender distribution of the pups was recorded. Females then continued with the experiment 
(Figure 7.15) or repeated the breeding assay (Figure 7.16) two to four more times.  
 
Experiments 
Three sets of experiments and one pilot study were conducted to determine what effect loss 
of Ednra in smooth muscle cells in the ovary has on ovulation and the ability of the ovary to 
contract, following confirmation of Ednra loss and model validation. 1) Twenty-eight day old 
SMACreERT2EdnraFlox and sibling EdnraFlox (control) female mice were treated with tamoxifen 
and given either two or 30 days to recover (Figure 7.1A). Mice were then superovulated. Young 
mice were chosen to prevent confounding estrous cycling from having already occurred. To allow 
for any potential delay in ovulation, ovaries were collected at hCG24 hours and histology was 
performed; concurrently, oocytes were collected from the oviduct and the number of oocytes were 
counted. Serum hormones were measured at hCG24 hours. Isometric tension analyses were 
performed with whole ovaries at hCG12-16 hours, approximately the time of ovulation, to measure 
the contractile effects of a physiological concentration of EDN2 peptide.  
2) Global loss of Ednra in smooth muscle cells occurs in SMACreERT2EdnraFlox mice after 
TAM as a confounding factor. In the second experiment, this effect was minimized by first 
exposing the mice to tamoxifen, then surgically transplanting half of an exposed ovary to a WT 
ovariectomized (OVX) recipient female mouse (Figure 7.13B). Recipients received one half ovary 
of each genotype (n=16). Vaginal smears were conducted to confirm return to estrous stage and 
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successful ovarian function. Mice were then superovulated and tissue was collected. Histology 
was performed on ovaries at hCG 24 hours; oocytes were collected at hCG24 hours, counted, and 
their ability to expand the cumulus oocyte complex was examined by treatment of hyaluronidase 
(80 IU/ml). Immunohistochemistry for P450scc was performed on ovaries, and progesterone was 
measured and compared to WT mice that had not received surgery to monitor if progesterone 
production remained normal.  
3) A third experiment was performed to examine the effect of Ednra loss after TAM 
treatment on fertility (Figure 7.15). Sixty day old OVX females received whole ovaries from 
untreated 28 day old donors, either SMACreERT2EdnraFlox or control mice. Recipients received 
two whole of the same genotype (n=4 of each). Vaginal smears were conducted to ensure normal 
ovarian function. Mice were then superovulated and a baseline blood sample was collected at 
hCG24 hours. Next, mice received TAM and then underwent a fertility study. Vaginal smears were 
again recorded after the fertility study to ensure normal cyclicity as a proxy for function. Mice then 
received TAM again for 5 days, were superovulated, and sacrificed. Tissues were collected and 
oocytes were counted at hCG24 hours. Blood was also collected, and histology was also performed 
on uterine tissues.  
4) In a fourth pilot experiment to examine the alternative hypothesis that loss of Ednra 
specifically in granulosa cells inhibits ovulation, Cyp19-iCre372 mice and Amhr2-Cre557-560 mice 
were crossed with EdnraFlox mice and underwent a fertility assay as described previously. Some 
mice were sacrificed, and ovarian histology was performed in naturally cycling adult female mice 
(age 3-7 months). Cyp19-iCre mice372 were obtained from Dr. Joanne Richards and Amrh2-Cre 
mice561 were purchased from Jackson Laboratories. 
 
Statistical Analysis 
 Data analyses were performed using statistical software (SPSS, Inc., released 2013, PASW 
Statistics for Windows, Version 22.0, Chicago, IL). Continuous data were tested for normal 
distribution by a Shapiro-Wilk test. All normally distributed continuous data were analyzed with 
parametric tests (student’s t-test, ANOVA, or paired student’s t-test) and a Bonferroni post hoc 
test. All non-normally distributed continuous data were analyzed by non-parametric tests (Mann 
Whitney U, Kruskal Wallis ANOVA). Ordinal data were similarly analyzed. Data are graphically 
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presented as the mean and standard error of the mean unless otherwise indicated. For all analyses 
the alpha value was set to 0.05. 
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RESULTS 
Recombination occurs in ovarian smooth muscle after tamoxifen (TAM) treatment 
This study sought to determine the role of endothelin receptor A (Ednra) in ovulation in 
the ovary, specifically in smooth muscle cells. To accomplish this, transgenic mouse models were 
utilized. A mouse that expresses Cre recombinase under the smooth muscle actin promoter with a 
tamoxifen-inducible mutation in the promoter was selected and validated to prevent developmental 
defects that otherwise occur555,562. These SMACreERT2 mice were crossed with Ai9 tomato reporter 
mice in order to demonstrate areas of Cre activity by red fluorescence. Mice were exposed to 
tamoxifen (TAM) and tissues were collected (Figure 7.1A). In control ovaries that did received 
vehicle (corn oil) injection without TAM, no fluorescence was observed grossly or histologically 
(Figure 7.1B, left). No fluorescence was observed in ovaries of mice that were superovulated 
immediately after vehicle treatment or that were allowed to recover for 30 days before 
superovulation (Figure 7.2, top right). With only vehicle treatment, mild fluorescence was 
observed in the bladder and several cells per section of the heart. When observed grossly, visible 
fluorescence was only present in the bladder but no other organs (data not shown). In general, Cre 
activity without TAM is punctate or scattered in the bladder, and severely limited in other organs 
including the heart, GI tract, ovary, aorta, and skeletal muscle; such limited recombination is 
unlikely to contribute to a phenotype when coupled with a floxed gene of interest. 
In mice that received TAM and were then superovulated (Figure 7.1B, center), marked 
fluorescence was observed in ovary, oviduct, and uterus grossly, indicating successful 
recombination. Fluorescence was observed in the smooth muscle cells surrounding the follicles, 
in the large and medium vessels, and in the newly forming corpora lutea of the ovaries as expected. 
Similarly, fluorescence was noted in the smooth muscle cells of the oviduct, the aorta, the GI tract 
(specifically in the longitudinal and circular muscle about the tubular organs as well as in the center 
of individually villi), in the myometrium of the uterus, in all three layers of the detrusor muscle of 
the bladder as well as on the luminal edge of the transitional epithelium therein, and in arteries and 
arterioles throughout the body (Figure 7.2). Consistent fluorescence was not observed after TAM 
treatment in cardiac or skeletal muscle, except for the vessels within (Figure 7.2, bottom right). In 
SMACreERT2Ai9 mice that received TAM treatment and then had a 30 day delay before 
superovulation, fluorescence was again grossly observed in the ovary, oviduct, and uterus (Figure 
7.1B, bottom right). However, gross intensity was decreased. Thirty days was chosen based on the 
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half-life of tamoxifen, which is approximately 7 days in vivo563,564; a time greater than four half-
lives was chosen as the potential effect of tamoxifen is reduced. When observed histologically 30 
days after TAM, ovaries had fewer red fluorescent cells. Cell number was reduced by 
approximately 75%. Those cells retaining fluorescence were present around follicles and vessels, 
and some were also present within corpora lutea. This indicates a relatively rapid turnover of 
smooth muscle cells within active mouse ovaries, and that this Cre recombinase is not active in 
parent stem cells giving rise to new smooth muscle cells. When SMACreERT2Ai9 mice that did not 
receive TAM were examined for expression (Figure 7.3), mild exogenous Cre activity was 
detected in the bladder and several cells of the heart, but not in the GI tract, the female reproductive 
tissues, aorta, or skeletal muscle. 
Additionally, it was observed that TAM treatment alone modified vaginal cytology when 
smears were performed. Beginning approximately 1-2 days after the first TAM injection, normal 
cyclicity (4-6 day cycle) ceased. On vaginal smears, cells were predominantly leukocytes, though 
many rounded anucleate epithelial cells lacking the more sharply defined edges commonly seen 
during estrus or diestrus were also present (Figure 7.4). This cytology remained consistent 
throughout TAM treatment and for several days following. Given the high prevalence of 
leukocytes, it is most similar to diestrus and was marked as such for later graphs of vaginal smears. 
These data indicate tamoxifen at the given dose causes significant changes in the vaginal 
epithelium that may affect function and receptivity. 
 
Ablation of Ednra in ovarian smooth muscle cells 
To determine the effect of loss of Ednra during ovulation, SMACreERT2 mice were crossed 
with EdnraFlox mice. Tamoxifen treatment and subsequent recombination resulted in the loss of 
three critical exons within the Ednra gene, exons 6, 7, and 8 (Figure 7.5). A 1200 base pair band 
was detected following successful recombination through PCR of genomic DNA extracted from 
whole ovaries. Amplification of this sequence occurred in SMACreERT2EdnraFlox following TAM 
treatment, but not with vehicle treatment (Figure 7.5A) or in any control ovaries with TAM or 
vehicle treatment. To roughly quantify the amount of recombination occurring in 
SMACreERT2EdnraFlox ovaries at hCG24 hours, total RNA was extracted from ovaries and 
subjected to semi-quantitative RT-PCR (Figure 7.5B). Ovaries were from control mice with 
vehicle treatment (lanes 1-2), control mice with TAM treatment (lanes 3-4), 
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SMACreERT2EdnraFlox mice with TAM treatment and a 30 day delay before superovulation (lanes 
5-6), or SMACreERT2EdnraFlox mice with TAM treatment and no delay (lanes 7-8). The gene 
Rpl19 was used as an internal control for each sample (n=5/group). Band intensity was quantified 
as a relative marker of the amount of RNA present (Figure 7.5C). No differences in the amount of 
Ednra RNA were observed, likely because of the many ovarian cells present in which 
recombination did not occur in each treatment group and the wide-spread expression of Ednra. As 
expected, only SMACreERT2EdnraFlox ovaries that had been exposed to TAM had a knockout 
band present. Amplification was significantly greater in ovaries that had recently been exposed to 
TAM rather than a 30 day delay before superovulation, likely indicating renewal of Ednra 
expression to some smooth muscle cells during the delay, though partial gene deletion remains 
present.  
 
Tamoxifen treatment does not prevent ovulation or corpus luteum formation 
To determine if TAM treatment modifies ovarian function, ovaries were collected from 
superovulated control adult mice 2 months of age at hCG18 hours immediately after TAM or 
vehicle treatment (Figure 7.6). Ovarian histology was performed and compared by hematoxylin 
and eosin staining. To examine the localization and effect of TAM on the smooth muscle network 
of the ovary, immunohistochemistry (IHC) was performed with anti-alpha smooth muscle actin 
(αSMA). Additionally, to examine one aspect of steroidogenic function necessary for progesterone 
production, IHC was performed with anti-P450scc. No significant qualitative differences were 
observed between treatments. Ovaries appear normal with follicles of all stages present as well as 
corpora lutea. No difference was observed in the smooth muscle network present; anti-αSMA 
staining is present around follicles and corpora lutea, around vessels, and within corpora lutea of 
each group. Staining is also visible within the oviduct on some slides. This pattern matches the red 
fluorescence pattern seen in SMACreERT2 Ai9 mice (Figure 7.1). Anti-P450scc staining was 
observed in the stroma of each ovary and also within the corpora lutea of each. Follicular 
development, the smooth muscle network, and P450scc expression were not modified during 
superovulation following TAM treatment. 
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Tamoxifen treatment reduces the number of oocytes ovulated 
To examine the effect of Ednra loss in the smooth muscle on ovulation, 28 day old mice 
were superovulated after TAM or vehicle treatment. Oocytes were collected from the oviduct 18 
hours after hCG was administered. Histology was performed on collected ovaries. No differences 
were noted between ovaries of any treatment group (Figure 7.7). There were no differences in 
follicle count by stage, number of corpora lutea, or ovarian size; mild hemorrhage was present 
within some ovaries of each treatment group. Oocyte quantification (Figure 7.7B) revealed a 
significant difference between WT ovaries with vehicle treatment and WT ovaries with TAM 
treatment (p=0.003). There was also a significant difference between WT ovaries with vehicle 
treatment and SMACreERT2EdnraFlox ovaries with TAM treatment (p<0.001), and between 
SMACreERT2EdnraFlox ovaries with vehicle treatment and either WT or SMACreERT2EdnraFlox 
ovaries with TAM treatment. There was no significant difference between WT and 
SMACreERT2EdnraFlox ovaries with vehicle treatment (p=1.000). However, there was no 
significant difference between WT and SMACreERT2EdnraFlox ovaries with TAM treatment 
(p=0.462). These data indicate that vehicle treatment alone has no difference in impact on 
ovulation. TAM treatment has a significant impact on ovulation in each group, likely because of 
its role as an estrogen receptor antagonist throughout the body. This is a confounding issue with 
this model system; TAM alone causes more than a 50% reduction in ovulation. Furthermore, as 
there is no difference between genotypes with TAM treatment, it is not possible to discern if a 
difference in ovulatory ability with loss of Ednra exists or not, as the changes caused by TAM 
may be masking any differences in ovulation. There is a slight decrease in the average number of 
oocytes ovulated in SMACreERT2EdnraFlox mice with TAM treatment, from 15.6±4.4 in the WT 
to 9.2±2.0 in conditional knockout animals, but this difference is not significant. The large 
variation may be accounted for by multiple ovaries failing to ovulate in each group (5 and 10, 
respectively) and the normal large variation seen even in WT ovaries with vehicle treatment 
(34.7±3.5, range 19-57). However, the percentage of ovaries that failed to ovulate in each group 
(0% in WT+vehicle, 4.5% in SMACreERT2EdnraFlox +vehicle, 35.7% in WT+TAM, and 43.5% 
in SMACreERT2EdnraFlox +TAM) indicate that TAM alone prevents nearly half of the exposed 
ovaries from ovulating regardless of genotype. Also of note, the majority of the time it was only 
one ovary in each mouse that failed to ovulate. These data support that TAM treatment alone 
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inhibits ovulation regardless of gene loss, preventing conclusion on the effect of Ednra loss on 
ovulation alone.  
 
No difference in contraction immediately after TAM treatment 
To determine if smooth muscle loss of Ednra influences ovarian contraction in response to 
EDN2 peptide, isometric contraction was performed on ovaries at hCG12-16 hours. First, the 
response of WT ovaries to EDN2 was compared without TAM treatment (Figure 7.8). Following 
mounting, ovaries were normalized to K+PSS and then exposed to increasing concentration of 
EDN2 in PSS, from 50pM to 50nM (n=4). Contraction increased linearly in response to increasing 
doses of EDN2. At 50nM, contraction response reached a near maximum with little increase in 
tension from previous concentration (Figure 7.8, bottom graphs). The average increase in tension 
from baseline in response to 50nM EDN2 for an ovary without TAM treatment was approximately 
0.3 mN, or about 2.5 times the average response to K+PSS. This concentration was also used 
previously by Ko et al. 20066, and allows for simple comparison. Thus 50nM was used as an EDN2 
concentration for future study on EDN2-induced contraction in conditional Ednra knockout 
ovaries. 
Ovaries at hCG 12-16 hours from SMACreERT2EdnraFlox and control mice (n=8) that had 
previously received TAM were mounted and the response to compared EDN2 was compared 
(Figure 7.9). Representative responses are shown. The average response to EDN2 at 50nM in 
control ovaries was 0.4 mN and 2.2 times the average response to K+PSS. Similarly, the average 
response to SMACreERT2EdnraFlox ovaries to EDN2 was 0.3 mN and 2.0 times the average 
response to K+PSS. To confirm that this was specific to endothelin receptors, the dual endothelin 
receptor antagonist tezosentan was added at a concentration of 140nM after EDN2 and without 
washing away the solution. This concentration of tezosentan was previously shown to prevent 
EDN2-induced contraction when administered first (data not shown). The average reduction in 
tension after tezosentan in control tissues was 0.2 mN and 0.9 times the response to K+PSS; 
similarly, the response to tezosentan in SMACreERT2EdnraFlox ovaries was 0.1 mN and 0.9 times 
the response to K+PSS. There were no significant differences in tensile response to K+PSS, EDN2 
at 50nM, or tezosentan at 140nM in ovaries of either genotype (p>0.05 for all comparisons). It is 
also interesting that the response to K+PSS occurs immediately after the solution is changed. 
However, there is a delay of between 5 and 10 minutes from when EDN2 50nM solution is added 
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and ovarian contraction occurs, demonstrating that smooth muscle depolarization is not immediate. 
This may occur simply because of the signaling response time required for the GPCR endothelin 
receptors to act through downstream mediators, or because signaling may be occurring between 
cell types in an autocrine or paracrine fashion. 
 
No difference in oocytes ovulated 30 days after TAM treatment 
Ovaries were collected at hCG24 hours from superovulated PND 65 mice, 30 days after 
receiving TAM treatment (Figure 7.10). Oocytes were collected from the oviduct and counted after 
hyaluronidase treatment. There was no significant difference (p=0.389) in the number of oocytes 
ovulated between control mice (n=4) and SMACreERT2EdnraFlox mice (n=6); all ovaries ovulated. 
The amount of oocytes ovulated per ovary (12.8±1.2 vs 10.1±2.5, respectively) was more similar 
to that ovulated by younger mice with TAM and no delay than to vehicle treated mice with no 
delay before superovulation. Histologically (Figure 7.10), there were no differences in ovarian 
morphology between groups. Follicles of various stages and corpora lutea were present in ovaries 
of each group. There was no significant difference between control and conditional knockout mice 
in the number of corpora lutea per ovary (19.8±2.1 vs 18.0±1.4, p=0.494), the number of antral 
follicles per ovary (6.8±1.3 vs 8.8±2.5, p=0.550), or the ratio between them (3.7±1.3 vs 4.9±2.8, 
p=0.522). Serum sex hormones were also compared at hCG24 hours (Figure 7.11). There were no 
significant differences between progesterone (6.4±2.2 vs 5.7±0.6 ng/mL, p=0.779), 5β-
corticosterone (1.9±0.5 vs 3.6±1.2 ng/mL, p=0.331), deoxycorticosterone (9.1±0.9 vs 14.7±4.6 
ng/mL, p=0.354), or pregnenolone (0.8±0.2 vs 2.3±1.1 ng/mL, p=0.295). Though the n-value is 
relatively low, the high variation in this sample size and the similar means indicate that a very 
large number of animals would be needed to determine if slight differences between groups exist. 
As there are no significant differences between groups, it is possible that either Ednra loss has 
little effect on ovulation and related parameters, that Ednra loss was only partial given 75% 
reduction in red fluorescence in ovaries in earlier experiments after 30 days and this loss did not 
have a significant phenotype, or that TAM treatment permanently alters ovulatory ability given 
relatedness of the number of oocytes ovulated compared to superovulated mice with and without 
TAM treatment. 
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No difference in contraction 30 days after TAM treatment 
Isometric contraction was performed on ovaries at hCG12-16 hours 30 days after TAM 
treatment from SMACreERT2EdnraFlox (n=6) and control mice (n=4). The response to K+PSS, 
50nM EDN2, and 140nM tezosentan was quantified (Figure 7.12). Representative responses from 
each genotype are shown. The average response to EDN2 at 50nM in control ovaries was 0.4 mN 
and 2.7 times the average response to K+PSS. Similarly, the average response to 
SMACreERT2EdnraFlox ovaries to EDN2 was 0.4 mN and 3.1 times the average response to 
K+PSS. To confirm that this was specific to endothelin receptors, the dual endothelin receptor 
antagonist tezosentan was added at a concentration of 140nM after EDN2 and without washing 
away the solution. The average reduction in tension after tezosentan in control tissues was 0.3 mN 
and 1.7 times the response to K+PSS; similarly, the response to tezosentan in 
SMACreERT2EdnraFlox ovaries was 0.3 mN and 2.8 times the response to K+PSS. There were no 
significant differences in tensile response to K+PSS, EDN2 at 50nM, or tezosentan at 140nM in 
ovaries of either genotype (p>0.05 for all comparisons). These contractile responses were also 
similar to younger ovaries that did not have 30 day delay before collection. All ovaries demonstrate 
approximately a 0.4mN response to EDN2. Ovaries after the 30 day delay have a slightly stronger 
contraction in response to EDN2 relative to K+PSS than younger ovaries. Similarly, ovaries after 
the 30 day delay have a similar absolute change in tension in response to tezosentan, but this 
response is again elevated relative to the K+PSS response compared to younger ovaries. These 
slight differences in contraction response between age groups, but not genotypes, suggest that 
50nM EDN2 is a consistently potent contractile agent, but that the response to K+PSS is slightly 
decreased in older mice. 
 
Half ovary transplantation decreases oocytes ovulated 
In a second set of experiments, half of an ovary from a control mouse and half of an ovary 
from a SMACreERT2EdnraFlox mouse were transplanted into the bursas of ovariectomized WT 
recipient mice. Half ovaries were used for their small size, which decreases the chances of leaving 
the bursa after surgery (Figure 7.13); additionally, the cut side of the ovary may expose the 
vasculature allowing for improved angiogenesis. The goal of this method was to decrease 
potentially confounding effects of TAM on the hypothalamus and pituitary within the reproductive 
axis, while allowing one ovary of each genotype to be under the same influence from a mature WT 
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reproductive axis. Previous data (Lin et al., submitted for review) indicates that half ovaries are 
integrated normally after vascular reestablishment and can successfully respond to gonadotropins 
and ovulate within one week of surgery. Ovaries were exposed to TAM prior to transplantation 
and were superovulated after a recovery period. Though shorter than 30 days, this recovery period 
may have modified gene ablation; it was chosen as being necessary to allow vascular reformation 
and being one half-life of tamoxifen. However, tamoxifen concentrations inside the transplanted 
ovary likely decreased after the vascular supply was reestablished.  
To confirm ovarian function and return of blood supply after surgery, vaginal smears were 
performed on the day of surgery before transplantation and for 8 days afterwards. All but one 
mouse was able to reach estrus (Figure 7.14A). Mice were superovulated and euthanized at hCG 
24 hours. Ovaries were collected (n=16) and fixed for histology and oocytes within the oviduct 
were counted. Few oocytes were ovulated by ovaries of either genotype (Figure 7.14B) and though 
there was no significant difference between control and SMACreERT2EdnraFlox ovaries (1.4±0.7 
vs 0.3±0.1 oocytes/ovary, p=0.093), there was a trend for more oocytes to be ovulated by control 
ovaries than SMACreERT2EdnraFlox ovaries (range 0-13 vs 0-2). The majority of the ovaries (9 
and 11 per group, respectively) from either genotype failed to ovulate. Histologically (Figure 
7.14E), ovaries exhibited infiltration of many leukocytes in each genotype. This may represent 
vascular remodeling continuing to occur after surgery; it may also represent graft rejection, though 
previous pilot studies demonstrated successful graft survival for up to 60 days and successful 
ovulation. Leukocyte invasion may also be occurring in response to previous TAM exposure. 
Ovaries of each genotype also had multiple corpora lutea and antral follicles. There were 
significantly more corpora lutea in control ovaries (8.8±1.3 vs 5.1±0.6, p=0.012), though there was 
no difference between control mice and SMACreERT2EdnraFlox in the number of antral follicles 
(4.7±1.0 vs 6.3±1.0, p=0.258). If corpora lutea are used as a proxy for ovulation, this suggests that 
move ovulations occur in SMACreERT2EdnraFlox ovaries in this treatment. However, as so few 
oocytes are recovered from any ovary, the oocytes themselves may be atretic prior to ovulation, or 
luteinization may occur without ovulation, though oocytes trapped within corpora lutea were not 
observed in either group of ovaries. 
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Transplanted half ovaries have normal CL formation and progesterone production 
The functionality of the corpora lutea in each ovary was additionally examined. Ovarian 
sections were stained with anti-P450scc as a steroidogenic marker. Positive staining was seen in 
the new or forming corpora lutea in ovaries of each genotype (Figure 7.15A), confirming CL 
presence and presence of steroidogenic enzymes. Additionally, progesterone was measured from 
blood collected at hCG24 hours (Figure 7.15B). It was not possible to collect blood that had 
received steroids from only one ovarian genotype. However, if one or both ovaries were deficient 
in progesterone production, serum progesterone levels may have been lower overall, either from 
surgical treatment, TAM treatment, bisection, and/or gene loss. However, when serum 
progesterone from WT intact mice without TAM at hCG24 hours was compared to serum 
progesterone from mice receiving transplanted TAM treated half ovaries of each genotype, there 
was no significant difference (2.2±0.3 vs 1.9±0.1 ng/mL, p=0.320) (Figure 7.15B). Thus, even 
ovaries that have been exposed to tamoxifen, bisected, and surgically transplanted can still 
successfully ovulate within one week of surgery and exposure, albeit to a lower number of oocytes 
than non-surgical ovaries; these ovaries can also produce progesterone at concentrations similar to 
control mice, implying that they are likely able to maintain uterine function for implantation and 
pregnancy. Oocytes collected from these ovaries (Figure 7.15C) appear histologically normal and 
may be dissociated from the cumulus oocyte complex with hyaluronidase treatment as well. 
 
Tamoxifen exposure prevents pregnancy 
As mice given half ovary transplants after ovarian TAM exposure demonstrated severe 
ovulatory defects in each genotype whereas previous work demonstrates that half ovary transplant 
alone does not prevent ovulation, the TAM exposure might prevent transplant integration and 
function. To circumvent this issue, mice were generated with ovary-specific genotypes (n=4) and 
then provided TAM treatment for gene removal (Figure 7.16). Whole ovaries were transplanted to 
WT recipients; mice received two ovaries of the same genotype, either WT ovaries or 
SMACreERT2EdnraFlox ovaries. After recovering from surgery, mice were superovulated for 
baseline blood hormones, then exposed to TAM before immediately undergoing a breeding assay. 
Considering the loss of fluorescence previously observed 30 days after TAM in SMACreERT2Ai9 
mice, these double ovarian transplant females received a second dose of TAM for five days before 
being superovulated and sacrificed at hCG24 hours (see Figure 7.16 for timeline).  
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After surgery, vaginal smears were used to confirm return of ovarian function (Figure 
7.17). Each mouse experienced estrus at least once after surgery, confirming functionality of at 
least one ovary for sufficient hormone production to induce cycling. Blood was then collected at 
hCG24 hours, and mice were next dosed with TAM. Immediately after, mice underwent a breeding 
assay. Interestingly, no mouse became pregnant after being placed with a male for 10 days; thus 
TAM exposure inhibits reproductive receptivity up to 10 days after exposure. Though mice were 
not checked during fertility assay, vaginal smears after the last day of potential births indicated 
that mice were still cycling normally and were able to enter estrus (Figure 7.17); a fertility assay 
occurring with an intermittent period after TAM exposure may have yielded different results, 
though this may also have decreased the percentage of smooth muscle cells with Ednra ablation. 
Mice were again exposed to TAM and tissues were collected at hCG24 hours. No oocytes were 
obtained from any ovary of either genotype, further demonstrating that chronic TAM exposure 
alone prevents ovulation despite gonadotropin stimulation. Histologically (Figure 7.17C), some 
ovaries of each genotype appeared healthy with obvious follicles in multiple stages and visible 
corpora lutea, likely from previous ovulations. Alternatively, multiple ovaries of each genotype 
were shrunken, fibrotic, and lacked discernable follicles or even oocytes with no corpora lutea. 
Additionally, a high degree of inflammation was observed; these are likely from transplanted 
ovaries that did not establish a healthy vascular supply or/and were rejected. No remarkable 
changes were histologically observed in the oviducts of the mice. The uteri from the double TAM 
treated mice all had obvious and severe cystic endometrial hyperplasia at the end of the study 
(Figure 7.17C). The many large uterine cysts may likely have prevented pregnancy from occurring 
during the breeding study, even though mice may have been cycling. It is possible that an effect 
of TAM in the oviduct may also prevent oocytes from reaching the uterus, and would account for 
their absence during tissue collection.  
 
TAM exposure after surgery decreases 5β-corticosterone and deoxycorticosterone production 
At hCG24 hours at the time of euthanasia, mice with double whole ovarian transplants 
were weighed; ovaries were removed and weighed as well, and serum was collected for hormone 
analysis and comparison to serum hormones prior to TAM exposure at hCG24 but after surgery 
(Figure 7.18). There were no significant differences in body weight between mice with different 
ovarian genotype transplants. Additionally, there was no significant difference in ovarian weight 
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or the ovarian weight to body weight ratio between control and SMACreERT2EdnraFlox ovaries. 
When serum hormones were measured, there was no significant difference in serum progesterone 
between mice with differing ovarian genotypes either before TAM treatment or after TAM 
treatment, nor from before TAM to after TAM within a group. Similarly, there was no difference 
in 5β-corticosterone and deoxycorticosterone between mice of different ovarian genotypes at either 
time point. However, there was a significant decrease in 5β-corticosterone in mice from before 
TAM to after TAM treatment, though this was present in mice with ovaries of each genotype. The 
same is true for deoxycorticosterone, which sharply decreased from before to after TAM treatment 
(Figure 7.18). These decreases in steroid production outside what are normally considered 
reproductive hormones likely indicate a decrease throughout the body of all steroid production, as 
corticosterone is produced from cholesterol at an upstream junction in the steroid synthesis 
pathway from estrogen or testosterone. Parsimoniously, this is most likely occurring through the 
rejection of transplanted ovaries and their chronic inflammation throughout the duration of the 
experiment; similar changes in progesterone are likely not observed because it is lower in serum 
concentration and more highly variable within groups, though progesterone in all groups is lower 
than in WT intact control mice at hCG24 hours (Figure 7.18). Overall, it appears that two 
treatments with TAM decrease steroid production in general and inhibit pregnancy, ovulation, 
transplanted organ uptake, and cyclicity during the time of TAM exposure. Tamoxifen-dependent 
gene ablation in cells with a rapid turnover such as smooth muscle is considered a poor tool for 
reproductive studies in vivo where multiple systems are at the regulation of numerous steroids. 
Tamoxifen itself demonstrates a systemic confounding effect, and its modifications of steroid 
production similarly create a lasting systemic confounding effect as well. 
 
Granulosa-cell specific loss of Ednra causes decreased fertility and litter size 
Given challenges using tamoxifen dependent models, a new pilot study was conducted to 
examine the role of Ednra in the ovary in granulosa cells as an alternative hypothesis. It was 
postulated that Ednra expression in the granulosa cells may instead mediate endothelin action 
during ovulation. It was hypothesized that loss of Ednra in the granulosa cells would cause fewer 
or smaller litters during normal mating as a consequence of decreased oocyte release. Mice that 
produce Cre recombinase under the Cyp19 (aromatase) promoter or the Amhr2 promoter were 
crossed with EdnraFlox/Flox mice. These mice express Cre recombinase in the granulosa cells, 
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specifically during and after the primary follicle stage, thus preventing most developmental 
confounding influences. Two Cre lines were used because of their different Cre recombinase DNA 
sequences: Cyp19-iCre mice use codon improved Cre recombinase, which is reported to have 
better recombination efficacy than traditional Cre lines like the Amhr2-Cre mouse, the latter of 
which has been widely used and well characterized. Both of these granulosa cell-specific Ednra 
knockout mice underwent a fertility assay in comparison to WT mice. Mice were sacrificed 
without gonadotropin stimulation after several rounds of breeding and histology was performed 
(Figure 7.19). Reproductive function of the resulting mice was measured by fertility and litter size 
(number of pups per mouse and pups per litter, respectively) after breeding with proven males. 
Amhr2CreEdnraFlox mice demonstrated a slight trend towards reduced fertility while 
Cyp19iCreEdnraFlox mice had significantly reduced fertility (57.9% in Amhr2Cre mice and 
42.3% in Cyp19iCre mice compared to 76.5% in WT mice, p=0.22 and p=0.02, respectively). In 
addition, Amhr2Cre and Cyp19iCre mice had significantly smaller litter sizes (3.55 +/-0.45 and 
4.56+/- 0.53 vs 7.08 +/- 0.48 in WT, p<0.01 for each). Interestingly, these data are similar to 
fertility data observed in female mice that have lost endothelin-2 production specifically in the 
granulosa cells (data not published, previous chapter). Each group demonstrates approximately a 
50% reduction in litter size, though only mice with loss of Ednra and not Edn2 demonstrated 
decreased litters / pairing. These early data suggest that EDN2 plays a role in reproduction in the 
granulosa cells from which it is produced via an autocrine/paracrine pathway through Ednra 
signaling, as opposed to direct receptor stimulation of smooth muscle cells, and this pilot study 
conclusively demonstrates that Ednra in granulosa cells plays an important role for female fertility 
in mice and should be further explored.  
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DISCUSSION 
 A smooth muscle-specific tamoxifen-inducible Cre mouse (SMACreERT2) was crossed with 
an endothelin receptor A floxed (EdnraFlox) mouse to create a conditional loss of Ednra after 
tamoxifen (TAM) treatment in smooth muscle cells. It was hypothesized that loss of Ednra in 
ovarian smooth muscle cells would prevent ovulation by inhibiting the physiological contractile 
mechanism during ovulation. The data presented here established that tamoxifen successfully 
induced Cre recombinase throughout the smooth muscle system of the ovary as well as the rest of 
body when provided in the once per day for five day injection scheme developed by Jackson 
Laboratories for that purpose. Additionally, mild Cre recombinase activity occurred without TAM, 
particularly in the bladder in a punctate manner, though also in other organs in a highly dispersed 
and likely non-influential manner. At 30 days after TAM treatment, some smooth muscle cells 
within the ovary were no longer fluorescent in an Ai9 reporter line, indicative of cellular turnover 
and replacement by a precursor cell that lacks Cre activity. Use of this mouse model established 
that impaired ovulation occurs in mice after loss of Ednra in ovarian smooth muscle. However, 
TAM treatment alone significantly impacts ovulation, preventing further conclusions from being 
drawn. Loss of Ednra in granulosa cells also impaired ovulation in a pilot study, suggesting that 
EDNRA may influence ovulation through other pathways beyond smooth muscle contraction. 
Tamoxifen is a known endocrine disrupting chemical (EDC) and acts as a competitive 
estrogen receptor antagonist throughout the body. It is now widely used for the treatment of human 
breast cancer. Estrogen receptors normally form a complex with the natural steroid hormones in 
the cellular cytosol and are then translocated to the nucleus565 to influence RNA and DNA 
polymerase, estrogen response elements within the DNA, and RNA synthesis566, which in turn 
modify protein production, metabolism, and cell cycling and proliferation567. Thus, estrogen exerts 
a profound and widespread influence throughout the body in both males and females. Chronic and 
acute TAM treatment inhibit estradiol uptake in vivo568. A single dose will produce an 
antiestrogenic effect in rats for up to three weeks after treatment569,570. Similarly, mice exhibit long 
term vaginal refractoriness570, and both the uterus and vagina have inhibited estrogen binding for 
up to 6 weeks in vivo with a 1.5mg dose on two consecutive days571. The influence of tamoxifen 
is related both to the concentration of the drug given and to the relative estrogen concentration in 
the animal, the latter of which influences bioavailability through receptor presence572. TAM has a 
dissociation almost 100 times faster than estradiol573; it was generally considered to have 
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estrogenic effects in mice and will cause vaginal cornification at 1.5mg/kg doses574 and increases 
in uterine weight. However, prolonged administration can cause antiestrogenic and antifertility 
responses570,571,575-577. TAM also inhibits estrogen-induced pituitary sensitization578, terminates 
pregnancy579-581, and induces cystic endometrial hyperplasia of the uterus582,583. At the given dose 
of 2mg/mouse/5 days or 75mg/kg/5 days used for successful Cre recombinase induction, TAM 
assuredly has an effect lasting multiple weeks with a systemic antiestrogenic influence. This is the 
major weakness of the approach presented in this study, and of using tamoxifen-inducible Cre 
mice in general. It is important to consider the systemic impact of both tamoxifen and estrogen for 
future use of tamoxifen-inducible Cre model organisms. It is unsurprising that roughly 50% of 
adult mice without any surgery or delay after TAM of either genotype tested failed to ovulate in 
response to gonadotropins after TAM treatment, and those that did ovulate had a marked reduction 
from vehicle treated mice (Figure 7.7). Additionally, as TAM has a lasting effect for up to 6 weeks 
at a lower dose, it is not unexpected that treated mice ovulated relatively few oocytes even 30 days 
after TAM (Figure 7.10) and did not become pregnant during a fertility test.  TAM treatment may 
also account for the decreased steroidogenesis in the whole ovary transplant mice as well (Figure 
7.18), which showed low progesterone levels at all points relative to the expected concentration, 
and a decrease in both corticosterone pathway products after TAM. The presented results are 
similar to those from early studies that focused on TAM alone without genetic modification. 
This study presents novel data on ovarian contraction relative to endothelin-2 (EDN2) 
treatment. Previous work by Ko et al. (2006)6 demonstrated that rat ovaries contract in response 
to EDN2 at a 50nM dose and that this tension could be modified by treatment with tezosentan at 
605nM (10mg/mL) as well, when compared to a K+ control (concentration not reported). The 
presented data show that EDN2 at 50nM produces a similar relative response in mouse ovaries 
(2.5x K+ solution) and that tezosentan reduces this contraction (1x-1.5x), albeit at approximately 
15% the dose of tezosentan previously reported. This is also the first reported use of a 
commercially available digital system to measure mouse ovarian contraction, whereas previous 
experiments have used custom analog systems. The dose of EDN2 used for contraction in these 
experiments was chosen based on the concentration needed for maximal contractile response 
(Figure 7.8). This is approximately 500 times the calculated amount of EDN2 present in a human 
ovarian follicle when collected for IVF (100pg/mL14 and 3.7mL volume584, about 0.1nM). 
However, 100pg/mL was determined in follicular fluid that was collected prior to ovulation14, and 
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rat ovaries have many more follicles and a larger change in ovarian volume than humans near 
ovulation585,586. As IVF collection occurs prior to ovulation when EDN2 mRNA dramatically 
increases in rodents, it is possible that much higher EDN2 concentrations are present in antral fluid 
during ovulation, which may be similar to 50nM used in this study. An additional finding in mouse 
ovarian contraction was a linear response to EDN2 concentrations between 50pM and 1nM, 
showing that EDN2 may exerts a contractile effect on smooth muscle cells after ovulation when 
antral fluid has become diluted. Considering the expulsion of antral fluid into the peri-ovarian 
space and the oviduct during ovulation, EDN2 may act to cause rupture of multiple follicles at the 
same time as a coordinator of ovulation or may modify oviductal motion for oocyte conduction. 
Indeed, ovarian contraction was present even with EDN2 concentrations as low as 0.05nM; lower 
concentrations were not tested. Also, EDN-induced oviductal contraction has been previously 
reported314,315,587,588, which may facilitate sperm, oocyte, or zygote transfer. 
Despite consistent contraction in response to EDN2 in all treated ovaries, no difference 
was observed in contraction between genotypes in response to EDN2 after TAM treatment (Figure 
7.9, Figure 7.12). This is in contrast to expected results. Previous recent work with EdnraFlox mice 
by Donato et al. (2014)562 using a smooth muscle Cre recombinase (that is not inducible) 
demonstrated a decreased vasoconstrictive response to EDN1 peptide from 10pM to 100nM 
compared to control mice. However, the sensitivity to EDN1 did not differ in that study; 
additionally, there was no difference in maximal diameter of isolated femoral arteries in response 
to EDN1 when an EDNRB antagonist was present. Key differences between studies are that 
application of a passive tension was not reported by Donato et al., and EDNRB antagonists were 
not employed in the presented data. Furthermore, smooth muscle in vessels is arranged in a 
uniform circular pattern within the tunica media whereas ovarian smooth muscle is haphazardly 
arranged relative to the follicles, meaning strong and directional contractions are not possible on 
the whole ovarian level and are not directly comparable to that of vessels. The lack of difference 
in contraction between genotypes in the present study may be a result of incomplete loss of 
EDNRA via TAM or return of EDNRA after TAM and prior to tension analysis, signaling through 
EDNRB, or signaling through other cell types. Future work using a high dose of EDNRB 
antagonist drugs or Ednrb-knock out mice may determine if EDN2 can induce contraction through 
EDNRB alone, though this seems unlikely given the higher fertility of Ednrb-knock out mice. If 
EDN2 signals through EDNRA in only a few cells to induce contraction, this may be sufficient for 
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ovarian contraction; it remains unknown how long Ednra ablation lasts after TAM treatment but 
if TAM effects are present six weeks after treatment but fluorescence as a marker of gene ablation 
is mostly lost by 30 days then Ednra may return quickly after TAM treatment ceases. As Ednra 
was not lost throughout the ovary, it is possible that other cells may signal for contraction through 
a secondary method; the 5-10 minute delay between EDN2 addition and observed contraction 
(Figures 7.9) as well as the phenotype of Cyp19-iCre EdnraFlox mice (Figure 7.19) lends credence 
to this idea.  
Furthermore, it was reported by Donato et al. that mice with constitutively active smooth 
muscle Cre recombinase and EdnraFlox were growth retarded with vascular deformations, thymic 
insufficiencies, and decreased viability (85% fatality rate before weaning). However, fertility was 
not notably affected (personal communication, Tokyo 2013) in breeding mothers that carried both 
transgenes, though fertility defects may have been overshadowed by other more obvious 
phenotypic differences and the few pups that survived to weaning. A strength of the Donato et al. 
study in this aspect is the lack of TAM needed, thus preventing systemic interference with the 
estrogen receptor system; however, as global changes to vascular development, vascular reactivity, 
and blood pressure were present which are all potentially influential in follicular rupture, it also 
fails to prevent a conclusive result on the role of EDNRA during ovulation in smooth muscle cells. 
It may be possible to transplant ovaries from the mice used in the Donato study to control mice 
prior to superovulation; if smooth muscles about follicles develop from local stem cells and not 
from the recipients’ population, this mouse would conclusively demonstrate the role of EDNRA 
in ovulation without the confounding influence of TAM, though the effect of surgery must still be 
considered. 
Ovarian transplantation or ovarian grafting has been previously used to transfer live 
ovarian tissues between animals, and is a procedure that is now being undertaken in humans as 
well, particularly in cancer survivors589,590. Lack of blood flow to the ovary (ischemia) is the main 
complication following surgery that prevents ovarian survival591-594. Reformation of vessels takes 
more than 48 hours after ovarian grafting595,596, but corpora lutea are present within 7 days in non-
stimulated ovaries597. In this study, ovarian transplantation was used to create ovary-specific 
transgenic models; in the second set of experiments, TAM was provided before surgery, and in the 
third set, TAM was provided after surgery; half ovaries were used in the second set and whole 
ovaries were used in the third. Marked leukocyte infiltration in a large number of ovaries of each 
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group was observed; this is likely not due to transplant rejection in a conventional sense. Mice are 
inbred and have the same genotypes excepting the presence of the Cre, and previous work by Lin 
and Ko (2013, unpublished) in an aging study demonstrates that bisected ovarian grafts transferred 
into the bursa of WT C57B/6 mice from GFP mice remain viable for up to 45 days and can 
successfully ovulate. It is more likely that the observed leukocyte infiltration follows an ischemic 
event that causes widespread apoptosis, necessitating collagen deposition and scar tissue formation 
as some of the tissue is also resorbed. This is a result of a surgical complication, and not of genetic 
incompatibility. Future surgeries may consider the use of gonadotropins following surgery to 
induce vascular reformation via VEGF signaling as well597. Also, as the kidneys are more highly 
vascular, studies looking at ovarian expression or corpus luteum formation, and not directly 
requiring oocytes passage through the reproductive tract, should consider kidney grafting to 
increase the likelihood of vascular reformation598-600. Additionally, the use of histology and/or RT-
PCR to check ovaries for leukocyte invasion in the future and screen out unsuccessful transplants 
may improve accuracy of results by removing unhealthy ovary bias. 
 Vascular formation in a graft begins from the recipient’s tissue and grows into the donor 
ovary601. The larger incoming vessels are surrounded by smooth muscle at the completion of the 
revascularization process. In our study where TAM was applied before transplantation, it is 
possible that the change in estrogen signaling modified graft uptake and increased ischemia as 
estrogen is known to be involved in cellular growth and angiogenesis602-605. Additionally, TAM 
has been shown to directly decrease angiogenesis in mice after experimental pulmonic ligation606. 
In our third study using whole ovary transplantation, even though TAM was given about two weeks 
after surgery, it is still possible that it prevented further angiogenesis prior to the breeding study 
as well as having effects on ovulation itself. As some of the grafts from this experiment appeared 
healthy (Figure 7.17, top row) and gonadotropins were supplied before TAM, it is more likely that 
TAM had an effect on ovulation than graft survival. A second point to consider is the effect of 
Ednra loss on angiogenesis in the second experimental set where TAM was supplied before the 
transplantation. Endothelin receptors have been shown to modify angiogenesis. Recently, Rattner 
et al. (2013) showed that EDNRA signaling in the retina prevents angiogenesis by maintaining tip 
cell endothelial state in growing vessels263.  In support of this, Zhang et al. (2014) also showed 
that EDNRB mediates EDN1-induced pulmonary angiogenesis in mice with hepatopulmonary 
syndrome607, and Leonard and Gulati (2013) reported that the EDNRB agonist IRL-1620 enhances 
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angiogenesis in rat brains after ischemia608,609, though there is some conflict from past 
pharmacological approaches610,611. Therefore it is likely that loss of EDNRA before transplantation 
does not prevent angiogenesis, and may in fact enhance it. This may also help explain the increased 
fertility in EDNRB-knock out mice233, as increased vascularity via VEGF has been shown to 
increase fertility by promoting follicle growth612,613. EDNRA-selective inhibition may enhance 
surgical recovery in ovarian transplantation, as well as a multitude of other surgeries. However, 
the potential for EDNRA-loss to influence ischemia and reperfusion remains an important 
consideration and limitation of the present study.  
 Though TAM treatment presents obvious complications, this study did consistently 
demonstrate a slight difference in ovulation and ovarian histology throughout. In young 
SMACreERT2EdnraFlox mice, there was no significant difference in the number of oocytes 
ovulated, but there was a 40% difference in the average number of oocytes obtained from control 
mice also treated with TAM. Similarly, after a 30 day delay, intact mice also had a slightly lower 
average number of oocytes ovulated. This was seen in mice that had received a half ovary from 
transplantation surgery as well. The range in this half ovary transplantation group, from the second 
experiment, was quite different between genotypes as well (0-13 vs 0-2, n=16). In support, mice 
in the 30 day delay experiment and the half ovary transplant experiment had ovaries with more 
antral follicles and fewer CL on average when Ednra was lost than in controls, although differences 
were only significant for CL count in the half ovary transplant group. As CL form after successful 
ovulation, these data taken together suggest that there is a slight difference in ovulation resulting 
from loss of Ednra, but that it is masked in the present model by TAM.  
 A strength of this study is that a second and alternative hypothesis was tested in a pilot 
study with a relatively large number of mice, and it yielded significant and interesting results. A 
fertility assay was used to test if the loss of Ednra in granulosa cells in the ovaries of naturally 
cycling mice influences fertility. Mice lacking Ednra via a codon-improved Cre recombinase 
driven by the aromatase promoter had a lower percentage of litters per pairing and a decreased 
number of pups per litter (Figure 7.19), with no difference in the expected 50/50 ratio of females 
to males. Pups born to these mothers appeared healthy and matured into healthy breeders. As 
Cyp19-iCre is specific to the ovary, this implies that the signaling defect may lie in the ovary itself 
but that it is not a major change preventing all functionality. Ovarian histology revealed multiple 
CL and antral follicles in each group with no obvious differences, though mice were sacrificed 
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after reaching maturity and going through multiple cycles, and no gonadotropin stimulation was 
performed. It is interesting to note that the reduction in litter size, from about 8 pups to about 4 
pups per litter, was similar to that observed in mice that lack Edn2 in the granulosa cells by the 
same or a related Cre recombinase system (Cacioppo et al. 2015, unpublished). As significance 
was observed in both granulosa cell-specific gene knockout studies and the same fertility 
phenotype was observed, a different fertility effect from whole-ovarian loss of EDNRB by Cho et 
al. (2012), it may be that EDN2 acts through EDNRA in the granulosa cells rather than the smooth 
muscle cells of the ovary in a manner that facilitates up to 50% of oocyte expulsion. This may be 
occurring through an autocrine or paracrine method to facilitate contraction as a physiological 
mechanism, or EDNRA may induce further downstream genetic changes to weaken follicle walls 
or promote vascular invasion which then aid in rupture. It must also be cautiously considered that 
EDN2 may act through EDNRA in granulosa cells in a positive feedback loop, and that effects 
seen in Cyp19-iCreEdnraFlox mice simply result from lack of EDN2 ligand production which 
would otherwise stimulate receptors on smooth muscle cells. These new and significant data do 
not rule out that Ednra may also play a role through the muscle cells of the ovary. The results of 
this entire study as a whole suggest that the granulosa cells of the ovary may be significant 
contributors to ovulation via the endothelin system, particularly EDN2 and EDNRA.  
 Future work in the ovarian endothelin system may take several routes to determine which 
endothelin receptor mediates ovulation. At present, the use of a granulosa-cell specific Ednra 
knock out mouse appears promising given fertility differences, and further downstream genetic 
and physiological implications can be explored in the immediate future, as well as confirming 
normal endothelin protein production. To better examine the role of Ednra in smooth muscle cells, 
and rule out its direct effect on contractility or not, a new mouse line may be generated in which 
smooth muscle actin-drive Cre is induced under a tetracycline system, which would remove the 
confounding effects of TAM or surgery. As a mouse of this type is not currently available, such 
questions may be examined at a future date. A third approach is to modify the ligand rather than 
the receptor, such as with a granulosa cell-specific loss of Edn2. The phenotype of this model may 
then be matched to receptor-specific deletions. Recovery experiments that induce ovarian 
contraction via non-endothelin candidates can then be tested. As two of these three proposed 
models are already available, the role of endothelin receptors in the ovary during ovulation may 
soon be elucidated; this may in turn offer recommendations for improvement of infertility 
200 
treatment or contraceptive development, and will help explain what changes occur in the ovary 
during treatment with endothelin antagonists such as macitentan for nonreproductive issues, 
including pulmonary arterial hypertension, systemic sclerosis, and renovascular disease.   
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Figure 7.1. Tamoxifen treatment induces Cre recombinase activity in smooth muscle cells of the ovary in SMACreERT2 Ai9 mice. A. Schema 
used for tamoxifen (TAM) treatment to induce Cre recombinase activity in smooth muscle cells. Tamoxifen was given once daily for five days by 
i.p. injection to 28 day old mice. Mice were then allowed to recover for two or 32 days. Mice then received superovulation treatment to induce 
ovulation with injections of PMSG and hCG 48 hours apart. Tissues were collected 24 hours after hCG injection. B. SMACreERT2 mice were bred 
with Ai9 reporter mice. Red fluorescence indicates areas of successful recombination. No recombination is visualized in the vehicle treated ovary. 
When ovaries are superovulated and collected immediately after TAM treatment, red fluorescence is visible in the smooth muscle cells of the ovary 
which surround follicles and vessels. Recombination is also present in the smooth muscle cells of the oviduct and uterus. When there is a 30 day 
delay between TAM treatment and superovulation and tissue collection, smooth muscle cells of the ovary, oviduct, and uterus continue to 
demonstrate fluorescence. However, gross intensity is decreased from tissues with no delay. Histology reveals that fewer smooth muscle cells of the 
ovary maintain red fluorescence after 30 days, though some fluorescence around follicles is visible. Fluorescence is reduced by approximately 75%.  
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Figure 7.2. Tamoxifen treatment induces Cre recombinase activity in smooth muscle cells throughout 
the body. SMACreERT2 Ai9 mice at 28 days old received TAM treatment for 5 days and were then 
superovulated after a two day recovery period. In addition to the ovary, smooth muscle cells of the oviduct, 
uterus, GI tract, aorta, and bladder demonstrate red fluorescence and successful recombination. There is 
limited to no Cre recombinase activity in skeletal and cardiac muscle, except for in the smooth muscle cells 
in the walls of the arteries and arterioles.  
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Figure 7.3. Exogenous SMACreERT2 expression occurs without tamoxifen treatment. Twenty-eight day old SMACreERT2 Ai9 mice received 
vehicle injection for five days and were then superovulated and sacrificed without delay as in Figure 7.1A.  Red fluorescence indicates areas of 
exogenous Cre recombination in the bladder and several cells of the heart, but not in the GI tract, ovary, aorta, skeletal muscle, or uterus. 
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Figure 7.4. Tamoxifen causes prolonged acyclicity in exposed mice. Vaginal cytology from three 
naturally cycling (left) and three tamoxifen-treated (right) shows abnormal cell patterning seen in 
tamoxifen-treated mice. Cytology matches none of the four major stages seen in mice (proestrus(P), 
estrus(E), and diestrus(D) pictured for reference from mice prior to tamoxifen treatment). Cytology is 
consistent with multiple leukocytes present as well as many rounded anuclear epithelial cells that lack the 
sharp polyhedral edges normally seen on estrus swabs. No change in this cytology result is seen throughout 
the duration of tamoxifen treatment; this result is most consistent with diestrus owing to the high number 
of leukocytes present. 
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Figure 7.5. Tamoxifen treatment induces loss of endothelin receptor A (Ednra) in smooth muscle cells. A. Schematic of Cre recombinase-
mediated deletion of Exons 6, 7, and 8 of the Ednra gene following five days of TAM treatment. Horizontal arrows indicate primer binding sites for 
the Ednra-KO band. The Ednra-KO amplicon is 1200 bp following successful deletion of Ednra exons; areas of primer binding are indicated by 
horizontal arrows. Recombination was confirmed by PCR from genomic DNA extracted from whole ovaries following TAM treatment as in Figure 
7.1A. Both vehicle treatment of SMACreERT2 EdnraFlox mice and TAM treatment of control mice fail to induce recombination. M: 1000bp ladder 
(New England Biolabs). “SMACre” indicates SMACreERT2EdnraFlox ovarian gDNA; n=3. B. TAM treatment induces loss of Ednra in the ovary of 
SMACreERT2EdnraFlox mice when superovulation immediately follows TAM (lanes 7-8, red) or when there is a 30 day delay prior to superovulation 
(lanes 5-6, maroon). Semi-quantitative RT-PCR was performed on RNA extracts from whole ovaries. No recombination is observed in control mice 
(lanes 1-4) with vehicle or TAM treatment. C. Quantification of semi-quantitative RT-PCR of whole ovary RNA after TAM or vehicle treatment 
reveals no difference in Ednra expression between groups (blue, teal). There is a significant decrease in Ednra-KO transcript in SMACreERT2 
EdnraFlox mice when there is a 30 day delay between TAM treatment and superovulation (maroon) compared to two days (red), though the gene 
deletion remains present. Error bars represent the SEM; n=5. 
Ednra Ednra-KO 
Ednra-KO 
Ednra 
SMACreERT2EdnraFlox WT 
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Figure 7.6. Ovarian immunohistochemistry demonstrates smooth muscle in the stroma and functional corpora lutea. Ovaries were collected 
from adult female (2 months of age) WT mice 18 hours after hCG injection, and were frozen, serially sectioned, and stained with hematoxylin and 
eosin, anti-SMA, and anti-P450scc. Note the presence of the smooth muscle network throughout the ovarian stroma around follicles and within 
corpora lutea (CL), and the positive staining of corpora lutea by P450scc. No differences were noted between ovaries of any treatment group in 
staining. Tamoxifen treatment does not prevent CL formation following gonadotropin induced ovulation nor does it modify the intraovarian smooth 
muscle scaffolding of either the stroma or forming CL. Magnification is shown at 4X and 20X. 
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Figure 7.7. Tamoxifen treatment reduces the number of oocytes ovulated. Twenty eight day old adult mice received intraperitoneal injections 
of 0.5mg tamoxifen in oil 1/day for 5 days and were then given gonadotropins to induce ovulation. Oocytes were collected 18 hours after hCG 
injection and were quantified to determine the effect of tamoxifen and Ednra loss on ovulation. A. Histology of ovaries at hCG 18hrs following 
TAM treatment and superovulation. No differences were noted between ovaries of any treatment group in staining, follicle count by stage, CL count, 
or size. Mild hemorrhage was present within some ovaries of each group. Note the presence of antral follicles in each group. Images are shown at 
4X, 10X, and 20X. Numbers in upper-left corner indicate oocytes ovulated by each ovary. B. Tamoxifen treatment significantly reduces the number 
of oocytes ovulated in both SMACreERT2EdnraFlox and control mice. P-values are displayed above the brackets between the two groups being 
compared. There is no significant difference in oocytes ovulated between SMACreERT2EdnraFlox mice and control mice of the same treatment. 
Numbers in parenthesis indicate the n-value for each group (ovaries). Error bars represent the SEM.  
SMACreERT2EdnraFlox+TAM 
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Figure 7.8. WT ovaries contract in response to EDN2 administration. Control mice (n=4) were 
superovulated at 28 days old and ovaries were collected at hCG12-16 hours. Ovaries were placed in a 
myograph machine for tension analysis. A. A representative control ovary (blue) response to a 60mM 
K+PSS solution (for normalization) and increasing concentrations of EDN2 solution. This ovary 
demonstrates a contraction in response to EDN2 that linearly increases with concentration. Vertical axis: 
tension in millinewtons where 9.81mN = 1.00gram-force. Horizontal axis: Time (Hours:Minutes:Seconds). 
B. Comparison of tension between concentrations with absolute (left) and relative (right) responses to 
endothelin receptor agonization by EDN2. Ovarian contraction was normalized to the response to K+PSS 
to compare relative contractile responses. The lowest increase in tension occurs at 50.0nM EDN2, 
indicating near saturation of receptors. Error bars represent the SEM. This treatment schema was similarly 
used to measure responses from treated ovaries, where EDN2 at 50.0 induces a strong contraction near the 
receptor saturation point, approximately 3.0 times as strong as the contraction from a 60mM K+ solution. 
210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.9. No difference in EDN2-induced ovarian contraction after TAM treatment. 
SMACreERT2EdnraFlox mice (n=8) and control mice (n=8) were exposed to tamoxifen for 5 days at 28 days 
old and were then given superovulation protocol to induce ovulation without delay. Ovaries were collected 
at hCG12-16 hours and were placed in a myograph machine for tension analysis. A. A representative control 
ovary (blue) response to a 60mM K+PSS solution (for normalization), a 50nM EDN2 solution, and a 140nM 
tezosentan solution. This ovary demonstrated contraction in response to the K+PSS and the EDN2 solution. 
This treatment schema was similarly used to measure responses in B. SMACreERT2EdnraFlox ovaries, 
orange. Vertical axis: tension in millinewtons where 9.81mN = 1.00gram-force. Horizontal axis: Time 
(Hours:Minutes:Seconds). C. Comparison of tension between treatment groups of absolute (left) and 
relative (right) responses to endothelin receptor agonization and subsequent antagonization. Ovarian 
contraction was normalized to the response to K+PSS to compare relative contractile responses. No 
significant differences were present. Blue bars (left) indicate WT tissues and red bars (right) indicate 
SMACreERT2EdnraFlox tissues. P-values are provided with each graph. Error bars represent the SEM. 
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Figure 7.10. Superovulation 30 days after TAM treatment shows no difference in oocytes ovulated or ovarian histology. 
SMACreERT2EdnraFlox mice (n=6) and control mice (n=4) were exposed to tamoxifen for 5 days at 28 days old, allowed to recover for 30 days, and 
were then given superovulation protocol to induce ovulation. A. Ovaries were collected at hCG24 hours and were fixed and serially sectioned; B. 
oocytes were also collected from the oviduct at this time and counted. There was no significant difference in the average number of oocytes ovulated 
per ovary (n=8-12). No obvious histological differences were present between ovaries in each group. All ovaries appeared healthy and contained 
both corpora lutea and antral follicles. There was no significant difference in the number of C. corpora lutea or D. antral follicles per ovary between 
treatment groups. Additionally, there was no significant difference in E. the ratio of corpora lutea to antral follicles per ovary.  Images are shown at 
4X and 20X magnification. Blue bars (left) indicate WT tissues and red bars (right) indicate SMACreERT2EdnraFlox tissues. P-values are provided 
with each graph. Error bars represent the SEM.  
SMACreERT2EdnraFlox+TAM+30 days 
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.11. No difference in serum sex hormone concentrations 30 days after tamoxifen treatment. SMACreERT2EdnraFlox mice (n=6) and 
control mice (n=4) were exposed to tamoxifen for 5 days at 28 days old, allowed to recover for 30 days, and were then given superovulation protocol 
to induce ovulation. Serum was collected 24 hours after hCG was administered and serum sex hormones were quantified by LC/MS. No significant 
differences were present in serum hormones of progesterone, 5β-corticosterone, deoxycorticosterone/11β-hydroxyprogesterone, or pregnenolone. 
Blue bars (left) indicate WT tissues and red bars (right) indicate SMACreERT2EdnraFlox tissues. P-values are provided with each graph. Error bars 
represent the SEM.  
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Figure 7.12. No difference in EDN2-induced ovarian contraction 30 days after TAM treatment. 
SMACreERT2EdnraFlox mice (n=6) and control mice (n=4) were exposed to tamoxifen for 5 days at 28 days 
old, allowed to recover for 30 days, and were then given superovulation protocol to induce ovulation. 
Ovaries were collected at hCG12-16 hours and were placed in a myograph machine for tension analysis. 
A. A representative control ovary (blue) response to a 60mM K+PSS solution (for normalization), a 50nM 
EDN2 solution, and a 140nM tezosentan solution. This ovary demonstrates a contraction in response to the 
K+PSS and the EDN2 solution. This treatment schema was similarly used to measure responses in B. 
SMACreERT2EdnraFlox ovaries, orange. Vertical axis: tension in millinewtons where 9.81mN = 1.00gram-
force. Horizontal axis: Time (Hours:Minutes:Seconds). C. Comparison of tension between treatment 
groups of absolute (left) and relative (right) responses to endothelin receptor agonization and subsequent 
antagonization. Ovarian contraction was normalized to the response to K+PSS to compare relative 
contractile responses. No significant differences were present. Blue bars (left) indicate WT tissues and red 
bars (right) indicate SMACreERT2EdnraFlox tissues. P-values are provided with each graph. Error bars 
represent the SEM. 
214 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13. Transplantation of half ovary after TAM treatment creates ovary-specific smooth muscle cell Ednra loss. A. Visualization of 
transplantation procedure. Twenty-eight day old SMACreERT2EdnraFlox and control mice received tamoxifen (TAM) treatment for 5 days to activate 
Cre recombinase and remove the Ednra gene in smooth muscle cells. Ovaries were then removed and bisected to limit graft size. Ovaries were 
transplanted into the ovarian bursa of 60 day old WT ovariectomized recipients. Each recipient received one half knockout ovary and one half control 
ovary that had each been treated with tamoxifen. Following surgery, mice were checked by vaginal smear for ovarian cyclicity as a marker of return 
to ovarian functionality. After one week recovery from surgery, mice were superovulated and tissues were collected 24 hours after hCG stimulation 
as previously. B. Timeline of TAM treatment, surgery, recovery, superovulation, and collection. Note that days elapsed are not to scale. 
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Figure 7.14. Ovary-specific Ednra loss decreases oocytes ovulated. Tamoxifen treatment followed by half-ovary transplantation was performed 
prior to superovulation. A. Vaginal cytology was performed once per day following surgery to monitor estrous cyclicity. Mice were able to enter 
estrus following ovary transplantation, usually after 5-7 days. Each line in graph represents one mouse; peaks represent estrus and base represents 
diestrus, proestrus, or metestrus. B. At hCG24 hours, mice were euthanized, ovaries were removed and fixed, and oocytes were collected from the 
oviduct of each mouse. Left bar (blue) is control ovaries and right bar (red) is SMACreERT2EdnraFlox ovaries. There was a trend towards B. fewer 
oocytes ovulated and D. more antral follicles present in the SMACreERT2EdnraFlox ovaries, and there were C. significantly fewer corpora lutea 
present when ovaries were histologically examined. There was a high degree of variation in the number of antral follicles in each group, while many 
ovaries from each group failed to ovulate. E. Representative histological comparison of superovulated ovaries at hCG24hrs. Left: Control ½ mouse 
ovaries with TAM treatment and surgical transplant to WT recipient. Right: SMACreERT2EdnraFlox mouse ½ ovary with TAM treatment and surgical 
transplant to WT recipient. Marked leukocyte infiltration was present in the majority of ovaries of each group. Images at 4X and 20X. N=16 animals 
and 16 ovaries of each genotype. Error bars represent the SEM. 
SMACreERT2EdnraFlox 
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Figure 7.15. SMACreERT2EdnraFlox half ovaries have normal cytochrome P450scc expression, progesterone secretion, and oocyte 
expansion. To determine if mice could produce corpora lutea after half ovary transplantation, histology was performed on ovaries at hCG24. A. 
Ovaries were stained with anti-P450scc, a steroidogenic enzyme and CL marker. Newly forming corpora lutea are present in both the 
SMACreERT2EdnraFlox and control ovaries. Images are shown at 4X and 10X magnification. To determine if these corpora lutea were functionally 
capable of steroidogenesis necessary for pregnancy maintenance, B. serum progesterone was measured in mice that had received ovarian 
transplantation, one half ovary of each treatment, and compared to intact control mice at hCG24. Error bars represent the SEM. There was no 
significant difference in serum progesterone concentration between groups. Teal bar: control; maroon bar: SMACreERT2EdnraFlox. C. To determine 
if oocytes ovulated form SMACreERT2EdnraFlox ovaries were healthy, oocytes were collected from the oviduct at hCG24. Cumulus complexes were 
successfully dissociated with hyaluronidase treatment in each group and no differences were observed in oocyte gross morphology. 
SMACreERT2EdnraFlox+TAM 
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Figure 7.16. Transplantation of whole ovary before TAM treatment creates ovary-specific smooth muscle cell Ednra loss. A. Visualization 
of transplantation procedure for model generation. Twenty-eight day old SMACreERT2EdnraFlox and control mice were sacrificed with no prior 
treatment and whole ovaries were removed and transplanted into the ovarian bursa of 60 day old WT female recipient mice. Each recipient received 
two whole ovaries of the same genotype.  B. Timeline of treatment procedure which was the same for each genotype group. Following surgery, mice 
were checked by vaginal smear for ovarian cyclicity as a marker of return to ovarian functionality. After one week recovery from surgery, mice were 
superovulated and serum samples were collected 24 hours after hCG stimulation from the mandibular vein. Mice then received tamoxifen treatment 
for five days to induce Cre recombinase and Ednra loss. Following this, mice were bred proven breeder males for 10 days. Females were then 
isolated for 21 days during pregnancy period. After the fertility assay, mice again received tamoxifen for five days to induce Cre recombinase. Mice 
were then again superovulated and serum and tissue samples were collected at 24 hours after hCG stimulation for serum hormone assays and 
histological examination. 
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Figure 7.17. Tamoxifen-treated mice with ovarian transplantation do not ovulate normally or become pregnant. A. Vaginal smears of mice 
were taken daily following double ovarian transplantation procedure and prior to tamoxifen treatment. All mice were able to return to normal 
cyclicity within one week of surgery. Peaks represent estrus. Top four blue lines represent mice with two control ovaries. Bottom four red lines 
represent mice with two SMACreERT2EdnraFlox ovaries. Arrow represents time of surgical transplant. No pups were born to any mother of either 
group during the breeding study. B. Vaginal smears of mice were taken daily following the breeding study. Peaks represent estrus. Top four blue 
lines represent mice with two control ovaries. Bottom four red lines represent mice with two SMACreERT2EdnraFlox ovaries. Arrow represents start 
day of second tamoxifen treatment. Mice displayed normally cyclicity prior to second tamoxifen treatment, and no mouse entered estrus following 
tamoxifen treatment until the end of the study. C. Histology of mouse ovaries and uteri at the completion of the experiment, hCG 24 hours, 
hematoxylin and eosin staining. Representative ovaries of each group are shown that appear generally healthy with multiple follicles (top row) and 
unhealthy ovaries with a high degree of fibrosis and inflammation (middle row). Images are shown at 4X and 20X. No oocytes were obtained from 
any oviduct of either group at hCG 24 hours. All uteri from mice consistently demonstrate severe cystic endometrial hyperplasia (bottom row); all 
uteri are WT. Images are shown at 4X. 
SMACreERT2EdnraFlox 
219 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.18. Tamoxifen-treated mice with ovarian transplantation do not differ in body weight, ovarian weight, or serum progesterone 
concentration. Mice with double whole ovary transplantation were superovulated and had serum collected at hCG24, then received tamoxifen 
treatment twice and were superovulated again and euthanized at hCG24 as in Figure 7.16. Mice were weighed, and then ovaries were removed and 
gross wet weight was recorded. Serum was separated from whole blood and analyzed for concentrations of progesterone, 5β-corticosterone, and 
deoxycorticosterone/11β-hydroxyprogesterone. Mice with double ovarian transplantation of WT ovaries (dov/WT) are displayed at left in blue and 
mice with double ovarian transplantation of SMACreERT2EdnraFlox ovaries (dov/SMACre) are displayed at right in red. No significant differences 
were present between body weight (n=4), ovarian weight (n=8), or the ratio of ovarian to body weight (n=8). No significant differences were present 
in progesterone concentration at any time (n=4). Both 5β-corticosterone , and deoxycorticosterone/11β-hydroxyprogesterone were significantly 
decreased from before tamoxifen treatment (teal and maroon) to after tamoxifen treatment (blue and red) at euthanasia in each group, but no 
difference existed between ovarian transplant genotype  at either serum sampling point (n=4). Error bars represent the SEM.  
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Figure 7.19. Granulosa-cell specific loss of EDNRA causes decreased fertility and litter size. Two granulosa cell-specific Ednra-knockout 
transgenic mouse lines were generated and compared by fertility assay. Females were bred with control fertile males for 10 days and then isolated. 
A,B. Mice containing Cre recombinase under the aromatase promoter (Cyp19, red) had significantly fewer litters per total mating cycles and also 
significantly fewer pups per litter. Mice with Cre recombinase under the anti-Mullerian hormone receptor type II (Amhr2, maroon) trended towards 
decreased fertility and also had a significant reduction in the average number of pups per litter. There was no difference between groups in the gender 
ratio of females to males. Error bars represent the SEM. Mice were sacrificed without stimulation after breeding and ovaries were collected and 
fixed. C. Histological comparison of WT and Cyp19iCreEdnraFlox ovaries. Each genotype is capable of producing normal corpora lutea and antral 
follicles; no obvious morphological differences are present between treatments. Representative images are shown at 4X and 20X. 
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ABSTRACT 
 Endothelin-2 (EDN2, ET-2) is a short 21 amino acid peptide that is produced in a variety 
of tissues. It plays a role in the cardiovascular system, in the ovary during ovulation, in the immune 
system as a chemoattractant or for chemotactic response induction, and likely in a variety of 
cancers. EDN2 is produced from prepro-form, which must be cleaved to become active. However, 
the regulation of expression of the Edn2 gene has yet to be determined. First, two pilot studies 
were performed: the role of progesterone receptor in Edn2 regulation within the ovary by using 
progesterone receptor knockout (PRKO) mice was confirmed, and then it was determined whether 
acute hypoxia could induce expression throughout the body. Expression of Edn2 was 
downregulated approximately 90 fold in PRKO mice; there was no difference in Edn2 expression 
in mouse ovaries, kidneys, or lungs immediately after 2 hours of hypoxia in an 8% O2 chamber, 
or 6 hours after normoxia recovery. Second, a promoter analysis was performed that examined 
3000 base pairs upstream and downstream of the Edn2 gene as well as the internal intron 
sequences. The analysis identified 88 transcription factors that may directly regulate Edn2 
expression. When coupled with ovarian microarray data, the hypothesis that Edn2 is regulated by 
Runx1 within the ovary during ovulation was developed, and a possible mechanism for this 
regulation through repression by BCL6 has been generated for future experimental testing. 
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INTRODUCTION 
Endothelin-2 (EDN2, also ET-2) is a short 21 amino acid peptide212 that plays an important 
role throughout the body during development223, and it also regulates vessel growth and 
formation263,614, tissue fibrosis615,616, and leukocyte migration270. Mice that lack the gene Edn2 do 
not survive long after birth from starvation, hypothermia, and emphysema223; mice that lack 
endothelin receptor A (Ednra, EDNRA) do not survive in utero to birth617. Though important, the 
mechanisms that control Edn2 expression have not been fully explored, in the ovary or in other 
tissues throughout the body. Similar to the nearly identical EDN1 protein from Edn1, EDN2 is 
first translated as a prepro form and then cleaved twice into an active form618. The Edn2 gene is 
believed to be under transcriptional regulation619,620. Control by transcription factors may involve 
binding to promoters, enhancers, and locus-control regions of DNA to help recruit the DNA 
polymerase complex and/or co-activators. Transcription factors may also act as repressors to 
prevent transcription; transcription factors exhibit sequence-specific binding and form bonds of 
varying strength to specific DNA sequences621. Transcription factors that bind weakly to one 
sequence but strongly to another may yet influence the transcription of each. Identification of a 
binding site that a transcription factor has a high affinity for in the promoter region of a gene 
suggests that that transcription factor plays a role in regulating that gene’s expression. But the 
sequences transcription factors recognize are often only several base pairs long and allow for 
partial mismatch. Thus specific binding sites for any one factor can be found at random every few 
hundred to a thousand base pairs, making the search for transcriptional regulators difficult while 
adding complexity to a whole organism. This overall mechanism allows for different cells to 
express the same gene at different times or at different levels. As Edn2 expression is widespread 
throughout the body but in a punctate manner368, Edn2 expression is likely regulated by different 
mechanisms in different tissues.  
EDN2 has been shown to be expressed in the ovary at the time of ovulation after 
gonadotropin stimulation in rodents, where it is necessary for normal oocyte release and corpus 
luteum formation for pregnancy maintenance6,171. It is thought to induce contraction of the outer 
theca cells as a final trigger for follicle rupture200. Endothelin-2 is specifically expressed in the 
granulosa cells in a two hour window, from 11 to 12 hours after stimulation by a luteinizing 
hormone (LH) mimetic gonadotropin7, while ovulation occurs from 12 – 14 hours in mice after 
this gonadotropin stimulation622-624. It has been previously shown that ovarian Edn2 expression is 
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sharply decreased when the progesterone receptor gene (Pgr) is removed7. However, the peak 
timing of Pgr expression is nearly six hours before Edn2 expression in mice (six hours after 
stimulation)70,244,625, implying an indirect mechanism for regulation which is supported by the 
many downstream signaling cascades triggered by Pgr. Additionally, a study where mice were 
treated with RU-486 (progesterone receptor antagonist) or indomethacin (cyclooxygenase 
inhibitor, PTGS2 inhibitor) did not change Edn2 expression247, indicating further exploration is 
needed into the direct regulation of Edn2. 
Hypoxia has also been shown to induce Edn2 expression, specifically through hypoxia-
inducible factors (HIFs) that couple to enhance expression246,247,250,626. However, luciferase assays 
have revealed that hypoxia inducible factors are not solely responsible for Edn2 transcriptional 
regulation in mice247. The Edn2 gene has multiple binding sequences for HIF upstream of exon 1, 
and HIF action is increased in the ovary during ovulation, but removal of HIF binding sites shows 
only a partial reduction in Edn2 expression by luciferase assay247, indicating that HIF factors may 
play a role in Edn2 induction in the ovary, but may not be solely responsible for expression. Other 
work using granulosa cell cultures also indicates that HIF may play a role in the timing of Edn2 
expression245,246,626. A challenge in studying hypoxia and ovulation is examining the event at a 
whole tissue level, as multiple organs participate in ovulation from hormonal signaling from the 
pituitary to leukocyte invasion from the spleen58. Whole-animal hypoxic exposure also effects the 
other systems of the body as well. Specifically, the kidneys suffer necrosis that becomes obvious 
within 12 hours of acute hypoxia (ischemic injury)627,628 via downregulation of vascular 
endothelial growth factor (VEGF) and hypoxia inducible factor 1 alpha (HIF1α)629. However, 
endothelin receptor antagonization may prevent hypoxia-induced damage630; additionally, 
osteopontin (secreted phosophoprotein 1, Spp1) knockout mice have reduced macrophage invasion 
and reduced fibrosis628, and osteopontin expression itself is decreased in Edn2-knockout ovaries 
during ovulation while Pgr is increased (Cacioppo et al., unpublished). Generally, these organs 
have not been well evaluated for Edn2 expression after acute hypoxia in the mouse, but acute 
hypoxia may directly or indirectly regulate Edn2 expression. 
To examine potential transcription factors that regulate a new gene of interest, recent large 
collaborative efforts have produced databases relating the genomic sequences of many species to 
sequenced RNA and protein sources. Regulatory elements have been investigated through DNA 
hypersensitivity assays, methylation assays, and now through chromatin immunoprecipitation 
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(ChIP) assays of proteins themselves631. Sequencing of ChIP results relative to DNA regions 
(ChIP-Seq) allows construction of a library of the proteins that interact with specific DNA regions 
and also allows for quantification of the strength of these interactions. Other scientists have 
recorded the specific DNA sequences that known transcription factors interact with and compiled 
these into a library from previous work using consensus sequence binding621. The collaborative 
ENCODE Consortium effort aims to build a list of regulatory elements that interact with the human 
genome and utilizes many search options, including ChIP-Seq data, to display possible 
transcription factors631. Alternatively, the program TESS allows for transcription factor 
identification through string and positional weight matrices that identify DNA sequences related 
to known consensus sequences621. Furthermore, the new MET tool from the University of Illinois 
statistically examines DNA for over-represented DNA sequences in a promoter region and then 
incorporates ChIP-Seq and DNA-Seq data from ENCODE or modENCODE to more accurately 
identify likely transcription factors for a particular gene632. One or each of these tools may be used 
to identify transcription factors responsible for Edn2 regulation. To then expand upon results from 
TESS, ENCODE, or MET, species-specific tissue-specific time-specific RNA or protein 
microarray data may be used to eliminate transcription factors that are not present or not 
transcribed, or show no change. Transcription search tools and gene expression or protein 
microarray results are now available publicly online and may be coupled for a powerful new search 
method. In the interest of Edn2 in the ovary during ovulation, related microarrays are present 
through the University of Kentucky examining rats199 and Stanford University examining 
humans198,268,633,634, and may also now be relatively cheaply privately generated for a specific 
species, tissues, or situations635-638. Given the wide utilization of knockout mouse models and the 
necessity of examining ovulation in vivo, transcription factor expression observed through a mouse 
RNA microarray during ovulation would provide a tool to generate hypotheses on Edn2 regulation. 
The goals of this study were to confirm previous findings regarding Pgr regulation of Edn2, 
to test the effect of acute hypoxia in vivo on Edn2 expression in the mouse, to examine potential 
direct regulators of Edn2 expression in the body through computational analysis of the gene and 
known transcription factors, and to generate a model method and testable hypothesis for a possible 
molecular mechanism underlying ovarian Edn2 expression based on known expression in that 
tissue specifically during ovulation. It was hypothesized that genetic loss of Pgr would 
significantly impair expression of Edn2, but exposure to a low oxygen environment would not be 
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sufficient to increase Edn2 expression. It was further postulated that combined analyses of 
microarray and ChIP-Seq data would reveal a single transcription factor that binds to the Edn2 
gene that is increased in expression during ovulation just prior to Edn2 induction. 
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MATERIALS AND METHODS 
 
Ethics Statement 
 This study was carried out in tight accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocol was 
approved by the University of Illinois Animal Care and Use Committee (Protocols: 11184, 13336, 
and 14222) and the University of Kentucky Animal Care and Use Committee (Protocol: 
1111M2006), and all efforts were made to minimize unnecessary animal suffering. 
 
Animals 
Progesterone knockout mice (PRKO) were generated by crossing mice with a floxed 
progesterone receptor243 (PgrFlox/Flox) gene with mice that express Cre recombinase under the 
zone pellucida 3 protein promoter173 (ZP3-Cre) to cause the deletion of exon 2 in both alleles. 
Genotyping for progesterone receptor was performed with the primers FPRf 5’-GTA TGT TTA 
TGG TCC TAG GAG CTG GG-3’, fPR-R 5’-TGC TAA AGG TCT CCT CAT GTA ATT GGG-
3’, and fPR-DR 5’-ATA TTT ATG ACT TTG AGA CTT G-3’. Amplicons of 226, 276, and 481 
base pairs indicate WT, floxed, and knockout alleles, respectively; PCR annealing temperature 
was 58°C with 30 cycles. These mice were on an inbred C57B/6 background. Thirteen global 
PRKO and 13 control immature (PND25-28) female mice received superovulation. 
Superovulation consists of intraperitoneal (i.p.) injections of 5IU of pregnant mare serum 
gonadotropin (PMSG, Sigma-Aldrich, St. Louis, MO) in 100uL saline followed 48 hours later by 
i.p. injection of 5IU of human chorionic gonadotropin (hCG, Sigma-Aldrich, St. Louis, MO). Mice 
ovulate 12-14 hours after hCG injection. Mice were euthanized by CO2 asphyxiation and cervical 
luxation at hCG0 (PMSG48), hCG6, hCG9, and hCG12 hours and ovaries and uteri were collected 
(n=4) and flash frozen before RNA extraction. WT mice for hypoxia examination were produced 
from pairings from the authors’ breeding colony on an inbred C57B/6 background. Mice used for 
ovarian database production were purchased from Jackson Laboratories (Bar Harbor, Maine). 
These mice were superovulated at 25 days of age and were sacrificed for RNA extraction at 
PMSG0, PMSG12, PMSG48/hCG0, hCG6, hCG12, and hCG24 hours, and were on a CD31/J 
background.  
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RT-qPCR and semi-quantitative PCR 
Following euthanasia, ovaries, lungs, or kidneys were removed, and homogenized in Trizol 
solution (Life Technologies, Grand Island, NY) for RNA extraction. RNA was purified with an 
RNeasy kit (Qiagen, Germantown, MD), and cDNA was generated using a reverse transcription 
superscript VILO synthesis kit (Invitrogen). Real time-qPCR was performed to assess Edn2 and 
Rpl19 expression in PRKO and control mice. Rpl19, encoding murine ribosomal 60S protein L19, 
was chosen as an internal control based on previous publications280,281. RT-qPCR was run with 
primers purchased from Life Technologies (Carlsbad, CA): Edn2 was quantified with primers 
catalog number Mm00432983_m1 (74bp) and Rpl19 was quantified with primers catalog number 
Mm02601633_g1 (69bp) on an ABI 7500 machine. Results were quantified by the delta delta Ct 
method472. Semi-quantitative PCR was similarly used to quantify Edn2 and Rpl19 expression after 
hypoxia exposure in mice. The Edn2 gene was amplified with (5'-
CTCCTGGCTTGACAAGGAATG-3') and (5'-GCTGTCTGTCCCGCAGTGTT-3'), and Rpl19 
was amplified with (5'-CCTGAAGGTCAAAGGGAATGTG-3') and (5'-
GTCTGCCTTCAGCTTGTGGAT-3'). PCR products were visualized on an agarose gel; band 
intensity was analyzed using ImageJ software (NIH, Bethesda, MD) for relative intensity. 
 
Hypoxia Induction 
To determine the effect of acute moderate hypoxia on Edn2 expression in the ovary, lungs, 
and kidney, mice were exposed to a reduced oxygen atmosphere for two hours. Adult female mice 
(n=3/group) in diestrus, approximately 125 days of age (125±15.4 days), were placed into a 
hypoxia chamber (normal ventilation initially) and allowed to acclimate for two days. The chamber 
is a Plexiglas box with dimensions 12 x 6 x 4 in. At time=0 hours during diestrus, hypoxia was 
induced for the experimental group of mice by connecting the chamber to a S. J. Smith & Co. 
(Davenport, IA)-certified gas cylinder containing 8% O2 and excess nitrogen. Control mice were 
exposed to normal room air (20.9% O2) from a similar cylinder at matching times and rates. The 
hypoxia chamber was flushed for 5 minutes by using a high rate of gas flow (8L/min) to achieve 
the desired FiO2. The flow was then maintained for 2 hours at 1L/minutes to induce moderate 
hypoxia in the experimental group. The O2 concentration was continually monitored using a gas 
analyzer (OxyStar-100; CWE, Inc., Ardmore, PA). Following hypoxia exposure, gas flow was 
shut off and mice were returned to normal room atmospheric conditions. Mouse tissues were 
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collected at times t=0 (after hypoxia) and t=6 hour (6 hour recovery after hypoxia). The animals 
were sacrificed using CO2 inhalation and cervical luxation, and tissues were collected, snap frozen, 
and stored at -80°C until RNA extraction.  
 
Histology 
Tissues were fixed in the 4% paraformaldehyde overnight and were then embedded in 
paraffin and sectioned at 5 μm, mounted on charged glass slides. Tissues were then stained with 
hematoxylin (Harris) and eosin (Surgipath) for cellular visualization. Molecular reagents were 
purchased from Invitrogen (Invitrogen, Carlsbad, CA). 
 
Transcription factor search with TESS, ENCODE, and MET and binding site consensus 
alignment 
To determine potential transcription factors that may regulate expression of Edn2 during 
ovulation, multiple searches were conducted using the Transcriptional Element Search System 
(TESS)621 and the motif cluster search through ENCODE631 and the Motif Enrichment Tool 
(MET)632. TESS predicts transcription factor binding sites based on DNA sequences provided by 
the user using information pulled from TRANSFAC639,640, JASPAR641,642, IMD643, and CBIL-
GibbsMat644. TESS was publicly available through the University of Pennsylvania 
(http://www.cbil.upenn.edu/tess). MET predicts transcription factors through enrichment tests on 
user-defined genes by first determining a set of genes that are targets of a transcription factor and 
then quantifying the significance of their overlap with the gene in question. Data used for mouse 
and human genomes were extracted from chromatin immunoprecipitation (ChIP) data representing 
known binding sites and used to generate probability scores integrating strength of transcription 
factor binding. MET is publicly available through the University of Illinois at Urbana-Champaign 
(http://veda.cs.uiuc.edu/cgi-bin/MET/interface.pl). The ENCODE (Encyclopedia of DNA 
Elements Consortium) human genome database was examined for possible binding sites through 
the in a similar manner using ChIP data. The ENCODE data set is publicly available through the 
University of California, Santa Cruz (http://genome.ucsc.edu/ENCODE/). The TESS computation 
search examined 2000 base pairs upstream of the Edn2 ATG start codon for DNA sequences in 
the mouse genome that match known sequences for transcription factor binding. The ENCODE 
and MET cluster searches examined 3000 base pairs upstream and downstream, as well as introns 
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of the Edn2 gene in the human and mouse genomes. Potential transcription factors identified by 
TESS were scored as 1 per site. ENCODE and MET motif cluster searches were scored as 1.0 for 
sites above two standard deviations above the binding threshold and 1.5 for sites above four 
standard deviations above the binding threshold. The total score from all search methods was 
summed as ‘Total Hits’ in column 2. All genes identified by any of the three search tools are 
provided. Binding consensus alignment of RUNX1 was done by first identifying binding sites in 
the mouse Edn2 gene. The mouse Edn2 gene was then aligned using VISTA645 (Visual Tools for 
Alignments) to rat, human, and multiple mammal genomes that are annotated and available 
through the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). 
VISTA is publicly available through the University of California, the DOE Joint Genome Institute, 
and US Department of Energy (http://genome.lbl.gov/vista/index.shtml).  
 
Mouse Ovarian Gene Database (mOGED) generation and use for change in gene expression 
searches 
The mOGED was constructed in 2005 following the same principles as the publicly 
available rOGED freeware hosted by the University of Kentucky199. Briefly, RNA was extracted 
from four whole ovaries per time point from CD31/J mice and run in duplicate. Five micrograms 
of RNA were used as template for cDNA synthesis, and biotinylated antisense cRNA probe was 
prepared by the SuperScript System kit (Invitrogen) and the ENZO BioArray HighYield RNA 
labeling kit (Enzo Diagnostics, Farmingdale, NY) according to the manufacturer’s instructions. 
Unincorporated nucleotides were removed by using the RNeasy Mini kit (Qiagen). The Affymetrix 
Mouse oligonucleotide array sets were hybridized, washed, and scanned using Affymetrix 
equipment and protocols (Affymetrix; DNA Microarray Core Facility, University of Kentucky, 
Lexington, KY). The total data were compiled as an Access Database file in Excel (Microsoft, 
Redmond, WA) and run with the GEDT software previously developed for use with rOGED. This 
allows interface users to search for mapped gene expression at various time points during 
ovulation. Gene expression at PMSG0 hours was considered baseline expression. P=Present, 
A=Absent, M=Marginal. Genes with a call of “absent” were considered too low to be detected at 
that time point and were not considered. Data from mOGED were compared to potential 
transcription factors identified by TESS and MET to identify genes that had both increased 
expression and possible binding sites about the Edn2 gene. Data from mOGED were scored based 
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on the standard deviation from hCG0, hCG6, and hCG12 hours divided by the mean of those time 
points, times 100%, to generate a percentage describing relative change in expression just prior to 
ovulation. Values of less than 50% were not considered significant.  
 
Statistical Analyses 
 Data analyses were performed using statistical software (SPSS, Inc., released 2013, PASW 
Statistics for Windows, Version 22.0, Chicago, IL). Continuous data were tested for normal 
distribution by a Shapiro-Wilk test. All data were normally distributed and were analyzed with 
parametric tests (student’s t-test, ANOVA) and a Bonferroni post hoc test. Data are graphically 
presented as the mean and standard error of the mean. For all analyses the alpha value was set to 
0.05. 
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RESULTS AND DISCUSSION 
 The endothelin-2 gene (Edn2) is implicated in several diseases and is proven important for 
development and ovulation in mouse models. However, the mechanistic regulation of Edn2 
expression is largely unexplored. The ovary was focused on owing to the predictable and high 
expression pattern of Edn2 there during stimulated ovulation. The data demonstrated below 
confirm that Edn2 is under regulation by PGR in the ovary, that acute exposure to low oxygen 
content is insufficient to induce expression, and RUNX1 is a likely regulator of ovarian Edn2 
expression through an epigenetic mechanism. 
There are currently two conflicting studies that claim or refute that Edn2 is under regulation 
by the progesterone receptor gene (Pgr); one utilizes a knockout animal approach7 while the other 
uses a pharmacological approach247. To first determine if Edn2 is under regulation of Pgr, a novel 
Pgr-deficient mouse (PRKO) was generated by globally deleting the second exon of the gene. 
These mice were superovulated and compared to control age-matched (25 days) mice. Mice were 
sacrificed at hCG0 and hCG12 hours, and relative expression of Edn2 was quantified by RT-PCR 
and normalized to Rpl19. In control mice, Edn2 expression rose from 1.0±0.1 at hCG0 hours to 
926.7±177.5 units at hCG12 hours. (Figure 8.1A). However, in PRKO mice Edn2 expression 
increased only from 0.48±0.1 to 10.3±1.2 units. There was no significant difference at hCG0 hours 
(p=0.845), but Edn2 expression was greatly decreased at hCG12 hours (p=0.019, Figure 8.1B). 
Thus global loss of functional progesterone receptor decreases Edn2 expression during ovulation 
approximately 90 fold. This initial study confirms that PGR directly or indirectly regulates Edn2 
expression as described originally by Palanisamy et al. 2006. Further study may definitively 
determine if lack of follicle rupture from PGR loss is responsible for loss of Edn2 induction, or 
vice-versa. Conflicting results from Na et al. 2008 may have resulted from insufficient RU-486 
dosing, a short-acting halflife, late administration of RU-486 relative to PGR action prior to 
ovulation, or incomplete blockage of PGR. It has been shown by Lin et al. (2015, unpublished) 
that genetic knockout of Pgr by a lower efficiency Cyp19-iCre transgene is insufficient to prevent 
ovulation and it may be that only a small amount of granulosa cells need to express progesterone 
receptor to mediate its effects. Future work may examine the signaling that occurs between PGR 
activation and Edn2 expression, as Edn2 does not seem to contain a PGR-response element 
(below).  
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 The aforementioned conflicting authors do both agree that Edn2 expression is regulated 
through hypoxic factors. Na et al. 2008 state that Edn2 is under hypoxia inducible factor 1 (HIF1) 
regulation through ACGTG sequence sites in the promoter. Kim et al. 2009 similarly state that 
HIF1-alpha, HIF2-alpha, and HIF1-beta are transcription factors that form heterodimers during 
ovulation in PGR-dependent manner251. Na et al. 2008 utilized a dual luciferase assay to 
demonstrate loss of certain promoter regions decreased Edn2 expression; however, Edn2 
expression was never fully lost to the extent seen in PRKO mice and was at most reduced by 2-
fold. Kim et al. 2009 showed a 90% reduction in Edn2 expression in the ovary at hCG11 hours 
when mice were treated with 5mg/kg echinomycin which inhibits HIF heterodimer binding, which 
is more similar to the changes in expression observed through PRKO mice. As a brief and non-
exhaustive pilot study into physiological hypoxia as a trigger for Edn2 expression, hypoxemia and 
consequently hypoxia were induced by exposing adult mice to 8% O2 for two hours. Mice were 
then sacrificed immediately after hypoxia, or at 6 hours after hypoxia to mimic the time seen 
between the rise in HIF factors at hCG6 (Figure 8.3B) and expression of Edn2 at hCG11-12. It is 
interesting to note here that in the rOGED, HIF1-alpha expression throughout the whole ovary 
increases from hCG0 hours to hCG6 hours, but that this occurs within the theca cells; there is no 
change observed within the granulosa cells during this time where Edn2 expression occurs199. 
Although mice underwent obvious hypoxic stress and remained in sternal recumbency with 
labored rapid breathing for the duration of low oxygen exposure, no increase in Edn2 expression 
was observed in the ovary, kidney, or lungs at either time point (Figure 8.2A, p>0.05). Kidney 
histology was performed as noticeable histologic changes occur there after ischemia-reperfusion 
injury. However, no major changes could be observed (Figure 8.2B), though this is attributed to 
the early time of kidney collection at hCG6 hours. At 12-24 hours after hypoxia, tubular lumen 
dilation of the kidney, flattened epithelial cells, nuclear loss, and apoptosis would be histologically 
visible646. Together, these data suggest that physiological hypoxia and consequential damage is 
not sufficient to induce Edn2 expression, at least at the two examined time points. However, one 
weakness of this study is the lack of confirmation of increases in HIF1-alpha subunit expression; 
the alpha subunit is oxygen-labile and is rapidly degraded under normoxia while the beta subunit 
is constantly present647, and increased presence of HIF1-alpha would be a positive confirmation of 
hypoxia and presence of one factor that may influence Edn2 expression. Similarly, qPCR would 
also be useful for examining the HIF2-alpha subunit as described by Kim et al. 2009 to further 
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confirm or deny that hypoxic factors regulate Edn2 expression in the ovary. Additionally, as the 
body has many ways of coping with low atmospheric oxygen to keep tissues viable, it may be 
more beneficial to study the effect of ovarian artery clamping on Edn2 expression to ensure tissue 
hypoxia occurs and is not managed through low activity and high respiration rate. 
 Though they are the most closely explored, it is possible that other transcription factors 
beyond HIF1 and downstream of PGR may directly regulate Edn2 expression; these factors may 
also vary between tissue types and may not all be present in the granulosa cells of the ovary. To 
identify potential transcription factors that directly regulate Edn2 expression in any tissue, four 
computational searches were used based on the Edn2 gene sequence in humans and mice and 
available ChIP-Seq data or a transcription factor consensus binding sequence library. Searches 
were conducted through TESS, ENCODE, and MET, and the methods are described above. A 
summary of results are listed in Table 8.1 (continued on multiple pages in two sections). 
Transcription factor scores ranged from 1-6, with the average being 1.90. Agreement between 
searches was surprisingly low and few genes were identified in multiple search methods or in the 
same position across searches. The highest scoring transcription factors were Sp1 (6), CTCF (5), 
EBF1 (5), NFKB1 (5), Zfp423 (5), Tcfcp2l1 (4), TFAP2A (4), and TLX1_NFIC (4); the full name 
of these factors are Sp1 transcription factor, CCCTC-binding factor (zinc finger protein), early b-
cell factor 1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1, zinc finger 
protein 423, transcription factor CP2-like 1, transcription factor AP-2 alpha, and t-cell leukemia 
homeobox 1 - nuclear factor 1/c(CCAAT-binding transcription factor) complex. These 
transcription factors are of the greatest interest, though presence of any single binding site for any 
of the transcription factors listed in Table 8.1 may be sufficient for increasing expression. Of these 
eight transcription factors, none were similarly identified through all searches. NFKB1 scored 2 
for binding within the mouse and human Edn2 genes within both MET searches, and was the most 
similar between searches. No papers exist at present in NCBI’s PubMed linking any of these eight 
transcription factors with Edn2. Also of interest, HIF1 scored 1.5 and HIF1A-ARNT (HIF1 is 
synonymous with alpha-aryl hydrocarbon nuclear translocator, ARNT) scored 2.0 (Table 8.1); 
these hits occurred in TESS and both MET searches and indicate that HIF1 has DNA binding about 
the Edn2 gene, specifically within the 3kbp downstream of the gene as confirmed by ChIP-Seq, 
though this did not matched published TESS search data247. Lastly, though both ESR1 and ESR2 
(estrogen receptor alpha and beta) had possible sites for Edn2 regulation, no search identified PGR 
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as a possible transcriptional regulator of Edn2. This implicates that Edn2 is indirectly downstream 
of PGR during ovulation in the ovary, given both binding sequence data and ChIP-Seq data in the 
human and mouse genome.  
 Transcription factor search data identify what factors associate with DNA at particular 
regions; however, they do not identify if those factors are present in the tissue of interest at the 
time of interest. Transcription factor searches require a second negative filter of what transcription 
factors are truly present. In examination of Edn2 expression in the ovary, it is necessary that such 
a transcription factor is present during ovulation, but is absent prior to and after ovulation. To 
generate a negative filter for a transcription factor regulating Edn2 expression during ovulation, it 
was postulated that such a factor would have a large change, either increase or decrease, in 
expression and protein presence just prior to ovulation when Edn2 expression spikes. A mouse 
ovarian gene expression database was created using CD31 mice by extracting RNA from various 
time points during ovulation and comparing expression through Affymetrix microarrays, similar 
to the construction of the rOGED database199. The change in transcription factor expression during 
ovulation was calculated as the percent standard deviation divided by the mean expression of the 
transcription factor. Gene expression and expression changes during ovulation were compared to 
transcription factors previously identified (Table 8.2). Transcription factors that scored 50% or 
lower were discarded. Not all genes were present as transcript in the ovary during ovulation 
according to microarray data (A=absent, P=present, M=marginal). Sixteen genes scored greater 
than 50% deviation/mean change; the average number of transcription factor binding site hits 
among these was 1.72. Of those eight factors that scored 4 or higher, only EBF1 had a major 
change in transcript level during ovulation. However, of those 16 genes with a large transcript 
change, 13 were called as Absent for all or part of the critical time periods leading up to ovulation 
and Edn2 expression. These 13 included EBF1. Those three transcription factors that had >50% 
change and were called as present and were identified by transcription factor search included 
JUNB (Jun B proto oncogene), RUNX1 (runt related transcription factor 1), and EGR1 (early 
growth response 1, also Krox24, NGFIA, zif268, Zenk, and TZs8,) (Table 8.2, bold). Each of these 
demonstrates significant increase in transcript just prior to ovulation, similar to Edn2 which spikes 
at hCG12 hours (Figure 8.3A). JUNB increases from 127 transcriptional units (AU) at hCG0 to 
629 at hCG6 to 1633 at hCG12 hours. RUNX1 increases from 106 at hCG0 to 2029 at hCG6 to 
1537 at hCG12 hours. EGR1 increases from 1103 at hCG0 to 4620 at hCG6 to 7443 at hCG 12 
237 
hours (Figure 8.3). Of these three transcription factors, RUNX1 has peak expression at about hCG6 
hours while JUNB and EGR1 peak at hCG12 hours near ovulation. In the first transcription factor 
search, JUNB scored 1 with one site identified by ENCODE upstream of human Edn2; RUNX1 
scored 2 with one site upstream and one site within introns of Edn2 with each site identified by 
MET in the human genome; EGR1 scored 2 with one site upstream and one stream downstream 
of mouse Edn2 with each identified by MET (Table 8.1). 
 Each of these transcription factors is quite different, and it is unlikely that they 
simultaneously regulated Edn2. JUNB is a member of the activator protein-1 (AP-1) transcription 
factor family, similar to FOS and other JUN proteins, and is best known for its ability to modulate 
cellular proliferation648,649. JUNB inhibits cell growth through antagonization of c-Jun and 
suppresses proliferation by inhibiting transcription of p16INK4A650 and cyclin-D651, but promotes 
transcription of cyclin A to induce proliferation652. JUNB responds to plasma insulin and glucose 
concentrations as well653. Importantly, JunB-KO mice were recently generated and characterized; 
JunB-KO mice have growth retardation, low survival rate, and reduced fat654. About 65% of JunB-
KO mice die by age 12 weeks, and weigh less by 3 months of age even though they are born at the 
same weight and have nearly the same food intake654. This phenotype is similar to Edn2 global 
knockout mice, which also die young from starvation and demonstrate reduced rate of growth223. 
As JUNB may not be the only regulator of Edn2, and because JunB-KO mice were generated 
through crossing flox mice with Cre mice rather than ablating alleles in the oocyte, it is possible 
that JUNB regulates Edn2 expression and the less severe phenotype seen in JunB-KO mice results 
from some remaining Edn2 function. 
 RUNX1 and RUNX function as transcriptional activators or repressors depending on the 
target gene, cell type, and available cofactors655. RUNX1 has been implicated in stem cell 
homeostasis and lineage specification in many cell types. RUNX1 binds to DNA and associates 
with HATs (histone acetyltransferases) or HDACs (histone deacetylases) to direct 
deacetylation656. Deacetylation modulates DNA affinity for histones by exposing positive charges 
of lysine residues of the histones and increasing the interaction of histone lysine N-termini with 
negatively charged phosphate groups of DNA, while HATs have the opposite effect. An increased 
histone-DNA interaction generally promotes a heterochromatic structure and prevents gene 
transcription657. RUNX1 interacts with a DNA sequence known as MTG8 (myeloid translocation 
gene on chromosome 8, also ETO) or similar sequences; this sequence specifically recruits NCOR 
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(nuclear receptor corepressor), SMRT (silencing mediator of retinoid and thyroid hormone 
receptors, also NCoR2), and several HDACs658. To mediate these actions, RUNX1 interacts with 
CBFβ (core binding factor-beta) to form a heterodimer659 that then binds the DNA. Global loss of 
RUNX1 is embryonically lethal660. In the ovary, RUNX1 has been shown to modulate expression 
of many genes following the LH surge483. Expression of Runx1 is controlled by PGR483. 
Specifically, RUNX1 knockdown in cultured granulosa cells showed downregulation of Mt1a, 
Hapln1, Rgc32, and Ptgs2483,661, while changes in Edn2 expression were not then reported. 
RUNX1 has been knocked out in the intestines using a Villin-Cre system, though no phenotypes 
were observed in development though the incidence of tumor growth was higher655. Similarly, loss 
of Edn2 using Villin-Cre showed no early phenotype that might lead to starvation, as seen in global 
Edn2-KO mice223.  
 EGR1 is a transcription factor with three zinc finger structures that was originally identified 
for its expression by nerve growth factor in rat cell lines662. EGR1 has consequently been largely 
studied for its role in the brain, particularly on neuron growth and memory. It has also been shown 
that EGR1 is necessary for macrophage differentiation and T lymphocyte proliferation663,664. A 
global EGR1 knockout mouse line was generated in 2005 by Lee et al.662. The mice exhibit normal 
growth and lack defects in cellular differentiation, though reproductive characteristics were not 
explored662. However, given their normal growth and survival, it is unlikely that EGR1 influences 
Edn2 expression unless it is specific to the ovary.  
 To specifically influence the effect of Edn2 during ovulation for only a brief time period, 
it is necessary that the promoting transcription factor also be active for a brief period of time, and 
that it is expressed and translated prior to EDN2 peptide. Of the three likely factors examined, only 
RUNX1 is higher at hCG6 hours than hCG12 hours in the ovary. Given its role as a transcriptional 
activator and the lethal phenotype resulting from Runx1 ablation, RUNX1 is a likely transcription 
factor to influence Edn2 expression. To further examine its potential, consensus binding sites for 
RUNX1 were examined (Figure 8.4A). In the mouse Edn2 gene, four binding sites were observed 
based on the consensus sequences TGTGGTT, TGTGGTC, TGCGGTT, and TGCGGTC or their 
reverse complements. Of these, one site that is present between the second and third exon of Edn2 
is conserved across mammals, excepting the rabbit and panda. This high level of conservation 
within an intron suggests the binding RUNX1 is important within Edn2.  
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RUNX1 is associated indirectly with BCL6 (B cell lymphoma 6 protein), which may be 
responsible in turn for regulation of Edn2 in the ovarian granulosa cells. BCL6 is a sequence-
specific repressor that binds to DNA that interacts with NCOR and SMRT656, and also binds to 
MTG8/ETO665. Thus BCL6 and RUNX1 compete for the same or similar sites. During ovulation, 
Bcl6 is constitutively expressed except for the time points hCG6 and hCG12 hours, where it is 
absent (Figure 8.3F), which is inverse to Runx1 and is prior to and during Edn2 expression. BCL6 
consensus sequences were also examined; as in RUNX1, four sites were observed in the mouse 
and one of these, upstream of the first exon, is conserved across all mammals’ sequences examined 
(Figure 8.4B); this region is within 70 basepairs of a conserved binding RUNX1 region in rats and 
mice. Also, as both RUNX1 and BCL6 are known to associate with MTG8-similar regions, a 
directly matching consensus sequence may not be required between them for DNA binding 
competition.  
 As BCL6 interacts with NCOR and SMRT, and RUNX1 with CBFβ, their expression levels 
were examined in the mOGED. NCOR decreases slightly from baseline at hCG6 and hCG12 hours 
and is present throughout ovulation; SMRT is present throughout ovulation and decreases 
markedly during hCG6 and hCG12 hours; and CBFβ is relative constant and present throughout 
ovulation with slight increase of about 10% expressing at hCG6 hours. Lastly, the protein CRLZ1 
(charged amino acid rich leucine zipper 1, Utp3) was also examined. CRLZ1 was recently 
discovered as a CBFβ binding factor, which mobilizes CBFβ from the cytoplasm to the nucleus666 
where it can then associate with RUNX1. CRLZ1 also remains bound to the RUNX1-CBFβ 
heterodimer throughout DNA binding. CRLZ1 is present throughout ovulation in the mOGED; it 
remains relatively constant during ovulation except for hCG6 hours, where it increases in 
expression by 22%, before dropping again at hCG12 hours.  
 Taken together, a hypothesis for a mechanism of molecular control of Edn2 transcription 
may now be constructed (Figure 8.5): Prior to ovulation and during the majority of the cycle in the 
mouse granulosa cells, the repressor BCL6 is bound about the Edn2 gene with the corepressors 
NCOR and SMRT. These corepressors recruit HDACs which deacetylate histones to cause tight 
DNA binding and prevent transcription. Following the LH surge, via PGR downstream signaling, 
expression of BCL6, NOCR, and SMRT all decrease at hCG6 hours. Concurrently, RUNX1, 
CBFβ, and CRLZ1 levels increase. As BCL6 expression is absent at hCG6-hCg12 hours, this then 
allows the binding of RUNX1 to the Edn2 gene; this binding is mediated by the heterodimer 
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formed with CBFβ and mediated through CRLZ1 translocation. RUNX1 binding recruits HATs 
(likely MOZ, MORF, or p300656), which acetylate lysine residues to decrease histone-DNA 
affinity and allow for rapid Edn2 transcription. This transcription is further enhanced through the 
presence of the HIF1 complex. After translation, EDN2 causes follicular rupture through a 
contractile mechanism, and mediates other downstream effects through local endothelin receptors.  
 Future experiments may focus on all or portions of this mechanistic hypothesis for the 
ovarian regulation of Edn2 via RUNX1, and may also rule out the possible involvement of JUNB 
and EGR1. A solid early approach may utilize breeding studies with conditional knockout mice in 
which Runx1 is lost specifically in the granulosa cells. Of note, a mouse that expresses Cre 
recombinase under the progesterone receptor promoter has been crossed with Runx1-flox mice. 
This mouse demonstrates normal ovulation (Kannan, 2015, unpublished data, personal 
communication). However, Pgr is expressed relatively late in ovulation at nearly the same time 
point as Runx1 and Cre recombinase may not have time to sufficiently remove the Runx1 gene 
before transcription begins. Furthermore, Pgr-Cre may not remove Runx1 from all granulosa cells 
and incomplete ablation may result in no change. It is thus important for protein analyses to 
accompany transgenic mouse studies of this nature. The use of the new Esr2-iCre mouse line may 
be sufficient to remove Runx1 prior to ovulation in the granulosa cells to determine if RUNX1 
directly regulates Edn2 expression; phenotypes of Runx1-FloxFlox Esr2-iCre mouse are 
postulated to match those of Edn2-Flox/Flox Esr2-iCre mice and exhibit significant reduction in 
oocytes ovulated and pups per litter. In vitro studies using granulosa derived from this mouse 
model may then allow use of pharmacological stimulation, antagonization, and knockdown 
technology to confirm the role of the protein intermediaries. 
 Overall, this study confirms the role of progesterone receptor as a regulator of Edn2 
expression within the ovary and presents a molecular hypothesis for the mechanism behind it 
centered about RUNX1 modulation of acetylation. The method of comparison used here between 
DNA sequence analyses, transcription factor binding analyses through ChIP-Seq, and tissue and 
time-specific microarrays may be similarly implemented to develop and test future hypothesis for 
genetic regulation as well, and may also combine developing protein arrays to improve accuracy 
and success.  
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TABLES 
 
Table 8.1. Transcription factor search using Transcriptional Element Search System (TESS) computational search and 
ENCODE and Motif Enrichment Tool (MET) motif cluster searches. Multiple searches were performed to identify potential 
transcription factors that regulate Edn2 expression. The TESS computation search examined 2000 base pairs upstream of the Edn2 ATG 
start codon for DNA sequences in the mouse genome that match known sequences for transcription factor binding. The motif cluster 
searches through UCSC and UIUC examined 3000 base pairs upstream and downstream, as well as introns of the Edn2 gene in the 
human and mouse genomes. Potential transcription factors identified by TESS were scored as 1 per site. Motif cluster searches were 
scored as 1.0 for sites above two standard deviations above the binding threshold and 1.5 for sites above four standard deviations above 
the binding threshold. The total score from all search methods was summed as ‘Total Hits’ in column 2. Transcription factors with a 
high number of hits include CTCF, EBF1, NFKB1, Sp1, and Zfp423; however, different transcription factors are likely present in 
different tissues or at different times. No transcription factor examined had a score of less than 1 or greater than 6. HIF-1 and HIF1A-
ARNT had a combined score of 3.5 and is the only representative score from a known inducer of Edn2 in multiple tissues and species. 
Continued on multiple pages, shown as left side followed by right side: 
Left side: 
  TESS Upstream 
Computational 
Search 
ENCODE Human Edn2 Search 
Transcription Factor Name Total 
Hits 
Upstream 2Kbp Upstream 
3Kbp 
In Gene Downstream 
3Kbp 
AP-2alpha 1       1 
AP-2gamma 3   2   1 
Arnt 2         
Arnt_Ahr 2         
CEBPB 1.5       1.5 
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Table 8.1, left side. Continued from previous page. 
c-Fos 1   1     
c-Jun 1   1     
c-Myc 2   2     
CTCF 5   1   1 
CTCF_(C-20) 1   1     
CTCF_(SC-5916) 1   1     
E2F1 1         
EBF1 5         
eGFP-FOS 1.5   1.5     
eGFP-GATA2 1   1     
eGFP-JunB 1   1     
eGFP-JunD 1.5   1.5     
Egr1 2         
ELK1 1         
ELK4 2         
ERalpha-a 3   1 1 1 
ESR1 2         
ESR2 1         
Esrrb 2         
FOX1 1 1       
FOXA1_(C-20) 1   1     
FOXC1 1         
FOXF2 1         
GABPA 2         
GATA-2 2.5   1.5   1 
GR 3   3     
HA-E2F1 1     1   
HIF-1 1 1       
HIF1A_ARNT 2         
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Table 8.1, left side. Continued from previous page. 
HNF41 1         
HNF4A 1       1 
HNF4A_(H-171) 1.5       1.5 
HNF4G_(SC-6558) 1       1 
Ini1 2   2     
INSM1 1         
JunD 1   1     
Klf4 3         
Max 1   1     
Myb 3         
Myc 2         
Myc_Max 2         
Myf 3         
MZF1_5-13 2         
NF-1 1 1       
NFIC 1         
NF-kappaB 2         
NFKB 2   1 1   
NFKB1 5         
NHLH1 1         
NR1H2_RXRA 2         
NR2F1 2         
p300 1       1 
Pax5 1         
PAX5-C20 1   1     
Pax6 1         
Pit-1 1 1       
PLAG1 2         
Pol2 1.5   1.5     
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Table 8.1, left side. Continued from previous page. 
PPARG_RXRA 1         
PU.1 1 1       
Rad21 2   1   1 
REL 1         
RELA 2         
REST 1         
RUNX1 2         
RXR_RAR_DR5 4         
RXRα 1 1       
Sp1 6 3       
Spz1 1         
STAT1 3.5   1.5     
STAT3 1         
T 1         
TBP 2 1 1     
Tcfcp2l1 4         
TEAD1 2         
TFAP2A 4         
TLX1_NFIC 4         
TP53 1         
USF1 3         
XPF-1 1 1       
Zfp423 5         
Zfx 3         
ZNF263 1   1     
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Table 8.1, right side. Continued on multiple pages. 
 MET Human Edn2 Search MET Mouse Edn2 Search 
Transcription Factor Name Upstream 
3Kbp 
In 
Gene 
Downstream 
3Kbp 
Upstream 
3Kbp 
In 
Gene 
Downstream 
3Kbp 
AP-2alpha             
AP-2gamma             
Arnt   1       1 
Arnt_Ahr   1       1 
CEBPB             
c-Fos             
c-Jun             
c-Myc             
CTCF 1 2         
CTCF_(C-20)             
CTCF_(SC-5916)             
E2F1       1     
EBF1 1 1 1   2   
eGFP-FOS             
eGFP-GATA2             
eGFP-JunB             
eGFP-JunD             
Egr1       1   1 
ELK1   1         
ELK4   2         
ERalpha-a             
ESR1 1 1         
ESR2 1           
Esrrb     1 1     
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Table 8.1, right side. Continued from previous page. 
FOX1             
FOXA1_(C-20)             
FOXC1           1 
FOXF2           1 
GABPA   1 1       
GATA-2             
GR             
HA-E2F1             
HIF-1             
HIF1A_ARNT     1     1 
HNF41       1     
HNF4A             
HNF4A_(H-171)             
HNF4G_(SC-6558)             
Ini1             
INSM1   1         
JunD             
Klf4   1   1 1   
Max             
Myb   1 1   1   
Myc     1     1 
Myc_Max     1     1 
Myf   1     1 1 
MZF1_5-13   1   1     
NF-1             
NFIC   1         
NF-kappaB   1     1   
NFKB             
NFKB1   2   1 2   
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Table 8.1, right side. Continued from previous page. 
NHLH1         1   
NR1H2_RXRA   1   1     
NR2F1   1   1     
p300             
Pax5     1       
PAX5-C20             
Pax6     1       
Pit-1             
PLAG1 1     1     
Pol2             
PPARG_RXRA     1       
PU.1             
Rad21             
REL         1   
RELA     1   1   
REST 1           
RUNX1 1 1         
RXR_RAR_DR5     1 1 1 1 
RXRα             
Sp1   1   1 1   
Spz1           1 
STAT1   1   1     
STAT3     1       
T         1   
TBP             
Tcfcp2l1   1   1 1 1 
TEAD1   1 1       
TFAP2A   2 1 1     
TLX1_NFIC   1   1   2 
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Table 8.1, right side. Continued from previous page. 
TP53   1         
USF1   1 1     1 
XPF-1             
Zfp423   1 1 1 2   
Zfx   1   1 1   
ZNF263             
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Table 8.2. Comparison of potential regulatory transcription factors to mouse ovarian gene expression changes during ovulation. 
For transcription factors identified by gene search (Table 1), expression of each was examined in mouse ovaries during ovulation through 
microarray data downloaded from the mouse ovarian gene expression database (mOGED, unpublished). The amount of transcript at 
hCG0, 6, and 12 hours was recorded. To search for large changes in expression during ovulation, the standard deviation of expression 
from the three time points was recorded and divided by the mean of expression from those times to generate a percentage of change 
during ovulation. Transcription factors were ranked by decreasing percent deviation. Those with changes greater than 50% were also 
examined for presence or absence of transcript from the mOGED. Two transcription factors, RUNX1 and EGR1, were identified as 
having a large change in transcript that were also present during ovulation. No gene had a percentage greater than 100% (range 0-93%). 
Twenty transcription factors were not present in the mOGED and were not analyzed for expression change or presence during ovulation. 
Continued on multiple pages. 
TF Name Sum Score 
mOGED Expression: Ovary 
StDev/Mean mOGED ID Presence 
hCG0 hCG6 hCG12 
eGFP-JunB 1 127 629 1633 96.29% [jun-b] P for all 
FOXC1 1 3 30 51 85.94% [foxc1] A for all 
EBF1 5 6 16 3 81.68% [irebf1] A for all 
RUNX1 2 106 2029 1537 81.62% [runx1] P for all 
INSM1 1 4 36 35 72.77% [insm1] A for all 
Egr1 2 1103 4620 7443 72.38% [egr1] P for all 
HIF1A_ARNT 2 35 123 184 65.71% [hif1a] cDNA 
A hCG0  
A hCG6 
ELK1 1 146 42 64 65.25% [elk1] A hCG12 
E2F1 1 224 100 72 61.28% [e2f1] 
A hCG6  
A hCG12 
HA-E2F1 1 224 100 72 61.28% [e2f1] 
A hCG6  
A hCG12 
Spz1 1 23 18 5 60.60% [spz1] A for all 
Pax6 1 18 67 39 59.48% [pax6] A for all 
eGFP-GATA2 1 85 117 30 56.90% [gata2] cDNA A hCG6 
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Table 8.2. Continued from previous page. 
GATA-2 2.5 85 117 30 56.90% [gata2] cDNA A hCG6 
AP-2gamma 3 37 25 10 56.37% [tcfap2c] A for all 
ELK4 2 112 140 38 54.52% [elk4] A for all 
T 1 6 9 3 50.00%   
Klf4 3 225 654 466 47.97%   
STAT3 1 956 2355 2790 47.12%   
Myb 3 34 27 12 46.19%   
Pax5 1 42 32 16 43.72%   
Myf 3 5 2 5 43.30%   
PPARG_RXRA 1 1462 1390 584 42.56%   
ESR2 1 1183 682 564 40.59%   
c-Fos 1 433 215 523 40.57%   
eGFP-FOS 1.5 433 215 523 40.57%   
TEAD1 2 47 113 91 40.17%   
CEBPB 1.5 2098 4968 3968 39.61%   
Esrrb 2 49 25 52 35.23%   
Myc 2 709 789 1300 34.38%   
GABPA 2 176 344 347 33.87%   
PU.1 1 47 27 55 33.54%   
NR2F1 2 84 45 55 33.03%   
Ini1 2 188 122 238 31.85%   
FOXF2 1 26 41 50 31.09%   
NFKB 2 327 439 605 30.61%   
TLX1_NFIC 4 58 37 34 30.41%   
NFIC 1 43 35 23 29.90%   
Pit-1 1 15 16 25 29.50%   
ERalpha-a 3 33 48 58 27.16%   
ESR1 2 33 48 58 27.16%   
RXRα 1 182 244 151 24.62%   
GR 3 53 86 66 24.33%   
MZF1_5-13 2 26 23 36 24.02%   
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Table 8.2. Continued from previous page. 
Zfx 3 93 143 103 23.41%   
RXR_RAR_DR5 4 655 453 445 22.99%   
REST 1 57 57 38 21.65%   
eGFP-JunD 1.5 1035 1555 1510 21.08%   
JunD 1 1036 1555 1510 21.03%   
USF1 3 239 366 329 20.98%   
STAT1 3.5 275 180 250 20.96%   
NF-kappaB 2 545 771 604 18.32%   
NFKB1 5 545 771 604 18.32%   
HIF-1 1.5 794 1107 921 16.74%   
NHLH1 1 74 80 59 15.23%   
Sp1 6 1748 1347 1431 14.02%   
NR1H2_RXRA 2 840 637 718 13.97%   
PLAG1 2 21 26 21 12.74%   
Zfp423 5 5 5 4 12.37%   
TBP 2 338 309 388 11.58%   
Rad21 2 1313 1047 1169 11.32%   
Arnt_Ahr 2 284 230 253 10.60%   
CTCF 5 985 1063 897 8.46%   
Arnt 2 64 57 56 7.39%   
Max 1 642 649 608 3.46%   
Tcfcp2l1 4 251 265 258 2.71%   
AP-2alpha 1 58 55 57 2.70%   
FOXA1_(C-20) 1 2 2 2 0.00%   
c-Jun 1 not in database 100807 N/A   
c-Myc 2 not in database 100807 N/A   
CTCF_(C-20) 1 not in database 100807 N/A   
CTCF_(SC-5916) 1 not in database 100807 N/A   
FOX1 1 not in database 100807 N/A   
HNF41 1 not in database 100807 N/A   
HNF4A 1 not in database 100807 N/A   
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Table 8.2. Continued from previous page. 
HNF4A_(H-171) 1.5 not in database 100807 N/A   
HNF4G_(SC-6558) 1 not in database 100807 N/A   
Myc_Max 2 not in database 100807 N/A   
NF-1 1 not in database 100807 N/A   
p300 1 not in database 100807 N/A   
PAX5-C20 1 not in database 100807 N/A   
Pol2 1.5 not in database 100807 N/A   
REL 1 not in database 100807 N/A   
RELA 2 not in database 100807 N/A   
TFAP2A 4 not in database 100807 N/A   
TP53 1 not in database 100807 N/A   
XPF-1 1 not in database 100807 N/A   
ZNF263 1 not in database 100807 N/A   
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Figure 8.1. PRKO mice lack Edn2 expression during ovulation. Female mice that globally lack the progesterone receptor gene and control 
siblings were superovulated at 25 days of age. Mice were sacrificed at hCG 0 hours or hCG 12 hours and ovaries were removed. Total RNA was 
extracted and RT-PCR was performed for Edn2 expression (n=4 mice / group), and normalized to Rpl19. A. The change in Edn2 expression was 
quantified relative to control mice at hCG 0 hours. In control mice Edn2 expression increases 926.7±177.5 times from 1.0±0.1 from hCG0 to hCG12 
hours; in PRKO mice Edn2 expression increases from 0.48±0.1 to 10.3±1.2. B. Relative to control mice, PRKO mice have a significant reduction 
in Edn2 expression at hCG 12 hours (p=0.019). In PRKO mice, expression of Edn2 is decreased approximately 90 fold at hCG12 hours (1.06±0.20 
to 0.01±0.00). There was no significant difference in Edn2 expression at hCG0 hours (p=0.845). Error bars show the S.E.M. 
Relative Edn2 expression Relative Edn2 expression 
255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2. Edn2 expression is not changed in ovaries, kidneys, or lungs following acute hypoxia. A. Adult WT mice (n=3 / group) of 
approximately 125 days of age (±15.4) in diestrus were exposed to 8% oxygen in a hypoxia chamber for two hours. Mice were sacrificed immediately 
after (0 hours), or were returned to normoxia for 6 hours and then sacrificed. Ovaries, lungs, and kidneys were collected, RNA was extracted, and 
mRNA expression of Edn2 was examined by semi-quantitative RT-PCR. No significant differences were observed (p>0.05 for all). Rpl19 was used 
as internal control. B. Kidney histology was examined for early signs of hypoxic damage. No qualitative differences were observed between kidneys 
of mice that had and had not been exposed to hypoxia. Pathological analysis at the University of Illinois suggested that microscopic changes may be 
apparent on a cellular level by SEM, but no histologic changes were able to be observed. 
A. 
Edn2 
Rpl19 
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Figure 8.3. Mouse ovarian expression of Edn2, Hif1α, Runx1, and Bcl6 during ovulation.  
Legend continued on next page.  
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Figure 8.3. Mouse ovarian expression of Edn2, Hif1α, Runx1, and Bcl6 during ovulation. Continued 
from previous page. Expression levels of genes of interest were determined from the microchip-based 
mouse ovarian gene expression database (mOGED). A. Endothelin-2 remains low or undetectable at all 
points assayed, excepting hCG12 hours where it spikes during early ovulation before returning to basal 
levels. B. Hypoxia inducible factor 1-alpha has a moderate increase throughout the ovulatory period with 
the highest point during hCG12 hours. Hif1α has a 50-100% increase from baseline during ovulation. C. 
Jun-B proto-oncogene increases sharply during ovulation with peak transcript levels at hCG12 hours, which 
is nearly three times as high as expression at hCG6 hours and about 15 times higher than baseline levels. 
D. Runt related transcription factor 1 is present throughout ovulation; expression of Runx1 increases nearly 
10-fold at hCG6 hours, prior to ovulation and the increase in Edn2 expression; Runx1 declines to about a 
5-fold increase from baseline at hCG12 hours and returns to nearly baseline at hCG24 hours. E. Transcripts 
from early growth response 1 increase at hCG6 hours and are highest at hCG12 hours, approximately four 
times higher than baseline, before dropping again at hCG24 hours. Expression of Egr1 increases until 
ovulation occurs. F. B cell leukemia/lymphoma 6 expression increases slightly during early ovulation and 
is highest at hCG0 hours before dropping to basal levels at hCG6 hours and hCG12 hours. Bcl6 expression 
is low during ovulation and has an inverse relationship to Runx1. Of these genes, only Runx1 peaks at hCG6 
and Bcl6 is low at hCG6 and hCG12 hours. The mOGED database was constructed from total RNA isolated 
from intact mouse ovaries following superovulation and run on Affymetrix Mouse Expression Arrays (n=5 
animals/time point). PMSG48 hours is synonymous with hCG0 hours. P=present, A=absent, M=marginal. 
Chart title above line graph provides Affymetrix gene ID numbers and gene name or alternate name.  
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Figure 8.4. Consensus binding sites of RUNX1 and BCL6 in the mouse endothelin-2 gene. The consensus binding sequences of RUNX1 and 
BCL6 were compared to the mouse endothelin-2 gene sequence and 5000 basepairs upstream and downstream of the first and fifth exon, respectively, 
using freeware made available by the University of Guelph. Matching binding sequences are indicated with vertical arrows. Blue arrows indicate 
mouse-specific binding sites, black arrows indicate sites conserved in mice and rats, and red arrows indicate sites conserved amongst mammals 
including humans (unless otherwise indicated). The five exons are indicated by blue boxes; the DNA runs 5’ to 3’ from left to right. A. Four binding 
sites were determined for RUNX1. One binding site, 851 base downstream of the ATG start codon and in intron 2, is conserved amongst mammals 
except for the panda and rabbit. The sequence in this section was either TGCGGTT or TGCGGTC in all animals (red). B. Four binding sites were 
also determined for BCL6. One site that was 2101 base pairs upstream of the start codon was conserved throughout mammals; this sequences was 
TTTNNNGNNAT.  
Consensus binding sites of RUNX1 in the mouse endothelin-2 gene: 
Consensus binding sites of BCL6 in the mouse endothelin-2 gene: 
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Figure 8.5. Postulated molecular mechanism for ovarian regulation of endothelin-2 during ovulation. A hypothetical mechanism was generated 
from previous publications examining RUNX1 and BCL6 protein interactions. A. Prior to ovulation and during the majority of the cycle in the 
mouse granulosa cells, the repressor BCL6 is bound about the Edn2 gene with the corepressors NCOR and SMRT. These corepressors recruit 
HDACs which deacetylate histones to cause tight DNA binding and prevent transcription. Following the LH surge, via PGR downstream signaling, 
expression of Bcl6, Ncor, and Smrt all decrease at hCG6 hours. Concurrently, Runx1, Cbfβ, and Crlz1 expression levels increase. As Bcl6 expression 
is absent at hCG6-hCg12 hours, this then allows the binding of RUNX1 to the Edn2 gene; this binding is mediated by the heterodimer formed with 
CBFβ and mediated through CRLZ1 translocation. RUNX1 binding recruits HATs, which acetylate lysine residues to decrease histone-DNA affinity 
and allow for rapid Edn2 transcription. This transcription is further enhanced through the presence of the HIF1 complex. After translation, EDN2 
causes follicular rupture through a contractile mechanism, and mediates other downstream effects through local endothelin receptors. B. Relative 
expression of relevant genes from the mOGED. Expression is relative to each individual gene in arbitrary units (Y-axes). X-axis describes time 
during ovulation; each tick mark represents 6 hours. X-axis represents 72 hours in total. Measurements were made at PMSG0, PMSG12, PMSG48 
/ hCG0, hCG6, hCG12, and hCG24 hours.  
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CHAPTER 9: CONCLUSIONS AND FUTURE DIRECTIONS 
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 The above work within this dissertation further describes the role for endothelin-2 (EDN2) 
in ovulation and generates new questions for further research in the molecular mechanisms of 
ovulation. EDN2, a potent vasoconstrictor, is produced in the granulosa cells of mature follicles 
just prior to ovulation. Chapter 3 shows that Edn2 is expressed in multiple tissues throughout the 
body using a new Edn2-iCre mouse. Areas of expression are particularly interesting, and raise new 
questions for the role of EDN2 in the cornea and retina of the eye, the villi of the GI tract, and 
select cells within the kidney. The Edn2-iCre mice may also be used to remove floxed genes within 
the ovary during ovulation to dissect the roles of individual genes in corpus luteum formation from 
folliculogenesis.  
 Through exploration within the ovaries of multiple species, Chapter 4 highlights the 
discovery that EDN2 induces similar contractile responses in the ovaries of multiple species, even 
non-mammals, and that this force is associated with the amount of smooth muscle present within 
the ovary. The location of smooth muscle actin is conserved about the growing follicle in cats and 
chickens, and is not limited to only the arteries and arterioles within an ovary. Domestic cat and 
chicken ovaries demonstrate stronger contraction than dog ovaries owing to differential smooth 
muscle presence. Cat and dog ovaries express the components of the endothelin system, while 
chickens demonstrate expression of Ednrb. Future work may explore the expression and 
localization of Edn2 in non-primates and non-rodents throughout the reproductive cycle, such as 
in fish, lagomorphs, and Gallus gallus where ovulation can be easily timed. Conservation of timed 
ligand expression, or at least potential receptor activation, would be further indicative of a 
conserved necessary role in ovulation. 
 Key findings from this dissertation are centered about the role of EDN2 in the ovary, as 
detailed in Chapter 6. This is the first study to focus on the role of the EDN2 ligand specifically 
rather than its associated receptors. EDN2 was removed from the ovary using Esr2-iCre mice. The 
novel Esr2-iCre mice, which are characterized in Chapter 5 with a description of their design and 
generation, are themselves expected to be useful for numerous future studies in multiple fields. 
Loss of EDN2 results in reduced fecundity by a deficit in follicle rupture, as previously 
hypothesized. However, pregnancies of smaller litters are carried to parturition in a normal time 
span; these mice also retain the ability to produce functional corpora lutea, albeit fewer owing to 
the lack of follicular rupture. Serum hormone progesterone levels remain normal, and no key genes 
such as Mmp2, Mmp9, Timp1, Hifα, Esr1, Esr2, Pgr2, or Casp3 are significantly changed 
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compared to WT mice. Together, this strongly suggests that EDN2 is important, though not 
required, for follicle rupture and not CL formation, and that the mechanism of action lies through 
EDNRA signaling in mammals, and potentially through EDNRB in chickens. Stimulation of 
EDNRA is likely critical for contraction of the theca externa cell layer as a final mechanism for 
follicular rupture. Future experiments may further confirm this by inducing contraction in the 
ovary to restore ovulatory function to these conditional knockout mice, though this is complicated 
by an inverse relationship between follicular pressure and ovulatory ability versus systemic blood 
pressure and likely necessitates either ex vivo or ovary-localized effect. These data may be of 
clinical relevance for assistance in artificial reproductive technologies.  
Using a tamoxifen-inducible alpha-smooth muscle actin Cre system in the next logical area 
of inquiry, Chapter 7 discusses the removal of EDNRA from contractile cells in mice, either 
throughout the whole body or the ovary specifically. This did not totally inhibit ovulation. 
However, tamoxifen acts as an endocrine disrupting chemical (EDC) to antagonize estrogen 
receptor action and prevent normal ovulation in control mice, making it difficult to tease apart the 
role of EDNRA from tamoxifen treatment. A final pilot experiment using two different Cre lines 
that instead ablate genes within granulosa cells suggests that EDNRA may be important there for 
signaling during ovulation, either in addition to or separately from smooth muscle cells. Mice with 
granulosa cell loss of Ednra demonstrate a phenotype likely to granulosa-cell loss of Edn2. Future 
work may use a different granulosa cell-specific Cre, such as Esr2-iCre, to remove Ednra. The 
resulting phenotype may be compared to results from whole ovary or granulosa cell-specific loss 
of EDN2. Ovarian cells from those mice may also be used to dissect the ovarian signaling pathway 
downstream of EDN2 receptor binding. Additionally, when a novel smooth muscle-specific 
inducible Cre (such as under regulation of tetracycline) becomes available, this may then be used 
to explore the role of EDNRA in smooth muscle cells during ovulation. 
 Lastly, the data in Chapter 8 of this dissertation confirm that endothelin-2 is a downstream 
gene of progesterone receptor (PGR) activity and also demonstrates that acute environmental 
oxygen deficiency is not sufficient to induce Edn2 expression in the lungs, kidney, or ovary. New 
“big-data” tools utilizing global RNA expression profiling at various time points in specific tissues 
coupled with ChIP-Seq transcription factor analyses allow for generation of the hypothesis that 
EDN2 action is downstream of RUNX1, which acts through an epigenetic method to modify 
acetylation. Future work in the endothelin system may utilize ovarian cell cultures from wild type 
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mice to confirm or reject this proposed mechanistic hypothesis; epigenetic promoter modification 
via PGR signaling represents a newly developing and exciting topic within reproductive genomics. 
Such findings may also be extrapolated to endothelin isoform transcriptional regulation in multiple 
other systems, and may be utilized to develop potential therapies for diseases such as Waardenburg 
syndrome or Hirschsprung’s disease type II which are specific to endothelin ligand or receptor B 
signaling deficiencies. Overall, the findings from this body of work are useful for understanding 
the involvement of a complimentary contractile mechanism in ovulation through endothelin-2 and 
endothelin receptor A signaling. Furthermore, tools and hypotheses developed herein will be of 
great importance in the field of reproductive biology and steroid hormone signaling within the 
context of clinical biology research. 
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